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Abstract
γ-Interferon stimulates human macrophages to produce 7,8-dihydroneopterin (7,8-
NP). 7,8-NP and its oxidation product neopterin are excellent inflammatory markers
for a variety of chronic conditions, including atherosclerosis. The biological signifi-
cance of 7,8-NP in atherosclerosis is not fully understood, but 7,8-NP has been shown
to protect macrophage cells from oxidised low density lipoprotein (oxLDL). Cellular
accumulation of oxLDL–derived lipids and oxLDL–induced cytotoxicity are major
drivers of atherosclerotic plaque progression.
This thesis investigated the mechanisms of 7,8-NP–mediated protection against oxLDL–
induced damage to macrophage cells. The research assessed the relative contribution
of the previously identified antioxidant capacity of 7,8-NP and its ability to down-
regulate oxLDL uptake. OxLDL cytotoxicity was characterised by high intracellular
oxidative stress within the first 12 hours of exposure, which was critical to oxLDL
toxicity. Exogenously added 7,8-NP effectively scavenged the intracellular oxidants
generated in response to oxLDL, shown by the oxidation of 7,8-NP to neopterin. The
ability of 7,8-NP to alleviate oxidative stress during the critical time-frame of acute
toxicity was the primary mechanism of protection. 7,8-NP was also found to down-
regulate the levels of intracellular oxysterol esters in oxLDL–treated macrophages.
This decrease was associated with the reduction of CD36 scavenger receptor protein
and mRNA expression. The late onset of these processes in the second half of the
24 hour incubation highlighted their potential role in foam cell formation. Research
indicated that 7,8-NP may play a role in the reverse cholesterol transport in these
cholesterol ester-loaded cells. The CD36 down-regulation by 7,8-NP did not protect
macrophages from acute oxLDL cytotoxicity.
This research reveals novel detail about the mechanism of 7,8-NP protection of
macrophages from cytotoxic effects of oxLDL. It is suggested that 7,8-NP may pro-
tect macrophage cells in the atherosclerotic plaques by scavenging ROS produced
during acute cytotoxicity and alleviate oxysterol ester accumulation, thus stabilising
macrophage cells during chronic oxLDL exposure.
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1Introduction
1.1 Overview and research question
Oxidative stress and inflammatory cell death are the core pathologies in many chronic
diseases, including cardiovascular disease (CVD). CVD manifests as angina, stroke
and myocardial infarction and is one of the leading causes of morbidity and mortality
worldwide (Roger et al., 2011). CVD is caused by the occlusion of the blood flow as
a consequence of atheroslerosis (Naghavi et al., 2003). Atherosclerosis, or vascular
wall hardening, is characterised by lipid and cellular deposition in the arterial walls
(Lusis, 2000). It is thought to be driven by the death of inflammatory cells recruited
to the atherosclerotic site (Libby, 2002).
One of the key interactions during atherosclerosis is the death of macrophage cells in
response to oxidatively modified low-density lipoprotein (LDL) (oxLDL), the main
cholesterol carrier in the circulation (Moore & Tabas, 2011). Macrophages partici-
pate in the clearance of damaged host molecules (Fox & Rossi, 2010), which include
oxLDL. OxLDL is toxic to cells, possesses pro-inflammatory properties and is abun-
dant inside developing atherosclerotic lesions (Berliner & Heinecke, 1996; Steinberg
& Witztum, 2010; Yla¨-Herttuala et al., 1989). Many studies have investigated the
oxLDL–induced toxicity to macrophage cells, yet certain aspects of the process are
not completely understood (Hessler et al., 1983; Hodis et al., 1994; Wintergerst et al.,
2000). The initial interaction and subsequent uptake of oxLDL by macrophages is
facilitated by the cell surface receptors for oxLDL, called scavenger receptors. CD36
is the scavenger receptor most commonly associated with oxLDL–induced cytotoxic-
ity and cell death (Collot-Teixeira et al., 2007). OxLDL binding to CD36 triggers a
signalling cascade that results in the production of reactive oxygen species (ROS) and
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oxidative stress (Park et al., 2009). This also affects the intracellular redox balance,
which leads to the oxidative modification of key cellular enzymes, followed by changes
in the cell metabolism and, ultimately, by cell death (Katouah, 2012; Sukhanov et al.,
2006).
The macrophage cells rely on a large pool of intracellular ROS-dismutating enzymes
and small antioxidant molecules like glutathione (Gotoh et al., 1993; Pietarinen-
Runtti et al., 2000) to withstand oxLDL–induced oxidative stress. Moreover, macrophages
are known to release extracellular reduced thiols (Gmu¨nder et al., 1990) and a reduced
pyrimidine 7,8-dihydroneopterin (7,8-NP) (Werner et al., 1989). 7,8-NP is a redox
sensitive molecule which has been shown to protect macrophage cells from oxLDL-
induced cell death (Baird et al., 2005; Gieseg et al., 2010a).
7,8-NP and its oxidised counterpart, neopterin, have been linked to the atherosclerotic
burden in cardiovascular disease. Both compounds had been detected in atheroscle-
rotic plaques (Gieseg et al., 2009) and neopterin was identified as a possible inde-
pendent predictor of atherosclerosis complications (Ray et al., 2007; Sugioka et al.,
2010). This suggests a plausible connection between oxLDL–induced cell death and
7,8-NP/neopterin availability (Gieseg et al., 2009). Indeed, a number of studies have
shown that 7,8-NP protects cells of myelocytic origin from the cytotoxic effects of
oxLDL (Baird et al., 2005; Gieseg et al., 2001b, 2010a). The aim of this research is to
establish the mechanism of this protection. Previous studies suggested that the pro-
tective effect of 7,8-NP on oxLDL–treated cells could be due to its ability to neutralise
oxidants (Baird et al., 2005; Gieseg et al., 2001b). Recently, however, 7,8-NP has also
been reported to reduce the uptake of oxLDL by macrophages (Gieseg et al., 2010a).
This thesis will investigate how the two capacities of 7,8-NP may contribute to its
protective effect on human monocyte-derived macrophage (HMDM) cells treated with
oxLDL.
1.2 Macrophages, oxLDL and 7,8-NP in atherosclerosis
Atherosclerosis is characterised by the hardening, occlusion and vascular modifica-
tion of the arterial wall as a result of lipid deposition, immune cell recruitment and
cellular death (Ross, 1999). The development of atherosclerotic lesions (also known
as plaques) is thought to involve lipid deposition below the arterial endothelium and
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the recruitment of inflammatory cells such as macrophages (Hansson & Hermansson,
2011; Libby, 2002; Packard & Libby, 2008; Ross, 1999).
Macrophage
Macrophage infiltration has been shown to contribute to all stages of atherosclerotic
lesion development, from the early arterial wall thickening (Nakashima et al., 2008)
to the extensively remodelled, rupture-prone advanced plaque (Shaikh et al., 2012).
Moreover, mouse models with deficient monocyte-macrophage attracting mechanisms
display significantly reduced lipid deposition in the arterial wall (Gu et al., 1998; Pot-
teaux et al., 2011; Smith et al., 1995). Many histological studies also report that
macrophage markers co-stain with the lipid-rich areas of the plaque core, suggesting
a relationship between the two (Ball et al., 1995; Shaikh et al., 2012).
Macrophages are involved in both innate and adaptive immunity and ensure an ade-
quate response to stimuli in host defence (Fox & Rossi, 2010). This response includes
the clearance of pathogens, damaged host cells and large molecules, as well as the pro-
duction of molecules that are used in host defence (Fox & Rossi, 2010). Macrophage
activation and the associated oxidative stress are common to a large number of chronic
diseases, in addition to atherosclerosis. These include rheumatoid arthritis, inflam-
matory bowel disease, multiple sclerosis and obesity (Boyle, 2005; Fox & Rossi, 2010;
Haider et al., 2011; Nathan, 2008; Weisberg, 2003). Therefore, although this thesis
focuses on macrophage cell death in response to oxLDL as implicated in atheroscle-
rosis (Moore & Tabas, 2011), parts of this work could be applied to a wider range of
inflammatory conditions.
Oxidised LDL
The lipoprotein pool is an important source of lipids in the circulation and within
the atherosclerotic plaques. Low density lipoprotein, in particular, has been linked
to atherosclerosis (Lusis, 2000; Steinberg & Witztum, 2010). The majority of mouse
models of this disease are based on the apolipoprotein E and/or LDL-receptor de-
ficient genetic background, suggesting a direct link between low density lipoprotein
homeostasis and atherosclerosis (reviewed in Jawien´ et al. (2004)). LDL can undergo
oxidative modification which renders it cytotoxic to the cells in the vasculature, in-
cluding macrophages. The resulting oxLDL is a pro-inflammatory stimulus that in-
duces the proliferation and spreading of macrophages and triggers oxidative stress
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(Berliner & Heinecke, 1996; Glass & Witztum, 2001). OxLDL had been shown to con-
tribute to macrophage death in vitro and was suggested to do so within atherosclerotic
plaque (Ball et al., 1995; Li et al., 1998; Reid & Mitchinson, 1993).
7,8-Dihydroneopterin
7,8-Dihydroneopterin (7,8-NP) is associated with the process of atherosclerosis due
to its origin within the activated human macrophage (Huber et al., 1984). Both 7,8-
NP and its oxidation product neopterin have been detected in atherosclerotic plaques
(Gieseg et al., 2008) and appear to be associated with acute CVD events (Ray et al.,
2007; Weiss et al., 1994). A recent meta-analysis by Sugioka et al. (2010) suggested
that neopterin is an important biomarker of plaque instability in both coronary and
carotid atherosclerotic lesions. The role of 7,8-NP in atherosclerosis may be related
to its macrophage origin and antioxidant properties. In vitro, 7,8-NP has been shown
to interfere with LDL oxidation (Firth et al., 2008a; Gieseg et al., 1995; Greilberger
et al., 2004), ROS-mediated reactions (Da´ntola et al., 2008a; Oettl et al., 1997, 2004a)
and cellular death induced by free radical species and oxLDL (Baird et al., 2005;
Duggan et al., 2002). Therefore, 7,8-NP may mediate significant protection against
inflammatory oxidative stress and thus protect macrophages trapped in the vicinity
of oxidised LDL inside the atherosclerotic plaque.
1.3 Atherosclerotic lesion development:
from onset to maturity
Atherosclerotic plaque classification
The atherosclerotic plaque development is a complicated process that can span a
lifetime of an individual. Six stages of atherosclerotic plaque progression have been
characterised according to lesion complexity (Ross, 1995). Type I and II plaques are
often found in adolescents. These plaques manifest as the initial thickening of an
arterial wall and a fatty streak, caused by the monocyte infiltration and the presence
of what is believed to be plasma–derived lipid in the intimal layer of the vascular wall
(fig. 1.1) (Ross, 1986; Stary et al., 1995; Steinberg et al., 1989). Continued expansion
of the lipid and cell–enriched region and cellular death in this area produce type III
lesions. These feature what appears as small extracellular pools of lipid on a histology
sample (Stary et al., 1995). The next stages of atherosclerosis are characterised by the
development of extensive lipid–rich area devoid of cells. This is located deep within
4
1.3 Atherosclerotic lesion development:
from onset to maturity
the intimal layer of the artery and is referred to as the “necrotic core” region (1.1). In
type IV lesions, the tissue that separates the “core” from the lumen is relatively thin,
whereas in type V plaques it constitutes a thick fibrous structure, known as the “cap”.
Mature type VI atherosclerotic lesions are referred to as atheromas and are often more
complex, containing regions of calcium deposits, ulceration and arteriogenesis with
signs of vascular remodelling (Ross, 1986; Stary et al., 1995; Steinberg et al., 1989).
Plaque initiation hypotheses
At least three hypotheses have been proposed to explain the events that lead up to the
formation of the arterial thickening and fatty streak (reviewed in Stocker & Keaney
(2004)). The early response-to-injury hypothesis was developed by Ross (1986). He
suggested that the perturbation of vascular homeostasis is the initial step in the dis-
ease (Ross, 1986). Endothelial injury frequently triggers compensating responses that
upset the vascular homeostasis. The causes associated with endothelial injury are:
non-laminar and oscillatory shear stress at the arterial bifurcation, local infection of
the vascular wall and myeloperoxidase activity associated with phagocytes (Malek
et al., 1999). The disturbed endothelium produces leukocyte adhesion molecules (in-
tercellular adhesion molecule-1 (ICAM-1), vascular cell adhesion molecule-1 (VCAM-
1)) (Khan & Sefton, 2010). It also loses the ability to vaso-regulate becoming more
permeable to atherogenic lipoproteins circulating in the blood (Malek et al., 1999).
The immune cells that are recruited to the site of injury release cytokines that pro-
mote and propagate the inflammatory response (Wick et al., 2004). Monocytes are
recruited to the arterial wall, being attracted by the cytokine stimuli. They then
differentiate into macrophages and take up the infiltrated low density lipoprotein,
forming lipid-laden cells (Lusis, 2000).
The response-to-retention hypothesis developed by Williams & Tabas (1998) sug-
gests that atherogenesis is initiated by lipoprotein retention inside the arterial wall.
The LDL aggregates in the intimal layer of the vascular wall and is taken up by the
recruited macrophages. These develop into the lipid-laden “foam” cells, named so
after their “foamy” appearance under the microscope.
The oxidative modification hypothesis also states that LDL traverses the sub-endothelial
space and is retained for longer than the usual period of time in the atherosclerosis-
prone sites (reviewed in Steinberg et al. (1989) and Stocker & Keaney (2004)). During
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Figure 1.1: Six stages of atherosclerotic coronary lesion formation: cross-
sectional drawing.
The progression of atherosclerosis is depicted from the earliest Type I and II stages
to the most advanced Type VI stage, culminating in plaque rupture and associated
thrombosis. Identical morphologies may be found in other lesion-prone parts of the
coronary and many other arteries. From (Stary et al., 1995).
this time it undergoes oxidative modification, which renders it a high-uptake molecule
for residing and recruited cells in the vascular wall, enhancing foam cell formation.
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The dual nature of atherosclerosis
Atherosclerosis is recognised for its binary nature, with both lipid imbalance and
chronic inflammation playing a part in the pathology (Libby, 2002).
It has long been considered a lipid storage disease due to multiple lines of evidence
(Ross, 1986; Stocker & Keaney, 2004). Firstly, LDL – one of the major lipid and
cholesterol carriers in the blood – constitutes both a risk factor and a mechanism of
atheroslerosis development (Lusis, 2000). An increased low to high density lipopro-
tein (LDL/HDL) ratio in the blood is indicative of potential for the development of
atherosclerotic complications (National Cholesterol Education Program NCEP Ex-
pert Panel on Detection & of High Blood Cholesterol in Adults Adult Treatment
Panel III, 2002). The modified LDL is pro-atherogenic and can directly contribute
to atherosclerotic plaque growth. It displays pro-inflammatory properties, inhibiting
macrophage migration (Park et al., 2009; Quinn et al., 1987) and inducing prolif-
eration (Gordon et al., 1990) of the cells found in the atherosclerotic plaque. It is
also toxic to a variety of cells, directly contributing to the growth of the plaque core
region (Salvayre et al., 2002). The second line of evidence is the success of the so
called “lipid-lowering” statin therapy in the primary and secondary prevention of
CVD complications in “at risk” populations (de Lorenzo et al., 2006; Edwards &
Moore, 2003; Taylor et al., 2011). The third line of evidence comes from animal mod-
els of atherosclerosis. Mouse and rabbit models, bred to study the disease, develop
atherosclerosis only when fed a high cholesterol diet (Dornas et al., 2010; Jawien´
et al., 2004; Nakashima et al., 1994). They also show a positive response to the lipid–
lowering therapies (Aikawa et al., 2002).
While being sensitive to lipid imbalance, the atherosclerotic plaques also present
features of a chronic inflammatory disease (Pearson et al., 2003; Wick et al., 2004).
Moreover, inflammatory cell infiltration is observed at all stages of atherosclerotic
plaque development, from fatty streak to advanced atheroma (Moore & Tabas, 2011;
Nakashima et al., 2008; Shaikh et al., 2012). Coincidentally, a large proportion of
biochemical markers used in the clinical diagnosis and prognosis of atherosclerosis
indicate immune system activation. An example of this is acute response C-reactive
protein
Advancement of the atherosclerotic lesion: macrophage cell death
While in the early fatty streaks the cellular component is primarily derived from
smooth muscle cells (SMCs), more advanced atherosclerotic plaques contain higher
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proportion of macrophage cells (Gown et al., 1986; Katsuda et al., 1992; Kockx et al.,
1998). As the plaque develops, undifferentiated monocytes infiltrate the lesion at-
tracted by a suite of cytokines produced by activated T cells and other cells (Ross,
1993). Monocytes are also attracted by oxLDL, as opposed to macrophages in which
migration is inhibited by the oxLDL (Quinn et al., 1987). Monocyte adhesion to the
vascular endothelium is facilitated by the cell adhesion molecules ICAM-1 and VCAM-
1, the expression of which is also induced by oxLDL (Amberger et al., 1997). Pen-
etrated monocytes differentiate into macrophages upon exposure to various growth
factors released by other cells within the plaque. Meanwhile, the continued accumu-
lation of modified LDL within the atherosclerotic lesion leads to an increased uptake
by the resident macrophages (professional phagocytes). This drives the “foam” cell
formation and culminates in cellular death (Stary et al., 1992; Steinberg, 2009). From
type III onwards, the plaques feature an extensive area of extracellular lipid, known
as the “necrotic core” region of an atherosclerotic plaque. This is believed to develop
through the cellular death processes within the plaque (Seimon & Tabas, 2009).
Many reviewers suggest that macrophage cell death induced by oxidised lipids is one
of the key drivers of atherosclerotic plaque advancement (Ball et al., 1995; Bjorkerud
& Bjorkerud, 1996b; Boyle, 2005). This hypothesis is based on the following ob-
servations. Firstly, there is strong evidence that atherosclerotic lesions, in both hu-
mans and rabbits, contain oxidatively modified LDL constituents (Li et al., 2006;
Waddington et al., 2003; Yla¨-Herttuala et al., 1989). Secondly, the oxidised lipid–rich
regions on histological samples of advanced atherosclerotic plaques co-localise with
the macrophage cell epitopes (Ball et al., 1995; Waldo et al., 2008). Thirdly, these
regions are also characterised by extensive cellular death (Hegyi et al., 1996; Isner
et al., 1995; Kockx et al., 1998; Martinet et al., 2011). The combined evidence points
towards oxLDL–mediated macrophage cell death as a distinctive feature of the ad-
vanced atherosclerotic plaque. Indeed, this hypothesis is supported by the numerous
in vitro studies showing oxLDL cytotoxicity to macrophages (Asmis & Wintergerst,
1998; Gieseg et al., 2010a; Hardwick et al., 1996; Wintergerst et al., 2000).
1.3.1 Oxidative modification of LDL in vivo and in vitro
Lesion–modified LDL and in vitro oxidised LDL share many physical and chemical
properties, which are significantly different from the plasma LDL. These include: in-
creased negative charge resulting in higher electrophoretic mobility; increased density;
8
1.3 Atherosclerotic lesion development:
from onset to maturity
increased free cholesterol content; altered phospholipid fraction; and an increased pro-
portion of oxidised lipids (Yla¨-Herttuala et al., 1989). Most lipid oxidation markers
observed in atherosclerotic plaques are common to in vitro produced oxLDL. Oxys-
terols (advanced products of cholesterol oxidation) and thiobarbituric acid reactive
substances (TBARS) (a product of polyunsaturated fatty acid (PUFA) oxidation)
have been found within atherosclerotic lesions and on Cu-oxLDL (Brown et al., 1997;
Carpenter et al., 1995; Waddington et al., 2003). Numerous products of protein ox-
idation such as carbonyls, protein-bound L-3,4-dihydroxyphenylalanine (DOPA), di-
tyrosine and chloramines, some of which are common to both Cu- and HOCl-oxLDL
were also detected in atherosclerotic plaques (Fu et al., 1998).
The biological properties were also similar. For example, the lesion LDL was inter-
nalised through the scavenger receptors; it produced a greater stimulation of choles-
terol esterification, and was degraded more rapidly by macrophages (Yla¨-Herttuala
et al., 1989). When added to murine cell line and human cultured macrophages,
plaque gruel was phagocytosed, followed by progressive cellular death (Li et al.,
2006). Another group demonstrated that the gruel induced peroxidation in micro-
somes (Smith et al., 1992). Atheromatous ceroid, an insoluble polymer of oxidised
lipid and protein that contains abundant carbonyls/aldehydes, was found to be even
more cytotoxic than oxLDL (Li et al., 2006).
The exact nature of the LDL modification has been difficult to identify. To reproduce
some of the natural heterogeneity, multiple in vitro oxidation mechanisms have been
tested and characterised (Aviram et al., 1996; Berliner & Heinecke, 1996; Ju¨rgens
et al., 1987). Furthermore, non-oxidative modifications of LDL such as aggregation,
acetylation, glycosylation and immunocomplexing, have also been extensively used in
research (Al Gadban et al., 2010; Levitan et al., 2010). It is likely that in vivo, re-
searchers are presented with a heterogeneous population of oxLDL molecules oxidised
to various degrees and displaying various types of oxidative modifications. This work
focuses on the so-called “heavily” oxidised LDL, produced by the Cu2+–mediated
oxidation of LDL at 37 ◦C for 24 hours. Such oxLDL is rich in TBARS and oxys-
terols (Gerry et al., 2008). Since these markers of lipid and cholesterol oxidation had
been detected in plaques and plaque gruel, the assumption that heavily oxidised LDL
resembles its in vivo counterpart is supported by experimental evidence (Carpenter
et al., 1995; Gerry et al., 2008; Shchepetkina, 2008).
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Copper-mediated oxidation is often used to generate a high uptake oxLDL in vitro.
This reasonably well–controlled, well–characterised and replicable system yields oxLDL
with extensive fragmentation of apoB-100 (protein moiety on LDL) and the formation
of large quantities of oxysterols and some protein hydroperoxides (Esterbauer et al.,
1990). Extensive peroxidation of polyunsaturated fatty acids and decomposition of
lipid hydroperoxides into aldehyde fragmentation products is also observed (Gieseg &
Esterbauer, 1994). This study used an adaptation of the method developed by Gerry
et al. (2008).
1.4 Macrophage and oxLDL: recognition and in-
teraction
Early studies of endothelial cells co-incubated with LDL indicated that it could be
oxidatively modified in the presence of cells (Henriksen et al., 1979; Hessler et al.,
1979). The oxidative modification of the LDL molecule facilitated the formation of
macrophage “foam” cells (Henriksen et al., 1983) with subsequent cell death. These
observations led to the development of the oxidative hypothesis of atherosclerosis.
The theory was founded partly on the fact that cultured monocytes/macrophages
internalise oxLDL much more rapidly than native LDL (Ho et al., 1976). Specific
receptors on macrophages (and other vascular wall cells: SMC and, to an extent, en-
dothelial cell (EC)) bind oxLDL with high affinity (Boullier et al., 2001). These are
not down-regulated by the increasing intracellular cholesterol levels and thus allow
cholesteryl ester accumulation to the point of foam cell formation (Ho et al., 1976).
Effectively, oxLDL contents (oxidised apoB-100 and oxidised phospholipids) are the
structural features recognised by the immune system as foreign ligands (Steinberg,
2009).
The second part of the oxidative hypothesis of atherosclerosis rests on the fact that
oxLDL elicits a detrimental effect on cellular viability. This is believed to be me-
diated via multiple oxidised moieties on oxLDL. Attempts have been made to link
oxysterols, ox-phospholipids and oxidised protein with the cytotoxicity exerted by the
oxLDL molecule (Larsson et al., 2006; Salvayre et al., 2002). The majority of these
studies, however, have investigated only the effect of a specific ligand in isolation,
upon direct binding or internalisation by the cell. This approach is problematic as a
toxic component incorporated within another ligand (for example, an oxysterol within
the oxLDL particle) will interact with the cell differently from how an oxysterol added
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directly to the cell medium will. This concept was illustrated by Rutherford & Gieseg
(2012) who showed that the incorporation of 7-ketocholesterol (7KC) into acetylated
LDL particles completely aborted its cytotoxicity. Thus, many of the aforementioned
studies may be of little relevance until our understanding of the intracellular traffick-
ing of the complex oxLDL molecule is increased to a point where we can state in what
form these individual moieties are indeed present within the cell, and exert a specific
function. This work will, therefore, focus on the holistic effect of the oxLDL and the
resulting cellular response.
The following sections will outline the mechanisms of macrophage cell death in re-
sponse to oxLDL by giving a brief overview of the recognition, binding, uptake, pro-
cessing and cellular response to oxidised LDL. Special attention will be paid to the
redox processes within the macrophage.
1.4.1 Role of scavenger receptors in atherosclerosis
OxLDL is initially recognised by macrophage scavenger receptors (SRs), a family of
cellular transmembrane proteins that are implicated in the recognition and clearance
of foreign bodies and apoptotic cells (Ashraf & Gupta, 2011). A number of SR classes
with a large sequence variation have been identified to date (Ashraf & Gupta, 2011).
Only a select few of those, however, have been shown to contribute significantly to
oxLDL uptake by macrophages (reviewed in Moore (2006)). The most abundant
evidence exists for the following receptors: class A scavenger receptor A (SR-A) (Ko-
dama et al., 1988), class B scavenger receptors SR-BI and CD36 (de Villiers & Smart,
1999; Endemann et al., 1993), class D scavenger receptor CD68 (which has been impli-
cated in endosomal utilisation of oxLDL and acLDL (Ramprasad et al., 1996; Zeibig
et al., 2011) and class E scavenger receptor, lectin-like oxidised low–density lipopro-
tein receptor-1 (LOX-1) (Boullier et al., 2001; Yoshida et al., 1998). In addition, some
of the toll-like receptors (TLRs), a family of pattern recognition receptors implicated
in host defense against bacterial pathogens, were recently shown to facilitate lipid
uptake and foam cell formation (Keyel et al., 2012; Miller et al., 2009).
While the relative contribution of each of the aforementioned receptors to oxLDL
uptake by macrophage in vivo is unknown, experimental evidence supports an im-
portant role for both SR-A and CD36 in the pathogenesis of atherosclerosis (Boullier
et al., 2001). Specifically, mice deficient in SR-A or CD36 on a pro-atherosclerotic
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background (apolipoprotein E deficiency coupled with a so-called Western diet) ex-
hibit a significant reduction in atherosclerotic lesion development (Febbraio et al.,
2000; Suzuki et al., 1997). The monocytes/macrophages derived from these murine
models displayed a significantly decreased uptake of oxLDL. Another mouse model
deficient in both SR-A and CD36 showed a 70 to 90% decrease in the uptake of
oxLDL (Kunjathoor et al., 2002). In contrast, the effect of combined CD36 and SR-A
knockout on the atherosclerotic lesion area in mice in the Kuchibhotla et al. (2008)
study was not additive. Yet another study had observed no reduction of the lesion or
“foam” cell formation in a similar CD36– SRA– mice but the lesions did not progress
to an advanced state (Manning-Tobin et al., 2008). Thus, while the involvement of
SR-A and CD36 scavenger receptors in the pathogenesis of atherosclerosis is undis-
puted, it is likely to be multi-factorial.
Evidence from the previous studies for SR-A–specific contribution to the develop-
ment of atherosclerotic lesions in animals or oxLDL uptake in vitro is not in absolute
agreement. Kuchibhotla et al. (2008) did not detect any significant difference in
the size of atherosclerotic lesion in SR-A–null male mice, while a CD36-null back-
ground was protective irrespective of gender. Terpstra et al. (1997) showed that the
macrophages of SR-A knockout mice internalised significantly less acetylated LDL
(acLDL) than the wild type, but the trend was much less marked for oxLDL uptake.
The degree of and conditions for SR-A involvement in macrophage cell death are also
unclear. While some authors have reported a necessary SR-A engagement in the ini-
tiation of apoptosis (DeVries-Seimon et al., 2005), others showed that although the
SR-A route accounted for half of the oxLDL uptake, this receptor was not involved in
oxLDL–mediated apoptosis of HMDM cells (Wintergerst et al., 2000). Based on this
evidence, a number of reviewers have suggested that SR-A–mediated uptake may be
more important for the acetylated/aggregated LDL than oxidised LDL (de Villiers &
Smart, 1999; Gough et al., 1999).
1.4.2 The role of CD36 in oxLDL uptake by macrophages
The evidence for CD36 involvement in atherosclerotic plaque development is more
substantial and extensive than that of the SR-A, potentially due to its ubiquity
of expression (Febbraio et al., 2001). While the expression of SR-A is restricted
to macrophages, CD36 is also expressed in adipocytes, microvascular endothelium,
platelets, erythroid precursors, and smooth muscle cells, where it facilitates oxLDL
uptake (Moore, 2006; Ricciarelli et al., 2000). CD36 plays a role in platelet adhesion
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(Asch et al., 1987), fatty acid transport in adipose tissue (Abumrad et al., 1998) and
the clearance of apoptotic cells by macrophages (Ren et al., 1995; Rigotti et al., 1995).
In addition, a soluble form of the CD36 receptor with a role in metabolic syndrome
and atherosclerosis has recently been identified (Handberg et al., 2006; Koonen et al.,
2011).
Binding
CD36 is an 88 kDa glycoprotein which traverses the membrane twice, and comprises
a heavily glycosylated extracellular loop with 2 short intracellular tails. The extra-
cellular portion of the protein contains motifs that are able to recognise and bind
oxidised moieties on oxLDL. Specifically, suggestions have been made that it recog-
nises oxidised lysine residues on the apo B-100 and oxidised phospholipids in the lipid
fraction (Bird et al., 1999; Boullier et al., 2001; Silverstein et al., 2010; Steinbrecher,
1999). Interestingly, CD36 binding of apoptotic bodies has also been proposed to pro-
ceed through the binding of modified cellular phospholipid membrane (Boullier et al.,
2001). It is known that monocytes almost lack CD36 (and a number of other recep-
tors) and that CD36 expression is enhanced upon the maturation into macrophages
(Alessio et al., 1996; Nakagawa et al., 1998).
In atherosclerosis, CD36 has been proposed to contribute to the development of lesions
through the pro-atherogenic and pro-inflammatory properties of CD36–mediated macrophage–
oxLDL interaction (reviewed in Moore (2006); Silverstein et al. (2010); Steinbrecher
(1999)). OxLDL binding to CD36 activates the cells to produce and release pro-
inflammatory cytokines and ROS (Boyle, 2005). The signalling pathways have been
extensively reviewed in Silverstein et al. (2010), but, briefly, CD36 can associate with
Src kinases (Lyn, Fyn) and MAP-kinase kinase family member MEKK2 via its intra-
cellular “tail” domains. Src kinase activation leads to phosphorylation of mitogen–
activated protein kinase (MAPK) family members p38 and c-Jun-N-terminal kinase
(JNK). The effect of this activation may be cellular death, inflammatory gene expres-
sion, adhesion, and migration. The latter modulates cytoskeletal dynamics which
leads to trapping of macrophages in plaques (Park et al., 2009).
Regulation of CD36 expression
Receptor–facilitated uptake of oxidised LDL is not regulated by the same mechanism
as that of native LDL, where the LDL-receptor is feedback down-regulated by the
intracellular cholesterol content (Heinecke et al., 1993; Hoff & O’Neil, 1988; Steinberg
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& Witztum, 2010). In contrast, the ligand(s) that bind(s) to the CD36 have been
demonstrated to up-regulate this receptor. Acetylated LDL, and oxidised LDL cause
an increase in the levels of CD36 mRNA and protein in monocytes, macrophages,
macrophage-like cells and SMCs (Han et al., 1997; Munteanu et al., 2006; Naka-
gawa et al., 1998; Ricciarelli et al., 2000). The regulatory mechanism proceeds via
the nuclear hormone receptor peroxisome proliferator activator receptor-γ (PPAR-γ),
which, once activated by a lipid-like ligand, drives the transcriptional activation of
CD36 expression (Munteanu et al., 2006; Tontonoz et al., 1998). Cholesteryl ester
hydroperoxides on oxLDL have been proposed to drive this activation (Jedidi et al.,
2006). In addition, little evidence exists with respect to the feedback regulation of
the uptake by the processes and/or products governing the oxLDL internalisation or
breakdown.
OxLDL uptake and processing
The intracellular processes that control the internalisation and trafficking of oxLDL
components are fairly well understood. It is thought that the receptors congregate
in coated pits/lipid rafts of plasma membrane, called caveolae (Patel & Insel, 2009).
Upon oxLDL binding to receptors, the plasma membrane in such regions is pulled
inward to form a vesicle that encapsulates oxLDL (Collins et al., 2009). This vesi-
cle merges with the endosome and lysosome where the oxLDL is then targeted for
degradation and/or esterification (Jerome & Yancey, 2003; Wang et al., 2005). Nor-
mally, the intracellular concentration of unmodified LDL cholesterol is maintained
via the mechanism presented in fig. 1.2 . Cholesteryl esters within the LDL particle
are hydrolysed either by acidic cholesteryl ester hydrolase in the endosome (Wang
et al., 2005) or lysosomal acid cholesterol esterase (LACE) in the lysosome (Jerome
& Yancey, 2003), which seem to be the same enzyme EC 3.1.1.13 (Sando & Rosen-
baum, 1985). Free cholesterol is trafficked out of the lysosome for membrane syn-
thesis or efflux. Any excess free cholesterol is directed to the endoplasmic reticulum
where it is re-esterified by the enzyme acyl coenzymeA: cholesterol acyltransferase
(ACAT). The esterified cholesterol is stored in the cytoplasmic inclusions and can be
hydrolysed when necessary by a neutral cholesterol esterase (Jerome & Yancey, 2003;
Sekiya et al., 2011; Yvan-Charvet et al., 2010). Cholesterol efflux onto high-density
lipoprotein (HDL) apo-A1 is facilitated via adenosine triphosphate (ATP)–binding
cassette transporters ATP binding cassette A1 (ABCA1) and ATP binding cassette
G1 (ABCG1) (Yvan-Charvet et al., 2010). SR-BI receptor has also been shown to
mediate cholesterol efflux (Chroni et al., 2005). LDL modification, however, have
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been shown to reduce the rate of its degradation and efflux from the macrophage
(Hoff et al., 1993). In addition, certain oxysterols (7KC) have been shown to in-
hibit the action of cholesterol transporters (Jessup & Kritharides, 2000; Jessup et al.,
2002). Thus, not only is oxLDL taken up in higher amount than LDL, but its efflux
is reduced, facilitating the formation of lipid-rich foam cells.
Figure 1.2: Cholesteryl ester metabolism in cells.
Intracellular cholesterol processing mechanism (from Jerome & Yancey (2003))
Cholesteryl esters within the LDL particle are hydrolysed by LACE and free choles-
terol is trafficked out of the lysosome for membrane synthesis or efflux. Any excess
free cholesterol is directed to the endoplasmic reticulum where it is re-esterified by the
enzyme ACAT. The esterified cholesterol is stored in the cytoplasmic inclusions and can
be hydrolysed when necessary by a neutral cholesterol esterase (Jerome & Yancey, 2003;
Sekiya et al., 2011; Yvan-Charvet et al., 2010). Cholesterol efflux onto HDL Apo-A1 is
facilitated via ATP–binding cassette transporters ABCA1 and ABCG1.
CD36 and macrophage cell death
It is highly probable that CD36–facilitated uptake, processing and accumulation of
oxLDL is controlled by multiple cellular processes, because the results of CD36 bind-
ing or signaling inhibition studies vary significantly. While Rahaman et al. (2006)
observed a 70-80% inhibition of foam cell formation in macrophages of CD36–null
mice, Nozaki et al. (1995) reported up to 40% inhibition of oxLDL uptake in the
CD36-null human macrophages and Wintergerst et al. (2000) saw no effect of CD36
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ligand inhibition on oxLDL uptake by macrophages. In contrast to uptake, the evi-
dence for CD36 involvement in oxLDL–induced cellular death is more discreet. For
example, sequestration of CD36 with an antibody blocked ROS production and cell
death in SMCs and macrophages (Higashi et al., 2005; Park et al., 2009; Winterg-
erst et al., 2000). This has been further confirmed by Wintergerst et al. (2000) who
observed that CD36-negative macrophage cells did not undergo apoptosis.
1.5 Macrophage cell death processes mediated by
oxLDL
High concentrations of oxLDL exhibit a cytotoxic effect on macrophages, endothe-
lial and smooth muscle cells in vitro. This suggests that oxLDL may promote the
formation of atherosclerotic plaques by inducing damage to the arterial tissue (Galle
et al., 2006; Hsieh et al., 2001; Wintergerst et al., 2000). Macrophage cell death in
response to oxLDL is central to the growth of the plaque necrotic core. Hence, the
mechanisms of oxLDL–induced macrophage cell death in vivo and in vitro have been
the subject of extensive research since the end of 1970’s. The signaling cascades and
intracellular processes that lead to cell death are diverse, but a few common features
can be identified.
1.5.1 Types of cell death
The complexity of the cellular response to oxLDL makes it difficult to ascribe a partic-
ular pathway to the process of cell viability loss. The two widely recognised types of
cellular death, apoptosis and necrosis, have both been implicated in oxLDL–induced
macrophage cell death (Boullier et al., 2001; Martinet et al., 2011). Apoptosis is
the physiological process (that can become pathological) of programmed cellular self-
destruction (Edinger & Thompson, 2004; Krysko et al., 2008). The process involves a
tightly controlled series of events, the execution of which is powered by ATP (Edinger
& Thompson, 2004; Krysko et al., 2008) (for a non-oxLDL related review of apop-
tosis: Ashkenazi & Dixit (1998)). Conversely, necrosis is a pathological process of
unrestrained cell death, which has been described as a “bioenergetic catastrophe”
(Edinger & Thompson, 2004). Necrotic death results in a pro-inflammatory response
from the surrounding cells . The key features of the two pathways are presented
in the table 1.1 (Salvayre et al., 2002). The main distinguishing property between
the two is the availability of cellular energy in the form of ATP and nicotinamide
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adenine dinucleotide phosphate (NADPH) (Edinger & Thompson, 2004; Skulachev,
2006). The features of cell death pathways are of particular interest since they are
often employed in the cell death detection assays.
Apoptosis proceeds if the apoptotic machinery is in place and could be activated,
Table 1.1: Morphological features of cells undergoing apoptosis and necrosis
from Salvayre et al. (2002) and Fiers et al. (1999).
Apoptosis Necrosis
Cell volume decreased increased
Cytoplasmic appearance electron densea normala
Plasma membrane integrity intact defective
trypan blue permeability non-permeantb permeantb
propidium permeability non-permeantc permeantc
morphology blebbinga,b
phosphatidyl serine exposure yes no/sometimes
Mitochondrial appearance densificationa swelling, rupturea
Nuclear morphology fragmentedb normalb
chromatin appearance condenseda loosea
nuclear membrane presence absenta presenta
Cell fragmentation apoptotic bodiesa,b debrisa,b
Caspase activation yes/sometimes no
Cytochrome c release yes no
aElectron microscopy bOptical microscopy cFluorescence microscopy
i.e. the energy (ATP and NADPH) is sufficient to ensure that the damaged cell is
packaged and removed cleanly (Skulachev, 2006). If, on the other hand, the apop-
totic processes fail to activate and/or the cellular energy is insufficient to complete
the apoptotic liquidation, the cell undergoes “secondary” necrosis. This can happen
in the circumstances of excessive intracellular damage or damage to key metabolic
enzymes (Katouah, 2012).
The two best described alternative cell death pathways are “programmed necrosis”
and autophagy (Edinger & Thompson, 2004). The concept of programmed necro-
sis is sometimes considered a separate cell death mechanism (Han et al., 2011). It
manifests as a necrosis–like cell death pathway but is triggered by a set of signaling
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cues. However, because the net result of the “necrotic” signaling is also ATP de-
pletion, it is incorporated into the aforementioned definition of necrosis (Han et al.,
2011). Autophagy has been described as a self-sacrificing mechanism with the cell
degrading its own constituents for energy production under nutrient stress conditions
or as a suicide (Edinger & Thompson, 2004; Mihalache & Simon, 2012). It had been
associated with oxLDL-induced endoplasmic reticulum stress and lysosomal oxLDL
degradation, a more chronic type of cellular death (as discussed below) (Muller et al.,
2010; Ouimet et al., 2011). In fact, all of these cellular death processes have been
named in association with oxLDL-induced cellular death and atherosclerosis (Boullier
et al., 2001; De Meyer & Martinet, 2009; Martinet et al., 2011; Verheye et al., 2007).
1.5.2 OxLDL–mediated cellular death in the literature
In vitro, the cytotoxicity of oxLDL can be measured experimentally by the loss
of various cell viability markers, including: 3-[4,5-dimethylthiazol-2-yl]-2,5-diphenyl-
tetrazolium bromide (MTT) reduction (Gieseg et al., 2009); trypan blue exclusion
(Baird et al., 2005); the release of lactate dehydrogenase (Carpenter et al., 2003); ra-
dioactive adenine (Wang et al., 2006); or detection of the classical apoptosis/necrosis
features like DNA fragmentation (propidium iodide (PI) binding) and phosphatidyl
serine (PS) exposure (Annexin V binding) (Muller et al., 2001). Some of these mark-
ers have been observed within complex plaques (Bjorkerud & Bjorkerud, 1996b; Isner
et al., 1995; Kockx et al., 1998). The reported cytotoxicity of oxLDL in vitro varies
considerably between different laboratories. The experimental protocols are very di-
verse with respect to the range of oxLDL concentrations (25 to 3000 µg per mL LDL)
and incubation times (4-48 hours), as well as the measured cytotoxicity outcomes
(Asmis et al., 2005; Gieseg et al., 2009; Kinscherf et al., 1998). The cytotoxicity out-
come may depend on the oxLDL preparation, type of cells, or possibly, experimental
conditions. This topic will be addressed in more detail in Chapter 3.
The type of cellular death (apoptosis vs. necrosis) in response to oxLDL may also be
subject to inter-cellular variations, as highlighted by a comparative study of THP-1
and U937 monocyte-like cell lines (Baird et al., 2004). Baird et al. (2004) found that
THP-1 underwent a caspase–mediated apoptosis characterised by a relatively slow
loss of intracellular glutathione, whereas U937 cells displayed no caspase activation
combined with rapid glutathione (GSH) loss and lack of phosphatidyl serine (PS)
externalisation characteristic of necrosis. In HMDM cells, both caspase–dependent
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(Wintergerst et al., 2000) and independent cell death have been reported (Asmis & Be-
gley, 2003; Gieseg et al., 2010a). With the current experimental setting in the Gieseg
laboratory, HMDM cells were observed to undergo caspase-3 independent necrosis
and a rapid loss of glutathione (Gieseg et al., 2010a).
1.6 Oxidative stress in macrophage–oxLDL
The key feature of oxLDL cytotoxicity to all cell types is the generation of intracellu-
lar ROS. In a large proportion of cell types, the production of ROS plays a significant
role in the cellular death process. Oxidative stress, or the prevalence of ROS pro-
duction over the cellular antioxidant defence, can originate from multiple sources in
oxLDL-treated macrophages: phagocytic NADPH oxidase (NOX), mitochondrial and
lysosomal destabilisation and endoplasmic reticulum stress (Moore & Tabas, 2011).
The key role of oxLDL–induced ROS production in atherosclerotic cell death is sup-
ported by the studies of compounds with a free radical-neutralising ability. Probucol,
probucol analogs and vitamin E have been shown to inhibit cell death in vitro and
the progression of atherosclerosis in the animal models, thus suggesting that ROS is
important to the disease pathology (Steinberg, 2009). A water soluble antioxidant
7,8-NP was also shown to inhibit cellular death in U937 cells from a variety of sources
of oxidative stress, including oxLDL (Baird et al., 2005; Gieseg et al., 2001b).
1.6.1 Reactive oxygen species
Reactive oxygen species are involved in both signaling and oxidative stress, and thus
have the capacity to be both beneficial and detrimental to cells (Carmody & Cot-
ter, 2001). The biological effects of ROS range from cell activation to proliferation,
survival to apoptosis. These are mediated by multiple signaling pathways, includ-
ing MAPK kinases, Akt, nuclear factor kappa B (NF-κB), caspases and calcium
(Carmody & Cotter, 2001; Dro¨ge, 2001). OxLDL has been shown to induce intra-
cellular ROS production in all vascular cell types examined (Salvayre et al., 2002).
The role of ROS in oxLDL-mediated cytotoxicity has been reported to proceed both
through the activation of the caspase cascade, causing apoptosis (Baird et al., 2004);
and without caspase-3 activation through oxidative inactivation of metabolic enzyme,
glyceradehyde-3-phosphate dehydrogenase (GAPDH) causing necrosis (Gieseg et al.,
2010a).
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A large proportion of oxidative damage in biological systems is done via free rad-
icals. Free radical is a reactive chemical species that contains one or more unpaired
electrons and is capable of independent existence (Stocker & Keaney, 2004). Free
radicals can be extremely damaging to biological molecules due to their ability to ini-
tiate a self-propagating chain reaction, where for each initial radical many more are
generated (Buettner, 1993; Halliwell & Whiteman, 2004). Of the four different types
of free radical species: oxygen, nitrogen, carbon and sulphur–centered free radicals,
oxygen–centered radicals (ROS) are the most abundant during the cellular response to
oxLDL (Dro¨ge, 2001; Valko et al., 2007). Superoxide anion radical (O2
•–) is the main
source of ROS in the cell (Dro¨ge, 2001; Valko et al., 2007). It serves as a precursor to
a range of other ROS (fig. 1.3) (Buettner, 1993; Stocker & Keaney, 2004). The O2
•–
gives rise to hydrogen peroxide (H2O2), hydroxyl radical (HO
•–) and hypochlorus acid
(HOCl) as well as participating in the formation of reactive nitrogen intermediates
(Beckman & Koppenol, 1996; Dro¨ge, 2001; Valko et al., 2007). Hydroxyl radicals
are highly reactive but short-lived, attacking a wide range of molecules in the im-
mediate vicinity of the site of origin (Buettner, 1993). This type of free radical can
be formed from O2
•– and H2O2 via the Haber-Weiss reaction or via the Fenton in-
teraction of H2O2 with copper or iron ions (Kehrer, 2000; Morel & Barouki, 1999).
These reactions are biologically significant as the substrates can be found within cells
and tissues and can easily interact. H2O2 can also serve as substrate for myeloper-
oxidase (MPO) enzyme thus leading to the formation of hypochlorous acid, which
had been implicated in many pathophysiological conditions, including atherosclerosis
(Klebanoff, 2005; Podrez et al., 2000).
1.6.2 Macrophage NADPH oxidase
Macrophage phagocytic NADPH oxidase (NOX) is one of the main immediate sources
of superoxide radicals upon cellular activation by a ligand, such as oxLDL (Bedard
& Krause, 2007). The NADPH oxidase complex exists as a cluster of membrane-
bound subunits and associated cytoplasmic soluble subunits that donate an electron
from NADPH to molecular oxygen (O2) which produces superoxide (O2
•–) (Bedard
& Krause, 2007). Superoxide can then be enzymatically dismutated into H2O2 by su-
peroxide dismutases and further to or HO•– by Fenton reaction (Mate´s et al., 1999).
This initiates a respiratory burst which is a key step in the immune defence against
bacterial and fungal pathogens (Bedard & Krause, 2007) and, it seems, during the
oxLDL binding (Park et al., 2009).
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Figure 1.3: Reactive oxygen species.
Molecular oxygen undergoes successive reductions which yield the superoxide radical
anion (O2
•–), hydrogen peroxide (H2O2), hypochlorite (HOCl) and hydroxyl radical
(HO•–). Antioxidant systems act as ROS scavengers to maintain the intracellular redox
status.SODs dismutate superoxide into oxygen and hydrogen peroxide and catalase
neutralises hydrogen peroxide into oxygen and water. Glutathione peroxidase (GPx)
acts like catalase on various peroxide compounds, including H2O2. The catalytic cycle
of glutathione peroxidase involves the oxidation of GSH. GSSG can be reduced back to
GSH by glutathione reductase. Adapted from Mate´s et al. (1999)
In its resting state the NADPH complex consists of the cytosolic and plasma membrane–
integrated components (fig. 1.4). The membrane-bound gp91phox (primary active
component) and p22phox are collectively referred to as cytochrome b558 (Groemping
& Rittinger, 2005). The smaller p22phox protein has an SH3 binding domain, sug-
gesting that it is a docking site for the soluble cytosolic components of NOX, p40phox,
p47phox and p67phox (Groemping & Rittinger, 2005).
A variety of stimuli may lead to the activation of NOX and superoxide production.
With respect to oxLDL binding, CD36 and TLR4 were identified to cause a NOX-
dependant oxidative flux (Bae et al., 2009; Park et al., 2009). Receptor activation
upon ligand binding initiates a cytosolic signaling cascade that culminates with the
release of Ca2+ from the ER and the activation of the protein kinase C (PKC) (Bedard
& Krause, 2007). PKC, in turn, phosphorylates p47phox which results in its translo-
cation and binding to the p22phox on the membrane. Other stimuli activate several
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Figure 1.4: NADPH oxidase components and activation.
The transmembrane portion of a phagocytic NADPH oxidase consists of p22phox and
gp91phox which constitute the smaller and larger chain of the cytochrome-b558, re-
spectively. The cytosolic part of the complex is comprised of two p67phox and p47phox
subunits, accessory protein p40phox and a Rac-GTP binding protein The cytosolic sub-
units translocate to the cell membrane upon cell activation to form the active NADPH
oxidase complex which generates superoxide radical. Adapted from Assari (2006).
other kinases (e.g. Akt, c-Src, MAPK) which can also phosphorylate p47phox (Bedard
& Krause, 2007). OxLDL has been proposed to activate NOX through CD36 binding
in SMCs as well (Sukhanov et al., 2006). In Sukhanov et al. (2006), ROS production
after oxLDL treatment caused the loss of the glycolytic enzyme glyceraldehyde-3-
phosphate dehydrogenase (GAPDH). This curbed the cellular ATP stores and led
to subsequent necrosis (Sukhanov et al., 2006). The loss of GAPDH was prevented
by various antioxidants and NADPH oxidase inhibitor. Anti-CD36 antibodies also
blocked ROS production and GAPDH loss suggesting that activation of NADPH
oxidase was triggered by oxLDL binding to CD36 (Sukhanov et al., 2006).
1.6.3 Mitochondrion
Mitochondrion is another source of ROS (Turrens, 2003). The uncoupling of the elec-
tron transport chain can occur as a result of mitochondrial damage or destabilisation.
It leads to the transfer of electrons onto molecular oxygen to yield the superoxide radi-
cal (Morel & Barouki, 1999). Under normal circumstances, this superoxide is quickly
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dismutated by a suite of antioxidant enzymes into hydrogen peroxide, followed by
water and hydrogen (Turrens, 2003). In contrast, under conditions of high oxida-
tive stress or redox imbalance, the ROS are not dismutated fully and can, therefore,
react with proteins and membranes, inflicting damage (Valko et al., 2007). This
damage can perpetuate further uncoupling of the electron transport chain, leading to
energy loss, release of cytochrome c into the cytoplasm and the formation of the mi-
tochondrial transition pore, which constitutes a part of apoptotic shut-down process
(Madamanchi & Runge, 2007).
The role of mitochondrion has been discussed in relation to oxLDL-induced cellular
death. Reports of both the involvement and relative redundancy of the mitochon-
drial ROS in macrophage death have been made (Amit, 2008; Asmis & Begley, 2003;
Ryan et al., 2003). Previous study in the Gieseg laboratory by Amit (2008) indi-
cated that during acute cellular death inflicted by the oxLDL damage, mitochondrial
involvement was minor (as shown by limited cytochrome c release into the cytosol).
Ryan et al. (2003) also showed that the ROS production from the mitochondria in
response to the oxLDL oxysterol 7-ketocholesterol was relatively modest, causing only
a small yet significant reduction in cellular glutathione. Asmis & Begley (2003), how-
ever, reported that oxLDL–mediated decrease in mitochondrial membrane potential
contributed to macrophage lysis.
1.6.4 ROS–mediated damage to cells
Gieseg et al. (2010b) proposed that in macrophage cells which express high levels of
NOX or NOX–activating receptor(s), oxLDL–induced ROS production and release
overtakes the slower mitochondrial destabilisation and caspase–dependent cell death.
It is likely that in phagocytic cells such as macrophages, the magnitude of oxidative
stress produced in response to the binding and internalisation of oxLDL is the distin-
guishing parameter between apoptotic and necrotic cell death. During high cellular
ROS production and/or reduced intracellular antioxidant defence (e.g. glutathione
or ascorbate), the cellular ATP-producing and apoptotic machineries will become ox-
idised (Gieseg et al., 2010a,b). This will result in a failure of apoptosis and lead to
secondary necrosis. The most prominent feature of this hypothesis is the magnitude
and rapidness of the oxidative stress. This model has been demonstrated experimen-
tally by Troyano et al. (2003), who showed that during intensified H2O2–mediated
oxidative stress, cell death by apoptosis was switched to necrosis.
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Associated with the magnitude of the oxidative stress is the timing of ROS release.
Presumably, a longer (chronic) time-frame due to a slower activation of cytotoxic
mechanisms would allow for a more controlled shut-down of the cellular processes
and liquidation of the cell via apoptosis. Importantly, during the conditions of slow
sub-toxic ROS release, cellular compensatory mechanisms, like the up-regulation of
GSH or superoxide dismutase (SOD) enzymes allow sufficient time for the antioxi-
dant capacity of the cell to increase and deactivate ROS (Sagara et al., 1998). It is
also possible that during the chronic oxLDL-induced cell death ROS does not play the
primary cytotoxic role and other responses like mitochondrial and lysosomal destabil-
isation, as well as ER stress, become the ultimate causes of cellular death. However,
in the conditions of acute toxicity, cellular antioxidant defense like GSH and other
dismutating enzymes become overwhelmed and damaged beyond repair, leading to
the oxidation of the key cellular enzymes and uncontrolled necrotic death.
1.6.5 Cellular defence against oxidative stress
Cellular antioxidant defence system plays a very important role in maintaining the
redox balance and combating oxidative stress. In macrophages these defences in-
clude antioxidant enzymes that catalyse the conversion of reactive species into benign
molecules (such as catalase, superoxide dismutase, superoxide reductase and perox-
idise enzymes) and low molecular weight molecules that scavenge oxidants (such as
GSH, ascorbate, α-tocopherol and urate) (Stocker & Keaney, 2004). Another defence
mechanism involves sequestration of pro-oxidants such as transition metal ions by
proteins (for example, transferrins, metalloproteins and albumin) and repair systems
that repair oxidised compounds or remove the damaged proteins (such as thioredoxin,
methionine sulphoxide reductase and ubiquitination) (Stocker & Keaney, 2004). GSH
in the cytoplasm plays an important role in the ROS–induced cellular death. Reduced
GSH/oxidised GSSG ratio is the primary redox sensor of the cell and an important
defense machanism against oxidant flux (Dro¨ge, 2001; Valko et al., 2007). This was
observed by Yang et al. (2012) in HMDM treated with HOCl, where the cellular
death followed the loss of GSH. The role of intracellular GSH in the oxLDL–mediated
macrophage death has also been well documented. The loss of cellular GSH through
various inhibitors or derivatising agents increased the cells’ sensitivity to oxLDL cyto-
toxicity while up-regulation of GSH had been shown to decrease toxicity (Bea, 2003;
Cho et al., 1999; Gotoh et al., 1993; Shen & Sevanian, 2001).
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1.7 7,8-Dihydroneopterin:
origins, biochemistry and role in atherosclerosis
1.6.5.1 Protective role of the extracellular environment
There is some evidence that the extracellular environment at atherosclerotic sites
plays a protective role against the oxLDL–induced cellular damage and death (Gieseg
et al., 2009). Human serum has been described as the source of a variety of ROS
scavenging molecules and enzymes (Stocker & Keaney, 2004). The small antioxidant
molecules in human serum like uric acid, GSH and bilirubin compete with the cellu-
lar protein for oxidising power of the released ROS and any other source of oxidative
stress. Serum albumin has been proposed as an antioxidant “sink” (Roche et al.,
2008). Serum HDL could contribute to the efflux of oxLDL from cells (Zanotti et al.,
2012) as well as having some direct antioxidant effect via an HDL-associated paraox-
onase enzyme (Graham et al., 1997). The composition of extracellular environment
in the atherosclerotic plaque is unclear. It is evident from the published studies that
the atherosclerotic plaques contain both oxidised and reduced forms of α-tocopherol
(α-TocH), ascorbate, albumin and other molecules (Carpenter et al., 1995; Gieseg
et al., 2009; Shchepetkina, 2008). Generally, the inclusion of serum into the incuba-
tion mix varies in the published reports (Asmis & Wintergerst, 1998; Harris et al.,
2006; Terasaka et al., 2007), which makes it difficult to compare the experimental
results. Although the standardisation of laboratory procedures is not a viable option
for a variety of reasons, consistent reporting of the methodology is necessary for a
successful comparison. This issue will be further discussed in chapter 6.
1.7 7,8-Dihydroneopterin:
origins, biochemistry and role in atherosclerosis
7,8-Dihydroneopterin is the product of the inflammatory activation of human macrophage
cells. As mentioned earlier, many studies have used 7,8-NP and, especially, its oxidised
counterpart neopterin, as markers of macrophage activation and oxidative stress in
chronic and acute inflammatory diseases (Berdowska & Zwirska-Korczala, 2001; Firth
et al., 2008b; Sucher et al., 2010). Due to the link between neopterin and atheroscle-
rotic plaque instability (Adachi et al., 2007), it is of both scientific and clinical interest
to unravel the mechanisms of 7,8-NP–mediated action during the macrophage–oxLDL
interaction in the context of CVD.
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1.7.1 7,8-NP production
7,8-dihydroneopterin is synthesised by the truncated biopterin pathway of primate
and human cells of myelocytic lineage, i.e. monocytes/macrophages, dendritic cells,
monocyte-like cell lines; and, to a lesser extent, fibroblasts, endothelial cells and kid-
ney cells (Andert et al., 1992; Henderson et al., 1991; Weiss et al., 1999; Werner
et al., 1989, 1991; Werner-Felmayer et al., 1990, 1993, 1995; Wirleitner et al., 2002).
Two enzymes are involved in the process, GTP cyclohydrolase-I (GCH-I) and a “non-
specific” phosphatase, the description of which probably reflects the ubiquity of the
performed reaction (Fuchs et al., 2009). In the first step of the 7,8-NP biosynthesis,
GCH-I converts guanosine-5’-triphosphate (GTP) into dihydroneopterin triphosphate
(fig. 1.5) (Walter et al., 2001).
During normal biopterin synthesis, the next step would be the elimination of inorganic
triphosphate by the enzyme 6-pyruvoyl-tetrahydropterin synthase (PTS), followed by
the processing into tetrahydrobiopterin by sepiapterin reductase (SR) (Walter et al.,
2001). Interestingly, this pathway is altered in human and primate cells of myelocytic
origin. These cells lack a PTS activity due to the alternative splicing of the PTS
mRNA (Leitner et al., 2003). Thus, in the absence of functional PTS protein, dihy-
droneopterin triphosphate accumulates and gives rise to 7,8-NP after a phosphatase-
mediated cleavage (Leitner et al., 2003). Neopterin is a product of 7,8-NP oxidation
and the reactions that yield neopterin will be discussed in the next section.
The major stimulant for 7,8-NP production is an inflammatory cytokine interferon-
γ (IFN-γ). IFN-γ is released from Th1 and natural killer cells during innate and
adaptive immune responses (Huber et al., 1984; Schoedon et al., 1986). Thus, 7,8-NP
production reflects a multi-cellular cooperation between immuno-competent cells. To
date, only IFN-γ has been shown to significantly induce the activity of GCH-I enzyme
and, therefore, 7,8-NP production (Henderson et al., 1991; Huber et al., 1984). With
the exception of tumour necrosis factor-α (TNF-α) and bacterial lipopolysaccharide
(LPS) which have been shown to synergistically enhance IFN-γ–induced neopterin
production, IFN-γ remains indispensable for this process in cell culture (Henderson
et al., 1991; Weiss et al., 1999). In vivo, however, the elevated serum neopterin
levels have been found in the absence of functional IFN-γ (Sghiri et al., 2005). El-
evated neopterin levels were found in the plasma of patients with a rare condition
- the syndrome of Mendelian susceptibility to mycobacterial disease, which is char-
acterised by deeply impaired or absent IFN-γ signaling (Sghiri et al., 2005). Sghiri
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Figure 1.5: 7,8-NP biosynthesis and metabolism pathway
During 7,8-NP synthesis in human macrophages, GTP cyclohydrolase-1 (GTP-CH1)
converts GTP into 7,8-dihydroneopterin triphosphate, which accumulates due to de-
ficient 6-pyruvoyl-tetrahydropterin synthase (PTS) enzyme. Subsequently, phosphate
groups are removed by phosphatase to 7,8-dihydroneopterin which could be oxidised to
neopterin. Adopted from Fuchs et al. (2009) and Leitner et al. (2003).
et al. (2005) suggested that other stimuli apart from IFN-γ induced neopterin syn-
thesis in vivo. Therefore, it remains to be seen whether stimuli other than IFN-γ or
disease-associated ligands like bacterial LPS are able to induce 7,8-NP production.
1.7.2 Clinical utility
Neopterin is routinely used as a marker of adverse immune system activation in
the screening of donor blood in Austria due to its stability and ease of detection
(Ho¨nlinger et al., 2008; Murr et al., 2005). A stable ratio of 7,8-NP to neopterin
for arterial blood (2:1) and for venous blood (3:1) have been reported in vivo, which
makes both compounds useful markers of inflammatory cell activation (Fuchs et al.,
1989; Weiss et al., 1992). Clinical studies have demonstrated a strong correlation
between neopterin levels in body fluids and the severity, progression, and outcome of
infectious and inflammatory diseases. The literature suggests that high neopterin con-
centration in serum and urine is a reliable indicator of the severity of viral (including
HIV-1), bacterial, protozoic, parasitic and fungal infections (reviewed in Berdowska
& Zwirska-Korczala (2001); Fuchs et al. (2009); Hoffmann et al. (2003); Sucher et al.
(2010)). For example, Denz et al. (1990) concluded that neopterin could prove to be a
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useful parameter for distinguishing between viral and bacterial origins of infection (in
combination with other markers). The authors noted that the patients with bacte-
rial infections had significantly lower urinary neopterin concentrations than patients
with viral pneumonia, although it rose after 5 days of illness (Denz et al., 1990). In
contrast to the bacterial infection, neopterin became elevated before the specific an-
tibodies were formed during viral infections, serving as a distinguishing parameter in
diagnosis (Denz et al., 1990). Correlations between neopterin levels and the state of
disease were also reported for rheumatoid arthritis, insulin-dependent diabetes mel-
litus, systemic lupus erythematosus, multiple sclerosis, coeliac disease, cancer and
rheumatic fever (Hoffmann et al., 2003; Reibnegger et al., 1991). Potentially, an im-
proved understanding of the biological role(s) of 7,8-NP will aid in the interpretation
of the clinical results of the blood screening in the context of the multiple aforemen-
tioned pathologies.
The normal baseline level for neopterin in healthy subjects is 5.2 ± 2.7 nM in blood
and 100-200 µmol/mol creatinine in urine (Wachter et al., 1989) or 6.7 ± 1.5 nM
in blood (Murr et al., 2005). For 7,8-NP the reported normal measurements vary
between ∼5.8 nM (Flavall et al., 2008) and ∼18 nM (Genet, 2011). However, these
levels are significantly elevated during disease. Weiss et al. (1992) reported 15-25
nmol/L of total neopterin in cancer patients with 7,8-NP concentration being twice
as high as neopterin concentration. Weiss et al. (1992) reported that highly elevated
leveld of neopterin (109-1679 nmol/L) post mortem; these varied depending on the
site of sampling. Flavall et al. (2008) reported an average of approximately 40 nM
total neopterin in the plasma of septicaemia patients and approximately 68 nmol/L
was observed in the plasma of coronary heart disease patients undergoing angioplasy
(Genet, 2011).
Elevation of neopterin levels during cardiovascular disease probably reflects the Th1-
type immune response activation. A comprehensive review by Fuchs et al. (2009)
addresses many underlying mechanisms and the prognostic utility of neopterin as
a marker of acute CVD progression. Briefly, neopterin levels in plasma have been
reported to correlate with the progression of cerebrovascular and peripheral artery
atherosclerosis, carotid artery atherosclerosis, coronary atheromatous disease and its
complications, such as acute coronary syndrome, and acute myocardial infarction
(Fuchs et al., 2009). Moreover, two large studies by Ray et al. (2007) and Kaski
et al. (2008) identified the prognostic value of neopterin as an independent predictor
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of adverse cardiac events.
It is likely that in disease, neopterin and its reduced form 7,8-NP in the circula-
tion originate and diffuse out from the sites of inflammation as proposed by (Firth
et al., 2008b). Firth et al. (2008b) detected neopterin levels in pus of septicemia
patients up to 100 times higher than those reported in plasma (1.28 µM vs. 10 nM).
Furthermore, Gieseg et al. (2008) observed 2.2 nmoles neopterin per gram of tissue
in some sections of an atherosclerotic plaque (2.2 µM if 1 g = 1 mL). Given such
high availability inside the inflammatory sites, neopterin and 7,8-NP are likely to not
only serve as a potential laboratory marker for an IFN-γ–mediated immune response,
but they are also likely to exert biochemical and physiological functions in the course
of host-defense interactions. These functions are of significant clinical and scientific
interest.
1.7.3 Biochemistry and potential physiological roles of 7,8-
NP
7,8-Dihydroneopterin (IUPAC: 2-amino-6-[(1S,2R)-1,2,3-trihydroxypropyl]-7,8- dihydropteridin-
4(3H)-one) is an aromatic heterocyclic pteridine that has reducing properties. It is
structurally related to the flavins (flavin-adenine dinucleotide (FAD), flavin mononu-
cleotide (FMN)), to nicotinamide dinucleotides (NAD, NADP), acetyl coenzyme A,
biotin and many other pyrimidine-containing enzyme cofactors and biologically active
molecules. 7,8-NP can be readily oxidised by a range of electrophiles to form either
neopterin or 7,8-dihydroxanthopterin (7,8-DXP) (fig. 1.6). Neopterin is produced by
the oxidation of the 7,8-NP pterin moiety by hypochlorous acid and acidic iodide.
While the HOCl–mediated reaction is a physiological one, the 7,8-NP oxidation by
acidic iodide has been used in the laboratory, enabling the detection of the compound
(Widner et al., 2000). Recently, a reaction of 7,8-NP with 1O2 (singlet oxygen), that
also produces neopterin has been characterised (Da´ntola et al., 2007).
It is generally believed that 7,8-DXP is the product of 7,8-NP oxidation by oxygen–
centered radicals (Widner et al., 2000). 7,8-DXP is formed when 7,8-NP is exposed to
oxygen in the air, or to H2O2, which abstracts the side chain (Da´ntola et al., 2008a,b).
7,8-DXP dismutates to form xanthopterin at a relatively slow rate (Da´ntola et al.,
2008b). During oxidative stress, this reaction is likely to prevail over the neopterin-
generation processes unless the oxidative stress is driven by HOCl. Unfortunately, the
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Figure 1.6: 7,8-NP oxidation
7,8-NP is oxidised to neopterin by the action of HOCl and to 7,8-dihydroxanthopterin
by the action of peroxyl and hydroxyl radicals. Figure adopted from (Gieseg et al.,
2009).
clinical utility of 7,8-DXP for in vivo analysis of 7,8-NP oxidation is limited. In addi-
tion to the slow dismutation rate which would be difficult to predict in a complex sys-
tem, xanthopterin is not exclusive to the 7,8-NP oxidation. Xanthopterin is an impor-
tant oxidation product of other biologically important biopterins: dihydrobiopterin
and dihydrofolic acid and thus would not solely reflect monocyte/macrophage im-
mune activation (Va´squez-Vivar, 2009).
In contrast, neopterin is a good marker of immune system activation because it is
derived only from 7,8-NP or dihydroneopterin triphosphate (Fuchs et al., 2009), is
stable in body fluids and has a relatively long half–life (90 min) that is only depen-
dant on urinary excretion (Fuchs et al., 1989). These properties make NP a good
diagnistic tool for a variety of pathological conditions (reviewed in Berdowska &
Zwirska-Korczala (2001), Fuchs et al. (2009) and Sucher et al. (2010)).
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Known antioxidant properties of 7,8-NP
Reduced pterins, including 7,8-NP are known for their antioxidant properties (Rezk
et al., 2003). 7,8-NP has been shown to act as a weak scavenger of superoxide (rate
constant 103 M-1s-1) and a strong scavenger of peroxyl radicals (107 M-1s-1) gener-
ated by 2,2’-azobis-2-methyl-propanimidamide, dihydrochloride (AAPH) (Oettl et al.,
1997, 2004a). 7,8-NP also reacts with hydrogen peroxide and chloramine-T (Weiss
et al., 1993). In addition, 7,8-NP inhibited peroxinitrite–driven reaction with a spin
probe and the nitration of tyrosine (Oettl et al., 2004a). These chemical properties
of 7,8-NP are relevant in a biological context as discussed below.
7,8-NP is a very efficient inhibitor of AAPH–mediated oxidation of biological molecules
as its reaction rate with peroxyl radical approaches the rate of diffusion, as demon-
strated in a number of studies (Duggan et al., 2001; Gieseg et al., 1995, 2001a).
7,8-NP was shown to inhibit oxidation of linoleate by AAPH and diene formation
on LDL during AAPH– and copper–mediated oxidation and α-tochopherol loss in
LDL (Gieseg et al., 1995). During the course of the reaction, the authors observed
a formation of a neopterin-like fluorescent compound, along with conjugated diene
formation (Gieseg et al., 1995). 7,8-NP has also been shown to protect bovine serum
albumin (BSA) from AAPH–mediated oxidation. The results of this study suggested
the scavenging of the primary radical (Duggan et al., 2001).
Another study by Gieseg et al. (2001a) found a reduction in erythrocyte haemol-
ysis caused by HOCl, H2O2 and AAPH treatments. The degree of protection varied
from complete protection in the presence of AAPH, to about 40% in the presence
of H2O2 (Gieseg et al., 2001a). 7,8-NP reacted directly with the three oxidants,
forming neopterin in the reaction with HOCl and, predominantly, 7,8-DXP in the re-
actions with AAPH and H2O2 (<5% NP formed). The authors also reported 7,8-NP–
mediated protection against the lipid hydroperoxide formation and protein oxidation
(Gieseg et al., 2001a). Further studies confirmed the ability of 7,8-NP to inhibit/slow
down protein hydroxide formation and lipid peroxide formation on LDL, mediated by
HMDM and THP-1 cells (Firth et al., 2008a). In these conditions, (the presence of
LDL and cells) 7,8-NP was oxidised primarily to 7,8-DXP. In summary, this literature
suggests that 7,8-NP may act as an antioxidant in vivo, conveying protection against
reactive oxygen species.
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Effect of 7,8-NP on cell viability and survival
Over the years, the Gieseg laboratory has performed a number of studies aimed at
assessing whether 7,8-NP antioxidant capacity is maintained in a more complex cel-
lular system. It had been demonstrated that protein and thiol oxidation in U937
cells exposed to the peroxyl radical generator AAPH were also inhibited by 7,8-NP
(Duggan et al., 2002). This process was studied further to reveal that 7,8-NP inhib-
ited the cytotoxic effect of oxLDL on U937 cell line by protecting the intracellular
GSH, which was lost in response to oxLDL (Baird et al., 2005). The lack of effect
of 7,8-NP supplementation on oxLDL-mediated GSH loss or cytotoxicity to THP-1
was, thus, unclear but may relate to the mode of oxidative stress that each of the cell
lines experiences upon oxLDL treatment, as suggested by the disparity in the GSH
loss kinetics (Baird et al., 2005).
While these experiments confirmed the protective effect of 7,8-NP, another set of
studies found 7,8-NP to be pro-apoptotic. At high concentrations and/or in other
cell lines 7,8-NP has been found to induce apoptotic cell death. Schobersberger et al.
(1996) reported that 100 µM of both 7,8-NP and neopterin induced 17% and 13%
apoptosis in rat alveolar epithelial cell line L2. At 5 mM (but not at 1 mM) 7,8-
NP also caused apoptosis in Jurkat T lymphocytes (Wirleitner et al., 1998). This
7,8-NP-mediated cell death was significantly blocked by an antioxidant pyrrolidine
dithiocarbamate, suggesting a role for a redox-sensitive signal transduction pathway
(Wirleitner et al., 1998). In a study by Enzinger et al. (2002), reduced 7,8-NP led
to an increase in apoptotic cells in rat pheochromocytoma cell line PC12 at a con-
centration of 5 mM but no such effect was observed at 1 mM 7,8-NP or neopterin.
Cells incubated with 5 mM 7,8-NP showed an activation of the MAPK and to a
lesser degree JUN/SAP kinase. Antioxidants (catalase, superoxide dismutase) par-
tially suppressed pteridine-induced apoptosis, suggesting the involvement of reactive
oxygen intermediates. Speth et al. (2000) also advocated for ROS involvement in 7,8-
NP–mediated apoptosis in astrocytes and neurons. As suggested by Wirleitner et al.
(2001), the overproduction of radicals caused by high levels of 7,8-dihydroneopterin
may be responsible for the pro-apoptotic effects observed in these cell cultures.
In contrast to the above, Bratslavska et al. (2007) showed that neither neopterin
nor 7,8-NP had any effect on the cellular viability of Hep-2. In Gieseg’s laboratory
no negative effect of 7,8-NP (up to 0.3 mM) on cellular viability of human monocyte-
derived macrophages, THP-1 or U937 cell lines has been observed. The described
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discrepancies may be determined by the tolerance of different cell lines to perturba-
tions of the intracellular redox balance.
Effect of neopterin on NOX activity in phagocytes
While 7,8-NP has been predominantly thought of as an antioxidant, neopterin has
been shown to play a specific role in the stimulation of the phagocytic ROS–producing
NADPH oxidase. A range of authors suggested and demonstrated neopterin-dependant
regulation of NOX—, xanthine oxidase– and myeloperoxidase–dependent oxidative
burst (Kojima et al., 1992, 1993; Nathan, 1986; Oettl et al., 1997; Razumovitch et al.,
2004). Some of these studies were performed on isolated enzymes, while others were
carried out on neutrophil and macrophage cell cultures. The results varied with Oettl
et al. (1997) showing that 20 µM neopterin almost completely inhibited the conver-
sion of xanthine into uric acid by xanthine oxidase, while others observed only a
slight reduction of the formation of superoxide radicals by xanthine/xanthine oxidase
system in the presence of 370 µM of neopterin (Kojima et al., 1992). Yet in the
same study neopterin significantly diminished superoxide in phorbol-12-myristate-13-
acetate (PMA)–stimulated macrophages (Kojima et al., 1992). The latter result was
further expanded with subsequent work, showing neopterin as a competitive inhibitor
of PMA–stimulated superoxide production in rat macrophage (whole cell system) and
in solubilised membranes (cell free system) (Kojima et al., 1993).
The macrophage cell may be significantly different from other phagocytes, such as
the neutrophil, in this area. Contrary to the described results, Razumovitch and
co-workers observed that in neutrophils neopterin increased the formation of ROS
detected by luminol chemiluminescence system (non-MPO associated) (Razumovitch
et al., 2004). Yet in the MPO/H2O2/luminol system the authors observed a sharp
drop of chemiluminescence signal after the addition of neopterin. Through a series
of inhibitor studies, the authors attributed this effect to the decrease in superoxide
and hydrogen peroxide. In their earlier publication the authors reported that NP in-
duced chemiluminescence in adherent and/or cells generating ROS in the presence of
luminol but not lucigenin (Razumovitch et al., 2003). The authors speculated that in
neutrophils, neopterin is able to induce the short-term generation of singlet oxygen,
hydroxyl radicals, and nitrogen oxide (II) by an NADPH-oxidase–independent mech-
anism, possibly MPO (Razumovitch et al., 2003). A recent paper by some of the same
authors investigated the influence of neopterin and 7,8-NP on MPO activity (Petukh
et al., 2009). Neopterin–mediated increase in the chemiluminescence of neutrophils
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was confirmed, but no additional mechanistic detail was proposed (Petukh et al.,
2009). The only study assessing the effect of 7,8-NP on the MPO activity (Petukh
et al., 2009) was inconclusive, as the authors reported “inhibition” of NOX–induced
ROS without controlling for the scavenger activity of 7,8-NP.
Neopterin is not just involved in the regulation of ROS–generating enzymes in phago-
cytic neutrophils and macrophages. A correlation of neopterin release and ROS–
generating and phagocytic potential has been reported (Nathan (1986)). This may
be partly dependent on neopterin’s ability to enhance ROS cytotoxicity (Murr et al.,
1994; Weiss et al., 1993) and its regulation of pro-inflammatory signaling molecules, as
neopterin has been associated with NF-κB and TNF-α (Hoffmann & Schobersberger,
2004; Hoffmann et al., 1996, 1998; Schroecksnadel et al., 2010). Thus, the majority of
the evidence described above and in the literature points towards anti-inflammatory
and antioxidant properties of 7,8-NP, whereas neopterin may be implicated in the
propagation of inflammatory response.
1.8 Research programme
A number of studies to date have shown that 7,8-NP protects cells of myelocytic
origin from the cytotoxic effects of oxLDL, yet the mechanism(s) of this protection
are poorly understood (Baird et al., 2005; Gieseg et al., 2001b, 2010a). While the
antioxidant capacity of 7,8-NP is predicted from the available literature and the as-
sessment of the 7,8-NP chemical structure, its inhibitory effect on the oxLDL uptake
is not obvious from examining the biochemical properties of 7,8-NP. This thesis will
investigate how the two capacities of 7,8-NP may contribute to its protective effect
towards HMDM cells treated with oxLDL. In particular, this thesis aims to estab-
lish which of the two biological activities of 7,8-NP is the primary mechanism for this
protection against acute cell death: the antioxidant or the uptake-regulatory capacity.
In order to achieve this goal, chapter 3 will establish the factors that influence the
acute oxLDL–induced cytotoxicity to HMDM in vitro. Chapter 4 will focus on the
antioxidant activity of 7,8-NP during oxLDL-mediated HMDM cell death, and will
allude to the sources of the oxidative stress that contribute to the process. Finally,
chapter 5 will investigate the effect and potential mechanisms of 7,8-NP on the oxLDL
uptake by the HMDM. It will also evaluate the significance of this process in the con-
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text of acute cell death. Chapter 6 will address problems that arose during this thesis,
and will investigate the effect of cell culture factors on HMDM cell death.
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2Materials & methods
2.1 Reagents, media and buffers
2.1.1 Reagents
All reagents used were of analytical grade or better. All solutions were prepared
with de-ionised water purified with Milli-Q ultrafiltration system (Millipore, Mas-
sachusetts, USA). This is referred to as nano-pure water.
β-Mercaptoethanol Sigma Chemical Co., MO, USA
3-[4,5-Dimethylthiazol-2-yl]-2,5
-diphenyl-tetrazolium bromide (MTT) Sigma-Aldrich Co. LLC, New Zealand
5,5’-Dithio-bis(2-nitrobenzoic acid) (DTNB) Sigma-Aldrich Co. LLC, New Zealand
7,8-Dihydroneopterin (7,8-NP) Schircks Laboratory, Switzerland
7,8-Dihydroxanthopterin (7,8-DXP) Schircks Laboratory, Switzerland
Acetic acid (glacial) Scharlau Chemie S.A., Barcelona, Spain
Acetonitrile (ACN) J.T. Baker, NJ, USA
Agarose AppliChem Gmbh, Germany
Ammonium chloride (NH4Cl) May & Baker Ltd, Dagenham, England
Ammonium phosphate dibasic (AmPO4) Sigma-Aldrich Co. LLC, New Zealand
Ascorbic acid Sigma Chemical Co., MO, USA
Butylated hydroxytoluene (BHT) Sigma-Aldrich Co. LLC, New Zealand
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Bovine serum albumin (BSA) Sigma-Aldrich Co. LLC, New Zealand
Bromophenol blue Sigma-Aldrich Co. LLC, New Zealand
Chelex–100 resin Bio-Rad Laboratories, California, USA
Ethylene-diamine-tetra-acetic acid (EDTA) Sigma-Aldrich Co. LLC, New Zealand
Diethyl ether BDH Lab Supplies Ltd, Poole, England
Diethyl pyrocarbonate (DEPC) Sigma-Aldrich Co. LLC, New Zealand
Dimethyl sufloxide (DMSO) BDH Lab Supplies Ltd, Poole, England
Dithiothreitol Invitrogen, Life Sciences, New Zealand
Ethanol BDH Lab Supplies Ltd, Poole, England
Glutathione (GSH), 99% reduced Sigma-Aldrich Co. LLC, New Zealand
Glycerol Sigma-Aldrich Co. LLC, New Zealand
Granulocyte-macrophage colony- Bayer Healthcare Pharma. LLC
stimulating factor (GM-CSF) as Seattle, USA
Leukine® sargamostim
HEPES buffer Sigma-Aldrich Co. LLC, New Zealand
Hexane, 95% pure Ajax Chemicals, Auburn, Australia
Hydrochloric acid (HCl) BDH Lab Supplies, Poole, England
Iodine (I) BDH Lab Supplies Ltd, Poole, England
Isopropanol BDH Lab Supplies Ltd, Poole, England
Lymphoprep® Axis-Shield PoC AS, Oslo, Norway
Methanol Merck, Darmstadt, Germany
MOPS buffer Sigma Chemical Co., MO, USA
Neopterin Schircks Laboratory, Switzerland
Phosphoric acid Sigma-Aldrich Co. LLC, New Zealand
Ponceau S Sigma Chemical Co., MO, USA
Potassium bicarbonate (KHCO3) May & Baker Ltd, Dagenham, England
Potassium chloride (KCl) Merck, Darmstadt, Germany
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Potassium hydroxide (KOH) Merck, Darmstadt, Germany
Potassium iodide (KI) May & Baker Ltd, Dagenham, England
Sodium bicarbonate (NaHCO3) May & Baker Ltd, Dagenham, England
Sodium chloride (NaCl) BDH Lab Supplies Ltd, Poole, England
Sodium dihydrogen orthophosphate Merck, Darmstadt, Germany
(NaH2PO4)
Sodium dodecyl sulphate (SDS) Sigma-Aldrich Co. LLC, New Zealand
Sodium hydroxide (NaOH) Merck, Darmstadt, Germany
Sodium hypochlorite (NaOCl) Clorogene Supplies, Petone, New Zealand
Thimerosal Sigma Chemical Co., MO, USA
Trichloroacetic acid (TCA) Merck, Darmstadt, Germany
Tris buffer Roche Diagnostics Corp., Indianopolis, USA
Trizol® Invitrogen, Life Sciences, New Zealand
Trypan blue solution (0.4%) Sigma-Aldrich Co. LLC, New Zealand
Tween 20® Sigma-Aldrich Co. LLC, New Zealand
2.1.2 Media
Penicillin/Streptomycin solution, Invitrogen, Life Technologies, New Zealand
1000 U of Penicillin G &
1000 µg of Streptomycin/mL
Roswell Park Memorial Institute 1640:
- RPMI 1640 media, with phenol red Sigma-Aldrich Co. LLC, New Zealand
- RPMI 1640 media, without phenol red Sigma-Aldrich Co. LLC, New Zealand
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2.1.3 General solutions and buffers
Phosphate buffered saline
Phosphate buffered saline (PBS) solution contained 150 mM sodium chloride (NaCl),
10 mM sodium dihydrogen orthophosphate (NaH2PO4) at pH 7.4, and was prepared
the following way. Fifty milliliters of 3M NaCl, 40 mL of 250 mM NaH2PO4, pH 7.4,
was mixed with 910 mL of nano-pure water. PBS required for cell culture work was
vacuum filtered through a 0.45 µm membrane (Phenomenex) and autoclaved for 15
minutes at 121 ◦C and 15 psi. The pH of the solution remained stable for 3 months.
7,8-Dihydroneopterin solution
A 2 mM 7,8-dihydroneopterin (7,8-NP) stock solution was prepared by dissolving
7,8-NP powder (Schircks Laboratories, Switzerland) in the appropriate medium in a
50 mL tube via a 10 minute ultrasonication. The solution was sterilised by filtration
through a 0.22 µm PES® syringe filter (Membrane Solutions, USA) before being
added to cells. The solution was kept on ice at all times and used within 1 hour of
preparation.
Apocynin solution
Apocynin stock solution was perpared by dissolving apocynin powder (Sigma-Aldrich)
in PBS to give a concentration of 1 mM before filter–sterilising it through a 0.22 µm
PES® syringe filter. The solution was stored at –4 ◦C and used within one month.
2.2 Cell culture technique
2.2.1 Aseptic practice
All cell culture work was performed under aseptic conditions in a Class II biological
safety cabinet (Clyde-Apex BH 200). All instruments and equipment were either
sterile–bought plastic-ware (Falcon, Bector Dickinson & Co.; Nunc, Nalge Nunc In-
ternational; Greiner, Greiner Bio-one, Neuburg, Germany) or had been sterilised by
autoclaving (15 min, 121 ◦C, 15 psi). All media and solutions added to cells were ster-
ilised by autoclaving or by filtration through a 0.22 µm membrane filter (Membrane
Solutions, USA). The cells were kept at 37 ◦C in a humidified atmosphere calibrated
to 5% carbon dioxide : 95% air (Sunnyo Electric Co. Ltd, Japan). All items were
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sprayed with 70% ethanol (diluted in distilled water) before being placed in the Class
II cabinet.
2.2.2 Cell culture medium and experimental conditions
A number of media with different chemical compositions are used for cell culture. In
the present study, Roswell Park Memorial Institute 1640 complete medium (RPMI-
1640) was used to culture HMDM cells and U937 monocyte-like cell line (U937).
RPMI-1640 is a complex medium containing an extensive list of essential amino-acids,
minerals and glucose (Freshney, 2010).
Roswell Park Memorial Institute 1640 Medium
Powdered RPMI-1640 was prepared according to the manufacturer’s instructions.
After the RPMI-1640 powder was dissolved in nano-pure water, sodium bicarbonate
(NaHCO3) was added and the pH adjusted to 7.4 by the addition of 11.4 M hy-
drochloric acid (HCl). The medium was sterilised by filtration through a 0.22 µm
Millex®-GP50 filter (Sartorius AG, Goettingen, Germany) and a peristaltic pump
(CP-600, Life Technologies, Maryland, USA) into sterile 500 mL bottles and stored
at 4 ◦C.
Cell culture experimental conditions
Unless stated otherwise, all the experiments with HMDM cells were performed in
RPMI-1640 with or without phenol red, supplemented with 100 U/mL penicillin, 100
µg/mL streptomycin and 10% (v/v) human serum. This solution is referred to as
whole medium. Unless stated otherwise, experiments were performed in the original
plates the cells were seeded into. Fresh medium was added to wells at least 30 minutes
prior to the addition of other constituents to allow cells to adapt to the change of
conditions.
The total volume of incubation medium during any treatment was 1 mL for HMDM
cells that were grown in 12 well plates, and 0.4 mL for HMDM cells grown in 48-well
plates. For comparison, surface to volume ratio in these conditions was 3.9 for 12
well and 2.5 for 48 well plates. All experiments with U937 cells were performed in
12 well suspension plates (Cellstar®), coated (unless stated otherwise) with 8 µL
of 50 mg/mL bovine serum albumin (Sigma-Aldrich) followed by air-drying, in the
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total experimental volume of 1 mL. The cells were counted and re-suspended in the
experimental medium before an experiment.
2.2.3 Preparation of human serum for macrophage cell culture
The procedure of plasma and cell isolation from unlinked haemochromatosis patient
blood was carried out under ethics approval CTY/98/07/069 granted by the Upper
South (B) Regional Ethics Committee.
Unlinked (no donor identification) blood from consenting patients was collected into
450 mL “dry” bags (no anticoagulant included, Fresenius Kabi, Homburg, Germany)
by the New Zealand Blood Bank (Riccarton branch, Christchurch). The blood bag
was left in the vertical position in the polypropylene container at room tempera-
ture for 2 hours to allow the formation of a blood clot and then transferred to 4 ◦C
overnight to provide sufficient time for the serum to separate from the clot.
The following day the bag was opened under aseptic conditions and the serum was
collected into 50 mL centrifuge tubes using a 20 mL syringe attached to a mixing
cannula. The tubes were centrifuged at 1000 g for 15 minutes (Heraeus Multifuge-
SR, BioStrategy, New Zealand) to pellet the remaining blood erythrocytes, and the
clear serum was carefully transferred to new 50 mL centrifuge tubes. If the resulting
serum appeared to contain any red blood cells, the centrifugation step was repeated.
Human serum was heat–inactivated at the beginning of the project, but this step
was omitted after the review of the literature (Biochrom AG, 2010; Hyclone®, 1996;
Leshem et al., 1999) and discussions with S.P. Gieseg and B. Hock. Further investi-
gation showed that the heat inactivation treatment had no effect on the cell growth
and activity (chapter 6). Throughout the following chapters, the abbreviation HIHS
is used for heat–inactivated human serum, whereas HS denotes non-heat inactivated
human serum. The serum was heat inactivated in a water bath at 56 ◦C for 30 min-
utes before being cooled to 4 ◦C. It was then transferred to a −− 20 ◦C followed by
a −− 80 ◦C freezer for long term storage. The serum was stored for up to 6 months,
but generally used within 3 months from preparation.
2.2.4 Preparation of foetal bovine serum for U937 cell culture
Foetal bovine serum (Invitrogen, New Zealand) was used directly without any ma-
nipulation.
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2.2.5 Cell culture of human monocyte-derived macrophage
cells
Isolation of Monocytes
Unlinked blood from clinically healthy consenting haemochromatosis patients was
collected into 500 ml autologous bag by the NZ Blood Service (Compoflex® contain-
ing the anticoagulant citrate-phophate-dextrose-adenine (CPDA-1)). It was kept at
4 ◦C for up to 18 hours before processing, although the cells were usually prepared
immediately.
The monocytes were isolated using the method described by Amit (2008) and Yang
(2009). The procedure involved taking a bag of whole blood, gently inverting it 10
times to distribute the cells evenly, aseptically placing into the CII cabinet and cut-
ting it open. The blood was transferred from the bag into 50 mL centrifuge tubes
and centrifuged at 1000 g with slow deceleration for 30 minutes at room temperature.
The centrifugation step produced a layer of erythrocytes at the bottom of the tube,
topped with a white layer of leukocytes (“buffy coat”) and overlaid with plasma.
The leukocyte layer was removed using a mixing cannula attached to a 10 mL sy-
ringe, pooled and mixed with the equal amount of PBS by thorough inversion. The
mixture was underlaid with 15 mL of Lymphoprep® (lymphoprep) using a mixing
cannula attached to a 20 mL syringe. After centrifugation at room temperature at
1000 g for 30 minutes with slow acceleration/deceleration, a white layer of mono-
cytes/lymphocytes was visible approximately halfway down the centrifuge tube sur-
rounded by clear plasma and lymphoprep layers (fig. 2.1).
The top layer was aspirated, leaving 2 cm of solution above the layer of leukocytes.
The cells were transferred into a new 50 mL tube by a syringe attached to a mix-
ing cannula. The cells were thoroughly re-suspended and evenly divided between
the appropriate number of tubes, each containing no more than 15 mL of solution.
Each tube was topped up with PBS, inverted to mix and centrifuged at 500 g for 15
min. After the centrifugation, the supernatant was aspirated, cell pellets tapped to
re-suspend the leukocytes and topped up with PBS. The tubes were inverted to mix
and centrifuged at 500 g for 10 min. The procedure was performed once more, after
which the cells were re-suspended in the RPMI-1640 containing pen/strep, counted on
the haemocytometer, plated into 6 well suspension plates (Cellstar) at 5x106 cells/mL
and incubated at 37 ◦C at 5% CO2 for 40 hours in the absence of serum.
43
2. MATERIALS & METHODS
-
Figure 2.1: Monocyte isolation: typical preparation. Leukocytes separated
from erythrocytes after the gradient centrifugation with Lymphoprep®. The arrow
indicates the layer of leukocytes.
Plating and culture of HMDM cells
The cells were incubated in the absence of serum for approximately 40 hours during
which time the T-cells died due to serum deprivation, the platelets attached to the
surface of the plate while the monocytes remained viable in suspension (Bennett et al.,
1992; Yang, 2009). The well content was aspirated, pooled, centrifuged at 500 g for
15 min at room temperature and re-suspended in RPMI-1640, supplemented with
10% (v/v) human serum at a concentration required for seeding (1x10 6 and 5x10 6)
cells/mL. A pulse of granulocyte macrophage colony stimulating factor (GM-CSF)
administered as Leukine® (Bayer, USA) was added to the cell suspension to drive
the differentiation of monocytes into macrophages. The final GM-CSF concentration
was either 25 or 50 ng/mL of cell suspension. The cells were plated (seeded) at
5x10 6 cells/well into 12 well plates (adherent, Nunc) and 1x10 6 cells/mL into 48 well
plates (adherent, Cellstar). Information on comparative growth in different plate
types and seeding densities could be found in chapter 6. RPMI-1640 containing 10%
human serum was renewed every 3 to 4 days and experiments were conducted once
the majority of monocytes had matured to macrophages, usually 11-16 days after the
seeding of cells.
Monitoring of HMDM culture
HMDM cell morphology was examined every 3–4 days through an inverted microscope
Leica DM IL (Leica Microsystems, Wetzlar, Germany), equipped with a camera and
connected to the computer featuring Leica Application Suite Version 2.8.1 (Build:
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1554). A satisfactory preparation of cells showed signs of differentiation, such as loss
of monocytic morphology by over 10% of the well population, by the 4th day after
seeding. By the 7th–8th day the well surface was dominated by round poached-egg-
like cells with a few elongated cells. At least 70% surface coverage was considered
acceptable.
2.2.6 Culture of U937 cells
The U937 monocyte-like cell line was originally developed from the pleural fluid of a
37-year old man with generalised lymphoma (Sundstrom & Nilsson, 1976). The U937
cells used in this research were a gift from the Haematology Research Laboratory of
the Christchurch School of Medicine, University of Otago.
To revive U937 stock after storage in liquid nitrogen, a 1 mL storage vial contain-
ing 20x10 6 cells/mL in dimethyl sulfoxide (DMSO) freezing medium was defrosted
in a 37 ◦C water bath until almost completely thawed. This cell suspension was
poured into 30 mL of RPMI-1640 and centrifuged at 500 g for 5 minutes to sepa-
rate the freezing medium from the cells. The cell pellet was re-suspended in 10 mL
of RPMI-1640 and initially cultured in 25 cm3 tissue culture flask (Falcon, BD, USA).
The cells were considered fit for experimental work when the cells reached an appro-
priate cell density (approximately 1x106 cells/mL) and their division rate normalized
(doubling time 92-96 hours (Sundstrom & Nilsson, 1976) followed by 20-48 hours in
subsequent passages (Harris & Ralph, 1985)). The “healthy” U937 cells displayed a
spherical morphology with small grain-like protrusions on the membrane (cytoplas-
mic granules) and without extensive clustering. The U937 cells were propagated in
culture for up to 6 months (passages 15-50 were used for experiments). Cell density
was maintained at 0.3-1.5x10 6 cells/mL by passaging in Cellstar® 150 cm3 tissue
culture flasks (Greiner Bio-one, Germany) every 2-4 days.
After a 6 month period a new stock of the original U937 cells was brought up to
avoid any artefacts associated with prolonged cell culture, such as genetic drift and
mycoplasma contamination.
45
2. MATERIALS & METHODS
2.3 Isolation and oxidation of low-density lipoprotein
2.3.1 Collection and preparation of donor plasma
Collection of blood from donors and preparation of LDL from plasma were carried
out under ethics approval CTY/98/07/069 granted by the Upper South (B) Re-
gional Ethics Committee. The blood was collected by venipuncture from consenting
healthy male and female donors after an overnight fast. In total, 200 mL of blood
was collected from each donor into 50 mL tubes containing 0.5 mL of 100 mg/mL
ethylene-diamine-tetra-acetic acid (EDTA). The tubes were centrifuged for 20 min-
utes at 4 ◦C in a swing-out rotor at 2350 g. Plasma was transferred to 50 mL round
bottomed centrifuge tubes and centrifuged for 30 minutes at 11,000 g with slow ac-
celeration/deceleration in a fixed angle rotor to remove any remaining cells. Plasma
from all donors (5-6 at a time) was pooled to minimise the inter-individual variation
(Gieseg & Esterbauer (1994)). The plasma was stored in 30-32 mL aliquots at -80 ◦C
for a maximum of 6 months.
2.3.2 Lipoprotein isolation by gradient centrifugation
The method used for LDL isolation involved creating a gradient that separated the
lipoproteins during centrifugation. A modification of a single vertical spin method
first reported by Chung et al. (1980), as described in Gieseg & Esterbauer (1994), was
used in this research. Briefly, 30 mL of EDTA-plasma was thawed under running cold
water and centrifuged at 2000 g for 10 minutes at 4 ◦C to remove any precipitated
fibrinogen. The supernatant was decanted into a beaker, placed on ice and the plasma
density was adjusted to a density of 1.3 by gradual addition of 381.6 mg of solid KBr
per mL of plasma. The solution was flushed with argon, capped with parafilm and
gently stirred to dissolve KBr. Eight milliliters of deoxygenated 1 mg/mL EDTA
(pH 7.4) solution was added to each of the 8 ultracentrifugation tubes (OptiSealTM,
Beckman Coulter, USA) before under-laying with 4 mL (or less) of KBr-plasma using
a long luer-fitting needle attached to a 5 ml syringe. The tubes were transferred to
Beckman Near Vertical Ti-65 rotor and centrifuged at 341,705 g (60,000 rpm) for 2
hours at 4 ◦C using slow acceleration/deceleration in OptimaTM L-90K Preparative
Ultracentrifuge (Beckman Coulter, Inc., Fullerton, California). A yellow band of LDL
(fig. 2.2) in the density range of 1.019 g/mL to 1.063 g/mL was collected using a
syringe attached to 90 ◦C–bent needle.
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Figure 2.2: LDL isolation: typical preparation.
LDL isolation from plasma via density centrifugation. Arrow indicates the LDL band.
.
2.3.3 LDL concentration
LDL was concentrated using Amicon® Ultra-15 membrane filter tubes (Millipore,
USA). Prior to use, the tubes were rinsed gently with nano-pure water and cen-
trifuged with PBS for 2 min at 2500 g to wash. After use, the tubes were rinsed with
nano-pure water, centrifuged for 2 min with nano-pure water, then for 1 min with
100% ethanol and stored in the fridge in 50% ethanol.
LDL was placed into Amicon® centrifuge tubes, topped up with PBS and centrifuged
at 2500 g, fast acceleration/deceleration, at 4 ◦C for 30 min. The procedure was re-
peated three more times in order to eliminate the remaining EDTA from the LDL.
The purified LDL was concentrated by centrifugation for 10-20 minutes using the
same procedure. The centrifugation time varied depending on the original concentra-
tion of the LDL. It was adjusted to give a final concentration of approximately 10 mg
of LDL per mL of solution (total mass), which was determined as described below.
2.3.4 Determination of LDL concentration
LDL concentration was determined as a function of total cholesterol level which was
measured by an enzymatic reaction using a CHOL® kit (Roche Diagnostics, Ger-
many).
The total cholesterol content of LDL was determined by incubating 10 µL of LDL
with 1 mL of the CHOL® reagent at room temperature. After incubation for 10 min,
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the absorbance was measured at 500 nm against a CHOL® reagent blank. LDL con-
centration was calculated from this absorbance, based on an estimate of LDL having
a molecular weight of 2500 kDa and cholesterol accounting for 31.69% of the LDL par-
ticle by weight (Gieseg & Esterbauer, 1994). The value used for LDL concentration
used in this thesis is in total mass rather than the mass of the apolipoprotein B-100
protein moiety as used by some other research teams (Asmis & Begley, 2003; Hard-
wick et al., 1996). The value of total LDL mass relates to the mass apolipoprotein
B-100 (protein component of the molecule) as 5:1 (Gieseg & Esterbauer, 1994).
2.3.5 Preparation of oxidised LDL
Preparation of dialysis tubing for LDL oxidation
The dry dialysis membrane tubing (Medical International Ltd, London, England) with
14.4 mm flat width and 14,000 D molecular weight cut off was pre-treated before use.
The dialysis tubing was cut into 25 cm sections and boiled in a glass beaker containing
5% (w/v) NaHCO3 and 1 mM EDTA for 20 minutes. The tubes were washed with
nano-pure water and boiled again in a glass beaker containing nano-pure water. After
20 minutes, the tubes were washed thoroughly with nano-pure water and stored in
solution of water:ethanol (50:50, v/v) at 4 ◦C. The tubes were rinsed thoroughly with
water and PBS prior to being used for LDL oxidation.
LDL oxidation
The method for LDL oxidation was adapted from that described by Gerry et al.
(2008). Concentrated LDL was mixed with 500 µM copper chloride (CuCl2), placed
into double–knotted dialysis tubing and secured with a zip clip and a knot. The
dialysis tubing was placed in a bottle of 37 ◦C PBS also containing 500 µM CuCl2.
The volume of PBS was adjusted according to the amount of LDL to constitute 1L
of buffer per 10 mg of LDL protein.
The loosely capped bottle containing the dialysis bag was placed on an orbital shaker
(Bioline, Edwards Instrument Company, Australia) at 37 ◦C for 24 hours during which
the yellow LDL solution turned colourless with a tinge of cloudy white. Following
this, the dialysis bag was transferred into 1L of 4 ◦C PBS containing a quarter of
a teaspoon of washed Chelex-100 resin and a magnetic flea. The solution was left
stirring for 2 hours at 4 ◦C after which the dialysis bag was transferred to a new bottle
of Chelex-containing PBS and stirred for 2 more hours. It was left overnight in the
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third change of PBS–Chelex.
Approximately 20 hours after the start of dialysis, oxidized low-density lipoprotein
(oxLDL) was taken out of the dialysis bag, filter-sterilised through a 0.22 µm mem-
brane filter in the CII cabinet and stored at 4 ◦C. The oxLDL solution was used
within one month from the time of oxidation.
2.4 Biochemical analysis
2.4.1 Determination of protein concentration
Protein concentration was determined using the bicincronic acid (BCA) protein anal-
ysis kit (Pierce, Rockford, USA). This method combines the reduction of Cu2+ to
Cu+ by protein in an alkaline medium (by oxidation of peptide bonds and reducing
protein groups, e.g. Cys-SH, Tyr-OH, Trp) coupled with the colorimetric detection
of Cu+ using a reagent containing bicincronic acid.
Sample preparation: The working reagent for BCA assay was freshly prepared
by mixing Reagent A (containing: sodium carbonate, sodium bicarbonate, BCA
and sodium tartrate in 0.1 M sodium hydroxide) and Reagent B of the kit (4%
CuSO4.5H2O) in a 50:1 ratio. Fifty microliters of diluted sample were mixed with
1 mL of working reagent and incubated at 60 ◦C for 30 minutes with gentle shak-
ing. The reaction was stopped by placing samples on ice. Protein concentration was
determined from the absorbance reading at 562 nm and compared to the standard
curve prepared by the incubation of known concentrations of BSA (0-250 µg/mL) in
1 mL of working reagent. The absorbance is nearly linear over 20-2000 µg/mL range
(Pierce Instruction manual).
2.4.2 Cell viability assays
One of the common ways to assess cytotoxicity is the loss of cellular viability following
a treatment with the toxic compound (Berridge et al., 1996). The reduction of MTT
is widely accepted as a reliable method to measure cell number and, therefore, can be
used to assess cell viability (Mosmann, 1983; Shen & Sevanian, 2001). The dehydro-
genase enzymes of metabolising cells generate reducing agents such as nicotinamide
adenine dinucleotide (NADH) and NADPH, which reduce yellow tetrazolium salt to
purple formazan. The resulting formazan crystals can be solubilised and quantified
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spectrophotometrically (Mosmann, 1983). The colour intensity provides a measure
of both the number of cells and their metabolic activity.
Another widely used method is Trypan blue exclusion assay, where the cell’s ability
to exclude a coloured dye (trypan blue) serves as a measure of membrane integrity,
and, thus, cell survival.
MTT reduction assay
MTT stock solution was prepared by dissolving the MTT powder (Sigma-Aldrich Co.,
St. Louis, USA) in RPMI-1640 without phenol red, to give the final concentration of
5 mg/mL. The stock solution was filter-sterilised through a 0.22 µm syringe filter and
stored at –20 ◦C in the dark. For the cellular viability assay the stock solution was
further diluted in pre-warmed RPMI-1640 without phenol red to give a 0.5 mg/mL
final MTT concentration.
Sample preparation: The adherent HMDM cells were washed briefly with room
temperature PBS and incubated with 0.6 mL of the MTT solution at 37 ◦C in the dark
for approximately 30 minutes. The time varied depending on the overall metabolic
activity of the control cells and plating density. The non-adherent cells were treated
in RPMI-1640 without phenol red, and the 5 mg/mL MTT reagent was added di-
rectly to the treatment wells to give a final concentration of 0.5 mg/mL. The plates
were incubated in the dark at 37 ◦C for 1 to 2 hours to allow for sufficient formazan
development.
The formazan crystals were solubilised by the addition of an equal volume of 10%
(w/v) sodium dodecyl sulphate (SDS) (in 0.01 M HCl) into each well and thorough
mixing. The absorbance was recorded at 570 nm against a blank containing the
reagents only.
PrestoBlueTM cell viability assay
PrestoBlueTM (Molecular Probes, Invitrogen, Life Technologies Inc., New Zealand)
is a viability assay based on the cellular capacity to reduce a non-fluorescent com-
pound to fluorescent resazurin. Similarly to MTT, PrestoBlueTM is reduced by the
metabolically active cells, thus providing a measure of cell number and viability.
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Sample preparation. The adherent HMDM cells were rinsed with warm PBS
and incubated with 200 µL of 10% PrestoBlueTM solution in RPMI-1640 without
phenol red. The cells were incubated at 37 ◦C for 50-90 minutes to allow for resazurin
reduction and fluorescence development. One hundred µL of the supernatant was
transferred into black polystyrene microplates (Nunc), for fluorescence to be recorded.
The data was collected on a POLARstar Galaxy plate reader (Alphatech Systems
Ltd., Auckland, New Zealand) equipped for fluorescence detection. The settings
were: 544 nm excitation and 590 nm emission wavelengths, gain: 4, number of cycles:
1, number of flashes: 20 and positioning delay: 1. Software used was FLUOstar
Control.
Trypan blue exclusion assay
The suspension cells were mixed by pipetting and 100 µL was collected into a separate
tube. Trypan blue dye was added at the appropriate ratio (usually 1:1 for U937
cells and 1:10 for monocytes) and the stained/unstained cells were counted using a
hemocytometer.
2.4.3 HPLC methods
High performance liquid chromatography (HPLC) is an analytical technique that en-
ables the separation and quantification of specific compounds from a complex mixture
based on their chemical properties. The HPLC system used in this study (Shimadzu
Corporation, Japan) consisted of LC20AD pump with on-line degasser, SIL-20AC
temperature controlled autosampler, CT0-20 column oven, RF10AXL fluorescence
detector and SPD-M20A photodiode array (PDA) detector. Peaks were integrated
and peak areas were determined using LCsolution software (Shimadzu Corporation,
Japan).
Pterin assay
Neopterin has high native fluorescence which can be used for its detection. 7,8-NP was
quantified after its oxidation to the fluorescent neopterin (labelled “total neopterin”)
as a function of (total neopterin – neopterin). The assumption of the method is that
all 7,8-NP is converted to neopterin and that only a small amount of the compound
is lost during the preparation of oxidised sample (Flavall et al., 2008).
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HPLC set-up: The HPLC set-up was Synergi 4µ Hydro-RP 80A, 250 x 4.6 mm, 5
µm column (Phenomenex, USA) as a stationary phase; 20 mM ammonium phosphate
(AmPO4) with 5% acetonitrile (ACN), pH 6 in mobile phase, pumped at a flow rate of
1 mL/min. The oven was set at 35 ◦C. The elutant was monitored using a fluorescence
detector set at 353 nm excitation and 438 nm emission wavelengths, 1.5 response, x4
gain, and medium sensitivity. Pure D-neopterin (Schircks Laboratory, Switzerland)
dissolved in the mobile phase was used as a standard. Due to the difficulty in the
resolution of neopterin and acetonitrile (ACN) peaks on the chromatogram, an ACN
standard was also run.
Sample preparation: Adherent cells were washed with cold PBS twice, incubated
with 300 µL of ice-cold acetonitrile:water (1:1) for 1 minute with the plate lid on. Cell
lysate was collected by scraping and aliquoted into 1.5 mL centrifuge tubes. After
sonification at 4 ◦C for 1 min, 10 µL of the sample were collected for protein analysis.
The remainder of the sample was centrifuged at 10,300 g at 4 ◦C for 5 min and 50
µL of the supernatant was taken for neopterin analysis (10 µL injection volume). For
the total pterin analysis, another 100 µL of the supernatant was further incubated
with 20 µL of acidic iodide (5.4% I2 : 10.8% KI in 1 M HCl) at room temperature
in the dark for 15 minutes. After that, 20 µL of 0.6 M ascorbic acid was added
to neutralise the excess acidic iodide. The samples were further centrifuged for 5
minutes as described above. Ten µL of supernatant were injected into the HPLC.
The neopterin-containing sample was stable for at least 3 days when stored at –20 ◦C
(Laich et al., 2002).
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(a) 25 nM neopterin standard
(b) 65 nM 7,8-NP oxidised to neopterin
(c) Cells control neoptern
(d) Cells control oxidised
Figure 2.3: Typical HPLC chromatograms after Pterin assay.
The standards and samples were prepared as outlined in 2.4.3. The arrows indicate
neopterin peak. The author is grateful to Tejraj Janmale for the images.
53
2. MATERIALS & METHODS
7-Ketocholesterol assay
Oxysterols are a product of advanced cholesterol oxidation. 7KC is an oxysterol that
received significant attention in the literature due to its reported cytotoxicity (Jessup
et al., 2002; Vejux & Lizard, 2009). It is found in copper and AAPH-oxidised LDL
and is also abundant in atherosclerotic plaques (Brown et al., 1996; Garcia-Cruset
et al., 2001). Oxysterols absorb at a range of wavelengths; 234 nm wavelength was
used in this study for 7KC. The method was adopted from Kritharides et al. (1993)
and Brown et al. (1997).
Sample preparation: Adherent cells were washed twice with cold PBS and in-
cubated with 500 µL of 0.2 M sodium hydroxide (NaOH), 0.2 mg/mL butylated
hydroxytoluene (BHT) and 2 mg/mL EDTA for 8 min on ice and harvested by scrap-
ing. After a two minute sonification, 10 µL of each sample were taken for protein
analysis. Three hundred µL of a sample were transferred into glass culture tubes
with a screw-on cap. Protein precipitation was induced by the addition of 0.5 mL
ice-cold ethanol followed by a brief vortex. Upon the addition of 5 mL of hexane, the
samples were vortexed for 60 sec to allow the migration of the lipid–soluble 7KC into
the hexane layer. These samples were stored at −80 ◦C.
On the day of the analysis, the samples were vortexed again and centrifuged at 200
g for 10 minutes at 4 ◦C to ensure phase separation. Two millilitres of the top layer
were transferred to tapered glass evaporation tubes and dried under nitrogen gas.
The residue was re-solubilised in ACN:isopropyl alcohol (IPA) in the ratio 4:5 and 20
µL was injected into the HPLC.
Alkaline hydrolysis of cholesterol esters: Alkaline hydrolysis with potassium
hydroxide (KOH) allows the conversion of 7KC esters into free 7KC and their detec-
tion by the same method. OxLDL and cell lysate were prepared as described above,
but evaporation tubes were substituted for the glass culture tubes with a screw top.
After evaporation, saponification was carried out as described by Brown et al. (1997).
Two and a half mL of diethyl ether and 2 mL of 20% (w/v) KOH solution in methanol
were added to the residue, vortexed to mix, flushed with argon and incubated on ice
for 3 hours with 30 second vortex every 30 minutes. The hydrolysis was stopped by
adding 2 mL of 20% (v/v) acetic acid followed by a 30 second vortex. Two and a half
mL of hexane were added to the tubes, vortexed for 1 minute allowing the transfer of
all hydrophobic material into the hexane-ether layer, and centrifuged at 200 g for 10
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minutes at 4 ◦C. Eighty percent of the top layer was collected into evaporation tubes,
dried under nitrogen, re-solubilised in ACN/IPA as described above and injected into
the HPLC.
HPLC set-up: HPLC set-up for 7KC assay consisted of a stationary phase, Pheno-
sphere C18, 250 x 6.60 mm, 5 µm column (Phenomenex, USA) and mobile phase,
comprising acetonitrile/isopropanol/water in the ratio of 44:54:2. The column was
maintained at 35 ◦C with a flow rate of 1 mL/min. The PDA detector was set to 190
nm starting wavelength and 370 nm end wavelength; 234nm was used for analysis.
The sampling was done at 1.5625 Hz; slit width was 1.2 nm. 7KC standard (Ser-
aloids Inc, USA) was dissolved in the mobile phase to 10 µM. The injection volume
for standard and samples was 20 µL.
Reduced glutathione assay
Intracellular GSH is an important intracellular antioxidant and can be used as a
marker of oxidative damage in cells (Valko et al., 2007). Monobromobimane, 1H,7H-
pyrazolo(1,2-0˘3B1)pyrazole-1,7-dione, 3-(bromomethyl)-2,5,6-trimethyl- (MBB) is a
cell permeable fluorescent compound that binds -SH groups, specifically that of GSH.
MBB-GSH adduct can be detected by the HPLC (Cotgreave & Moldeus, 1986). Be-
cause of the tight binding between GSH and MBB, the BCA protein assay of an
MBB–treated sample would yield an artificially lower protein concentration as –SH
groups would be unavailable for the BCA reagent binding. Therefore, the results
of the GSH assay in this thesis are presented without correction for cellular protein
concentration.
Sample preparation: All procedures were carried out under minimum light con-
ditions as MBB is light-sensitive. MBB (Fluka Analytical, Switzerland) was dissolved
in ACN to a 40 mM stock solution, which could be stored in the dark at 4 ◦C for up to
2 weeks. Commercially available reduced GSH served as a standard. It was dissolved
in PBS to 0, 5 and 10 µM on the day of the analysis. For cell lysate preparation,
incubation medium was aspirated from adherent cells and 400 µL of PBS, 9 µL of
0.1 NaOH (to adjust pH to 8.0), and 10 µL of 40 mM MBB were added to each well
in this order. After 20 minute incubation in the dark at room temperature, 20 µL
of 100% trichloroacetic acid (TCA) was added and swirled to precipitate the protein
and lyse the cells. The cell lysate was harvested by scraping and centrifuged at 13,000
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g, 4 ◦C for 5 min. Five or ten microliters of the supernatant was injected into the
HPLC.
HPLC set-up: The stationary phase consisted of Phenosphere reverse phase C-18
150x4.6 mm, 5 µm column (Phenomenex, Auckland, New Zealand) heated to 35 ◦C.
The mobile phase, flowing at a rate of 1.5 mL/min, was set as a gradient flow. For
the first 10 minutes, the mobile phase was a mixture of 10% acetonitrile and 90%
of 0.25% acetic acid. The concentration of ACN was raised to 100% during the 11th
minute of a sample run and kept at that for the following 5 minutes. The post-run
washing step started at minute 16 and was comprised of 95% of ACN and 5% of
0.25% acetic acid. The GSH–MBB adduct was detected by a fluorescence detector
with the following settings: 394 nm excitation and 480 nm emission wavelengths, 1.5
response, x4 gain and medium sensitivity.
2.5 Western blot technique
2.5.1 Solutions for Western blot
Cracker buffer: To prepare the cracker buffer, 125 mM Tris-HCl, pH 6.8 (ad-
justed with concentrated HCl), 1% SDS (w/v), 20% glycerol (w/v) and 0.1% bro-
mophenol blue (w/v) were mixed in nano-pure water. Prior to use, 2% (v/v) of
β–mercaptoethanol (β–MEtOH) and 0.5 mM EDTA was added to 1 mL of the above
solution.
Lysis Buffer: The lysis buffer consisted of 40 mM HEPES, 50 mM NaCl, 1 mM
EDTA, and 1 mM ethylene glycol-bis(2-aminoethylether)-N,N,N,N-tetraacetic acid
(EGTA) in nanopure water, pH 7.4 (adjusted with 5 M NaOH) and stored at 4 ◦C.
Protease inhibitor, reconstituted and frozen to the manufacturers recommendations
(ProteaseMini, Roche Diagnostics), was defrosted and added to the lysis buffer on
the day of sample collection.
MOPS buffer: A 10x stock solution of MOPS was prepared with 500 mM MOPS,
500 mM Tris base, 1% SDS (w/v), and 10 mM EDTA in water with pH adjusted to
7.7. This was diluted with water to 1x concentration before use.
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Transfer buffer: The transfer buffer incorporated 25 mM Tris, 200 mM glycine
and 20% methanol (v/v) in water and was stored at 4 ◦C. The transfer buffer was
re-used once.
Tris-buffered saline: Tris-buffered saline (TBS) used for nitrocellulose membrane
washing, consisted of 40 mM Tris-HCl, 150 mM NaCl at pH 7.5, 0.05% Tween20
(w/v) and 0.01% thimerosal (w/v) (contains Hg, toxic) dissolved in water.
TBSM: The membrane blocking solution (TBS-milk, TBSM) was 5% (w/v) of non-
fat milk powder (Anchor, New Zealand) made in TBS. It was stored at 4 ◦C for up
to one week.
Ponceau S stain: The Ponceau S stain consisted of 0.01% Ponceau S (w/v) in 5%
acetic acid (v/v).
2.5.2 Antibodies
Antibodies were stored at 4 ◦C and added directly to the incubation solution. A table
of antibodies and concentrations used is presented (table 2.3).
Table 2.3: List of antibodies used.
Agent Raised in Dilution Medium Inc. time Supplier Conj. Poly/monoclonal
CD36 rabbit 1:1,000 1% TBSM 1.5h Novus Biologicals - poly, aff. purified
anti-rabbit goat 1:2,000 2% TBSM 1h Novus Biologicals HRP -
β-actin mouse 1:7,500 1% TBSM 1 Sigma Aldrich - monoclonal
anti-mouse goat 1:7,500 2% TBSM 1.5 GE Healthcare HRP -
CD68 rabbit 1:500 1% TBSM 1 Novus Biologicals - monoclonal
p47phox mouse 1:250 2% TBSM 1.5 Santa Cruz - monoclonal
anti-mouse goat 1:750 2% TBSM 1 Santa Cruz HRP -
2.5.3 Sample preparation
Cell lysate preparation. HMDM samples for western blot were prepared the fol-
lowing way. All medium was aspirated from the wells and the adherent cells were
washed twice with cold PBS. Two hundred µL of ice-cold lysis buffer containing pro-
tease inhibitor was added to each well. The cells were harvested by scraping and
sonified for 1 minute to ensure complete lysis.
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Plaque homogenization. Atherosclerotic plaques for analysis were supplied by
the Department of Surgery, Christchurch Hospital. Consent was obtained from each
patient for their plaques to be included in the research prior to surgery. Ethical ap-
proval for this research has been granted by the Upper South (A) Regional Ethics
Committee, approval number CTY/01/04/036.
Plaques collected during carotid endarterectomy surgery were immediately trans-
ported to the Free Radical Biochemistry Laboratory on ice, snap frozen in liquid
nitrogen and stored at –80 ◦C. The plaques were dissected into 3-5 mm sections lon-
gitudinally starting with the leading end and proceeding in the direction of blood
flow. Each section was homogenized under liquid nitrogen using pestle and mortar
and mixed with 3 mL of water containing 50 µL of 100 mg/mL EDTA (pH 7.4) and
20 µL of 20 mg/mL BHT (in methanol). The protein content of the samples was
determined by BCA protein assay in order to achieve equal loading of protein onto
the gel.
2.5.4 SDS-polyacrylamide gel electrophoresis
The required amount of sample (based on the protein concentration, commonly up to
200 µL) was aliquoted into 1.7 mL centrifuge tubes. One mL of –20 ◦C acetone was
added to each tube and centrifuged at 15,000 g, at 0 ◦C for 10 min. The supernatant
was discarded and the tubes were left in the fume hood for the remaining acetone
to evaporate. The pellet was re-suspended in the cracker buffer containing 2% β–
MEtOH to the final protein concentration 0.5-1 µg protein per µL. The samples were
heated in a heating block at 95 ◦C for 3 minutes to denature the protein. This was
followed by centrifugation for 5 minutes at 20,000 g. Five microlitres of pre-stained
molecular weight marker mix (Fermentas International Inc, Ontario, Canada) and
5-25 µL/well (depending on required protein content) of samples were loaded into the
gel wells. The samples were subjected to electrophoresis on a gradient polyacrylamide
gel, (4-12% Bis-Tris Gel, Invitrogen, Carslband, CA, USA) in 1x MOPS buffer. The
gel was run at 200 V after the dye front eluted from the wells.
2.5.5 Immunoblotting and visualisation
After SDS-PAGE, the proteins were transferred onto an nitrocellulose (NC) mem-
brane (Invitrogen, USA, 0.45 µm pore size) over 10 h at 70 V in a tank transfer
electrophoresis unit (TE22, Hoefer, USA) containing the transfer buffer. At the end
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of the transfer, the NC membrane was taken out of the transfer cassette, rinsed with
nano-pure water and stained with 0.01% Ponceau S stain for 1 minute to examine
the transfer efficiency. Pink protein bands were visible with Ponceau S stain.
The following procedures were performed on a rocking platform mixer (Ratex In-
struments, Australia). After a quick rinse with water, the membrane was blocked
using 5% TBSM for 1.5 hours. The TBSM was changed every 30 minutes. Subse-
quently, the membrane was probed with rabbit polyclonal affinity purified antibody
raised against human CD36 (NB400-145, Novus Biologicals Inc., USA) or mouse mon-
oclonal antibody raised against β-actin (A5316, Sigma-Aldrich Chemical Co., USA)
for 1.5 hours. The primary antibody against CD36 was diluted to 1:1,000 in 1% TBSM
and against β-actin to 1:7,500 in 2% TBSM. The membrane was washed 3 times for
5 minutes in TBS followed by 1 hour incubation with the secondary antibody. The
secondary antibody to anti-CD36 was a goat polyclonal anti-rabbit IgG, conjugated
to HRP (NB730-H, Novus Biologicals Inc., USA) 1:2,000 dilution. β-Actin secondary
antibody was anti-mouse IgG Peroxidase-linked NA931 (GE Healthcare, UK) diluted
to 1:7,500 in 2% TBSM. This was followed by 5 of 5 minute washes in TBS and a
brief rinse with water before visualisation. The re-probing of the membrane with
β-actin antibody was done after the visualisation of the first desired protein. The
membranes were kept in TBS at 4 ◦C until re-probing. Usually, the membrane had to
be stripped off the anti-CD36 antibodies before probing it for β-actin. The membrane
was incubated with stripping buffer (2% SDS, 50 M Tris, 100 µM β–MEtOH, pH 6.8,
heated to 50 ◦C on a water bath) for 20 min, followed by 5 of 5 minute washes in TBS.
The membrane was then directly incubated with the primary anti-β-actin antibody
without blocking.
The chemiluminescence signal corresponding to the position of the hydrogen per-
oxidase (HRP)-conjugated secondary antibody was detected by incubating the mem-
brane with Supersignal West Dura Chemiluminescence (TerumoScientific, USA) sub-
strates, which were mixed at a ratio of 1:1. According to the manufacturer’s instruc-
tions, the image data was recorded 2.5 minutes after the application of the visuali-
sation HRP solution. The images were obtained at high resolution, without filter or
light, using time-lapse auto-exposure setting on a Syngene Chemigenius-2 bioimaging
system (USA). Exposure times varied for different antibodies – from a few seconds for
the detection of β-actin to 3.5 minutes for CD36 detection. The images were analyzed
for band intensity with GeneSnap (Syngene, USA) and ImageJ64 1.42q.
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2.6 Fluorescent microscopy
2.6.1 Dihydroethidium probe
Dihydroethidium (DHE) bromide is a fluorescent probe widely used to detect super-
oxide anion O2
•– production within cells. The precursor compound, DHE (dissolved
in DMSO) is readily taken up by cells and is retained intracellularly after cleavage by
esterases. Non-fluorescent DHE is oxidised to highly fluorescent ethidium through the
reaction with O2
•– (Kobzik et al., 1990; Rothe & Valet, 1990), or, according to a more
recent report, to 2-OH-hydroxyethidium (2-OH-HE) (Zhao et al., 2005). Originally,
DHE was reported to have a low affinity for hydrogen peroxide (Benov et al., 1998;
Bindokas et al., 1996), yet later the specificity of DHE has been questioned (Tarpey,
2004), although some reports still favour its specificity when the right product is
measured (Fernandes et al., 2006; Zhao et al., 2005). Despite this, DHE remains an
effective tool for measuring the overall intracellular reactive oxygen species’ burden
(Fernandes et al., 2006; Kobzik et al., 1990; Tarpey, 2004).
2.6.2 Sample preparation and processing
HMDM cells were seeded at a concentration of 5 x 106 cells per 22 x 22 mm sterile
glass cover slip in a 6 well plate. At the end of the experimental incubation, the cells
were washed with PBS twice, after which a coverslip was lifted off the plate with a
bent hypodermic needle and transferred to a clean 6 well tissue culture plate. DHE
stock in DMSO (1 mM) was dissolved in PBS just before use to a concentration of
10 µM and kept in the dark. A hundred and fifty microliters of the 10 µM DHE
solution was loaded on top of coverslips and the HMDM cells were incubated in a
humidified incubator for 20 minutes in the dark. Excess probe solution was washed
off with PBS (twice). Forty microlitres of PBS was placed on top of the glass slide
and the coverslip was carefully lowered onto the glass slide with the cells facing down.
The cells grown on coverslips and stained with fluorescent probes were examined using
a Zeiss AxioImager.M1 epifluorescent microscope (Carl Zeiss (NZ) Ltd, Wellington,
New Zealand), equipped for differential interference contrast (DIC). A condenser was
fitted with an HBO 100 W mercury vapour lamp. The cells were viewed using 20x and
40x Plan-NEOFLUAR objectives with numeric aperture of 0.5 and 0.75 respectively.
The fluorescent filter used for DHE staining was a Zeiss filter set 00 for propidium
iodide (PI). The images were captured using a Zeiss AxioCam HRc CCD camera with
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AxioVision Rel. 4.5 image analysis software (1300 x 1030 pixel resolution). Densio-
metric quantification was done with ImageJ64 1.42q software. After data collection,
the images were manipulated with Gimp version 2.6 used in conjunction with XQuartz
2.1.6 application to achieve the appropriate publication standard.
2.7 Flow cytometry
Analysis of intracellular processes was carried out by flow cytometry. This technique
is used for a vast number of biomedical applications of quantitative analytical nature
(Shapiro, 2003). Flow cytometry often operates on the same optical measurement as
the fluorescent microscope but allows high sample throughput. An Accuri C6 flow
cytometer (BD Biosciences, USA) was used to measure ethidium, propidium iodide
and annexin V probe fluorescence.
Sample preparation: After an experimental treatment, HMDM cells were rinsed
briefly with warm PBS and incubated with 130 µL AccutaseTM (Millipore Australia
Pty., New Zealand) for 20 min in the dark at 37 ◦C. AccutaseTM facilitates the detach-
ment of adherent cells from the bottom of the well (Simard et al., 2008). AccutaseTM
solution contained: 1 x Accutase enzymes in Dulbecco’s PBS (0.2 g/L KCl, 0.2 g/L
KH2PO4, 8 g/L NaCl, and 1.15 g/L Na2HPO4, containing 0.5 mM EDTA˙4Na and
3 mg/L Phenol Red (Millipore product description). After a 20 minute incubation,
the plate was removed from the incubator, the cells in each well were pipetted 7-
10 times to dislodge the detached cells and aliquoted into 1.5 mL tubes. For DHE
measurements, 10 µM DHE was added directly to AccutaseTM and analysed after
detachment using the Accuri C6. For apoptosis/necrosis measurements, the samples
were prepared according to the manufacturer’s instructions (ApoAlert kit, BD Bio-
science, USA) after detachment with AccutaseTM.
Data on HMDM was collected using the following settings: flow rate 55 µl/min,
core size 30 µm and number of events: 10,000 into the gated area. The gate con-
tained healthy HMDM cells as well as HMDM at the early stages of cell toxicity,
and was determined experimentally. The lazer settings used were: 488 nm excitation
wavelength and a range of emission filters including FL1 filter (533/30 nm) for FITC
and FL3 (>670 nm) for PI and DHE. All data were collected and analysed using the
cFlow Plus software (BD Biosciences).
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2.8 Polymerase chain reaction
2.8.1 RNA isolation and purification
Ribonucleic acid (RNA) was extracted into TRIzol (Invitrogen, Life Sciences, New
Zealand) according to the manufacturer’s instructions. Briefly, 200 µL of TRIzol
was added to each well after the medium was aspirated. The liquid was pipetted
10 times, accompanied by the scraping of the bottom of the well with the pipette
tip (RNase/DNase-free pipette tips were from Maxymum RecoveryTM). Three wells
were combined per treatment into a single 1.5 mL tube (Axygen Scientific, Inc, Union
City, CA, USA). Each tube was incubated for 5 min at room temperature and frozen
at –80 ◦C. The sample was processed for RNA isolation and cyclic DNA (cDNA)
synthesis within 7 days.
For the RNA isolation, the samples were thawed at room temperature, topped up
with chloroform (0.2 mL chloroform per 0.75 mL TRIzol), vortexed for 15 seconds,
incubated for 15 minutes at room temperature and centrifuged for 15 minutes at
12,000 g and 4 ◦C. Three quarters of the aqueous phase were transferred into a new
set of tubes and topped up with isopropanol (0.5 mL per 0.75 mL TRIzol in the
initial sample). The tubes were inverted to mix, incubated for 10 minutes at room
temperature and centrifuged at 12,000 g for 10 minutes at 4 ◦C. After centrifugation,
the supernatant was carefully removed and the pellet was topped up with at least 1
mL 75% ethanol in diethyl-pyro-carbonate (DEPC)–treated water and re-suspended
via vortexing. The samples were centrifuged at 7,500 g for 5 min at 4 ◦C.
To re-dissolve the RNA, the pellet was air dried at room temperature for approx-
imately 30 minutes, re-dissolved in 20 µL DEPC-water, heated for 10 minutes at
55 ◦C and assessed for absorbtion at 260 nm using the Nano Drop (ND-1000 Spec-
trophotometer, BioLab). The RNA suitable for further processing had an absorbance
reading above 1.8 on the 260/280 ration and a reading above 1.2 at 260/230 wave-
lengths ratio. The latter was lower than recommended (Nockengost, 2009), but the
corresponding RNA was successfully converted into cDNA that specifically amplified
by PCR. An absorbance of 1 unit at 260 nm corresponds to 40 µg of RNA per mL.
2.8.2 cDNA synthesis
All components of the qScriptTM Flex cDNA Synthesis Kit (Quanta Biosciences), ex-
cept for the reverse transcriptase enzyme (RT), were thawed, mixed thoroughly and
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centrifuged before use. Two microliters of Random Oligos (from the kit) and 2 µL
of Random Primers (kit) per tube were made up into a master-mix and 4 µL of this
solution was aliquoted into 200 µL PCR tubes. RNA was thawed and added to the
tubes to give 950-990 µg RNA per tube. Each tube was topped up with Nuclease-free
water (kit) to the final volume of 15 µL. The tubes were capped, vortexed gently,
centrifuged for 5 seconds, incubated for 5 minutes at 65 ◦C in Mastercycler epgradi-
ent S (Eppendorf, Hamburg, Germany) and snap-chilled on ice.
During this time, a master-mix of 4 µL of 5x Reaction Mix (kit) and 1 µL of RT
(kit) was prepared. Five µL of that was added to each RNA-containing tube with the
exception of one, which was prepared in a similar fashion but did not contain RT (no
RT control). The tubes were vortexed gently, centrifuged for 5 seconds and subjected
to the following incubation treatment: 80 minutes at 42 ◦C followed by 5 minutes
at 85 ◦C and held at 4 ◦C. After the final step, cDNA concentration was measured
spectrophotometrically at 260 nm (Nanodrop). The final cDNA concentration was
approximately 1000 ng/µL.
2.8.3 Real-time quantitative PCR
RT qPCR master mix was prepared using the following procedure. A 10 µL qPCR
reaction consisted of 1 µL dNTP, 1 µL 10x PCR reaction buffer (Invitrogen), 0.3 µL
Cyto9 probe, 0.05 µL of 5 U/µL Platinum TaQ polymerase (Invitrogen), 1 µL cDNA,
1 µL of 5 µM forward primer, 1 µL of 5 µM reverse primer topped with nano-pure
water. The reaction master mix containing everything but the cDNA and the primers
was prepared, vortexed and aliquoted into individual wells of a 48 well plate (dNature,
New Zealand). Each primer pair was pre-mixed before addition to the wells. Primer
pair mixes and the cDNA was added to the appropriate wells individually due to the
issues with dimerisation of one primer pair. The PCR plate included a no RT control
and a no template (no cDNA) control. The plates were sealed, centrifuged to remove
bubbles and subjected to the thermal profile outlined in table 2.4. The amplification
of the appropriate PCR products was judged by the product melting temperature.
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Table 2.4: qPCR thermal profile.
Step Temperature, ◦C Time
Polymerase activation 95 2 min
PCR Cycling step 1 95 30 sec
PCR Cycling step 2 57 1 min
PCR Cycling step 3 72 1 min
Melt Curve step 1 95 15 sec
Melt Curve step 2 55 15 sec
Melt Curve step 3 95 15 sec
2.8.4 Agarose gel electrophoresis
PCR products were examined by electrophoresis on 1-2% agarose gel and visualised.
The gels were prepared by melting agarose (AppliChem GmbH, Germany) in 1x
TBE in the microwave, cooling the agarose solution to 50-60 ◦C and pouring into
a gel-casting tray (Easy-CastTM Electrophoresis system, Owl separation systems,
Portsmouth, NH, USA). The solidified gel was covered by 1x TBE. The samples were
prepared in 0.7 mL tubes containing 2 µL of amplified sample and 2 µl of Loading
Dye Solution (Fermentas International Inc., Burlington, Otario, Canada) and loaded
into the wells. Five microlitres of 100bp GeneRulerTM DNA ladder (Fermentas) was
run as a molecular weight indicator. The gel was run at 100 V until the dye front had
migrated approximately three quarters of the length of the gel. The sample bands
were visualised under UV light (Bio-Rad Laboratories Pty Ltd, NSW, Australia),
equipped with Quantity One 4.6.1 software.
2.9 Statistical analysis
Statistical analysis was performed using GraphPad Prism Version 5.0d for Mac OS X
(GraphPad Software, San Diego, California, USA). All experiments, unless otherwise
stated, were performed in triplicate and each data point was replicated at least thrice
within an experiment. Unless stated otherwise, the results are displayed as mean
± SEM of mean values from (A) single experiment and (B) combined mean values
from three separate experiments. Where experiments were performed as a repetition
of the work done previously, a single experiment is presented (for example, figures 3.4
and 4.1).
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Statistical significance of the results was tested using one- and two-factor analy-
sis of variance (ANOVA), t-test with 95% confidence interval and linear regression.
Where indicated, a paired t-test or repeated measures (RM)-ANOVA (identical to
randomised block design) were conducted on the replicate data from combined exper-
iments as indicated the figure captions (Motulsky, 2007). One specific test (fig. 6.10)
was performed using linear mixed model function in R (R Core Team, 2012). One-
factor ANOVA was followed by Dunnetts post test, Bonferroni post test or Turkey’s
multiple comparison test, where appropriate. A two-tailed t-test with 95% confidence
interval was used when two sets of values were compared.
For quantitative factors (time and dose) regression lines were fitted using the least
squares fit. Non-linear (quadratic and segmented linear) regression was employed
if the response was not linear, and was carried out using the nonlinear regression
functionality in Prism5. Comparison between treatments or of two models within
a treatment was performed using extra sum-of squares F test in Prism5 (α=0.05).
The type of statistical test used in each experiment is indicated in the figure caption.
Statistical significance is denoted by *, p < 0.05, **, p < 0.01 and ***, p < 0.001.
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3OxLDL toxicity to human
monocyte–derived macrophages
3.1 Introduction
Macrophage cell death from oxLDL is a key event in the development of the atheroscle-
rotic plaque (Ball et al., 1995; Lusis, 2000; Moore & Tabas, 2011). Since oxLDL–
mediated cytotoxicity was described by Henriksen et al. (1979) and Hessler et al.
(1979), the underlying mechanisms have been investigated extensively (Steinberg &
Witztum, 2010). The present study will focus on modelling an aspect of this process
in cell culture.
OxLDL is toxic to human macrophages in vitro, with both apoptosis and necrosis
implicated in cell death (Asmis & Wintergerst, 1998; Gieseg et al., 2010a; Hardwick
et al., 1996; Wintergerst et al., 2000). Amongst many mechanisms proposed to gov-
ern oxLDL cytotoxicity, oxidative stress is very prominent (Galle et al., 2006; Gieseg
et al., 2010b; Salvayre et al., 2002). Intracellular glutathione/glutathione disulfide
(GSH/GSSG) acts as a buffer preventing fluctuations of redox status that may upset
intracellular homeostasis and lead to cell death. OxLDL has been shown to deplete
intracellular GSH, inhibit glutathione reductase, and reduce the GSH/GSSG ratio
(Wang et al., 2006). Depletion of intracellular GSH enhanced oxLDL toxicity, while
supplementation of intracellular GSH stores substantially diminished oxLDL toxicity
(Amit, 2008; Gotoh et al., 1993; Kinscherf et al., 1998; Wang et al., 2006).
GSH loss is proposed to be the consequence of increased ROS flux triggered by oxLDL
(Gieseg et al., 2010a). ROS generation in response to oxLDL has been demonstrated
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in all major vascular cell types: SMCs (Higashi et al., 2005; Hsieh et al., 2001), ECs
(Cho et al., 1999; Zmijewski et al., 2005) and macrophages (Asmis & Begley, 2003;
Bae et al., 2009; Gieseg et al., 2010a; Lee et al., 2010; Park et al., 2009). Despite this
wealth of research, very few studies have concentrated on the time–dependant activ-
ity of intracellular ROS formation. Thus, the understanding of the kinetics of ROS
production by macrophages in response to oxLDL is incomplete. To address this, the
research presented here aims to compare and contrast the kinetics of oxLDL–mediated
HMDM cell viability loss, oxidative stress and damage and establish the time-frame
for irreversible cellular damage.
In this thesis the terms “toxicity” and “cytotoxicity”, which could be used rather
broadly (Freshney, 2010), will refer to the loss of cellular viability in response to
oxLDL and the ability of oxLDL to cause that loss. The investigation will focus on
mechanisms of macrophage death upon acute exposure to toxic levels of oxLDL (but
not chronic exposure as may be implicated in foam cell formation (Kruth, 2001)). A
24 hour acute toxicity experimental design will be adopted in order to simplify the
complexity of the system for experimental purposes. HMDM cells cultured for two
weeks will be treated with a toxic LC50 concentration of Cu-oxLDL for 24 hours. The
term LC50 denotes a toxic concentration of oxLDL that is required to kill 50% of cells
within 24 hours (Zhang et al., 2006). This chapter will define the scope and basic
characteristics of the experimental setting, such as toxic concentrations of oxLDL to
HMDM cells and time-dependant kinetics of toxicity. These will be used to inform
experimental design in subsequent chapters. A time-course of ROS production and
subsequent oxidative damage will also be investigated, as the association between ki-
netics of toxicity and oxLDL–triggered oxidative stress have been largely overlooked
in the literature. Overall, the results obtained in this chapter will lay the foundation
for subsequent work by exploring important aspects of intracellular mechanisms of
oxLDL toxicity to macrophages.
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3.2 Results
3.2.1 OxLDL–induced cytotoxicity to HMDM is concentra-
tion and time dependant
The acute cytotoxicity of oxLDL to macrophages was examined by incubating HMDM
cells with increasing concentrations of oxLDL in the whole medium (RPMI-1640 sup-
plemented with 10% human serum and antibiotics as described in sec. 2.2.2). The
toxicity was measured by the ability of viable cells to reduce MTT to formazan via
the action of cellular NADPH–converting enzymes (Mosmann, 1983). The MTT as-
say is routinely used to determine the overall metabolic activity or number of viable
cells per well (Bjorkerud & Bjorkerud, 1996a; Mosmann, 1983). Previous work in this
laboratory observed a strong correlation between MTT reduction and trypan blue
exclusion assays (Amit, 2008; Baird et al., 2004) and studies are currently under way
to compare this to apoptosis/necrosis assays in the context of oxLDL–induced cellular
death (Mohd Othman, personal communication).
OxLDL caused a concentration–dependant loss of cellular viability in HMDM cells
(fig. 3.1). In a typical experiment (fig. 3.1a), oxLDL concentrations of above 1
mg/mL were significantly toxic (as determined by one-factor ANOVA with Dunnett
post test). Cellular viability decreased linearly at a rate of approximately 15% per
mg/mL of oxLDL. LC50 was 3 mg/mL, which agreed with some published HMDM cell
results from this laboratory (Gieseg et al., 2009), but contradicted another (Gieseg
et al., 2010a). Gieseg et al. (2010a) observed a 50% cell viability loss in response to
a much lower 1 mg/mL oxLDL.
In order to provide a more robust assessment of the oxLDL toxicity to HMDM cells,
a regression line was fitted to the mean values of cell viability from 14 combined ex-
periments (fig. 3.1b). A steeper slope of 20% cell viability drop per 1 mg/mL oxLDL
was observed on the combined data. Based on these results, the toxic range (LC50) of
oxLDL concentrations was established to be between 2 and 3 mg of oxLDL cholesterol
per mL, with some variation between HMDM cell preparations from different donors.
A time–course observation of HMDM cell viability during exposure to oxLDL re-
vealed that the majority (40%) of cell viability decline happened within the first 12
hours of incubation (fig. 3.2). The remaining 10% was lost during the following 12–
24 hours of incubation. A segmented regression fitted to the 0–12 hour and 12–24
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hour data confirmed that the slopes of the two parts were significantly different (fig.
3.2b). This result agreed with the observations of Katouah (2012) but differed from
those of Gieseg et al. (2010a), where the majority of oxLDL–mediated cell viability
loss was observed during the 12–24 hours. Previous experimental work by Gieseg
et al. (2010a) suggested that rapid loss of cellular viability could be associated with
oxidative damage. This mechanism was explored further.
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Figure 3.1: OxLDL causes concentration dependant HMDM cell viability
loss after 24 hours.
HMDM cells (5x106 cells mL-1) were incubated with increasing concentrations of oxLDL
for 24 hours, followed by cell viability assessment (MTT reduction). The results are
expressed as percentage relative to untreated control and the results are displayed as
mean ± SEM of (A) a single experiment or (B) combined experimental results from
n=14 experiments for [oxLDL] from 0 to 3 mg/mL and n=6 for [oxLDL]=4 mg/mL.
One-way ANOVA with Dunnetts post-test was performed on the raw data for (a) and
linear regression was fitted for (b). Significance is indicated from cell only control, **,
p<0.01, ***, p<0.001
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Figure 3.2: Time course of oxLDL–mediated HMDM cell viability loss.
HMDM cells (5x106 cells mL-1) were incubated with the LD50 oxLDL concentration
in the whole medium for the indicated time. Cell viability was determined via MTT
reduction assay and expressed as percentage relative to untreated control. Results
are displayed as mean ± SEM of mean values from (A) a single experiment and (B)
combined mean values from three separate experiments. Statistical analysis ((A) one-
factor-ANOVA with Dunnett’s post test or (B) RM–one-factor-ANOVA with Dunnett’s
post test compared to control) is as indicated: *, p<0.05, **, p<0.01, ***, p<0.001.
Segmented regression was a preferred model fit over linear regression, p=0.0015.
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3.2.2 Oxidative stress and damage is an early event in oxLDL
toxicity
Intracellular ROS generation and the resulting oxidative damage were studied in
HMDM cells exposed to oxLDL. ROS were detected using fluorescent products of
DHE oxidation. The following experiments repeated the work by Gieseg et al. (2010a)
but advanced further to quantify ROS flux. The DHE method (sec. 2.6.1) was
used as a generic proxy for determining the the overall intracellular oxidative flux.
The internalised DHE probe reacts with superoxide and a range of ROS with re-
lated chemistries to yield fluorescent ethidium and 2-OH-HE (Fernandes et al., 2006;
Kobzik et al., 1990; Tarpey, 2004). These were detected through an epifluorescent
microscope and quantified using densitometry.
Intracellular oxidative flux was an early event in the HMDM cell interaction with
oxLDL, reaching a 50-70% increase in mean cellular fluorescence as early as 3 hours
after the addition of oxLDL (fig. 3.3). Intracellular levels of ROS increased sharply
and continuously to almost double the initial level by 12 hours, followed by a grad-
ual decline to 3/4 of the peak value. Figure 3.3a represents a single experiment,
whereas three experiments are combined in one graph on figure 3.3b. It is important
to combine experimental means in order to eliminate the effects specific to individual
HMDM cell preparations, even at the expense of large error bars, which represent the
inter-experimental variation of absolute HMDM cell response to oxLDL (fig. 3.3b).
The results confirm that HMDM cells release intracellular ROS when treated with
oxLDL and that this oxidative flux is an early event in the acute toxicity setting.
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Figure 3.3: OxLDL triggers intracellular ROS release by HMDM cells.
HMDM cells, cultured on coverslips (5x106 cells mL-1) were incubated with 2 mg/mL
oxLDL in the whole medium. Oxidant production was measured by DHE using an
epifluorescent microscope at λex/λem of 500-530nm/590-620nm. Images were taken at
the indicated time points and fluorescence intensity was converted into the numerical
values using ImageJ64 software. Data are presented as percentage increase from the 0
hour control and shown as mean ± SEM of (A) duplicate measurements from a single
experiment or (B) three separate experiments combined. Statistical significance (one-
factor ANOVA performed on raw numerical data for (A) and RM-ANOVA for (B)) is
indicated between the treatments at a respective time point, ***, p<0.001.
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To confirm that ROS production and oxidative flux were damaging to the HMDM
cells, the loss of intracellular GSH was assessed. Intracellular GSH is one of the
primary antioxidant defence mechanisms and its decrease is an excellent marker of
oxidative damage (Valko et al., 2007). Previous studies in this laboratory and by
other groups showed that oxLDL incubation caused an oxidative depletion of GSH
(Amit, 2008; Gotoh et al., 1993; Kinscherf et al., 1998; Wang et al., 2006). Therefore,
this experiment was performed to confirm that the HMDM cells in the present study
responded to oxLDL in a manner similar to the published literature. The results
confirmed that toxic concentrations of oxLDL led to the loss of intracellular GSH in
HMDM cells (fig. 3.4). Two milligrams per mL oxLDL caused approximately 50%
GSH loss, while 3 mg/mL caused about a 70% loss (fig. 3.4a). Contrary to the
results observed by Amit (2008), 0.5 and 1 mg/mL oxLDL triggered an increase in
GSH, most likely due to the upregulation of GSH synthesis, as observed by Ha¨gg
et al. (2006). The decrease in GSH was lower after correction for cellular protein
(figures 3.4 a) and b) which was most likely due to the interference of MBB-based
GSH assay with bicicronic acid (BCA) assay for protein). The BCA based protein
assay which was used in this study relies, in part, on the -SH thiol functional group for
assessment of protein concentration. However, the same -SH functionality was utilised
in GSH detection by reaction with MBB. Therefore, the protein assay performed on
cellular lysates previously treated with MBB would be devoid of reactive protein–
free -SH groups. Thus, GSH results were not corrected for protein, as the sample
protein concentration was likely to be erroneous. This limitation of the methodology
probably resulted in the over-reporting of GSH loss per cell as the results could not
be corrected for cell lysis at toxic oxLDL concentrations. In addition, cells are known
to upregulate GSH upon in response to oxLDL, complicating the analysis (Bea, 2003;
Cho et al., 1999; Shen & Sevanian, 2001).
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Figure 3.4: OxLDL leads to concentration dependent intracellular GSH loss
in HMDM.
HMDM cells (5 x 106 cells mL-1) were incubated with increasing oxLDL concentrations
for 24 hours. Cell lysate was analyzed for reduced GSH via HPLC. Results are displayed
as mean ± SEM of triplicate measurements from a single experiment (A) expressed
uncorrected, (B) corrected for protein. Significance (one-way ANOVA, Dunnett’s test)
is indicated from 0 mg/mL oxLDL, *, p<0.05, ***, p<0.001. Average protein concen-
tration in control was 61.4 µg/well.
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3.2.3 When does HMDM cell become committed to cell death?
The results presented so far indicate that the mechanism of acute oxLDL toxicity to
HMDM cells involves rapid ROS production and oxidative damage. Identifying the
point at which the damage becomes irreversible is an important question in the in
vivo situation. Since cell viability loss became significant by the 6th hour of incuba-
tion (fig. 3.2b) and the rate of intracellular ROS release (corresponding to slope of
the graph, greatest increase of ROS over time) was highest at 0–6 hours (fig. 3.3),
6 hours was chosen as a cut-off point to test the reversibility of damage inflicted by
oxLDL on HMDM cells. The cells were treated with LC50 oxLDL for 6 hours, after
which the medium was removed and replenished with fresh whole medium for a fur-
ther 18 hours (referred to as the 6+18 hour treatment). Such experimental design
enabled comparison between the “oxLDL removed” treatment (6 hours) and “oxLDL
throughout” treatment (24 hours) to be made on the same time scale. Oxidative
damage to GSH and cell viability loss were assessed in this experimental setting.
Within the first 6 hours of oxLDL treatment, the HMDM culture lost almost 50% of
the intracellular GSH (fig. 3.5). The cells that were further incubated with oxLDL
continued to lose GSH until the 9th hour of incubation, after which the level of intra-
cellular GSH had plateaued. In contrast, the 6+18 HMDM cells in which oxLDL was
removed after the 6th hour had recovered their intracellular GSH by the 12th hour of
incubation. The GSH remained at this level for the rest of the incubation period. No
such recovery was observed for cellular viability. After the initial 20% viability loss in
the first 6 hours, the 6+18 cells continued to lose metabolic activity (fig. 3.6). Thus,
cellular metabolic activity was irreversibly affected by the 6 hour exposure to LC50
oxLDL. HMDM cells in the 6+18 treatment still had lower toxicity (higher cell via-
bility) at the end of 24 hours than their counterparts which were exposed to oxLDL
for the full duration (as indicated by # in fig. 3.6). This pointed towards additional
processes that may have occurred in these cells. Yet the 6+18 HMDM cells were
unable to regain cellular viability in a fashion similar to GSH recovery.
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Figure 3.5: Time course of intracellular GSH recovery by HMDM upon
oxLDL removal.
HMDM cells (1x106 cells mL-1) in whole medium were treated with 2 mg/mL oxLDL.
OxLDL was either replaced with fresh medium after 6 hours (empty rectangles) or
present for the indicated time (filled circles). Cell lysates were analysed via HPLC us-
ing the MBB method and expressed as percentage of untreated control. The results are
presented as mean ± SEM of mean values from (A) a single experiment and (B) com-
bined mean values from three separate experiments. Significance is indicated: between
treatments (one-factor ANOVA with Bonferroni post test of treatment pairs *, Dunnet
post test comparison to control $), *,$ p<0.05, ** p<0.01. Due to the inter-batch
variability in the GSH recovery, the data pairing was not effective and significance was
p=0.079 and p=0.165 at 24 and 12 hour time points, respectively.
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Figure 3.6: HMDM continues to lose cellular viability when oxLDL is re-
moved.
HMDM cells (1x106 cells mL-1) in whole medium were treated with 2 mg/mL oxLDL.
OxLDL was either removed after 6 hours (empty rectangles) followed by the incubation
in the whole medium or present for the indicated 24 hours (filled circles). Cell viability
was measured by MTT reduction and expressed as percentage of 0 hour control. Re-
sults are displayed as mean ± SEM of mean values from (A) single experiment and
(B) combined mean values from three separate experiments. Paired t-test (95% confi-
dence interval) was performed on the raw data and data expressed as a percentage of
control. Significant difference from 6 hour time point, *, p<0.05, **, p<0.01; between
the treatments #, p<0.05.
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Similar patterns of GSH recovery in the absence of viability recovery were observed in
a concentration study. HMDM cells in the whole medium were treated with increas-
ing concentrations of oxLDL for either 6+18 or for 24 hours, followed by GSH and
cell viability measurement (figures 3.7 and 3.8, respectively). Intracellular GSH was
considerably elevated in the cells exposed to oxLDL for 6 hours, compared to cells
exposed for 24 hours over the whole range of oxLDL concentrations (fig. 3.7). The
difference between the two treatments was higher at the sub-toxic concentrations of
oxLDL (1 and 2 mg/mL) than at a toxic 3 mg/mL (fig. 3.7, filled vs. clear bars).
Intracellular GSH was lower than control in the HMDM cells exposed to 3 mg/mL
oxLDL for 6 hours (fig. 3.7, clear bars). This was lower compared to cells treated
with 1 and 2 mg/mL oxLDL for 6 hours, which indicated that GSH recovery after 3
mg/mL was not as dramatic.
Despite GSH recovery at all oxLDL concentrations, cellular viability did not fol-
low the same trend (fig. 3.8). Cellular metabolic capacity dropped between 2 and 3
mg/mL oxLDL for both 6+18 and 24 hour treatments and no significant difference
was observed between the treatments for any of the concentrations tested.
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Figure 3.7: HMDM cells significantly recover intracellular GSH upon oxLDL
removal: effect of concentration.
HMDM cells (5x106 cells mL-1) in the whole medium were treated with varying con-
centrations of oxLDL for either 24 hours (filled bars) or 6 hours (empty bars) with
subsequent removal of oxLDL and incubation in whole medium for another 18 hours.
The intracellular GSH level was analysed at the end of the 24 hour period. Results are
displayed as mean ± SEM of triplicates from a single experiment. Statistical signifi-
cance (two-factor ANOVA, Dunnetts post test): time of exposure (6 vs. 24h), [oxLDL]
and the interaction are all statistically significant (p<0.001). One-factor ANOVA with
Bonferroni pairwise comparison of 6 vs. 24h was significant, #, p<0.05, #, p<0.001.
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Figure 3.8: HMDM cells do not recover viability upon oxLDL removal: ef-
fect of concentration.
HMDM cells (5x106 cells mL-1) in the whole medium were treated with varying con-
centrations of oxLDL for either 24 hours (filled bars) or 6 hours (empty bars) with
subsequent removal of oxLDL and incubation in whole medium for another 18 hours.
Cell viability was measured by MTT reduction and expressed as percentage of 0 hour
control. Results are displayed as mean ± SEM of experimental means (n=3, except for
[oxLDL]=3 mg/mL where n=2). The 24 and 6+18 hour treatments were not statisti-
cally different (one-factor ANOVA with Bonferroni post-test).
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3.3 Discussion: Oxidative stress as intracellular
mechanism of toxicity
OxLDL toxicity to HMDM cells
OxLDL toxicity was concentration and time dependant (figures 3.1 and 3.2), as had
been observed previously (Amit, 2008; Asmis & Begley, 2003; Asmis & Wintergerst,
1998; Gieseg et al., 2010a; Hardwick et al., 1996). It has to be noted that the concen-
trations of oxLDL presented in the literature could vary by a factor of 5 depending
on the unit. One hundred µg/mL oxLDL determined via protein assay equals 500
µg/mL oxLDL expressed as mg/mL of LDL cholesterol (Baird et al., 2004; Gieseg
et al., 2009, 2010a; Katouah, 2012), as apoB protein comprises 1/5 of total LDL
molecular mass (Gieseg & Esterbauer, 1994).
One hundred µg/mL of oxLDL protein caused approximately 50% cytotoxicity to
HMDM according to Asmis & Begley (2003) and Hardwick et al. (1996) and 31%
apoptosis in Asmis & Wintergerst (1998), which was considerably lower than the
10% cell viability loss observed with 500 µg/mL of oxLDL cholesterol in the present
study. However, different experimental conditions were used in this than in other
studies which prevented direct comparison of the results (see sec. 6.4 for detail).
LC50 was determined to be between 2 and 3 mg/mL based on the data from multiple
experiments (fig. 3.1) which was in agreement with the concentration used recently
by Katouah (2012) and Gieseg et al. (2009).
The first significant drop of cell viability was observed after 6 hours incubation with
LC50, similar to the MTT results observed by Hardwick et al. (1996) and Katouah
(2012). It continued to drop until reaching 40% at 12 hours and then another 10% in
the following 12 hours, showing significantly different rates of change during the first
and second half of the oxLDL treatment. The trend suggested that toxic processes
within the first half of the acute oxLDL incubation had a major contribution to cell
viability loss in HMDM cells. This agreed with the observation in Katouah (2012),
but was different to the trend observed in Gieseg et al. (2010a) where the majority
of toxicity took place in the second half of the incubation. However, Gieseg et al.
(2010a) observed a 50% decrease in intracellular GSH and ROS elevation in the first
6 hours after oxLDL exposure, just like the present study (figures 3.3 and 3.5), which
suggested that the intracellular processes mediated by oxLDL were similar.
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Oxidative stress as a mediator of cell damage and death
The cause of oxLDL toxicity to cells could be the inherent properties of the oxLDL
molecule, such as cytotoxic oxysterols, 4-hydroxynonenal, LOOH (Levitan et al.,
2010). Yet Rutherford & Gieseg (2012) showed that extrapolation from the effect
of a part onto the effect of the whole may be extremely limited. 7-Ketocholesterol,
which was found to be toxic when applied exogenously in solution, was not found to
be toxic when presented to U937 cells more physiologically as part of acetylated LDL
(Rutherford & Gieseg, 2012). This research is, therefore, focused on the cellular re-
sponse to oxLDL molecule as a whole. Oxidative stress is a characteristic response to
oxLDL, that has been proposed to mediate, at least in part, oxLDL toxicity (Gieseg
et al., 2010b).
Intracellular oxidant production in oxLDL-treated HMDM was assessed by dihy-
droethidium (DHE) probe. Non-fluorescent DHE is rapidly internalised and becomes
oxidised to highly fluorescent ethidium and 2-OH-HE through the reaction with O2
•–
(Kobzik et al., 1990; Rothe & Valet, 1990; Zhao et al., 2005). As mentioned in section
2.6.1 DHE is an effective tool for measuring the overall intracellular reactive oxygen
species’ burden, since it is not exclusively specific for O2
•– (Fernandes et al., 2006;
Kalyanaraman, 2011; Kobzik et al., 1990; Tarpey, 2004).
Mean cellular fluorescence in oxLDL-treated HMDM was highly elevated compared
to the control at all times, indicating substantial oxidant production in response to
oxLDL. Within the first 3 hours it increased by 50-70%, reached 75-100% at 12 hours
and then began declining (fig. 3.3). This pattern of a quick initial burst and fast es-
calation which wears off with time is that of an initial trigger→ propagation cascade
→ sequestration type that is common to free radical reactions. Alternatively, such
kinetics is similar to the phagocytic NOX activation and respiratory burst (Robinson,
2008). Such a type of oxidative flux is not obvious from the literature on the oxLDL–
HMDM cell interaction. For example, the kinetics observed here were different from
the steady DCFH-DA(6-carboxy-2’,7’-dichlorodihydrofluorescein diacetate)–detected
H2O2 increase in HMDM study by Asmis & Begley (2003). DHE primarily measures
O2
•–, while DCFH-DA is more specific for H2O2. Asmis & Begley (2003) reported
that oxLDL–mediated peroxide fluorescence intensity reached 300% by the 9th hour,
while its rate of formation appeared fairly constant. Asmis & Begley (2003), however,
did not observe any DHE–reactive O2
•–. In EC cells, DCFH-DA–detectable ROS was
shown to peak at 3 hours and remain constantly elevated for the duration of 24
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hour incubation with oxLDL. Both H2O2 and Mito-SOX–detectable O2
•– (Mito-SOX
is based on DHE chemistry) were elevated in U937 cells at 5 and 4 hours post-Cu-
oxLDL addition (Al Gadban et al., 2010; Ermak et al., 2010). In Gieseg et al. (2010a)
we also documented that oxLDL induced a DHE–reactive oxidative stress over the
first 6 hours. The present work observed and quantified the O2
•– dominated ROS
flux in HMDM cells exposed to oxLDL over time. Oxidative flux appeared to be an
early event in oxLDL toxicity which agreed with some, but not all, published studies
(Al Gadban et al., 2010; Ermak et al., 2010; Gieseg et al., 2010a).
The observed discrepancy could be caused by differences in cell culture conditions
or the type of cell: U937, EC and HMDM. Some of the observed discrepancy among
the published studies could be explained by the different ROS probes used, which
measure different types of ROS. It is difficult to interpret with certainty the com-
bined data from multiple studies. O2
•– is the precursor for most other cellular ROS
and reactive nitrogen species (RNS), thus the lack of O2
•– production observed by
Asmis & Begley (2003) is unclear. O2
•– dismutation by SOD yields H2O2. Accord-
ing to Beckman & Koppenol (1996), NO is the only molecule in the cell that can
out-compete SOD in the reaction with O2
•–, yielding peroxynitrite (ONOO-). Thus,
in the excess of O2
•– to NO, H2O2 will be produced. In the presence of transition
metal (TM) ions, H2O2 could give rise to HO
•– which will react further. The rapid
rate of elevation of DHE–reactive moieties could reflect the reactive oxygen/nitrogen
species generation, rather than the rate of de novo production of O2
•–. Potential
reactants that may oxidise DHE to fluorescent product are O2
•–, H2O2 and ONOO-
(Kalyanaraman, 2011). Alternatively, the source of rapid ROS production could be
NOX, which, as indicated in chapter 4, may be activated in HMDM cells upon oxLDL
exposure.
The net result of this exponentially growing ROS is rapid oxidant generation and,
likely, damage to cellular enzymes, membranes and structural proteins. Thus in the
first 6 hours, the cellular antioxidant defence may be overwhelmed by the generated
oxidants.
GSH recovery and cell viability
Oxidative flux has been suggested to precede oxidative damage, which would, in turn,
precede cell viability loss if it was caused by oxidative processes (Gieseg et al., 2010b;
85
3. OXLDL TOXICITY TO HUMAN MONOCYTE–DERIVED
MACROPHAGES
Yang et al., 2012). Glutathione is a key component of cellular defence against ox-
idative and nitrosative stress and an integral part of intracellular GSH/GSSG redox
buffer that maintains cellular redox homeostasis (Valko et al., 2007). Glutathione
loss as a consequence of oxidative flux thus serves as barometer of oxidative stress, as
GSH oxidation reflects oxidative damage to other cellular systems (Valko et al., 2007).
OxLDL in this study caused a concentration–dependant GSH loss (fig. 3.4), which
confirmed the oxidative nature of the damage inflicted by oxLDL on HMDM cells.
The time of the initial ROS generation observed in this study (fig. 3.3) was paral-
leled by the sharp drop in glutathione level (fig. 3.5 (solid squares)), suggesting a
correlation between the two. This was also previously reported by Wang et al. (2006)
and Gieseg et al. (2010a). The novelty of this work lies in answering the question of
whether oxidative (and other) stress that HMDM cells experience within the first 6
hours of exposure to oxLDL was sufficient to cause irreversible damage and cell death.
The results in this study showed that the initial oxidative and other processes initi-
ated in HMDM cells upon oxLDL exposure for six hours were sufficient to irreversibly
compromise cellular metabolic capacity. HMDM cells managed to restore GSH within
6 hours after oxLDL removal, while the cells incubated with oxLDL for the whole du-
ration lost the majority of their GSH by the 9th hour (fig. 3.5). Previously, Shen
& Sevanian (2001) also showed that 200 µg/ml oxLDL caused a rapid depletion of
intracellular GSH within 3 hours in J774 A.1 mouse macrophage cell line, followed by
an adaptive increase to 175% of control by 24 hours. Cho et al. (1999) reported that
50 µM oxLDL up-regulated GSH synthesis in EC cells. Thus it is not surprising that
removal of extracellular oxLDL after 6 hours of incubation led to an adaptive increase
of intracellular GSH to levels that were higher than in control cells. Yet, when cells in
both treatments were assessed for metabolic activity via MTT, the difference between
treatments was very small (fig. 3.6). The cells continued to loose viability even after
the removal of oxLDL after 6 hours of incubation.
The trend was repeated in a concentration study (fig. 3.7). GSH recovery after
oxLDL removal was observed at all concentrations (1-3 mg/mL), albeit smaller at 3
mg/mL (fig. 3.7). All the concentrations showed a lack of cellular viability recovery.
This suggests that oxLDL damage to cells caused or initiated within the first 6 hours
of incubation was irreversible, irrespective of the oxLDL concentration. This theory
contrasts with Gotoh et al. (1993) observation that THP-1 cell pre-incubation with
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sub-toxic oxLDL (100 µg/mL) to up-regulate GSH had a protective effect against
toxic oxLDL concentrations (400 µg/mL).
This has important implications for the understanding of the dynamics of atheroscle-
rotic plaque. The result might suggest that macrophages infiltrating the plaque are
destined for destruction when they encounter oxLDL at concentrations that cause
any level of metabolic impairment, as the damage to cells will be permanent over the
long term.
3.4 Summary
The results in this section confirmed that oxLDL is toxic to HMDM cells and es-
tablished that under the current experimental conditions the LC50 of oxLDL was
between 2 and 3 mg/mL. Cellular viability loss was faster in the first 12 hours of in-
cubation (40%), followed by a more gradual loss of 10% over the remaining 12 hours.
The results suggested that oxLDL induced damage to cellular metabolism and that
it was higher during the first half of the incubation. This is likely to be dependant
on the initial ROS generation and oxidative damage to cells. Intracellular ROS in-
creased dramatically in the first 6 hours, peaking at 12 hours, which correlated with
extensive loss of GSH by the 9th hour of incubation. When extracellular oxLDL was
removed from HMDM cells after 6 hours of incubation, the cellular viability failed to
recover despite the recovery of intracellular glutathione. This response suggested that
acute oxidative damage was irrepairable. These results imply that even a short-term
exposure of macrophages to toxic levels of oxLDL within atherosclerotic plaque may
compromise cellular function beyond repair thus leading to cell death and expansion
of the plaque necrotic core region.
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4Antioxidant capacity of
7,8-dihydroneopterin
4.1 Introduction
Atherosclerotic plaques infiltrated with activated monocytes/macropages are a likely
source of elevated levels of neopterin in the circulation (Firth et al., 2008b; Gieseg
et al., 2009). Thus, it is not surprising that neopterin and its reduced counterpart
7,8-NP have been associated with atherosclerotic burden in cardiovascular disease
(Fuchs et al., 2009). Although serum levels of neopterin have been shown to correlate
and even predict atherosclerotic complications and the disease instability (Adachi
et al., 2007; Ray et al., 2007; Sugioka et al., 2010), the biological role(s) of 7,8-NP in
atherosclerosis are not well understood.
A number of studies have shown that 7,8-NP protects cells of myelocytic origin from
the cytotoxic effects of oxLDL, which is one of the key drivers of atherosclerotic plaque
development (Baird et al., 2005; Gieseg et al., 2001b, 2010a). The mechanisms for this
protection are not entirely clear, but the available data suggest two plausible routes:
the antioxidant capacity of 7,8-NP and 7,8-NP–mediated reduction of oxLDL uptake
by macrophages (Gieseg et al., 2010a). The research in this chapter will address the
role of antioxidant activity of 7,8-NP in oxLDL–macrophage interaction and cellular
death.
Oxidative nature of macrophage-oxLDL interaction: sources of ROS
As discussed in the previous chapter 3, oxLDL–mediated acute HMDM cell death is
characterised by early oxidative stress. Therefore, antioxidant properties of 7,8-NP
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will be evaluated by observing its effect on the overall intracellular oxidative burden
induced by oxLDL and examining the evidence for 7,8-NP oxidation.
O2
•– has been proposed to be the primary ROS formed after oxLDL–triggered sig-
nalling (Deng et al., 2008; Gieseg et al., 2010a; Park et al., 2009). However, superoxide
is the precursor of a suite of ROS, that are more reactive and, consequently, toxic,
such as H2O2, HO
•–, ONOO- and HOCl (fig. 1.3) (Stocker & Keaney, 2004). For
example, Asmis & Begley (2003) showed that peroxide and the resulting peroxyl rad-
icals, rather than superoxide, were the main drivers of oxLDL–induced macrophage
lysis. The nature of cellular oxidants triggered by oxLDL signalling is difficult to dis-
cern as many molecular probes used to study these lack specificity. The unique nature
of 7,8-NP oxidation to neopterin will be used in this work to further understanding
of the identity of oxLDL–upregulated intracellular ROS. In addition, this work will
offer insight into potential physiological processes that give rise to neopterin within
atherosclerotic plaques.
Several enzymatic systems have been implicated in the production of cellular ROS.
These include NADPH oxidases, uncoupled inducible nitric oxide synthase (iNOS),
myeloperoxidase, and the enzymes of dysfunctional mitochondrial electron transport
chain (ETC) (Ignarro, 2009; Podrez et al., 2000; Stocker & Keaney, 2004). NOXs are
of major importance because their activation and subsequent O2
•– release seem to be
triggered by the initial binding of oxLDL to macrophage receptor(s) and are, therefore,
upstream of the other pathways (Park et al., 2009). However, the connection between
mitochondrial dysfunction and NOX is less clear as evidence for both cause-and-effect
relationships exists (Wingler et al., 2011; Wosniak et al., 2009). Recent evidence from
murine macrophage cell line J774A.1 suggests that cellular NOX–produced O2
•– con-
tributes to iNOS–mediated reactive nitrogen species (RNS) formation because apoc-
ynin, a NOX inhibitor, prevented both ROS and RNS formation (Muijsers et al.,
2000). Myeloperoxidase, too, requires O2
•–, dismutated into H2O2, to catalyse the
formation of HOCl (Podrez et al., 2000). A large body of evidence points towards
NOX as the source of ROS during oxLDL-mediated cellular oxidative stress (Aviram
et al., 1996; Brandes et al., 2010; Lee et al., 2010; Sheehan et al., 2011; Singh & Jialal,
2006). NOX complex assembly is activated by oxLDL binding and cellular signalling
(Park et al., 2009) and involves translocation and docking of cytosolic subunits to the
plasma membrane–bound NOX domains (Groemping & Rittinger, 2005). To investi-
gate the contribution of NOX–generated superoxide to the oxLDL-mediated oxidative
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stress in macrophages, a NOX inhibitor, apocynin, will be used in conjunction with
the assessment of intracellular oxidation of 7,8-NP. The 7,8-NP→NP oxidation chem-
istry will be used as a marker of oxidative processes within the cell. Apocynin is a
widely used inhibitor of NOX which acts by preventing the NOX complex assembly
via inhibiting p47phox phosphorylation and subsequent translocation to the plasma
membrane (Kanegae et al., 2007; Stefanska & Pawliczak, 2008; Stolk et al., 1994).
Apocynin had been repeatedly shown to inhibit ROS flux in different cell types in-
cluding macrophages (Holland et al., 1997; Stefanska & Pawliczak, 2008; Stolk et al.,
1994) but, to the researcher’s knowledge, had not been used to investigate the effect
of NOX inhibition on the secondary markers of oxidative stress, such as 7,8-NP oxida-
tion. Neither have there been any reports on how apocynin inhibition of NOX affects
cell survival of oxLDL–exposed HMDM cells. Since ROS-mediated oxidative stress is
reported to play an important role in oxLDL–mediated cell death, the contribution
of NOX to macrophage cell death triggered by oxLDL will be evaluated.
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4.2 Results
4.2.1 7,8-NP protects HMDM cells treated with oxLDL in a
concentration and time dependant fashion
7,8-Dihydroneopterin–mediated protection of HMDM cells was examined after treat-
ment with LC50 of oxLDL. Two hundred µM of exogenously added 7,8-NP showed
statistically significant protection (fig. 4.1). It was chosen as the working concen-
tration for subsequent experiments, as it was also similar to the previous findings
(Gieseg et al., 2010a).
In order to establish a time-frame for the protective activity of 7,8-NP, a time-course
study was performed. Two hundred µM of 7,8-NP provided protection of cell via-
bility at all times over the course of 24 hours, with a statistically significant effect
observed after 6 hours (fig. 4.2a). 7,8-NP inhibited oxLDL–induced cell viability loss
by approximately 30%, on average, at the end of 24 hours (fig. 4.2b). Interestingly,
the protection was almost complete until the 12th hour of incubation (95% for 7,8-
NP–treated HMDM vs. 63% for non 7,8-NP–treated HMDM), but reduced during
the next 12 hours of incubation (12–24 hours).
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Figure 4.1: 7,8-NP protects HMDM cells from oxLDL–mediated cell viabil-
ity loss in a concentration dependent manner.
HMDM cells (5x106 cells mL-1) were incubated with 2 mg/mL oxLDL in the presence
of increasing concentrations of 7,8-NP in the whole medium for 24 hours. Cell viability
was assessed via MTT reduction assay. The data are expressed as a percentage of the
untreated control. Results are displayed as mean ± SEM of triplicate measurements
from a single experiment. Statistical significance (one-factor ANOVA with Dunnet’s
post test) is indicated as *, p<0.05 from 0 µM 7,8-NP in the presence of oxLDL; ##,
p<0.01 from control in the absence of oxLDL.
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Figure 4.2: Time course of 7,8-NP–mediated protection of HMDM cells
from oxLDL–induced cytotoxicity.
HMDM cells (5x106 cells mL-1) were incubated with LC50 oxLDL either in the presence
(empty square) or absence (filled circle) of 200 µM 7,8-NP in the whole medium. Cell
viability was assessed at indicated times via MTT reduction and the data are expressed
as a percentage relative to the untreated control. Results are displayed as mean ±
SEM of mean values from (A) single experiment and (B) combined mean values from
three separate experiments. Statistical analysis (one-factor-ANOVA with Bonferroni
comparison between treatments at respective time points) is as indicated: *, p<0.05,
**, p<0.01, ***, p<0.001. Regression lines fitted to the 0–12 hour data (Prism5) were
different between treatments in the first 12 hours (not shown) (p<0.001).
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4.2.2 7,8-NP concentration and availability in cell culture
7,8-NP oxidises in HMDM cell medium over 24 hours
The extracellular availability of 7,8-NP in the medium during the course of 24 hours
was investigated. During the first 12 hours of incubation with HMDM cells, total
pterin, the majority of which was comprised of 7,8-NP, decreased by about 10% from
the starting concentration of 200 µM (fig. 4.3a). This was followed by a sharper drop
to ∼130 µM during the following 12 hour period (12–24 hours). Interestingly, this
decrease did not correspond with a reciprocal increase in neopterin concentration (fig.
4.3b), indicating that this extracellular 7,8-NP was converted to a different product,
most likely 7,8-dihydroxanthopterin (Gieseg et al., 2001a). Our research group has
previously reported a decrease of extracellular 7,8-NP added to HMDM cell culture
to 100 µM after 24 hours (Gieseg et al., 2010a). The difference between the kinetics
reported here and in Gieseg et al. (2010a) is likely due to inter-experimental variation.
Control cells incubated for 24 hours in the absence of 7,8-NP showed a slight increase
in extracellular total pterin and neopterin (results not displayed). The values rose
from 25 to 32 nM for total pterin and from 2 to 3.7 nM for neopterin, indicating
that some production and/or oxidative processes were taking place. A measurement
of 10% serum supplemented RPMI-1640 returned 32.5 nM neopterin and 35 nM of
total neopterin (data courtesy T. Janmale), indicating that the baseline extracellular
neopterin originated from serum.
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Figure 4.3: Time course of extracellular pterin concentration when incu-
bated with HMDM cells.
HMDM cells (5x106 cells mL-1) were incubated with 200 µM 7,8-NP in the whole
medium. The samples of the extracellular medium were taken at the indicated times
and neopterin and total neopterin were measured by HPLC. Results are displayed as
mean ± SEM of triplicate measurements from a single experiment.
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Measurement of effective intracellular [7,8-NP] when added exogenously
An initial hypothesis stated that 7,8-NP–mediated protection against oxLDL was
associated with its intracellular action. The effective intracellular concentration of
7,8-NP was, therefore, measured after exogenous application. HMDM cells were
treated with 200 µM 7,8-NP and assessed for neopterin and total neopterin (fig 4.4).
The level of total intracellular neopterin, the majority of which was comprised of
7,8-NP, rose sharply in the first 1 hour of incubation and continued to rise until the
12th hour of incubation, reaching 3.1 nmol/mg cellular protein or 142 pmol/well, to
then plateau. Neopterin levels remained small starting from 175 pmol/mg protein in
the 1st hour reaching 286 pmol/mg protein or 6.42 pmol/well at 24 hours.
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Figure 4.4: Time course of 7,8-NP accumulation of exogenously added 7,8-
NP in HMDM cells.
HMDM cells (5x106 cells mL-1) were incubated with 200 µM 7,8-NP (with a 10 minute
pre-incubation prior to the collection of 0 hour sample). Cell lysates were collected
at the indicated times and analysed for neopterin and total pterin via HPLC. Results
are displayed as mean ± SEM of triplicate measurements from a single experiment.
For reference, [total pterin]=142 pmol/well and [neopterin]=6.7 pmol/well at 12 hours;
average protein content was 196 µg/well. Statistical significance (one-factor ANOVA,
compared to control) is as indicated, **, p<0.01.
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Multiple preparations of HMDM cells were tested for intracellular 7,8-NP concentra-
tion and the data were pooled to assess the variation. The intracellular neopterin and
7,8-NP concentrations varied between HMDM preparations incubated with 200 µM
7,8-NP for 24 hours (fig. 4.5). As these data were analysed retrospectively, the exper-
iments should be treated as a pilot study. Five HMDM preparations were incubated
with 200 µM 7,8-NP for 24 hours. Two out of the five experiments were performed
on the HMDM cells seeded at 5x106 cells/mL in 12 well plates (fig. 4.5, squares). In
the remaining three experiments, HMDM cells were seeded at 1x106 cells/mL in 48
well plates. The intracellular neopterin and 7,8-NP concentrations measured in all
five experiments varied between 7 and 42 pmol/well for neopterin and between 82 and
286 for calculated 7,8-NP (fig. 4.5). Correction for cellular protein was performed
in order to mitigate the difference associated with the number of HMDM cells per
well in these different plate types (fig. 4.5b). Following the correction, however, the
variation in concentration (between 300–2065 pmol/mg protein) of calculated 7,8-NP
was still present.
An attempt was made to interpret the 7,8-NP uptake variation in the view of the
baseline intracellular levels of 7,8-NP and neopterin in these HMDM cells. Yet the
cells seeded at the same density demonstrated similar baseline total pterin levels:
5x106 cells/mL showed a ∼45 pmol of calculated 7,8-NP per mg protein, whereas in
the cells seeded at 1x106 cells/mL, ∼80 pmol/mg protein was consistently observed
(fig. 4.6). Pairwise comparison of the respective experiments in figures 4.6 and 4.5
showed that the pattern of high-low [7,8-NP] was not consistent. It thus remains
to be seen whether 7,8-NP uptake is variable due to the experimental conditions or
cellular physiology.
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Figure 4.5: Intracellular pterin concentration in HMDM after 7,8-NP addi-
tion.
HMDM cells (5x106 cells mL-1 (framed) and 1x106 cells mL-1) were incubated with
200 µM 7,8-NP for 24 hours. Total pterin and neopterin were measured by HPLC on
cell lysates, while 7,8-NP was calculated as a difference between the two measurements.
Protein concentration was measured by BCA assay. The results are presented as scatter
dot plot of five separate experimental measurements, each performed in triplicate. The
data is mean ± 95% CI, expressed as (A) pmol/well and (B) pmol/mg protein.
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Figure 4.6: Intracellular baseline pterin concentration in cultured HMDM.
HMDM cells seeded at 5x106 cells mL-1 (experiments 1 and 2) and 1x106 cells mL-1
(experiments 3-5) were cultured in the whole medium. Baseline levels of neopterin
(grey bars) and total neopterin (black bars) were measured by HPLC, while 7,8-NP
(white bars) was calculated as the difference between the two measurements. Protein
concentration was measured by BCA assay. Results are presented as mean ± SEM
of triplicate measurements from five separate experiments. For reference, [total pterin]
ranged from 3.7 to 53.6 pmol/well, [neoptrin] from 0.24 to 12.9 pmol/well, [protein] from
32.7 to 196 µg/well Statistical analysis (two-factor ANOVA) showed that the difference
between the experiments was significant, p<0.001
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HMDM cells produce small level of pterin in response to oxLDL
To determine whether the majority of 7,8-NP during HMDM cells’ incubation with
oxLDL was derived from an exogenous source, the ability of oxLDL to induce 7,8-NP
synthesis in HMDM cells was investigated. OxLDL elicited a small increase in total
pterin of 175, 43 and 17 pmol/mg protein, in the three HMDM preparations tested
(fig. 4.7). In two out of three experiments, this increase was due to an increase in
7,8-NP concentration. However, the inter-experimental variation in the pterin levels
comparative to the size of the effect was too large for the result to be statistically
significant.
The experiment was repeated with a sub-toxic concentration of oxLDL to discern
the effect of oxLDL levels that do not cause loss of cellular protein. HMDM cells,
treated with 1 mg/mL oxLDL for 24 hours in the whole medium, were assessed for
neopterin and total pterin (fig. 4.8). The intracellular 7,8-NP increase was much
smaller than demonstrated previously, showing a 8.6 and 2.4 pmol/mg protein in-
crease. No difference between treatments was observed in the extracellular pterin
levels (data not shown). Thus, the small level of 7,8-NP production up-regulated by
oxLDL appeared to be extremely small compared to the micromolar concentration
added exogenously. Consequently, the primary source of 7,8-NP during the HMDM
cell experiments with oxLDL was the exogenously added 7,8-NP.
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Figure 4.7: Endogenous neopterin production by HMDM cells in response
to toxic levels of oxLDL.
HMDM cells (1x106 cells mL-1) were incubated with (filled symbols) or without (clear
symbols) 2.5 mg/mL oxLDL for 24 hours in the 2% serum-containing medium. Cell
lysate was analysed for neoptein and total neopterin, and 7,8-NP was calculated as the
difference between the two measurements. Data is presented as a scatter dot plot of
three experiments, where each symbol represents the mean of triplicate measurements
from one experiment. For each type of pterin, the change in mean values after oxLDL
treatment is indicated with an arrow. Statistical analysis (two-tailed t-test on the
combined data, n=3) showed no significant difference between the treatments.
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Figure 4.8: Endogenous neopterin production by HMDM in response to
sub-toxic level of oxLDL.
HMDM cells (1x106 cells mL-1) were incubated with 1 mg/mL oxLDL for 24 hours in
the whole medium. Cell lysate was analysed for neoptein and total neopterin. Results
are displayed as mean ± SEM of mean values from single experiment; (A) and (B)
represent two separate experiments. No neopterin was detected. Fore reference, average
cellular protein in control wells of both experiments was approximately 45 µg/well.
Significance (two tailed t-test) on individual experiments is as indicated *, p<0.05;
t-test on combined data showed no significant effect of oxLDL treatment.
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4.2.3 7,8-NP alleviates oxLDL–mediated ROS stress in HMDM
The effect of 7,8-NP on the overall oxidative flux induced by oxLDL in HMDM cells
was determined in order to investigate the mechanism(s) of protection. Intracellu-
lar ROS were measured with dihydroethidium (DHE) probe, as described in section
3.2.2. 7,8-NP was very effective at stopping the ROS-related increase in the probe
fluorescence (fig. 4.9). The effect was, on average, most pronounced during the first 6
hours, with 7,8-NP preventing the rise in mean cellular fluorescence by approximately
50%. The capacity of 7,8-NP to scavenge/inhibit oxLDL–induced ROS decreased to
about 30% in the 12th hour (combined data) with a further drop by the 24th hour
(fig. 4.9b). The magnitude of the effect varied between the experiments, thus a single
experiment is presented alongside the combined data (fig. 4.9a and b, respectively).
The data suggest that 7,8-NP was highly effective at alleviating the initial oxidative
stress in HMDM cells, but was not always able to sustain the low levels of ROS be-
yond the 12th hour of incubation. The absorption/emission spectra of 7,8-NP and
DHE oxidation products did not overlap.
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Figure 4.9: 7,8-NP inhibits the oxLDL–driven elevation of intracellular ROS.
HMDM cells cultured on coverslips (5x106 cells mL-1) were incubated with 2 mg/mL
oxLDL in the whole medium in the presence (clear bars) or absence (filled bars) of 200
µM 7,8-NP. Oxidant production was measured by fluorescent microscopy with DHE
at λex/λem of 500-530nm/590-620nm. Images were taken at the indicated times and
fluorescence intensity per cell was digitised with ImageJ64. Both ± 7,8-NP data are
presented as percentage increase from the respective control shown as mean ± SEM of
mean values from (A) single experiment and (B) combined mean values from three
separate experiments. One-factor ANOVA with Bonferroni pairwise comparison of
treatments at each time point was performed on raw numerical data. Significance is
indicated between the treatments at a respective time: ***, p<0.001.
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4.2.4 7,8-NP is oxidised to neopterin in the HMDM cells
treated with oxLDL
The possible mechanism for 7,8-NP–mediated decrease of the intracellular oxidative
load is oxidant scavenging and/or prevention of oxidant formation. Oxidant scav-
enging can be tested by analysing the oxidation products of 7,8-NP: neopterin and
7,8-DXP (fig. 1.6). While direct 7,8-DXP detection was not pursued due to the
difficulty of assessing picomolar levels of this compound in cells, neopterin is highly
fluorescent and its levels were investigated further.
OxLDL treatment of HMDM cells pre-incubated with 200 µM 7,8-NP led to a con-
sistent increase in intracellular neopterin, which was 2.4 times higher than the non-
oxLDL control by the end of 24 hours (fig. 4.10). The rise in neopterin driven
by oxLDL followed linear kinetics after the first 3 hours of incubation. The levels
of neopterin reached 250 pmol/mg protein in two HMDM preparations and 1300
pmol/mg protein in another (fig. 4.10b). In contrast, neopterin level in 7,8-NP-only
HMDM cells plateaued at ∼100 (and 600) pmol/mg protein after the first 3 hours,
while 7,8-NP-free control cells did not produce any neopterin. There were notable
differences between HMDM preparations in the absolute levels of neopterin, yet the
trend and the magnitude were identical. Due to the toxicity of the oxLDL concentra-
tion used in this experiment, the data were corrected for protein to account for cell
loss due to oxLDL toxicity.
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Figure 4.10: 7,8-NP is oxidised to neopterin in HMDMs treated with oxLDL.
HMDM cells (1x106 cells mL-1) were incubated with 200 µM 7,8-NP in the presence
(solid line) or absence (dotted line) of 2.5 mg/mL oxLDL (in 2% serum). Cell lysates
were collected at the indicated times and analysed for intracellular neopterin. Results
are expressed as (A) mean ± SEM of triplicate measurements from a single experiment,
(B) three separate experiments. (B) Separate experiments are colour-coded, black and
pink are on the left Y-axis, blue is on the right Y-axis. For reference, [neopterin] in
control cells at 24 hours ranged from 16 to 42 pmol/well. [Protein] in control cells was
32.7, 125 and 150 µg/well. Regression analysis showed significant difference between the
slopes of oxLDL–treated and untreated cells (B); one-factor ANOVA with Bonferroni
pairwise comparison was significant as indicated in (A): **, p<0.01, ***, p<0.001.
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The level of remaining 7,8-NP was investigated to determine the relative magnitude of
its oxidation into neopterin. Also, any difference in the remaining 7,8-NP between the
treatments could be indicative of another 7,8-NP oxidation product, 7,8-DXP. The
level of intracellular 7,8-NP was measured by subtracting neopterin values from the
total intracellular pterin level. Total pterin and the calculated 7,8-NP levels are pre-
sented in figures 4.11 and 4.12, respectively. As above, HMDM cells were incubated
with 200 µM 7,8-NP in the presence or absence of LC50 of oxLDL. The treatments
were not statistically different from one another in total pterin or 7,8-NP1. How-
ever, given the size of the effect and the inter-experimental variance due to individual
HMDM batch response, is likely that the test does not have sufficient power to detect
a statistically significant effect of this magnitude.
OxLDL-induced oxidative stress resulted in the oxidation of 7,8-NP to neopterin
which comprised 34% ± 11 (SEM) of the total intracellular pterin in HMDM cells at
the end of 24 hours (figures 4.10 and 4.12). OxLDL treatment resulted in a slight
elevation of the intracellular total pterin starting at 3-6 hours post-oxLDL addition
(fig. 4.11). This was consistent with the onset of neopterin increase seen earlier (fig.
4.10) and continued during the remaining incubation time. Total pterin level encom-
passes both neopterin and 7,8-NP. Therefore, higher total pterin in oxLDL–treated
cells was reflecting the increase in neopterin levels.
OxLDL caused an incremental change in the intracellular 7,8-NP level compared
to the oxLDL–free control. This also commenced around 3-6 hours after the addition
of oxLDL, but, contrary to the level of total pterin, this difference in 7,8-NP level
between the treatments ceased by the 24th hour as indicated by the fitted curves con-
verging (fig. 4.12). Both oxLDL–treated and untreated cells showed slight decrease
in intracellular total pterin concentration (due to a decrease in 7,8-NP concentration)
after the first 12 hours of incubation, indicating potential oxidation to 7,8-DXP or
reduced uptake of 7,8-NP.
1Each data set (±oxLDL) was either fitted with an individual or a shared nonlinear regression
line in Prism5 as indicated (fig. 4.12a, b). The horizontal y asymptotes between the shared and
individual fits were compared with extra sum of squares F test (α=0.50) to determine whether
the treatments were significantly different from each other. The asymptotes were not significantly
different with p=0.85 for 7,8-NP and total pterin likewise. This result was confirmed with the
Bonferroni pairwise comparison of treatments at each individual time point after RM-one-factor
ANOVA (n=3).
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Extracellular concentrations of neopterin and total pterin were examined as well (fig.
4.13). The presence of oxLDL with HMDM led to a slightly reduced neopterin con-
centration in the extracellular medium (by ∼1 µM) and reduced total pterin concen-
tration (by ∼20 µM) (fig. 4.13a and b, respectively).
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Figure 4.11: Intracellular total pterin level is elevated in oxLDL–treated
HMDM cells.
HMDM cells (1x106 cells mL-1) in the 2% serum-containing medium were incubated
with 200 µM 7,8-NP in the presence (blue line, filled circles) or absence (red line,
empty circles) of 2.5 mg/mL oxLDL. Cell lysates were collected at the indicated times
and analysed for intracellular total pterin via HPLC. Protein was determined via BCA
assay. For reference, [total pterin] in control cells at 12 hours ranged from 165 to
400 pmol/well. Results are displayed as mean ± SEM of mean values from (A) single
experiment and (B) combined mean values from three separate experiments. Statistical
analysis (on B) showed that non-linear regression fitted to data was not significantly
different between the treatments.
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Figure 4.12: Intracellular 7,8-NP level is slightly altered by the presence of
oxLDL with HMDM cells.
HMDM cells (1x106 cells mL-1) in the 2% serum-containing medium were incubated
with 200 µM 7,8-NP in the presence (blue line, filled circles) or absence (red line,
empty circles) of 2.5 mg/mL oxLDL. Cell lysates were collected at the indicated times
and analysed for intracellular neopterin and total pterin via HPLC, while 7,8-NP was
calculated as the difference of the two. Protein was determined via BCA assay. Results
are displayed as mean ± SEM of mean values from (A) single experiment and (B)
combined mean values from three separate experiments. Statistical analysis (on B)
showed that nonlinear regression fitted to data was not significantly different between
the treatments.
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Figure 4.13: Extracellular neopterin and total pterin after oxLDL treatment
of 7,8-NP loaded HMDM cells.
HMDM cells (1x106 cells mL-1) in the 2% serum-containing medium were incubated
with 200 µM 7,8-NP in the presence (filled circles) or absence (empty circles) of 2.5
mg/mL oxLDL. Supernatants were collected at the indicated times and analysed for
neopterin and total pterin via HPLC. Results are displayed as mean ± SEM of combined
mean values from three separate experiments. (A) neopterin and (B) total neopterin.
Statistical analysis of regression line slopes did not reveal any difference between treat-
ments for A or B, the difference at the 24 hour was not statistically significant (RM
one factor ANOVA, Bonferroni test)
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4.2.5 Does NOX play a role in oxLDL toxicity to HMDM
cells?
Apocynin partially protects 7,8-NP from oxidation
In order to investigate the mechanism contributing to the oxidation of 7,8-NP and,
thus, the source of oxidants, a NOX inhibitor, apocynin, was added to the cells.
Apocynin was added to HMDM culture 3 hours prior to the addition of oxLDL to
allow for the full inhibitory action, followed by the oxLDL treatment at the LC50 (2.5
or 3 mg/mL). Cellular neopterin was measured after 12 hours, as ROS production
was previously shown to peak at this time point. The addition of 200 µM apocynin
reduced 7,8-NP oxidation to neopterin caused by oxLDL addition by approximately
50% (fig. 4.14a, b). This did not return the average intracellular neopterin levels to
the control levels of 173 pmol/mg cell protein (or 10.6 pmol/well) observed in 7,8-NP
treated HMDM cells in the absence of oxLDL (fig. 4.14a).
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Figure 4.14: Apocynin partially inhibits 7,8-NP oxidation to neopterin in
oxLDL-treated HMDM cells.
HMDM (1x106 cells mL-1), pre-treated with 200 µM apocynin (Apo) for 3 hours, were
incubated with 2.5 mg/mL oxLDL and 200 µM 7,8-NP in the presence of apocynin for
a further 12 hours. Cell lysates were analysed for intracellular neopterin via HPLC.
Results are displayed as mean ± SEM of mean values from (A) single experiment
and (B) combined mean values from three separate experiments. For reference, aver-
age [neopterin] in 7,8-NP control cells was 6.6 pmol/well. Statistical significance ((A)
one-factor ANOVA with Bonferroni pairwise comparison and (B) paired t-test) is as
indicated: *, p<0.05; **, p<0.01.
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Apocynin does not protect HMDM cells from oxLDL–mediated cell death
To investigate the effect of NOX–derived ROS on oxLDL–induced HMDM cell death
and survival, the apocynin treatment of macrophages exposed to oxLDL was fol-
lowed by a cell viability assay. Preliminary experiments showed that apocynin was
not toxic to HMDM over 27 hours (fig. 4.15) at the concentrations tested of up to
300 µM. Therefore, HMDM cells were incubated with apocynin and oxLDL for 24
hours and assessed for cellular viability. Despite the observed inhibition of oxidative
process in HMDM, 200 µM apocynin did not protect HMDM from oxLDL-induced
cell death after 24 hours of incubation (fig. 4.16a). Lower concentrations of 50 and
100 µM apocynin did not convey any protection against oxLDL toxicity, either, as
HMDM cells showed the similar levels of viability loss across the range of apocynin
concentrations tested (fig.4.16b).
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Figure 4.15: Apocynin is not toxic to HMDM cells.
HMDM (5x105 cells mL-1) in the whole medium were incubated with increasing concen-
trations of apocynin for 27 hours. Cell viability loss was measured by MTT reduction.
Results are displayed as percentage of remaining cell viability relative to untreated
control, shown as mean ± SEM of experimental means from two separate experiments.
Statistical analysis on raw data (one-factor ANOVA) revealed no significant differences.
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Figure 4.16: Apocynin does not protect HMDM cells against oxLDL (MTT).
HMDM (1x105 cells mL-1), pre-treated with the indicated concentrations of apocynin
for 3 hours, were incubated with oxLDL in the presence of apocynin for a further 24
hours. Cell viability loss was measured by MTT reduction. Results are displayed as
percentage of remaining cell viability relative to control, shown as mean ± SEM of
triplicate measurements from a single experiment. (A) and (B) represent two sepa-
rate experiments. ± Apocynin treatments were not statistically different (one-factor
ANOVA).
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Since oxidative stress in HMDM cells in response to oxLDL was an early event, the
incubation time of the experiments was shortened from 24 to 15 hours. HMDM cells
were treated with oxLDL for 15 instead of 24 hours and the cellular viability was
assessed with an ApoAlert kit (BD). HMDM cells were harvested into AccutaseTM,
incubated with Annexin V and propidium iodide (PI) and assessed for a shift in
cellular fluorescence that corresponded to apoptosis (annexin+) and necrosis (PI+) by
flow cytometery. The channels were compensated for spectral overlap by adjustment
with single dye control cells permeabilised with 2% paraformaldehyde. Each sample
output was gated based on forward/side scatter and split into annexin+/- and PI+/-
quadrants (fig. 4.17). The experimental results are presented as a comparison between
annexin+ and PI+ treatments (not mutually exclusive, fig. 4.18a) and a mutually
exclusive separation into four quadrants (fig. 4.18b). No significant difference in
the percentage of cells stained with PI or Annexin V was detected between the ±
apocynin treatments in the presence of 2.5 mg/mL oxLDL (fig.4.18a). A slight re-
distribution of annexin V staining was observed in the apocynin-oxLDL–treated cells
(fig. 4.18b, grey and black bars), yet the difference was not statistically significant
(p>0.05). The experiment was repeated with a range of apocynin concentrations (fig.
4.19). A slight concentration dependant reduction in the frequency of annexin+ cells
was observed, yet the result was not statistically significant (fig. 4.19a). No statistical
difference was observed in the relative quadrant frequency distribution, either. Thus,
the distribution of apoptotic, necrotic and live HMDM cells after oxLDL treatment
was unaffected by the presence of apocynin (fig. 4.18 and 4.19), which suggests that
apocynin was not protective against oxLDL toxicity, despite its ability to reduce
7,8-NP oxidation.
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Figure 4.17: Annexin V and PI quadrant identification on flow cytometer
output.
Break down of the flow cytometry output for Annexin V/PI HMDM cell staining is
presented. (A) Gating for HMDM cells (P2 gate); (B) HMDM cells autofluorescence;
(C) HMDM cells control; (D) oxLDL–treated HMDM cells; (E) oxLDL and apocynin–
treated HMDM cells; (F) apocynin only control HMDM cells.118
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Figure 4.18: Apocynin does not protect HMDM cells against oxLDL at 200
µM (Annexin V and PI).
HMDM (1x105 cells mL-1) pre-treated with 200 µM of apocynin (Apo) for 3 hours,
were incubated with 2.5 mg/mL oxLDL in the presence of apocynin for a further 15
hours. The presence of apoptosis/necrosis was measured by flow cytometry after the
cells were detached with AccutaseTMand stained for Annexin V and PI. Results are
displayed as percentage of cells with the respective staining (A) or in the respective
quadrant (B: next page), displayed as mean ± SEM of triplicate measurements from
a single experiment. No statistically significant difference was detected between ±
Apo treatments (one-factor ANOVA with Bonferroni post test comparing ± Apo on
oxLDL–treated HMDM cells).
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Figure 4.19: Apocynin at a range of concentrations does not protect HMDM
cells against oxLDL (Annexin V and PI).
HMDM (1x105 cells mL-1), pre-treated with the indicated concentrations of apocynin
(Apo) for 3 hours, were incubated with 2.5 mg/mL oxLDL in the presence of apocynin
for a further 15 hours. The presence of apoptosis/necrosis was measured by flow cy-
tometry after the cells were detached with AccutaseTMand stained for Annexin V and
PI. Results are displayed as percentage of cells with the respective staining (A) or in
the respective quadrant (B: next page), displayed as mean ± SEM of triplicate mea-
surements from a single experiment. No statistically significant difference was detected
between ± Apo treatments (one-factor ANOVA with Dunnett’s post test comparing to
oxLDL–treated HMDM cells).
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4.3 Discussion
4.3.1 7,8-NP–mediated protection of HMDM from oxLDL
Although 7,8-dihydroneopterin has been shown to protect HMDM cells from oxLDL–
mediated death (Gieseg et al., 2010a; Katouah, 2012), the result had to be con-
firmed in the current experimental setting to avoid any cell-specific artifacts. The
present study successfully confirmed that exogenously applied 200 µM 7,8-NP pro-
tects HMDM cells from acute cellular death triggered by oxidatively modified lipopro-
tein (fig. 4.1). The study went on to show that 200 µM 7,8-NP effectively inhibited
oxLDL–mediated HMDM cell viability loss at all time points over the course of 24
hours, providing, on average, a 30% protection at LC50 (fig. 4.2). The protective
effect was almost absolute at 12 hours, but reduced in the second half of the in-
cubation as indicated by a steeper slope (fig. 4.2b). A similar trend was observed
previously with 7,8-NP–mediated protection against GSH loss, characterised by com-
plete inhibition in the first 12 hours, followed by a gradual decrease over the 12–24
hours (Gieseg et al., 2010a). Such kinetics could indicate either that the magnitude
of 7,8-NP protection was a constant 30% of the remaining cell viability or that the ef-
fect of 7,8-NP–mediated protection diminished after the first 12 hours of acute toxic
exposure to oxLDL. The latter could result from two mechanisms: the nature of
the oxidative processes triggered in HMDM by oxLDL and/or a reduction of 7,8-NP
uptake by the cells.
4.3.2 Antioxidant activity of 7,8-NP
7,8-NP reduces oxidative flux in HMDM cells
Our research group has previously proposed that antioxidant properties of 7,8-NP me-
diate cell protection against oxLDL damage (Baird et al., 2005; Gieseg et al., 2010a).
This was based on the observations of 7,8-NP inhibiting GSH loss and protein hy-
droperoxide formation in THP-1 and monocyte cells treated with AAPH (Duggan
et al., 2002; Kappler et al., 2007). The present work is the first to quantitatively
assess the magnitude of 7,8-NP–mediated reduction of intracellular ROS as triggered
by oxLDL. 7,8-NP was most effective at scavenging/inhibiting ROS during the time
of severe oxidative flux (fig. 4.9). The highest rate of ROS production was observed
during the first 6 hours and the highest mean intracellular ROS was detected at 12
hours after oxLDL addition (fig. 4.9). This corresponded to the time period when
7,8-NP was most effective at suppressing intracellular ROS at 3, 6 and, to a lesser
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degree, 12 hours (fig. 4.9b). Higher 7,8-NP protection coincided with high oxidative
flux suggesting that 7,8-NP might be protecting HMDM via scavenging of ROS.
The slope of the cell viability regression in the absence of 7,8-NP was steeper during
the 0–12 hours than during 12–24 hours (fig. 4.2), indicating that toxic processes
during the first stage had more impact on the loss of metabolic capacity than the
processes in the second stage. The slope of viability loss by 7,8-NP-protected cells
was less steep during the first stage than during the second stage, indicating higher
protection. A hypothesis is proposed that antioxidant 7,8-NP is effective at protect-
ing HMDM cells from the detrimental effects of early acute oxidative flux, but is less
likely to confer protection over the second half of acute oxLDL exposure, perhaps,
due to cellular processes of a different nature. The ability of 7,8-NP to suppress ini-
tial ROS produced by HMDM cells in response to acutely toxic oxLDL concentration
may be highly beneficial in maintaining intracellular redox balance, as well as the
reducing environment within a plaque, thus delaying plaque development. In support
of this hypothesis, Gieseg et al. (2010a) reported that 7,8-NP completely protected
intracellular GSH from oxLDL up to 12 hours. This protection decreased by approxi-
mately 18% over the following 12 hours of incubation . The rate of intracellular GSH
loss was identical during 12–24 hours between 7,8-NP–treated and untreated HMDM
cells, which also suggests that the processes during the second half of incubation may
involve non-7,8-NP–amenable mechanisms. Taken together, the data suggest that the
nature of oxLDL toxicity (manifested as ROS generation and oxidative stress) during
the first 12 hours of incubation determined the effectiveness of 7,8-NP in protecting
HMDM from oxLDL-mediated cell death during this time period.
7,8-NP’s effect on viability and ROS decline may be due to its ability to scavenge
peroxyl radical as shown by Duggan et al. (2001, 2002); Oettl et al. (1997). Trolox,
also a peroxyl radical scavenger, was shown to restore mitochondrial polarisation and
completely prevent human macrophage death from oxLDL–induced death (Asmis &
Begley, 2003). Research from our laboratory demonstrated that 7,8-NP inhibited
cellular damage to erythrocytes and the monocyte-like U937 cells from a range of
oxidants such as hydrogen peroxide, hypochlorite, aqueous peroxyl and direct plasma
membrane oxidation by ferrous ions (Duggan et al., 2002; Gieseg et al., 2001a,b).
Thus, radical scavenging capacity of 7,8-NP may explain its effectiveness at the ini-
tial stages of ROS formation. Atherosclerotic plaques are often considered oxidative
environments (Stocker & Keaney, 2004). Extracellular availability of 7,8-NP in such
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environment would be advantageous at suppressing oxidative damage.
Inhibition of ROS formation by 7,8-NP was not investigated as part of this work
due to difficulty in discerning inhibition vs. direct scavenging of oxidants when mea-
suring oxidative flux. The inhibition of NOX assembly via p47phox phosphorylation
in a U937 monocyte-like cell line was found to be unaffected by 7,8-NP (Chen, 2012).
U937 cells are often used as a model for human macrophages due to the similarity
in manifestation of oxLDL–mediated toxicity, such as absence of caspase activation,
rapid oxidative stress and necrotic cell lysis as opposed to apoptotic cell shrinkage
(Baird et al., 2004; Katouah, 2012). This fact and the ability of 7,8-NP to protect
both U937 and HMDM cells (Baird et al., 2005; Gieseg et al., 2010a) suggest that
7,8-NP may act similarly in both cell types and, therefore, not inhibit NOX assem-
bly in HMDM cells. There is some evidence that neopterin, however, displays NOX
inhibition. Kojima et al. (1992) reported weak scavenging activity of neopterin in
the xanthine/xanthine oxidase system with 50% inhibitory concentration (IC50) of
370 µM and a stronger inhibitory activity in splenic macrophage/PMA-reaction sys-
tem with IC50 of 1.1 µM. On the basis of high vs. low IC50, the authors suggested
that neopterin acted as a scavenger in the former but inhibited the O2
•– production
in the latter system. The same group of authors also demonstrated that neopterin
competitively inhibited the superoxide generation in the whole-cell macrophage/PMA
reaction system; IC50 for neopterin was 1.39 µM and Ki was 6.5 µM (Kojima et al.,
1993). The authors did not propose a mechanism, but the structural similarity of
neopterin/7,8-NP to flavin adenine dinucleotide (FAD), a NOX co-factor, could play
a role. At present, it is difficult to evaluate whether neopterin-mediated inhibition of
NOX took place in the HMDM cells exposed to oxLDL in this study. ROS and O2
•–
in particular, measured by DHE-product fluorescence decreased after the 12th hour
of incubation, when intracellular neopterin levels started to raise, indicating poten-
tial association. Yet, the concentration of extracellular neopterin after the 3rd hour
was close to or above 5 µM even in the control (no oxLDL) wells (fig. 4.3b), which
exceeded the IC50 and approached Ki reported by Kojima et al. (1993) and Kojima
et al. (1992). Thus, conclusive assessment of the NOX inhibitory action of neopterin
generated through 7,8-NP oxidation in this study cannot be made and will require
further investigation.
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Neopterin formation from 7,8-NP in HMDM upon oxLDL exposure
If 7,8-NP were scavenging ROS generated by HMDM cells in response to oxLDL, it
would be oxidised in the process (Gieseg et al., 2001a). Indeed, an oxLDL–dependant
elevation of intracellular neopterin was observed in 7,8-NP–treated HMDM cells in
response to oxLDL (fig. 4.10). The rate of neopterin formation after the first 3 hours
was relatively constant. It is likely that the neopterin measured at 3 hours, was taken
up by the cells from the extracellular medium. The three hour sample was the first one
collected after the addition of 7,8-NP. It showed a similar level of neopterin in treat-
ment and control cells and followed similar kinetics to those observed in the cell-free
RPMI-1640 (fig. 4.3b). The process of cell culture alone has been proposed to gener-
ate substantial oxidative stress (Halliwell, 2003), perhaps contributing to the baseline
oxidation of 7,8-NP. Neopterin formation above control levels was evident as early
as at 6 hours, coinciding with the timing of oxidative stress. Intracellular neopterin
formed by the end of the 24 hour oxLDL incubation constituted 34 ± 11 % (SEM)
of the total intracellular pterin in HMDM cells. Linearity of increase demonstrated
a constant rate of neopterin formation, and, therefore, a constant rate of 7,8-NP ox-
idation over the course of the experiment. This implied a constant rate of oxidant
generation, which was contrary to the oxidative stress measurement by DHE, as the
rate of ethidium (E+)/2-OH-HE formation showed a third order polynomial kinetics
(Prism5). The DHE probe measured O2
•– and, potentially, other oxidants like H2O2
in the presence of heme proteins (Fernandes et al., 2006), whereas 7,8-NP oxidation
to neopterin was the result of a reaction with HOCl (Widner et al., 2000). The reac-
tion of 7,8-NP with HOCl is the only known physiologically relevant mechanism that
generates neopterin from 7,8-NP that has been experimentally demonstrated (Fuchs
et al., 2009; Widner et al., 2000). Macrophages differentiated with GM-CSF contain
MPO and produce HOCl (Sugiyama et al., 2001), thus making this mechanism a
likely route for 7,8-NP oxidation. This area deserves further investigation.
At this stage it is impossible to infer the relationship between O2
•– and the formation
of downstream ROS, such as peroxide and peroxyl radicals. The cumulative reaction
of a suite of such species with DHE may show a variable rate of ROS formation as
seen in fig. 4.9. Alternatively, non-linear rate of activation of ROS–producing en-
zymes may account for the increasing rate of ROS formation in the first 6 hours post
oxLDL addition. 7,8-NP was shown to delay (by 3 hours) and suppress this chain of
reactions (fig. 4.9). As opposed to superoxide measurement, neopterin formation is
a secondary marker of oxidative stress, it is not the initial product of radical gener-
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ation, and thus, could have different kinetics than the initial ROS release measured
by DHE.
Other ROS involvement in 7,8-oxidation.
To gain further understanding of the kinetics of 7,8-NP oxidation in cells, the level
of intracellular 7,8-NP during HMDM cell exposure to oxLDL was assessed. Due to
the nature of the assay, 7,8-NP was calculated as the difference between total pterin
and neopterin (figures 4.11 and 4.10). HMDM cells were found to maintain a rela-
tively constant level of 7,8-NP between control and oxLDL–treated cells throughout
incubation (fig. 4.12). Total pterin was slightly elevated in the oxLDL–treated cells,
starting between 3 and 6 hours after initial exposure, which was due to neopterin
increase in these cells (fig. 4.11). HMDM cells displayed a small difference between
control and oxLDL–exposed cells 7,8-NP levels at around 9 and 12 hours, but the
regression lines converged again at 24 hours (fig. 4.12). This difference was 17% at
12 hours as defined by the regression curves. One possible explanation for it could
be that oxLDL up-regulated the transport of 7,8-NP into the HMDM cells through
oxidative signaling, for example, IFN-γ which had been shown to rise after oxLDL
treatment Huang et al. (1995) and this cytokine can regulate concentrative nucleoside
transporter (CNT) (Soler et al., 2001). CNT is partially responsible for trafficking of
7,8-NP into the cells (Tejraj Janmale, unpublished observations).
Extracellular total pterin showed a 10% difference (20 µM of initial 200 µM) be-
tween the oxLDL–treated and non-treated cells (fig. 4.13). Due to the magnitude
of inter-experimental error, the result has to be interpreted with caution. Yet figure
4.13, perhaps, points towards a process, either intra- or extracellular, that guided a
conversion of 7,8-NP to a non-neopterin product in oxLDL–treated cells. This was
expected because the available literature proposes that a) oxygen–centered radicals,
like O2
•– and H2O2 and peroxyl radicals oxidise 7,8-NP into 7,8-DXP b) 7,8-NP had
been shown to react with these radicals (Gieseg et al., 2001a; Oettl et al., 1997) and
c) 7,8-NP had suppressed the intracellular O2
•– flux in this study (fig. 4.9).
7,8-NP decreased the levels of DHE–reactive ROS, proposed to be primarily O2
•–
and H2O2-derivatives (Kobzik et al., 1990; Rothe & Valet, 1990; Tarpey, 2004), sug-
gesting that 7,8-NP could scavenge these oxidants. The rate constants for reactions
of 7,8-NP with O2
•– and peroxyl radical are 103M-1s and 107M-1s, respectively (Oettl
et al., 1997), suggesting that 7,8-NP was likely scavenging peroxyl radicals rather
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than O2
•–. 7,8-NP was also more likely to react with ONOO-, a product of O2•–
reaction with , rather than superoxide itself (Oettl et al., 2004b), as ONOO- forma-
tion approaches the rate of diffusion (Beckman & Koppenol, 1996). Taken together,
the data indicates that during oxLDL-mediated oxidative stress, 7,8-NP could also
scavenge peroxyl radicals, not just HOCl, and the evidence for this is found in the
extracellular medium. Unfortunately, due to the maintenance of constant 7,8-NP in
the cell, the existence of these two processes could not be compared intracellularly.
Thus, the results discussed so far have established that oxLDL triggered oxidative
stress in HMDM cells that is partially suppressed by 7,8-NP. There is some debate,
however, over the source of these oxidants.
NOX as a source of oxidants that yield neopterin
The literature on phagocytic NOX suggests that it plays a pivotal role in the gen-
eration of ROS, and that NOX inhibition and ROS reduction result in alleviated
oxidative stress and cell survival (Aviram et al., 1996; Bae et al., 2009; Park et al.,
2009; Paterniti et al., 2010; Sukhanov et al., 2006). It was, therefore, hypothesised
that inhibition of NOX in HMDM cells would decrease oxLDL–triggered oxidative
processes and improve cell survival.
Although no specific inhibitors of NOX are known (Bedard & Krause, 2007), apocynin
has been widely used for this purpose. Apocynin is a well known inhibitor of NOX
(Bedard & Krause, 2007). Although recently a new class of NOX inhibitors with
improved specificity has emerged (Wingler et al., 2011), apocynin was used in this
study due to its availability. Most of known limitations of apocynin did not present
a problem for the present study. Firstly, apocynin is a pro-drug activated by cellular
peroxidases, including MPO (Stolk et al., 1994), which is present in the HMDM cells
cultured with GM-CSF as was done in this study (Sugiyama et al., 2001). Secondly,
the cytosolic subunits, whose translocation to the plasma membrane is inhibited by
apocynin are present in the phagocytic NOX2 homologue, classic of macrophages
(Bedard & Krause, 2007; Stolk et al., 1994). Thirdly, because this work focused on
phagocytes, a recent report of apocynin’s ROS scavenging activity in non-phagocytic
cells did not present an obstacle (Heumu¨ller et al., 2008). Thus, it was chosen as a
NOX inhibitor, while 7,8-NP oxidation to neopterin was used as an intracellular ROS
probe.
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Apocynin, incubated with 7,8-NP–containing HMDM cells for 12 hours in the pres-
ence of oxLDL, prevented the increase in intracellular 7,8-NP oxidation to neopterin
by half (fig. 4.14), suggesting that NOX is one of the key sources of ROS that lead
to 7,8-NP oxidation. Indeed, NOX has been responsible for oxLDL–mediated ROS
release in a number of cells: mouse peritoneal macrophages and HMDM cells (Park
et al., 2009), SMCs (Sukhanov et al., 2006) and J774 cells (Bae et al., 2009). Based
on this preliminary results, the following mechanism of ROS flux in oxLDL–mediated
cells is proposed: generation of O2
•– by activated NOX, which is then dismutated
into H2O2 by SOD, which is then reacted with chloride ion (Cl
-) via myeloperoxidase
(MPO) to produce HOCl that oxidises 7,8-NP to neopterin. Since NOX inhibition
did not prevent oxidation completely, the remaining HOCl could have had a different
source. For example, superoxide produced through the uncoupling of the mitochon-
drial electron transport chain. Recently, Chen (2012) demonstrated that mitochon-
drial superoxide was elevated upon oxLDL treatment of this monocyte-like cell line.
By analogy, this may be a mechanism for HMDM cells. Sukhanov et al. (2006) also
showed that apocynin and another NOX blocker only partially prevented GAPDH
downregulation by oxLDL, while Park et al. (2009) demonstrated a 40% restoration
by apocynin of macrophage migration inhibited by oxLDL. Since 7,8-NP was able
to recover/react with ROS from multiple sources, it was considered a more effective
intervention than NOX inhibitor apocynin, in terms of its oxidative-stress–mediating
action. Alternatively, incomplete inhibition of 7,8-NP oxidation could have been due
to the lack of specificity of apocynin, as NOX inhibitor. The use of recently de-
veloped inhibitors of VAS family is suggested for future investigation of the relative
contribution of ROS sources during oxLDL–mediated oxidative flux (Altenho¨fer et al.,
2012).
Significance of apocynin-mediated NOX inhibition for HMDM cell death
The developing hypothesis of this study alluded to ROS scavenging by 7,8-NP as a
protective mechanism against oxLDL–mediated cellular death. NOX inhibition by
apocynin reduced neopterin formation, suggesting reduced oxidative flux. Thence,
the role of apocynin–inhibitable ROS in oxLDL–mediated toxicity to HMDM cells
was also tested. Apocynin alone was not toxic to HMDM cells at the 50–200 µM
range of concentrations but was slightly toxic at 300 µM (fig. 4.15). Contrary to
the expectation, apocynin at the concentration that partially prevented neopterin
oxidation did not protect HMDM cells from cellular death (see below). This was
tested with both an MTT viability assay, which measures cellular metabolic activity,
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and with the ApoAlert kit, which is able to distinguish apoptosis and necrosis. Both
assays confirmed the absence of statistically significant protection (figures 4.16, 4.18,
4.19).
Apocynin concentrations of 50, 100 or 200 µM did not convey any protection against
oxLDL toxicity when tested with the MTT assay at 24 hours (fig. 4.16). The mode
of MTT cell viability assay is not completely understood but reports of both cytoso-
lic and mitochondrial mechanisms of formazan reduction have been made (Bernas &
Dobrucki, 2002). To exclude the possibility of an assay-specific result, conventional
apoptosis–necrosis labelling was used for the subsequent cell viability experiments
(ApoAlert kit, Clontech Laboratories, USA). To test the effect of the inhibitor during
a shorter time-frame, lest the oxidative processes lost relevance towards the 24th hour
of incubation, apoptosis and necrosis were determined at 15 rather than 24 hours af-
ter the addition of oxLDL (figures 4.18, 4.19). Apocynin treatment did not influence
the frequencies of total cells staining with annexin+ and PI+ (figures 4.18a, 4.19a)
or distribution to Annexin V and PI staining quadrants (figures 4.17, 4.18b, 4.19b).
In one instance, a small decrease of cell frequency in the annexin+ corresponding to
apoptosis or secondary necrosis quadrants of the flow cytometer output was observed
at 200 µM (fig. 4.19b). The decrease in annexin+ cells may indicate a reduction in
apoptotic marker phosphatidyl serine exposure. Yet the overall frequencies of cellular
death remained almost unchanged (fig. 4.19a). It is thus possible to conclude that
despite the contribution that NOX-generated oxidative flux may have at the initial
stages of oxLDL–mediated cell death, the effect of its inhibition by apocynin does not
provide significant protection from cellular death at the end of the acute incubation
period. The result was surprising given the abundance of literature that implicates
NOX involvement in cellular death. Despite the wealth of publications on the ROS-
generating effect of NOX in macrophages and other cells (Bedard & Krause, 2007;
Brandes et al., 2010; Dro¨ge, 2001), the evidence to prove the direct effect of NOX on
cell viability during oxLDL treatment in macrophages is lacking. This could be due
to the specificity issues associated with the known NOX inhibitors like and apocynin
(Altenho¨fer et al., 2012). A possibility of non-specific effects of apocynin also exists
(personal communication with Dr. DeHaan, Baker IDI, Australia). Similarly, the
results observed in this study could be confirmed with a more reliable NOX inhibitor
(Wingler et al., 2011).
Another interpretation of the results would be that either other non-NOX sources
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of ROS were sufficient to illicit cellular damage that resulted in cell death or that cell
death was not a consequence of oxidative processes at all. The latter is less likely
since ROS scavenger 7,8-NP could prevent HMDM cell death from acute oxLDL tox-
icity. Furthermore, other antioxidants have been shown to inhibit cellular death and
the associated perturbations of cellular redox balance in oxLDL–treated cells (Hard-
wick et al., 1999; Hsieh et al., 2001; Siow et al., 1999, 1998). This, however, was not
true of all antioxidant in all circumstances (Harris et al., 2006; Hsieh et al., 2001).
In addition, only 50% of 7,8-NP oxidation to neopterin was prevented by apocynin,
thus indicating that other source(s) of ROS contribute(s) to the oxidative flux and
these ROS are also scavenged by 7,8-NP. For example, mitochondrial ROS generation
could present a likely candidate for future investigation. Complex III was especially
identified as a source of O2
•– in compromised cells (Turrens, 2003). Asmis & Begley
(2003) showed that oxLDL–mediated mitochondrial depolarisation and dysfunction
contribute to macrophage cell death. It is also possible that oxidative processes, de-
spite being the initial cellular response to oxLDL, are not the only contributor to
cellular death, and in the absence of the first, non-oxidative processes such as lyso-
some destabilisation become more apparent and lead to the same net result of HMDM
cell death (Yuan et al., 1997; Zhang et al., 2010). The higher protection mediated by
7,8-NP suggests that it has an effect on other cellular processes and/or their products
and outcomes as well.
4.3.3 Intracellular levels of 7,8-NP
Intracellular 7,8-NP after exogenous addition
7,8-NP was rapidly internalised by HMDM cells, peaking at 12 hours and decreasing
by 10-20% over the 12–24 hours of incubation (figures 4.4 and 4.12b). This decrease
was unlikely to cause a loss of protection as the level of 7,8-NP at 24 hours was
identical to that of 6 hours when the protection was full. HMDM cells seemed to
maintain intracellular 7,8-NP levels even despite a drop in the extracellular 7,8-NP
availability (fig. 4.3). It is conceivable that an increased rate of disappearance of
extracellular 7,8-NP in the second half of the incubation contributed somewhat to
the changed protection slope. In the future, this could be addressed by a two-step
addition of freshly prepared 7,8-NP at 0 and 12th hour of incubation. In comparison
to the present study, Gieseg et al. (2010a) observed no decrease in intracellular 7,8-
NP, but the reason for this disparity is unknown.
131
4. ANTIOXIDANT CAPACITY OF 7,8-DIHYDRONEOPTERIN
The effective intracellular concentration of 7,8-NP in HMDM cells was of interest
since no data is available on the concentration of this compound in macrophages in
vivo. The majority of published studies report plasma concentrations of neopterin
and, occasionally, 7,8-NP (see section 1.7.2), but these are only remotely relevant to
understanding the physiological role of these compounds in the inflammatory sites.
The intracellular concentration of 7,8-NP within HMDM cells reached, on average,
∼1.3 nmol/mg protein or 180 pmol/well (fig. 4.5). To calculate the cellular 7,8-NP
concentration, the following empirical exercise was performed. Considering the cell
number to be 22,000 per well (appendix I), 7,8-NP amount could be calculated as
8.18 fmol/cell. In the absence of information on the exact distribution of HMDM
cell volume, the radius of HMDM cell was assumed at 20 µm, the concentration of
active 7,8-NP in the cell (assuming equal distribution inside a spherical cell) would
be 33.49x10-15/8.18x10-15 = 0.24 M (or 0.51 M assuming 15 µm HMDM radius).
This figure is a rough estimate and there are factors it does not take into account,
thus it will only be used as a guide. For comparison, intracellular GSH concentra-
tion is reported to range from 0.2 to 10 mM, much lower than the calculated 7,8-NP
(Anderson, 1998). A more precise estimation of intracellular 7,8-NP on per cell ba-
sis could be carried out by measuring the distribution of cellular volume of HMDM
cell population by flow cytometry in conjunction with pterin measurement by HPLC.
The protective 200 µM concentration of 7,8-NP in the experimental medium was
higher than that in serum during immune activation, such as 68 nM neopterin de-
tected in the plasma of coronary heart disease patients undergoing angioplasy (Genet,
2011). However, when activated monocytes, macrophages and T-lymphocytes accu-
mulate at the inflammatory sites and release pteridines locally into a confined envi-
ronment, the concentration of 7,8-NP in the proximity of those cells may be much
higher than that in serum. At present, the levels of neopterin reported to be generated
in cell culture are much lower than the levels required to account for the neopterin
levels in the blood of CVD patients. This could be illustrated by a rough calculation.
According to Weiss et al. (1999) polymorphonuclear blood monocytic cells (PBMC)
cells produce 14.9 nmol/L neopterin per 106 cells per mL when activated with 250
U/mL IFN-γ over 48 hours. This is equivalent to 0.31 pmol/106cells/hour given that
neopterin accumulation proceeded without any loss. Assuming an average person
has 3 liters of plasma (5% of bodyweight) (Barrett et al., 2010), the total amount of
neopterin carried (during acute CVD event) is 68 nmol/L x 3 L = 204 nmol (Genet,
2011). The half life of neopterin in the body is estimated to be 90 minutes (Fuchs
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et al., 1994). Therefore, to replenish 102 nmoles of neopterin within 90 minutes will
require action of 102 x 10-9 mol / 0.31 x 10-12 mol per 106cells x 1 hr / 1.5 hr =
219.35 x 109 cells. Human blood contains, on average 540 monocytes per µL (Barrett
et al., 2010). It would require 219.35 x 109 / 540 = 406 L of blood to replenish
excreted neopterin even if all blood monocytes were activated to the degree reported
by Weiss et al. (1999). The same calculation can be performed for 12.11 nmol/L
(instead of 68 nmol/L), reported as the predictive threshold for acute coronary com-
plications by Ray et al. (2007), to yield 72 L, which is still very high. The magnitude
of the outcome suggests that there are other sources of neopterin and 7,8-NP rather
than cells in the circulation with a much higher production rate than is currently
reported. Inflammatory sites were suggested as such a source (Firth et al., 2008b;
Gieseg et al., 2008). Therefore, the comparison of plasma 7,8-NP and neopterin con-
centrations with effective concentration of these compounds in the inflammatory sites
is unreasonable at this stage. It suggests that with the current knowledge of 7,8-NP
production mechanisms it is impossible to draw conclusions on the presence of effec-
tive 7,8-NP concentrations used in this study in macrophages in vivo.
The intracellular 7,8-NP concentrations after exogenous addition varied between HMDM
cell preparations from different donors (fig. 4.5). Two distinct groups of low and high
uptake were identified. Correction for cellular protein did not eliminate this differ-
ence, suggesting that the number of cells per well was not the determining factor.
The same HMDM preparations were assessed for baseline control levels of 7,8-NP in
an attempt to explain the observed variation (fig. 4.6). Baseline total pterin levels,
although varying between 12-well and 48-well seeded HMDM cells, were consistent
within each group, indicating that the observed disparity in experimental concentra-
tion was not associated with the different starting values.
The difference in total 7,8-NP uptake between preparations and the kinetics of up-
take over 24 hours may be associated with the variable levels of equilibrative and
concentrative nucleoside transporters, ENT and CST respectively. These have been
shown to orchestrate pterin internalisation (Ohashi et al., 2011) but no details of
7,8-NP cellular uptake kinetics have been published. As the name suggests, ENTs
facilitate pterin diffusion while CNTs couple nucleoside transport to the inwardly di-
rected sodium gradient (Beal et al., 2004; Gray et al., 2004). Multiple studies detected
large genetic and functional variation in human nucleoside transporters, highlighting
that the cumulative effects of multiple nucleoside alleles in the population are very
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complex (Leabman et al., 2003; Li et al., 2007; Owen et al., 2005). In addition, some
variants display substrate-specific defects in transport (Urban, 2005) and regulation
in response to the extracellular stimuli. For example, the levels of ENT1 were re-
ported to change during the course of differentiation from monocyte into macrophage
(Soler et al., 2001). Also, activation by IFN-γ inhibited this change but up-regulated
the levels of CNT1 and CNT2 (Soler et al., 2001). Thus, it is possible that the
HMDM cell preparations from three donors on figure 4.5 possessed higher function of
nucleoside transporters and were able to acquire and retain a higher level of 7,8-NP.
The mechanisms for this cannot be established at present. The present sample size
of five HMDM cell preparations is too small to draw comprehensive conclusions and
lacks the depth of investigation into mechanisms. Yet this pilot study is suggested to
be sufficient to highlight this area as one that warrants future investigation.
Intracellular 7,8-NP production
In vitro, only IFN-γ, TNF-α and bacterial LPS have been shown to enhance neopterin
production (Henderson et al., 1991; Weiss et al., 1999), yet in vivo other stimuli have
been suggested to drive neopterin elevation (Sghiri et al., 2005). As serum neopterin
was elevated in patients with CVD, it was not surprising to find that oxLDL slightly
up-regulated intracellular 7,8-NP level in HMDM cells (fig. 4.7). This was an order of
magnitude lower that the effective intracellular 7,8-NP detected in the HMDM cells
supplemented exogenously, (95 pmol/mg protein vs 1.3 nmol/mg protein). Toxic
levels of oxLDL induced a higher production of 7,8-NP than sub-toxic, producing
95.0 pmol/mg protein vs 5.5 pmol/mg protein (figures 4.7 and 4.8). Small neopterin
elevation was also observed in the toxic samples, but was below the detection limit
in the non-toxic samples. Published literature on the subject abounds with values
for neopterin released into supernatant, but intracellular concentration of 7,8-NP is
not available and even neopterin is scarce (Andert et al., 1992; Franscini et al., 2003;
Huber et al., 1984; Weiss et al., 1999). Werner et al. (1989) reported an increase in in-
tracellular HMDM neopterin from 1.95 ± 1.27 (SD) to 159.63 ± 51.22 (SD) pmol/mg
protein over 48 hours in the presence of 250 U/mL IFN-γ. The increase from 6.4 to
20.0 pmol/mg protein observed in the present study was very low compared to that,
but the incubation time was also shorter. The present result agreed well, however,
with that of Werner-Felmayer et al. (1990), which reported an increase from “not
determined” to 18 ± 2 pmol intracellular neopterin /mg protein in undifferentiated
THP-1 cells incubated with 250 U/mL of IFN-γ for 24 hours. Another study deter-
mined that EC over 24 hour of stimulation produced from 1.0 ± 0.3 (SD) to 1.9 ± 1.1
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(250 U/mL IFN-γ) or 2.8 ± 0.9 pmol/106 cells (Werner-Felmayer et al., 1993), which
was lower than the increase in the present study: from 1.23 ± 2.54 to 5 ± 3.5 (SD)
pmol/106 cells. However the latter is not surprising as macrophages are known to
produce higher amounts of neopterin. The results of the present work are comparable
in magnitude of neopterin production to some published reports, therefore suggesting
that oxLDL might be a physiologically-relevant stimulus for neopterin production in
some circumstances.
The spread of data in the present study, however, suggests that oxLDL–induced
pterin production is dependent on the individual HMDM cell preparations. Such
inter-experimental variability is expected when dealing with donor-associated vari-
ability of primary cells and small concentrations, those approaching the limit of de-
tection. To the best of the author’s knowledge, this is the first attempt to investigate
an effect of oxLDL as an agent stimulating 7,8-NP production by human monocyte–
derived macrophages. The small increase may be attributable to oxLDL induction
of inflammatory mediators such as TNF-α or IFN-γ, which, in turn, enhance 7,8-NP
production. This is plausible in the view that toxic concentration of oxLDL, which
elicited a higher inflammatory response in HMDM, caused a higher level of 7,8-NP
production. These experiments also showed that the effective intracellular 7,8-NP
concentration during experiments conducted in this study was primarily derived from
the uptake of exogenous 7,8-NP.
4.4 Summary
The research presented in this chapter demonstrated that antioxidant capacity of
7,8-NP is a likely mechanism that protects HMDM cells from acute oxLDL toxicity.
This work provides evidence that 7,8-NP scavengers ROS produced by HMDM cells
in response to oxLDL and is oxidised to neopterin in the process. The scavenging of
DHE-reactive ROS by 7,8-NP was an early event, while oxidation to neopterin pro-
ceeded at a constant rate during the 24 hour incubation. These results suggest that
protection against oxidative damage through oxidant scavenging may be a physiolog-
ical role of 7,8-NP in macrophages exposed to oxLDL within atherosclerotic plaques.
The present study identified NOX as a potential contributor to ROS formation during
oxLDL–mediated stress in HMDM cells. Intracellular neopterin oxidation was inhib-
ited by half in the presence of apocynin, a NOX enzyme assembly inhibitor. However,
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contrary to the current view of cellular processes during oxLDL cytotoxicity and the
original hypothesis, NOX inhibition by apocynin failed to prevent oxLDL–mediated
HMDM cell death. In conjunction with incomplete inhibition of neopterin formation
by apocynin, the result calls for a further investigation into the sources of ROS upon
oxLDL exposure. This, however, should be confirmed with a more specific NOX
inhibitor than apocynin. It is an important direction for future work, as relative con-
tribution of ROS sources may inform pharmaceutical design for disease treatment.
Mitochondrial and lysosomal destabilisation may provide initial targets.
Based on the results presented in this chapter, mechanistic pathway worthy of
further investigation is proposed: NOX activation→ O2•– → H2O2 → HOCl (MPO–
catalysed).
A retrospective pilot study detected inter-donor variation in macrophage 7,8-NP up-
take, which could be addressed in a prospective and targeted investigation. Since 7,8-
NP and neopterin are emerging as inflammatory markers of macrophage activation
in disease, the knowledge of inter-individual variation in uptake and/or production
of these compounds will be valuable in the clinical setting. The information about
kinetics of 7,8-NP uptake by HMDM cells will be beneficial for any future cell culture
based investigation that builds on the results of the present work.
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5Effect of 7,8-dihydroneopterin on
oxLDL uptake by macrophages
5.1 Introduction
Foam cell formation and cell death underpin the development and progression of
atherosclerotic plaques (Ball et al., 1995; Naito et al., 1997). Foam cells are charac-
terised by the accumulation of cholesterol esters (CE) and oxidation products similar
to those found in oxidatively modified lipoproteins (Jessup & Kritharides, 2000). In
vitro, macrophages were found to accumulate CE and oxysterols when exposed to
oxisided and aggregared LDL (Asmis & Jelk, 2000a; Bostrom, 2006; Brown et al.,
1996). Moreover, oxLDL was shown to contribute to macrophage death in vitro
(Reid & Mitchinson, 1993) and was suggested to do so within an atherosclerotic
plaque (Ball et al., 1995; Li et al., 1998). The exact mechanisms of these biologi-
cal processes are disputed; however, binding, uptake and intracellular processing of
oxLDL are important determinants of cell fate (Steinberg, 2009). Ultimately, the
understanding of these processes will allow researchers to target “weak links” in the
cellular design and, potentially, prevent, delay or alleviate atherosclerotic burden in
the patient. This chapter is concerned with the second aspect of the 7,8-NP–mediated
protection against oxLDL. It will examine the evidence for the effect of 7,8-NP on
oxLDL internalisation and investigate the underlying mechanisms.
Scavenger receptors on the cell surface recognise oxidised epitopes on oxLDL (Boullier
et al., 2001). As discussed in the Introduction (section 1.4.1), CD36 and scavenger
receptor A are considered to be the main mediators of oxLDL binding and uptake,
however, other scavenger receptors are also capable of binding oxLDL (Horiuchi et al.,
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2003). It is highly possible that CD36–facilitated uptake, processing, and accumu-
lation of oxLDL are controlled by multiple cellular processes, because the results of
CD36 binding or signalling inhibition studies vary significantly. These range from
complete inhibition of uptake (Rahaman et al., 2006) to no effect on uptake (Win-
tergerst et al., 2000).
CD36 protein and mRNA levels are up-regulated by its ligands, such as oxLDL, in a
number of cell types including macrophages (Han et al., 1997; Munteanu et al., 2006;
Nakagawa et al., 1998; Ricciarelli et al., 2000). The regulatory mechanism includes
nuclear hormone receptor PPAR-γ, which, once activated by a lipid-like ligand, drives
transcriptional activation of CD36 expression (Munteanu et al., 2006; Tontonoz et al.,
1998). PPAR-γ also plays a role in CD36 protein and mRNA down-regulation me-
diated by a number of agents including α-TocH and lovastatin (Pietsch et al., 1996;
Ricciarelli et al., 2000).
When taken up by macrophage scavenger receptors (SRs), modified lipoproteins are
delivered to endosomes and then lysosomes (Brown et al., 2000; Maor & Aviram,
1994). There, their cholesterol ester (CE) content is hydrolysed into free cholesterol
and fatty acids at acidic pH (Sekiya et al., 2011). Since SRs are not regulated by
intracellular cholesterol concentration, oxLDL uptake leads to accumulation of free
cholesterol, which is then re-esterified by ACAT. This leads to accumulation of large
pools of esterified cholesterol in the cytosol. Evidence suggests that esterification of
toxic oxLDL components to their less toxic esters is a protective response (Monier
et al., 2003). Under normal conditions, excessive LDL cholesterol is effluxed out
of the cells through a process called reverse cholesterol transport (RCT). RCT is
characterised by CE hydrolysis, performed by a a family of enzymes with carboxyl
ester hydrolase/esterase activity. Cholesterol and cholestrol products are then trans-
ported out of the cell onto HDL (Johnson et al., 1991) via ATP–binding cassette
transporters ABCA1 and ABCG1 (Yvan-Charvet et al., 2010). However, LDL mod-
ification have been shown to reduce or inhibit the rate of its degradation and efflux
from the macrophage (Hoff et al., 1993; Jessup & Kritharides, 2000; Jessup et al.,
2002). Thus, not only oxLDL is internalised in higher amounts, but its efflux is re-
duced, facilitating the formation of foam cells.
The research in this chapter aims to confirm the 7,8-NP–mediated regulation of
oxLDL uptake by HMDM cells with a different methodology to DiI (used in Gieseg
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et al. (2010a)). OxLDL uptake by cells will be measured using 7-ketocholesterol
(7KC), an inherent component of Cu-oxLDL. This marker will then be used to con-
firm the 7,8-NP–mediated inhibition of oxLDL uptake.
The mechanisms of oxLDL uptake regulation by 7,8-NP were unclear from the previ-
ous study (Amit, 2008). CD36 scavenger receptor down-regulation was proposed to
play a role in the process but was not identified with certainty. Thus, this chapter
will further explore the effect of 7,8-NP on CD36 receptor. It will also investigate the
contribution of this process to 7,8-NP–mediated protection from oxLDL toxicity. The
presence of CD36 and 7,8-NP in the plaque will be assessed. Finally, an alternative
hypothesis of the mechanism of 7,8-NP–facilitated regulation of oxLDL in HMDM
cells will be proposed and discussed.
5.2 Results
5.2.1 Measuring oxLDL uptake in macrophages with
7-ketocholesterol
7-Ketocholesterol (7KC) was used to measure the levels of intracellular oxLDL in
HMDM cells. 7KC is an advanced product of cholesterol oxidation in Cu–oxidised
LDL (Brown et al., 1996), and is taken up by the cells within the oxLDL particle
(Kritharides et al., 1995; Rutherford & Gieseg, 2012). 7KC was a suitable marker
of oxLDL uptake because oxLDL treated cells contained significantly higher levels of
intracellular 7KC than the untreated control (fig. 5.1). 7KC was measured as both
free and total (free+esterified) 7KC. The latter was expected to provide an overall
measure of oxLDL internalised by the HMDM cells. Average total 7KC in oxLDL
was 28.4 mol 7KC per mol of oxLDL and to 9.3 mol/mol of free 7KC. The ratio of
total to free 7KC in oxLDL was 3.4 ± 0.5 (SD, n=8), which meant that 7KC esters
comprised approximately 75% of the total 7KC in oxLDL.
HMDM cells in the whole medium (RPMI-1640 supplemented with 10% human serum
and antibiotics) were treated with 1mg/mL oxLDL (a sub-toxic level). The intracel-
lular concentration of total 7KC and, therefore, oxLDL, increased gradually over a 24
hour period (fig. 5.1). During the first 6 hours, this rise was due to the increase in free
7KC (4.5 nmol 7KC per mg cellular protein) (fig. 5.1). This indicated that cellular
oxysterols derived from oxLDL particle were de-esterified at the initial stage of oxLDL
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exposure. After the first 6 hours, however, the levels of free 7KC plateaued, while the
levels of total 7KC continued to rise (fig. 5.1). This suggested that esterification of
the internalised oxLDL oxysterol(s) (and other components) was taking place. The
levels of total 7KC did not reach a maximum during the 24 hours of incubation in-
dicating further uptake of oxLDL (the cells contained 12 and 22 nmol total 7KC per
mg cell protein at 24 hours in two experiments, fig. 5.1). Total intracellular 7KC in-
creased by about 50% from 6 to 24 hours, which was due to the increase in 7KC esters.
HMDM cells contained baseline levels of total 7KC. These were most likely derived
from the serum supplemented medium in which the cells were cultured for 2 weeks
prior to the experiment. The mean values of 7KC in the sera used in cell culture
were 11.67 ± 5.36 (SD) µM of free 7KC and 65.44 ± 23.87 (SD) µM of total 7KC.
This comprised less than 1.3% of the total reported serum cholesterol (Asmis & Jelk,
2000a). Two out of 8 batches of sera contained significantly lower levels of total
7KC (fig. 5.2). Serum lipoproteins were likely the source of 7KC in the medium, as
medium supplemented with lipoprotein deficient serum (LPDS) contained less total
7KC than the medium supplemented with normal serum. Brown et al. (1996) also
reported trace amounts of total 7KC in LDL.
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Figure 5.1: Intracellular 7-ketocholesterol (7KC) accumulation in HMDM
cells exposed to oxLDL.
HMDM cells (5x106 cells/mL) were treated with 1 mg/mL oxLDL. Cell lysates were
collected at the indicated time points and assessed for intracellular free (filled squares)
and total (clear diamonds) 7KC via HPLC. Protein was determined by BCA assay
and used to control for cellular content per well. Average protein concentrations in 0
hour control cells were 194 µg/well for A and 253 µg/well for B. Results are displayed
as mean ± SEM of triplicates from two separate experiments (A and B). Statistical
analysis: one-factor ANOVA with Dunnett’s test to compare each type of 7KC at each
time point to the 0h control (*) and Bonferroni test to compare types of 7KC at each
time point (#), *, p<0.05, **,##, p<0.01, ***, p<0.001. For B, *** refers to free
7KC.
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Figure 5.2: 7KC levels in human sera used in cell culture.
Human sera used in the culture of HMDM cells was analysed for total (black bars) and
free (clear bars) 7KC levels by HPLC analysis. Results are presented as mean ± SEM
of triplicate measurements. Significance (one-factor ANOVA with Turkey post test) is
as indicated: *, p<0.05, horizontal lines outline the significant treatments.
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Figure 5.3: Serum lipoproteins are the primary source of 7KC in culture
medium.
Total (black bars) and free (clear bars) 7KC concentration was measured in RPMI-1640
supplemented with 10% normal (NS) or lipoprotein deficient (LPDS) human serum
after 24 hour incubation in the absence of cells. Results are presented as mean ± SEM
of duplicate measurements from a single experiment. Statistical significance: t-test
p=0.14.
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5.2.2 7,8-NP reduces intracellular oxLDL uptake in HMDM
cells
7,8-NP reduces intracellular 7KC accumulation in HMDM cells
Gieseg et al. (2010a) have shown that 7,8-NP affected the accumulation of DiI–labelled
oxLDL by HMDM cells. Due to potential interference of DiI with cellular redox pro-
cesses (see discussion), this study aimed to confirm oxLDL uptake down-regulation
with a different intracellular marker of uptake, 7KC. The effect of 7,8-NP on the
intracellular 7KC levels was observed during the 24 hour incubation with 1 mg/mL
oxLDL (fig. 5.4). The presence of 7,8-NP had no effect on the total 7KC levels up
to 9 hours, but caused a decrease in total 7KC levels at 12 hours and a statistically
significant decrease at 24 hours (fig. 5.4a). Coincidentally, the free 7KC levels had
plateaued by the time 7,8-NP started to have an effect. 7,8-NP had a significant effect
on the levels of total 7KC but caused only a minor decrease (1 nmol/mg protein) in
the free 7KC levels (fig. 5.4b). This suggested that 7,8-NP only affected the esterified
7KC. The magnitude of oxLDL uptake reduction by 7,8-NP was approximately 40%.
After establishing the time-frame of the 7,8-NP effect (24 hours) the experiment
was replicated four more times (fig. 5.5)1. Total 7KC in HMDM cells was, as before,
reduced in the presence of 7,8-NP (40 to 60%), while free 7KC was unaffected.
1The intracellular 7KC concentrations between the figures 5.4 and 5.5 are different due to change
in plating density for repeated experiments.
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Figure 5.4: Time course of intracellular 7KC accumulation in HMDM cells
exposed to oxLDL in the presence and absence of 7,8-NP.
HMDM cells (5x106 cells/mL) in whole medium were treated with 1 mg/mL oxLDL,
with (empty squares) or without (filled circles) 200 µM 7,8-NP. Cell lysates were col-
lected at the indicated time points and assessed for intracellular 7KC and protein.
Results are displayed as mean ± SEM of triplicates from a single experiment: (A) total
(free and esterified) intracellular 7KC, (B) free intracellular 7KC. Significance is indi-
cated between the treatments (one-factor ANOVA with Bonferroni comparison between
treatments at each time point), **, p<0.01.
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Figure 5.5: 7,8-NP mediates reduction of intracellular total 7KC in HMDM
cells exposed to oxLDL.
HMDM cells (1x106 cells/mL) in the whole medium were treated with 1 mg/mL oxLDL
in the presence (empty bars) or absence (filled bars) of 200 µM 7,8-NP for 24 hours.
Cell lysates were assessed for intracellular free and total 7KC and protein and expressed
as increase above respective no oxLDL control. (Average control values over four treat-
ments: 13 and 23 nmol/mg protein for free and total 7KC, respectively). Results are
displayed as mean ± SEM of triplicates from (A) single experiment, (B) four separate
experiments combined. Paired t-test was performed on the data from 4 experiments,
significance as indicated, *, p<0.05.
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5.2.3 7,8-NP reduces the expression of CD36 scavenger re-
ceptor protein in HMDM
To establish the mechanism(s) of 7,8-NP mediated uptake reduction, the levels of
scavenger receptor for oxLDL, CD36, were assessed via immunoblotting. HMDM
cells were incubated in RPMI-1640 with 10% human serum containing increasing
concentrations of 7,8-NP for 24 hours. Subsequently, the cells were washed and lysed
in the presence of protease inhibitor. The lysates were immunoblotted for CD36 and
β-actin was used as loading control. Both visual and numerical data are presented in
figure 5.6. Densitometry analysis was done with GeneTool (SynGene) and ImageJ64
processing software and the CD36 intensity data were normalised by the respective
β-actin band intensity. At 200 and 250 µM, 7,8-NP caused a 50 and 60% decrease in
the CD36 100 kDa protein (fig. 5.6). The 83 kDa band was also decreased by 20%
in the presence of 250 µM 7,8-NP. Different bands represent different glycosylation
isoforms of CD36 protein. The 83 kDa band was reported to be the incompletely
glycosylated protein located in the Golgi, while fully glycosylated band >100 kDa
was shown to reside on plasma membrane (Alessio et al., 1996).
The time–course of CD36 down-regulation was investigated in order to compare it to
the time frame of uptake reduction (fig. 5.7). Two hundred µM 7,8-NP reduced the
levels of 100 kDa CD36 protein by 20% after 12 hours and by 40% after 24 hours of
incubation, compared to 0 hour control (fig. 5.7b). This conferred with the uptake
data temporally. CD36 levels in control cells were unaffected over the course of the 24
hour incubation (fig. 5.7a). A quarter of HMDM cells preparations did not respond
to 7,8-NP by down–regulating CD36 protein (data not shown). Lack of effect was
also observed during the 7KC uptake experiments in a quarter of the experiments,
suggesting a common cause.
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Figure 5.6: 7,8-NP reduces the expression of 100 kDa band of CD36 protein
in HMDM in a concentration–dependent manner.
HMDM cells (5x106 cells/mL) were treated with increasing concentrations of 7,8-NP
for 24 hours. Cell lysate was assessed for CD36 protein expression via Western blot
(A). Quantitative densitometry of Western blots displays down-regulation of the CD36
protein (incompletely glycosylated) 83 and (fully glycosylated) 100 kDa bands, relative
to the respective controls (B). Results were normalised by β-actin and displayed as
mean ± SEM of triplicate experiments.
Figure published in Gieseg et al. (2010a).
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Figure 5.7: Time course of 7,8-NP–mediated down-regulation of CD36 pro-
tein.
HMDM cells (5x106 cells/mL) were treated with 200 µM of 7,8-NP in the whole medium
for the indicated time. Cell lysate was assessed for CD36 protein expression via western
blot (A). (B) Quantitative densitometry of Western blots displaying time-dependent
down-regulation of the fully glycosylated 100 kDa band relative to 0 hour control. Re-
sults were normalised by actin and displayed as mean ± SEM of triplicate experiments.
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As seen previously (chapter 4), 7,8-NP could be oxidised to 7,8-dihydroxanthopterin
(7,8-DXP) or neopterin. The effect of these oxidation products on CD36 was estab-
lished to determine if 7,8-NP alone was responsible for the CD36 down-regulation (fig.
5.8). Neopterin slightly up-regulated the intensity of 100 kDa CD36 band, whereas
7,8-DXP slightly down-regulated it. Overall, neither 7,8-DXP nor neopterin oxidation
products could be responsible for the 7,8-NP–mediated reduction in the CD36 levels.
Figure 5.8: Effect of 7,8-NP degradation products, D-neopterin and 7,8-
dihydroxanthopterin on the level of CD36.
HMDM cells (5x106 cells/mL) were treated with 250 µM solutions of 7,8-NP, D-
neopterin and 7,8-dihydroxanthopterin (freshly dissolved in degassed RPMI-1640) for
24 hours. Cell lysates were assessed for CD36 protein expression via Western blot.
Results are displayed as a representative Western blot (n=3).
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5.2.4 7,8-NP reduces the mRNA expression of CD36 in HMDM
cells
To test the mechanism of 7,8-NP–mediated down-regulation of the CD36 protein in
HMDM cells, its effect on the CD36 mRNA was investigated. The RT-qPCR method
development is outlined in Appendix I. The cells were treated with varying concentra-
tions of 7,8-NP for 24 hours as for immunoblotting, but harvested into Trizol. mRNA
was isolated from Trizol samples, converted into cDNA and the cDNA was tested on
real time RT qPCR for a change of relative CD36 mRNA copy number. The target
gene expression was normalised by the expression of reference genes β-actin and us-
ing REST2009 software (Pfaffl et al., 2002). The data generated from three separate
experiments were combined on one graph using Prism5 (fig. 5.9).
CD36 mRNA expression decreased by 30% in the presence of 100 µM 7,8-NP and
by 40% in the presence of 200 µM 7,8-NP respectively (fig. 5.9). Three hundred µM
of 7,8-NP did not down-regulate CD36 mRNA levels (fig. 5.9).
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Figure 5.9: 7,8-NP reduces the CD36 mRNA expression in HMDM cells.
HMDM cells (1x106 cells/mL) in RPMI-1640 supplemented with 10% human serum
were treated with increasing concentrations of 7,8-NP for 24 hours. Two to three wells
per treatment were collected into TRIzol and assessed for CD36 mRNA expression
levels relevant to the untreated control. Reference genes were actin and HPRT and
assessment was done using real time RT qPCR. The data was normalised to reference
gene expression in REST2009 and plotted as a combined value from three separate
experiments using Prism5. Results are displayed as mean ± SEM. Significant difference
from 0 µM 7,8-NP using repeated measures one-way ANOVA with Dunnett’s post test
is indicated with *,p<0.05.
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5.2.5 Significance of 7,8-NP–mediated CD36 down–regulation
Relative abundance of 7,8-NP and CD36 in the atherosclerotic plaque
One approach to evaluate the significance of 7,8-NP–modulation of CD36 levels was
to assess the levels of both 7,8-NP and CD36 within atherosclerotic plaques. It
was hypothesised that higher 7,8-NP levels would coincide with low CD36 levels.
Atherosclerotic plaque material, sectioned longitudinally into 3 mm slices, was pro-
cessed as described in Materials and Methods, section 2.5.3. 7,8-NP was measured via
HPLC by T. Janmale and CD36 was assessed via Western blot. Two types of sample
were prepared: the whole homogenate and the ’supernatant only’ soluble fraction
(homogenate centrifuged at 11,000 g for 10 minutes). Both sample types were tested
for protein using BCA assay and loaded onto SDS-PAGE gel according to the protein
content (50 µg of sample protein per well). Immunoblotting was performed as for the
CD36 protein quantification in section 5.2.3.
The sample loading onto the wells, although standardised for the overall protein
content, could not be standardised for the macrophage content. Immunoblotting for
the macrophage marker CD68 was unsuccessful (data not shown). Thus, qualitative
assessment of the data is presented. CD36 protein levels differed from section to
section along the length of the plaque (figures 5.10a and 5.11a). Tissue-bound and
soluble CD36 also showed different profiles along the plaque. In plaque A, soluble
CD36 was present in sections 2, 3 and 6 (fig. 5.10a-top), but tissue-bound CD36
was absent from section 3 and present in sections 1, 2, 4 and 6 (fig. 5.10a-bottom),
with sections 2, 4 and 6 containing both 80 and 100 kDa isoforms. Plaque B showed
100 kDa protein in the soluble fraction of sections 6–8, and 71 kDa in section 2 (fig.
5.11a-top); whereas the whole homogenate had high levels of both isoforms in section
8, 100 kDa in section 7 and 71 kDa in sections 2 and 3 (fig. 5.11a-bottom). Overall,
plaque supernatant contained mostly the 100 kDa isoform, which supported the idea
that 100 kDa is the surface protein that is shed into the extracellular space by the
cells (Koonen et al., 2011). Section 2 of plaque B was an exception. No pattern of
CD36 presence in sections was evident with respect to plaque morphology.
7,8-NP detected in the plaque sections (figures 5.10b and 5.11b) did not associate
(inversely, as per hypothesis) with the levels of CD36 protein along the plaque. Sec-
tion 1 of plaque A contained the highest amount of 7,8-NP per g plaque protein (fig.
5.10b), and this section did not contain soluble CD36 (fig. 5.10a-top). Sections 4
and 5, however, which were low in 7,8-NP did not contain any soluble CD36 as well.
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Similarly, an absence of any trend was observed in plaque B with section 3 being high
in 7,8-NP and low in soluble CD36 (figures 5.11b and 5.11a-top, respectively). Yet,
out of sections 3-6 with medium relative 7,8-NP levels (fig. 5.11b), sections 4 and 6
contained some soluble CD36 (fig. 5.11a-top). The difference between 7,8-NP levels
in sections 1, 2, 7, 8 and 9 of plaque B was small (fig. 5.11b), but their profiles of
CD36 in whole plaque homogenate and soluble fraction are large (fig. 5.11a). No
association between low 7,8-NP levels and high CD36 levels was thus apparent in the
two plaques used for the pilot study.
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Figure 5.10: CD36 and 7,8-NP levels are differentially distributed across
the length of atherosclerotic plaque A.
(A) Homogenized atherosclerotic plaque sections were assessed for soluble and tissue-
bound CD36 by Western blot. The loading was normalised by the amount of protein
per section and the transfer efficiency was assessed by Coomassie Blue. CD36 in soluble
fraction (top) and whole homogenate (bottom) of atherosclerotic plaque.
(B) Neopterin and total pterin levels in homogenised atherosclerotic plaque sec-
tions were measured by T. Janmale via HPLC. 7,8-NP was calculated by subtracting
neopterin values from total neopterin for the section. Results are displayed as mean ±
SEM from triplicate measurements.
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Figure 5.13: CD36 and 7,8-NP levels are differentially distributed across
the length of atherosclerotic plaque B.
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Figure 5.11: CD36 and 7,8-NP levels are differentially distributed across
the length of atherosclerotic plaque B.
(A) Homogenized atherosclerotic plaque sections were assessed for soluble and tissue-
bound CD36 by Western blot. The loading was normalised by the amount of protein
per section and the transfer efficiency was assessed by Coomassie Blue. CD36 in soluble
fraction (top) and whole homogenate (bottom) of atherosclerotic plaque.
(B) Neopterin and total pterin levels in homogenised atherosclerotic plaque sec-
tions were measured by T. Janmale via HPLC. 7,8-NP was calculated by subtracting
neopterin values from total neopterin for the section. Results are displayed as mean ±
SEM from triplicate measurements.
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Effect of 7,8-NP–mediated down-regulation on cell survival
OxLDL toxicity has been the core theme of this project. Thus, the capacity for 7,8-
NP–mediated CD36 down–regulation to prevent oxLDL toxicity to HMDM cells was
investigated. As shown in chapter 3, a 6 hour exposure to oxLDL was sufficient to
induce cellular death. Down-regulated CD36 protein did not recover until after 6
hours post–7,8-NP removal1 (fig. 5.13). This fact was used to develop an experiment
which tested the effect of 7,8-NP–mediated down-regulation alone (fig. 5.12). HMDM
cells were pre-incubated with 200 µM of 7,8-NP for 24 hours to down-regulate CD36,
after which 7,8-NP was removed from the extracellular medium. The cells were rinsed
thoroughly and treated with increasing concentrations of oxLDL for 6 hours. As was
shown in chapter 3, oxLDL treatment of HMDM cells for 6 hours resulted in an
irreversible cell death. After 6 hours, the oxLDL–containing medium was replaced
with fresh medium and the cells were incubated for another 18 hours. At the end of
the second 24 hour period, cellular viability was measured via MTT reduction (fig.
5.14). 7,8-NP pre-treatment did not protect HMDM cells from oxLDL–induced cell
death. At concentrations below LC50, the metabolic capacity of the pre-treated cells
was approximately 10% higher than that of non pre-treated cells, yet such an effect of
7,8-NP was also observed in the non-oxLDL–treated HMDM (fig. 5.14a). Combined
data showed an even smaller protection of pre-treatment with 7,8-NP (fig. 5.14b).
Thus, pre-incubation with 7,8-NP was not protective.
1The recovery of the down-regulated CD36 band was small in the 6 hours post incubation with
7,8-NP. The level of 100 kDa protein, corrected for loading changed from 0.5 to 0.68 in the 6 hours
after the 7,8-NP removal. Western blot images were artificially enhanced for best appearance in
print, therefore the relative visual intensity of the bands may appear different from the quantitative
analysis, which was performed on the raw images.
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Figure 5.12: Experiment diagram.
Experiment designed to test the significance of 7,8-NP–mediated CD36 down-regulation
in the context of oxLDL toxicity to HMDM cells. HMDM cells were pre-treated with
200 of µM 7,8-NP for 24 hours to down–regulate CD36. The cells were then washed
thoroughly and incubated with oxLDL for 6 hours. After this oxLDL was aspirated,
the cells were washed and re-supplemented with fresh whole medium for additional 18
hours. Cellular viability was measured via MTT assay at the end of a 24 hour period
from the addition of oxLDL.
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Figure 5.13: CD36 recovery after 7,8-NP pre-treatment does not occur until
after 6 hours.
HMDM cells (5x106 cells/mL) were treated with (7,8-NP, 0h) or without (0h control)
200 µM of 7,8-NP for 24 hours, washed and collected 6 hours later. Cell lysate was
assessed for CD36 protein expression via western blot. Quantitative densitometry of
the fully glycosylated 100 kDa band, corrected for actin, was 0.5 at 0 hour relative to
control at 0 hour and 0.68 at 6 hours post pre-treatment compared to 0.92 at 6 hours
post–0 hour control.
160
5.2 Results
[A]
0 1 2 3
0
20
40
60
80
100
120
[oxLDL] (mg/mL)
C
el
l v
ia
bi
lit
y 
(%
 o
f c
on
tro
l) Pre-treatment with 7,8-NP
No pre-treatment
[B]
0 1 2 3
0
20
40
60
80
100
120
[OxLDL] (mg/mL)
C
el
l v
ia
bi
lit
y 
(%
 o
f c
on
tro
l)
No pre-treatment
Pre-treatment with 7,8-NP
Figure 5.14: Pre-treatment with 7,8-NP to down-regulate CD36 does not
protect HMDM cells from oxLDL–induced cell death.
HMDM cells (5x106 cells/mL) in the whole medium were pre-treated (empty circles)
or not (filled squares) with 200 of µM 7,8-NP to down-regulate CD36 and thoroughly
washed to remove residual 7,8-NP. The cells were then exposed to the increasing con-
centrations of oxLDL for 6 hours, washed and incubated in the fresh whole medium for
18 more hours. Cellular viability was assessed via MTT reduction at the end of the 24
hour period post-oxLDL addition and expressed as a percentage of the untreated con-
trol. Results are displayed as (A) mean ± SEM of triplicates from a single experiment,
(B) mean ± SEM from three experiments combined. Difference between treatments
was not significant (two-factor AVOVA).
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Pre-incubation with 7,8-NP led to a slight increase of intracellular GSH level in
HMDM cells exposed to oxLDL in comparison to non-pre–treated cells (fig. 5.15).
HMDM cells were treated as described above (fig. 5.12) and analysed for intracellular
GSH at the end of the second 24 hour period. At all oxLDL concentrations tested
the pre-treated HMDM cells had a slightly increased level of GSH, ∆ of 1 nmol/well
at 0 mg/mL oxLDL, 3 nmol/well at 1 mg/mL and 2 nmol/well at 2 and 3 mg/mL
oxLDL. This can be interpreted as a result of reduced oxidative flux. HMDM cells
with down-regulated CD36 receptor showed lower oxidative damage, especially at the
lower oxLDL exposure concentration (1 mg/mL).
Ultimately, the level of intracellular 7-ketocholesterol in the pre-treated cells was
assessed to determine whether pre-treatment was successful at reducing the uptake of
oxLDL (fig. 5.16). Contrary to the original hypothesis, the intracellular concentra-
tion of 7KC in the pre-treated cells was not different from the non-pre-treated cells
(fig. 5.16). This indicated that down-regulation of CD36 did not result in reduced
uptake of oxLDL over the first 6 hours of exposure. The hypothesis of CD36–driven
oxLDL uptake down-regulation was, therefore, reconsidered.
162
5.2 Results
0 1 2 3
0
5
10
15
20
[OxLDL] (mg/mL)
In
tra
ce
llu
la
r G
SH
 (n
m
ol
/w
el
l) Pre-treatment with 7,8-NP
No pre-treatment
Figure 5.15: Pre-treatment with 7,8-NP leads to a small increase of intra-
cellular GSH after subsequent exposure of HMDM to oxLDL.
HMDM cells (5x106 cells/mL) in the whole medium were pre-treated (empty circles)
or not (filled squares) with 200 µM 7,8-NP and thoroughly washed to remove residual
7,8-NP. The cells were then treated with the increasing concentrations of oxLDL for 6
hours, washed and incubated in the whole medium for additional 18 hours. Cell lysates
were analysed for GSH 24 hours after the addition of oxLDL. Results are displayed
as mean ± SEM of triplicates from a single experiment. Statistical significance: two-
factor ANOVA showed a significant difference between GSH levels in pre-treated and
non-pre-treated cells, p<0.05. Interaction between oxLDL concentration and treatment
was not significant.
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Figure 5.16: Pre-treatment with 7,8-NP does not affect free or total 7KC
uptake in HMDM exposed to oxLDL for 6 hours.
HMDM cells (5x106 cells/mL) in the whole medium were pre-treated (except for the no
7,8-NP control) with the indicated concentrations of 7,8-NP for 24 hours, thoroughly
washed to remove residual 7,8-NP, treated with 1 mg/mL oxLDL for 6 hours, collected
and assessed for free and total 7-ketocholesterol on the HPLC. The last treatment on
the left, “200 through” corresponds to the sample re-supplemented with 200 µM 7,8-NP
for the duration of the 6 hour incubation with oxLDL. Results are displayed as mean ±
SEM of triplicate measurements from a single experiment. Difference between 7,8-NP
concentrations was not significant (one-factor ANOVA with Dunnett post test).
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5.2.6 7,8-NP–mediated reduction of intracellular 7KC is serum
dependant
The effect of 7,8-NP on total 7KC levels in HMDM cells was, therefore, tested in
the absence of serum (fig. 5.17). Cholesterol efflux onto extracellular serum HDL is
well documented and is the final stage of reverse cholesterol transport . The decrease
in total 7KC was only observed in the presence but not the absence of extracellular
human serum supplemented at 10%. The overall level of total 7KC in the absence of
serum was lower than that in the serum–supplemented cells in one experiment and
higher in other, thus the combined experimental data is presented (fig. 5.17b). The
level of 7,8-NP–inhibited 7KC (serum present) was lower than that in cells incubated
with 7,8-NP and oxLDL in the absence of serum. This result indicated a preliminary
route that should be pursued through further experimentation.
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Figure 5.17: 7,8-NP mediates the reduction of intracellular total 7KC in
HMDM cells exposed to oxLDL only in the presence of extracellular serum.
HMDM cells (1x106 cells/mL) were treated with 1 mg/mL oxLDL in the presence or
absence of serum and with (empty bars) or without (filled bars) 200 µM 7,8-NP for 24
hours. Cell lysates were assessed for intracellular total 7-ketocholesterol and protein
and expressed as increase above respective no oxLDL control (average control values
over three experiments: 19 and 29 nmol/mg protein for no serum and 10% serum
respectively). Results are displayed as (A) mean ± SEM of triplicates from a single
experiment; (B) average values ± SEM from three experiments combined. Paired t-test
was done on the data from 3 experiments, significance (paired and unpaired t-test) as
indicated, *, p<0.05, **, p<0.01.
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5.3 Discussion
The research in this chapter attempted to confirm the down-regulation of macrophage
oxLDL uptake by 7,8-NP and investigated the mechanisms and significance of this
phenomenon. This chapter contributes to the overall aim of the thesis by charac-
terising the effect of 7,8-NP on oxLDL internalisation during acute oxLDL–induced
toxicity to HMDM cells.
5.3.1 7,8-NP down-regulates the levels of oxLDL in HMDM
cells
7KC as a marker of oxLDL uptake
Previous research showed 7,8-NP–mediated reduction of DiI–labelled intracellular
oxLDL (Gieseg et al., 2010a). However, due to the limitations associated with DiI,
the data had to be confirmed with a different oxLDL probe. DiI was thought to be
unreliable as probe for a number of reasons. Fluorescent DiI was unstable and faded
with time, suggesting it was being oxidised. Whether the oxidation proceeded via sin-
glet oxygen or other ROS–mediated reaction was not clear, but both these processes
decreased the reliability of the label. In addition, previous work in the laboratory
indicated that DiI–labelled oxLDL lost some of its toxicity and this was inhibitory to
the types of experiments that had to be performed with it. 7KC was preferred over
a fluorescent lipid label like DiI, because this oxysterol occurs naturally within the
oxLDL particle. It does not, therefore, unnaturally interfere with oxLDL clearance
in the cell or with other cellular processes. 7KC was also superior because its mea-
surement provided insight into oxLDL cholesterol metabolism in HMDM cells, as the
assay measured the levels of free and esterified 7KC in each sample. Average total
7KC was 28.4 mol 7KC per mol of oxLDL compared to 9.3 mol/mol of free 7KC.
Such results were comparable to the values of 143 ± 20 nmol/mg LDL protein (or
28.6 ± 4 mol 7KC per mol LDL) reported in Gerry et al. (2008). A proportion of
baseline intracellular esterified 7KC levels was likely derived from the extracellular
serum over the course of investigation. Sixty five µM levels of 7KC were detected
in the human serum used for cell culture. On average, the content of total 7KC in
the serum was less than 1.3% (fig. 5.2), as the concentration of total cholesterol in
plasma of apparently healthy donors was determined to be 5.11 ± 1.01 mM (Asmis
& Jelk, 2000a).
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Kinetics of 7KC and oxLDL uptake and processing
OxLDL was consistently taken up by HMDM cells over the course of 24 hour incuba-
tion (fig. 5.1) as measured by 7KC accumulation. The ratio of total 7KC to free 7KC
in cells differed from that in oxLDL (1:1 de novo uptake in cells vs. 3.37 in oxLDL),
which implied that oxLDL contents such as 7KC were processed by the cell. In-
ternalised oxLDL is initially compartmentalised in the endosomes/lysosomes (Brown
et al., 2000; Itabe et al., 2000; Maor & Aviram, 1994; Wang et al., 2005). During the
first 6 hours of incubation, the HMDM cells in this study contained predominantly
free 7KC, which suggested that oxLDL components were hydrolysed by the action of
cellular esterases and lipases within those compartments (Brown et al., 1979; Jerome
& Yancey, 2003; Wang et al., 2005). Modified LDL, however, and, especially, oxys-
terols, have been shown to reduce the rate and inhibit oxLDL degradation the efflux
from the macrophage (Hoff et al., 1993). 7KC has been shown to inhibit the action
of cholesterol transporters (Jessup & Kritharides, 2000; Jessup et al., 2002). OxLDL
moieties were reported to raise lysosomal pH, inactivating lysosomal enzymes and
thus inhibiting further oxLDL processing (Cox et al., 2007). These changes of cellu-
lar homeostasis lead to excessive cholesterol accumulation in the form of re-esterified
cholesterol and its products (Brown et al., 1979). Evidence of this process was ob-
served in the present study when, after 9-12 hours HMDM cells started accumulating
7KC esters (fig. 5.1). This was likely due to the action of acyl coenzymeA : choles-
terol acyltransferase-1 (ACAT-1) (Rudel et al., 2001).
A few studies have claimed that oxLDL incubation with macrophages had not led
to CE accumulation in cells in the same way that aggregated oxLDL did (Asmis &
Jelk, 2000a; Maor & Aviram, 1994). In this study, however, 7KC esters were evident
in the oxLDL–treated cells. Either oxLDL in the present study underwent a slight
aggregation sufficient to promote CE storage or the current HMDM experimental
design differs from the ones described by Asmis & Jelk (2000a) and Maor & Aviram
(1994).
Effect of 7,8-NP on oxLDL uptake
Two hundred µM of 7,8-NP reduced the levels of intracellular total 7KC and, there-
fore, oxLDL by 40–60% by the end of a 24 hour exposure (figures 5.4 and 5.5). This
agreed with the magnitude of inhibition observed by Gieseg et al. (2010a). The ef-
fect was predominantly evident in total 7KC, suggesting that esterified rather than
free component of intracellular 7KC was decreased in the presence of 7,8-NP. The
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effect was evident as early as 12 hours after the initial exposure and was significant
at 24 hours (5.4). Partial inhibition of total 7KC levels observed in this study was
on a similar time-frame as the onset of esterification (the implications of which will
be discussed below). Conversely, Gieseg et al. (2010a) observed a reduction in the
DiI–associated oxLDL as early as 3 hours after the exposure. The difference in the
time-frame could either signal the 7,8-NP–mediated interference of DiI probe with ox-
idative stress induced by oxLDL, or the processing of DiI–labelled oxLDL in a mode
that degrades the DiI probe. The latter is possible as some of the data presented here
suggest that 7,8-NP affects oxLDL processing by the cells.
A similar magnitude (40%) of oxLDL uptake inhibition was observed by (Nozaki
et al., 1995) in macrophages of CD36 scavenger receptor-deficient patients. In con-
trast, Wintergerst et al. (2000) reported only a small 20% inhibition of oxLDL uptake
in the presence of CD36 ligands like thrombospondin and antibodies to to CD36,
OKM-5 and SMO. CD36 scavenger receptor is prominent in atherosclerosis research
(Collot-Teixeira et al., 2007; Silverstein et al., 2010). It has been associated with
decreased uptake of modified lipoproteins and implicated in oxLDL toxicity (Higashi
et al., 2005; Nozaki et al., 1995; Park et al., 2009; Wintergerst et al., 2000). Therefore,
CD36 receptor down-regulation was examined as a potential mechanism of 7,8-NP
mediated reduction in intracellular oxLDL.
5.3.2 CD36 down-regulation by 7,8-NP: levels and signifi-
cance
Previous work by Amit (2008) determined that the levels of SR-A were not affected
by 7,8-NP, but the levels of CD36 protein were down-regulated in 40% of the ex-
periments. This effect on CD36 protein was confirmed by the present study (figures
5.6 and 5.7). However, the absence of down-regulation in a quarter of the experi-
ments was also observed. This proportion was similar to that observed with the lack
of 7,8-NP effect on uptake. These results suggest that there are likely to be as yet
undetermined factors contributing to this process. Some of the discrepancy could,
perhaps, be attributed to the heterogeneity of primary HMDM cell preparations both
in cholesterol processing (Kruth, 2001) and CD36 level expression (Wintergerst et al.,
1998).
7,8-NP decreased the protein expression of both ∼100 and ∼80 kDa CD36 glyco-
sylation products (fig. 5.6). Alessio et al. (1996) showed that the higher molecular
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weight protein was a mature, plasma-membrane–expressed protein species while the
lower MW product (74 kDa in the original publication) was the developing, not
fully glycosylated receptor present in the Golgi. Hoosdally et al. (2009), however,
demonstrated that some of the non-fully glycosylated CD36 protein isoforms were
successfully expressed on the cellular membrane. There are 10 putative glycosylation
sites on CD36. Not all of them are glycosylated to the same extent in different cell
types. 53kDa is unglycosylated protein weight, while most studies report 71, 74, 84,
88, 95 kDa glycosylated CD36 protein. Overall, CD36 glycosylation is considered to
be important for the trafficking of the protein to plasma membrane, rather than lig-
and binding (Hoosdally et al., 2009). Significant down-regulation of 100 kDa protein
by 50-60% was observed at 200 and 250 µM. This result, however, was variable in
magnitude since the time-course data for 200 µM 7,8-NP showed a consistent 40%
decrease of the 100 kDa band (fig. 5.4). The difference in absolute values could be
associated with different expression level of CD36 in macrophage culture as Winterg-
erst et al. (1998) reported between 35 and 75% of CD36–positive cells per well on the
10th day of HMDM cell culture.
The 100 kDa CD36 protein down-regulated by 20% after the first 12 hours of in-
cubation and by 40% after 24 hours (fig. 5.7). This down-regulation was likely due
to the decrease in mRNA copy number, as it was down by 40% by the end of 24
hours (fig. 5.7). This was different from the effect of ceramides reported by Luan &
Griffiths (2006). Ceramide, a signalling molecule, was shown to reduce both CD36
expression and oxLDL uptake (Luan & Griffiths, 2006). The effect was not dependant
on mRNA expression inhibition and was suggested to be caused by CD36 protein traf-
ficking blockade (Luan & Griffiths, 2006). The down-regulation with 7,8-NP is also
different from the inhibition of CD36 transcription induced by another antioxidant, α-
TocH (Ricciarelli et al., 2000). While in the present study a baseline down-regulation
of 7,8-NP was observed, α-TocH had an antagonistic effect on oxLDL-induced up-
regulated CD36. Ricciarelli et al. (2000) and Munteanu et al. (2006) reported that
oxLDL induced CD36 expression via enhancing the presence of PPAR-γ regulatory
element. Han et al. (1997) showed that incubation of macrophages with BSA and
HDL caused a dose-dependent reduction in the expression of CD36 mRNA. This was
independently confirmed by (Carvalho et al., 2010) The authors suggested that alter-
ations of cellular cholesterol levels due to efflux onto HDL and BSA were responsible
for the observed effect. This was confirmed in the authors’ subsequent publication
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(Han et al., 1999). Thus, cholesterol efflux is another mechanism that is able to reg-
ulate CD36.
Significance
OxLDL binding to CD36 has been suggested to mediate oxLDL uptake, activate the
production and release of pro-inflammatory cytokines and ROS (Boyle, 2005; Moore,
2006; Park et al., 2009; Silverstein et al., 2010). The range of possible effects of the
CD36 signalling includes cellular death, inflammatory gene expression, adhesion, and
migration (Park et al., 2009). Therefore, the significance of the observed CD36 down-
regulation by 7,8-NP was investigated.
A pilot qualitative assessment of two atherosclerotic plaques was performed to de-
termine whether there was an inverse correlation between 7,8-NP and CD36 levels
along the longitudinal axis of a plaque (figures 5.10 and 5.11). CD36 has been de-
tected in atherosclerotic plaques previously (Collot-Teixeira et al., 2008; Nakata et al.,
1999), but never in relation to 7,8-NP. The analysis was carried out despite the ob-
stacles with signal standardisation of CD36 (as alluded to in section 5.2.5). If this
work continued, an alternative protocol of standardising or referencing the gel load-
ing should be investigated. No association between the high 7,8-NP and CD36 levels
was observed. The absence of correlation between 7,8-NP and CD36 levels was not
surprising considering the a plaque is a milieu of material that had undergone exten-
sive remodelling over the decades of development (Gieseg et al., 2009). In addition,
plaque sectioning and homogenisation of the 3 mm slices might lack the necessary
precision needed to identify a subtle correlation between the markers. Other tests, for
example, direct immunoblotting of plaque slices with macrophage, CD36 and 7,8-NP
specific antibodies, might be more appropriate for this application. The difference in
the total and soluble CD36 profiles for each section probably reflects the complexity
of the interactions within the plaque. The variability between the plaque sections can
reflect a number of factors, including cellular content of those sections, inflammatory
status including the suite of cytokines/small signalling molecules present and plaque
section history, past and present activity (Gieseg et al., 2009; Shchepetkina, 2008).
The effect of CD36 down-regulation on HMDM cell death was also investigated. The
CD36 level was down-regulated by 7,8-NP treatment, after which the pterin was
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washed off and the cells were incubated with oxLDL for 6 hours (fig. 5.12). During
this time, the 7,8-NP–mediated CD36 knock-down did not recover (fig. 5.13). No
oxLDL–induced CD36 up-regulation was observed (data not shown) and the litera-
ture suggests that oxLDL–induced up-regulation takes place over a period of 24 hours
(Munteanu et al., 2006; Rios et al., 2011). This experiment tested the effect of CD36
knock-down on oxLDL cell viability in the absence of added 7,8-NP that could scav-
enge oxidants. Cell viability was measured 18 hours after the removal of oxLDL, or 24
hours after initial addition of oxLDL. This experiment, therefore, repeated the condi-
tions outlined in chapter 3. No significant protection was observed in the presence of
7,8-NP pre-treatment (fig. 5.14). It suggests that the down-regulation of CD36 did
not play a significant role in 7,8-NP–mediated protection against oxLDL toxicity to
the macrophage, which was contrary to the initial expectation.
Wintergerst et al. (2000) reported that binding of oxLDL to CD36 led to the rapid ac-
tivation of caspase-3 and resulted in apoptosis of human macrophages. However, no
caspase-3 activation was observed in the experimental design used in Gieseg et al.
(2010a). Whether the latter also implied that CD36 is not involved in oxLDL–
mediated toxicity remains to be seen. Such conclusion, however, would contradict
the observations of Higashi et al. (2005) and Park et al. (2009) who also showed the
importance of CD36 for oxLDL–mediated cell death. The down-regulation of CD36
receptor by 7,8-NP in the present study was not complete. At least 50% of CD36 was
still available for oxLDL binding. Moreover, another scavenger receptor could have
facilitated the uptake of oxLDL into the cells with down-regulated levels of CD36
(Horiuchi et al., 2003). Nozaki et al. (1995) illustrated this by showing a 40% uptake
reduction in CD36–negative macrophages. 7,8-NP pre-treatment and CD36 receptor
reduction did not affect the uptake of 7KC and, therefore, oxLDL by the cells (fig.
5.16), suggesting that some of the aforementioned mechanisms took place.
Intracellular GSH levels were, however, slightly protected by the pre-treatment, es-
pecially at a sub-toxic oxLDL concentration. The higher GSH levels might indicate a
reduced oxidative damage in the pre-treated cells. A possible mechanism was demon-
strated by Park et al. (2009): CD36–mediated NADPH oxidase activation and sub-
sequent ROS release. Nevertheless, this small increase of GSH levels did not lead to
a significant gain in cell viability.
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Alternative hypothesis
Assuming that total 7KC is the reflection of oxLDL internalised by the cell, the reduc-
tion of total 7KC in the presence of 7,8-NP could be interpreted as down-regulation
of uptake, especially in combination with the down-regulation of CD36 scavenger.
However, the down-regulation of the CD36 receptor by 7,8-NP (for 24 hours) did not
reduce oxLDL uptake in the first 6 hours of subsequent exposure (fig. 5.16). More-
over, the 7,8-NP–mediated down-regulation of intracellular 7KC ester levels was only
observed in the presence of extracellular human serum (fig. 5.17). (Complete absence
of serum, although, might have an adverse effect on HMDM cells, which could not be
ruled out). The combination of these results suggests that the effect of 7,8-NP might
be associated with cholesterol reverse cholesterol trafficking and efflux rather than
the uptake. Serum contains HDL apolipoprotein A1, which acts as an extracellular
acceptor for cholesterol and oxysterols (Johnson et al., 1991). 7KC esterification di-
rectly preceded the divergence of 7,8-NP and non-7,8-NP mediated rise in total 7KC
(figures 5.1b and 5.4). Thus it can be speculated, that 7,8-NP may interfere with the
esterification by ACAT-1 or ester hydrolysis by neutral ester hydrolase. Furthermore,
it would explain the absence of 7,8-NP–mediated effect over the first 6 hours of ex-
posure to oxLDL, as the esterification did not commence until after 6 hours.
CD36 protein and mRNA were also down-regulated by the presence of 7,8-NP. It
is plausible that 7,8-NP down–regulation of CD36, while not being the cause of lower
intracellular oxLDL, is associated with the oxLDL processing and efflux and is a con-
sequence of that. CD36 expression in mouse macrophage-like J774 cells was shown
to be down-regulated by cholesterol efflux which was induced by cyclodextrins (Han
et al., 1999). Therefore, if 7,8-NP enhances efflux, the latter may reduce CD36 pro-
tein and mRNA expression.
No added protection from cell viability loss was observed in the pre-treated cells
with the lower CD36 receptor levels (fig. 5.14). However, these cells showed slightly
elevated GSH levels, suggesting that some oxidative damage was alleviated. The size
of the effect, however, suggested that this process may not be a major protection
mechanism.
Cholesteryl ester accumulation is a characteristic feature of foam cells. AcLDL was
shown to inhibit CE efflux from foam cells (Brown et al., 1979), although not fully
(Kritharides et al., 1995), and so did oxLDL (Kritharides et al., 1995). Kritharides
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et al. (1995) and Gelissen et al. (1996) also reported that 7-KC inhibited the efflux
of sterols from macrophages. The authors concluded that it was “possible that this
impairment of efflux from oxLDL-loaded cells influences the generation and persis-
tence of the foam cell phenotype in vivo” (Kritharides et al., 1995). If 7,8-NP was
promoting the hydrolysis of oxidised cholestryl esters and governing the efflux of
oxLDL components from foam cell macrophages it could play a role in alleviating the
atherosclerotic burden.
Future work is required to verify this hypothesis. ACAT-1 inhibition was shown to
facilitate efflux and lead to the depletion of CE content (Liu et al., 2003). The effect
of 7,8-NP on ACAT-1 activity could be investigated. Brown et al. (1979) suggested
that hydrolysis and removal of the esterified cholesterol in their study was performed
by non-lysosomal esterases. The authors also observed that the activity of the enzyme
that hydrolyses cytoplasmic cholesteryl ester was suppressed during the incubation
with acLDL. The enzyme responsible for this process and its cellular activation could
be the first target of a future investigation of the mechanism of 7,8-NP effect on the
RCT during oxLDL exposure. Harrison et al. (1990) showed that cholestryl ester hy-
drolase was responsible for hydrolysis of CE associated with lipid droplets as opposed
to lysosomes. In addition, the effect of 7,8-NP on cholesterol transporter ABCA1 and
ABCG1 activity could also be investigated since they constitute the final stage of the
RCT pathway (Yvan-Charvet et al., 2010).
5.4 Summary
The research in this chapter has shown that 200 µM 7,8-NP decreased the levels
of intracellular total 7-ketocholesterol by at least 40% in HMDM cells over 24 hours.
This coincided with the 40% reduction in CD36 receptor (100 kDa) and mRNA levels.
Both of these were late effects, taking place in the second half of the 24 hour incu-
bation. Thus, 7,8-NP–mediated reduction in cellular oxLDL levels was a late effect
in the oxLDL toxicity. Since the majority of the HMDM cellular death occurred in
the first 12 hours of oxLDL treatment (chapter 3) and was heavily influenced by the
first 6 hours of exposure, the aforementioned processes might play a secondary role
in 7,8-NP–mediated protection of macrophages in the setting of acute oxLDL toxicity.
The effect of 7,8-NP on the levels 7KC esters coincided with the onset of esterifi-
cation of oxLDL components, and was dependent on the presence of extracellular
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serum. Based on this information, a new hypothesis of 7,8-NP role in oxLDL uptake
is proposed. 7,8-NP could mediate oxLDL efflux by promoting cholesteryl ester hy-
drolysis. in particular reverse cholesterol transport. Future research is necessary to
test this hypothesis. Cholestryl ester hydrolase(s) activity and other stages of reverse
cholesterol transport such as on ACAT-1 and cholesterol transporters ABCA1 and
ABCG1 are proposed as potential targets.
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6HMDM cell culture method
development and troubleshooting
6.1 Introduction
Variability and resistance of HMDM cell response to oxLDL toxicity was a significant
problem throughout the project. It manifested in LC50 being outside the experimental
range of 2-3 mg/mL. This chapter describes the attempts to standardise cell culture
methodology and investigate potential mechanisms that determine the variability of
response and resistance to toxicity. This chapter also aimed to compare and contrast
the available literature on the basis on current findings, since a range of oxLDL con-
centrations and experimental conditions has been used by different research groups.
Methodological improvements reported in the first part of this chapter constitute
an extension of the previous work in the laboratory (Amit, 2008; Firth, 2006; Yang,
2009) and are included for the benefit of future researchers. The data on HMDM cell
growth efficiency in the presence of GM-CSF is provided for benchmarking purposes.
HMDM cell growth in 48 well plates was investigated to improve experimental capac-
ity per HMDM cell preparation as 12 well plates were found to be limiting in number.
The present study addresses serum supplementation in greater detail than the original
reports from our laboratory (Amit, 2008; Firth, 2006; Yang, 2009). This was carried
out in an attempt to resolve the issue of variable oxLDL toxicity to macrophages.
The second and third parts of this chapter explore the factors governing variability
and resistance of HMDM cell response to oxLDL toxicity. In particular, the second
part of this chapter explores the effects of serum and cell density on macrophage cell
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death mediated by oxidised LDL. In the literature, varying concentrations of human
and bovine serum have been used to supplement macrophages and macrophage-like
cells during oxLDL treatment. For instance, Hardwick et al. (1999) and Gerry &
Leake (2008) used serum-free media, Terasaka et al. (2007) used 5% lipoprotein–
deficient serum, Harris et al. (2006) used 10% and Gieseg et al. (2010a) used 10%
heat–inactivated human serum (HIHS). In our laboratory, 5% serum was found to pre-
vent oxLDL toxicity to U937 cells, yet the HMDM cell experiments were performed
in the presence of 10% human serum (Katouah, 2012). The original experiments by
Henriksen et al. (1979) and Hessler et al. (1979) also showed that LDL toxicity to
ECs and SMCs was inhibited by the presence of serum in the incubation medium.
This was confirmed in HMDM cells as well (Asmis & Wintergerst, 1998; Wintergerst
et al., 2000). The present study aimes to establish the optimal serum conditions for
studying cell death in our laboratory and identify whether some of the variation in
published oxLDL toxicity levels could be attributed to the different conditions used
by those researchers. Another aspect of cell culture that had been largely overlooked
in the literature is cell density. A few early studies identified that oxLDL toxicity
decreased with the increased cell density and proliferative activity of SMC and fibrob-
lasts (Hessler et al., 1983, 1979). Therefore, effect of cell density on oxLDL toxicity
to HMDM and U937 cells is investigated.
The third and final part of this chapter addresses the phenomenon of HMDM re-
sistance to oxLDL, which was occasionally observed in cultured cells in this study.
The investigation was carried out at different serum concentrations as serum supple-
mentation was found to be a significant extracellular factor in oxLDL toxicity. The
oxidative nature of the underlying processes is explored by examining ROS produc-
tion and oxidative damage in “resistant” vs. “susceptible” HMDM cells. Overall, this
chapter explores the variation in cell culture technique and attempts to explain and
standardise the underlying causes.
6.2 Culture of human monocyte–derived macrophages
6.2.1 Effect of GM-CSF and overall HMDM culture success
Monocytes’ metabolic capability was greatly enhanced upon differentiation and de-
velopment into macrophages. The effect of GM-CSF on the HMDM cell growth
and development in the present study was assessed on seven HMDM cell prepara-
tions (batches) (fig. 6.1). Cellular metabolism per well (measured via MTT assay)
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was proportional to the number of differentiated macrophages as monocytes showed
minor MTT turnover (data not shown). The cell number output of non-GMCSF–
treated cells was normalised to the number of matched GM-CSF–treated cells. Cells
that were not supplemented with GM-CSF only developed to 44 ± 31% (SD) of the
number of supplemented cells (fig. 6.1). Thus, monocytes seeded without GM-CSF
showed some development into macrophages but the well coverage was lower than
in the presence of the growth factor. One batch of HMDM cells out of seven was
observed to have abnormally high differentiation in the absence of GM-CSF, high-
lighting the inter-donor variability (fig. 6.1). The term “differentiation” will be used
here to denote monocyte development into macrophage as based on morphology and
metabolic capacity.
The overall percentage of successful HMDM cell development (referred to as “dif-
ferentiation” from monocyte into macrophage) from different donors was investigated
to provide a reference for future work in this laboratory. Each batch was given a
rating (differentiated, marginal, not differentiated) based on cell morphology and the
data from 45 preparations was combined (fig. 6.2). Over the course of this research,
the HMDM were cultured in both Nunc® (Nalge Nunc Int., Roskilde, Denmark)
and Cellstar® (Greiner bio-one, Neuburg, Germany) plates at seeding densities of 1
and 5x106 cells/well. The data were pooled for all preparations cultured in the pres-
ence of GM-CSF, because no difference in HMDM cell culture was observed between
plates (as discussed below). Almost 70% of the HMDM preparations showed exten-
sive morphological differentiation to be considered fit for experimentation (fig. 6.2).
The cells produced a uniform lawn and displayed round “poached egg–like” morphol-
ogy with 10-30% cells showing slightly elongated morphology. Approximately 15% of
the HMDM preparations developed marginally, where either the morphology or the
well coverage were not acceptable. The remaining preparations failed to differentiate
properly even in the presence of GM-CSF.
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Figure 6.1: Effect of GM-CSF on HMDM cell differentiation.
HMDM (1x106 cells mL-1) were cultured in the presence of 10% human serum with
or without the initial 25 ng/mL GM-CSF. On days 11 to 14 of culture the HMDM
cell number for both treatments was determined via MTT assay. The results for non-
GM-CSF–treated HMDM were normalised to the cellular metabolism of matched GM-
CSF–treated cells (n=7). The data is expressed as a scatter dot plot with mean ±
SD. (B) and (C) represent HMDM cells cultured in the presence and absence of initial
GM-CSF, respectively. Images are from a representative experiment. Arrows indicate
macrophage (M)– and monocyte (m)–like morphology Scale bar = 50 µm.
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(a) % HMDM batches per category, n=45 (b) good
(c) marginal (d) not differentiated
Figure 6.2: Percentage of successful macrophage development in culture.
HMDM differentiation and development into macrophage-like morphology was assessed
over the course of the project. HMDM cells were cultured in either Nunc® or Cellstar®,
12 (5x106 cells mL-1) or 48 well plates (1x106 cells mL-1), in the presence of 10% human
serum with an initial pulse of GM-CSF. The cells were given a rating of “good” (b),
“marginal” (c) and “not differentiated” (d) according to the macrophage number and
morphology approximately on day 12 after seeding (n=45). Scale bar=50µm.
181
6. HMDM CELL CULTURE METHOD DEVELOPMENT AND
TROUBLESHOOTING
6.2.2 Culture plate trial
Nunc vs. Cellstar plates for HMDM cell growth
Cellular adhesion and differentiation are processes that involve more than one mech-
anism. They are often cell type specific and, therefore, the selection of the growth
surface for a particular cell line/type is based on the performance of the culture. His-
torically in this laboratory, the HMDM cells were cultured in 12 well Nunc adherent
plates. Yet HMDM culture in Cellstar plates, if successful, could potentially reduce
the cost of the operations. Thus, the two plate types were compared with respect
to their ability to support HMDM cell growth (fig. 6.3). For one batch of HMDM
(batch 2), Cellstar plate performed better than Nunc in sustaining cell differentiation
and growth as indicated by the MTT reduction capacity of cells in that plate (fig.
6.3a). Since no negative growth data was observed and the morphology of HMDM
cells grown in Cellstar and Nunc plates was identical, Cellstar plates were chosen for
future experiments.
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Figure 6.3: Effect of plate type on HMDM cell growth.
HMDM, seeded at 5x106 cells mL-1, were cultured in 12 well plates (Cellstar (B) and
Nunc (C)) in the presence of 10% human serum. Cell number/viability was assessed
by MTT reduction on the 12th day of culture, images were taken on day 9. Results
displayed as mean ± SEM of triplicate measurements from a single experiment (A).
HMDM batches 1 and 2 were from different donors. Significance (t-test) was as indi-
cated, *, p<0.05. Scale bar = 50 µm.
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Limitations of 12 well plates
Twelve well plates were initially used for HMDM growth. However, the low number
of experimental units (i.e. wells) was an obstacle to experimental throughput. When
seeded at 5x106 per well, the largest HMDM preparation would reach approximately
120–140 wells, with an average of around 96 wells. This proved to be a very low
number since every batch had to be tested for toxicity prior to any experiment. To
overcome this problem, smaller wells were tested for HMDM growth. Two 48 well
plates seeded at 1x106 cells/well produced the same number of experimental units
as the full batch previously, while constituting less than 1/3rd of the cells isolated
from an average donation. To determine the appropriate monocyte seeding density
for a 48 well plate, the cells were seeded at 0.25 to 3x106 cells/well (fig. 6.4). The
number of viable cells per well was assessed via MTT assay 11 days after seeding.
The differentiation success and capacity varied between the HMDM preparations, but
1x106 resulted in the highest numbers of cells without causing over-crowding. It was,
therefore, decided to seed 1x106 monocytes per well.
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Figure 6.4: Determination of monocyte seeding density for HMDM cell
growth in 48 well plate.
HMDM were seeded into 48 well plate at increasing cell densities. The cells were
cultured in the presence of 10% human serum with an initial pulse of 25 ng/well GM-
CSF. Cell viability was determined by MTT reduction 11 days after seeding (auto-zero
on reagent only). Results are displayed as mean ± SEM of triplicate measurements from
three batches of HMDM cells from different donors. Batches 1 and 3 lacked 0.25x106
and batch 3 lacked 3x106 measurements.
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6.2.3 Effect of human serum on HMDM development and
growth
Serum supplementation of monocyte/macrophage cultures is essential for successful
cell growth. Batches of serum from different donors, however, varied in their capacity
to promote macrophage differentiation (fig. 6.5). Monocytes were seeded in the
presence of 10% serum in RPMI-1640 and the number of developed macrophages
was assessed 12 days later by MTT assay. In order to achieve some replication, two
HMDM batches from different donors were grown with each serum batch at the same
time. Serum batches 2 and 7 in figure 6.5 a) and b), respectively, promoted higher
HMDM differentiation than the rest of the sera in each test. The majority of the
remaining sera (1,3 and 4,6) affected differentiation to a similar level (fig. 6.5b). An
interaction between macrophage and serum batch was also observed as not all sera
promoted differentiation in HMDM batches 1–4 equally (for example batches 6 and
7 in fig. 6.5b). Serum also played a role in HMDM growth after GM-CSF–facilitated
differentiation (fig. 6.6). For GM-CSF–differentiated HMDM cells, batches 3, 6 and
7 yielded the highest macrophage growth and metabolism (fig. 6.6). All sera were
non-autologous.
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Figure 6.5: Effect of sera on HMDM cell development.
HMDM (1x106 cells mL-1) seeded in the absence of GM-CSF were assessed for the cell
number with MTT assay on the 12th day of culture. Results are displayed as mean ±
SEM of triplicate absorbance measurements. HMDM batches 1-4 and serum batches
1-7 were all from different donors. Pooled serum was made by combining the indicated
batches of serum. “Cloudy” (lipid–rich) sera 3 and 7 were not pooled. Statistical
significance (one-factor ANOVA with Turkey post test): (A): serum 2 significantly
different from sera 1 and pooled for both HMDM batch 1 and 2, p<0.05; (B) for HMDM
batch 3: serum 7 significantly higher than all other sera, sera 4 and 5 significantly lower
than sera 6 and 7 and pooled, p<0.05; for HMDM batch 4: sera 5 and 7 significantly
higher than all other sera, p<0.01.
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Figure 6.6: Effect of sera on GM-CSF–differentiated HMDM cell growth.
HMDM (1x106 cells mL-1) seeded in the presence of 25 ng/mg GM-CSF were assessed
for the cell number with MTT assay on the 12th day of culture. Results are displayed
as mean ± SEM of triplicate absorbance measurements. HMDM batches 1-4 and serum
batches 1-7 were from different donors. Pooled serum was made by combining the indi-
cated batches of serum. “Cloudy” (lipid–rich) sera 3 and 7 were not pooled. Statistical
significance (one-factor ANOVA with Turkey post test): (A): sera 2 and 3 significantly
different from sera 1 and pooled for both HMDM batch 1 and 2, sera 2 and 3 different
from each other, p<0.05; (B) for HMDM batch 3: sera 4 and 5 significantly lower than
sera 6 and 7, p<0.05; for HMDM batch 4: sera 4 and 5 significantly lower than sera 6
and 7, sera 6 and 7 significantly higher than pooled serum p<0.05.188
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Effect of heat–inactivation of human serum on HMDM cell growth
Human serum was heat–inactivated in the initial stages of the project, but this step
was subsequently omitted (after the review of the literature (Biochrom AG, 2010;
Hyclone®, 1996; Leshem et al., 1999) and personal communication with Dr. S.P.
Gieseg and Dr. B. Hock of Otago Medical School Christchurch, New Zealand). Heat–
inactivation of serum had no effect on the cells’ ability to reduce MTT to formazan
after 24 hour incubation (fig. 6.6). This suggested that HMDM cell number and
metabolic capacity was equal across the two serum treatments.
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Figure 6.7: Heat–inactivation of human serum does not alter HMDM growth
in culture.
HMDM (1x106 cells mL-1) were cultured with 10% heat–inactivated (white bars) or
non-heat–inactivated (grey bars) human serum. Cell metabolism was assessed by MTT
reduction on the 12th day of culture. Results displayed as mean ± SEM of triplicate
measurements from two HMDM batches. The difference between heat–inactivated and
non-heat–inactivated serum for each batch was not statistically significant (t-test).
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6.3 Utility of U937 cells as a model of 7,8-NP–
mediated oxLDL uptake regulation
The use of the U937 cell line for CD36 down-regulation experiments was assessed,
since U937 cells comprised a more homogeneous system than primary HMDM cells.
The effect of 7,8-NP on uptake and CD36 was tested in U937 cells. A range of 7,8-
NP concentrations was tested on U937 cells incubated for 24 hours in the normal
culture medium (RPMI-1640 supplemented with 5% FBS and antibiotics) (fig. 6.8).
Monocyte-like U937 cells had a less prominent 100 kDa band than HMDM cells (fig.
6.8). 7,8-NP showed a concentration–dependant effect on the CD36 protein expression
in U937 cells (fig. 6.8). The heavily glycosylated 100 kDa band was down–regulated ,
while the 80 kDa band was up-regulated with the increasing concentrations of 7,8-NP.
At 250 µM, the 100 kDa band was 30% lower than control, while 80 kDa band was
45% higher than control.
OxLDL uptake in the presence of 7,8-NP in U937 cells was also measured (fig. 6.9).
U937 cells (1x106 cells/mL) in RPMI-1640 (without FBS as per U937 protocol for
oxLDL experiments in Katouah (2012)) were treated with 0.1 mg/mL oxLDL for
24 hours in the presence of increasing concentration of 7,8-NP. Sub-toxic level of
oxLDL was used to ensure consistency with HMDM data. OxLDL caused a 40-50%
rise in intracellular total 7KC levels compared to no oxLDL control (fig. 6.9). The
presence of 7,8-NP did not alter intracellular 7KC levels significantly, suggesting the
absence of effect on oxLDL uptake. Thus U937 cell were not used for the subsequent
experiments.
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Figure 6.8: Effect of 7,8-NP on the CD36 protein expression in U937 cells.
U937 cells were placed into BSA-coated wells at 106 cells/mL and incubated with in-
creasing concentrations of 7,8-NP for 24 hours in RPMI containing 5% FBS. The pres-
ence of CD36 protein in cell lysates was assessed by immunoblotting. β-Actin was used
as loading control. (A) A representative Western blot. (B) Quantitative densitome-
try of Western blots displaying concentration-dependent regulation of 80 and 100 kDa
bands relative to 0 hour control. Results were normalised by actin and displayed as
mean ± SEM of duplicate experiments. Neither decrease of fully glycosylated 100 kDa
band nor increase of incompletely glycosylated 80 kDa band were statistically significant
(one-factor ANOVA with Dunnett’s post test).
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Figure 6.9: 7,8-NP has no effect on the intracellular 7KC uptake by the
oxLDL–exposed U937 cells.
U937 cells (1x106 cells/mL) in RPMI-1640 were treated with 0.1 mg/mL oxLDL for 24
hours in the presence of increasing concentrations of 7,8-NP. The cells were collected
and assessed for free (clear) and total (filled) 7KC via HPLC. Results are displayed as
mean ± SEM of triplicates from a single experiment. Significant difference (one-factor
ANOVA with Dunnett’s post test) from 0 µM 7,8-NP exposed to oxLDL as indicated,
*, p<0.05.
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6.4 Extracellular experimental factors contribut-
ing to toxicity
6.4.1 Extracellular serum is a factor in oxLDL toxicity
OxLDL toxicity was established for each HMDM cell batch prior to conducting exper-
iments. Two experimental protocols were used throughout the study. The original
protocol involved treating cells (seeded at 5x106 cells/well in 12 well plates) a de-
creasing human serum concentration with increasing oxLDL concentration as whole
medium was pre-mixed to 10% serum before the addition of oxLDL. The results are
presented in figure 6.10a. To analyse the effect of progressively decreasing serum
concentration on oxLDL toxicity, a multiple regression analysis was performed on
the toxicity data, taking into account individual serum concentrations for each data
point. Linear mixed effects model analysis with [oxLDL] as a variate, [serum] as
co-variate and experiment as factor, was performed in R (R Core Team, 2012). The
effect of serum concentration was highly significant (p<0.001), as was the effect of
oxLDL concentration and the interaction between the two variables (p<0.05).
For the subsequent experiments (performed on HMDM cells seeded at 1x106 cells/well
in 48 well plates), extracellular serum concentration was fixed at 10% (fig. 6.10b).
In contrast to the original protocol, no cell viability loss was observed at 1 mg/mL
oxLDL (fig. 6.10b). Direct comparison between figures 6.10a and 6.10b was not per-
formed due to the different macrophage seeding density, but the effect of increasing
serum concentration was pursued further.
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Figure 6.10: Effect of experimental protocol on oxLDL toxicity to HMDM.
(A) HMDM cells (5x106 cells mL-1) were incubated with increasing concentrations of
oxLDL for 24 hours in the whole medium pre-mixed to 10% serum before the addition of
oxLDL. Therefore, the amount of human serum decreased proportionally to the increase
of oxLDL concentration. (B) HMDM cells (1x106 cells mL-1) were incubated in the
whole medium containing exactly 10% human serum. Cell viability was measured via
MTT assay. The data are expressed as percentage of untreated control and the results
are displayed as box-and-whiskers plots (mean ± range) of (A) n=14 experiments
for [oxLDL] from 0 to 3 mg/mL and n=6 for [oxLDL]=4 mg/mL; (B) n=5 from 0
to 2 mg/mL, n=4 for 3 mg/mL, n=1 for 4 mg/mL. Significance (one-way ANOVA
with Dunnetts post-test) is indicated from untreated control **, p<0.01, ***, p<0.001.
Regression lines were fitted using Prism5.
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A targeted experiment was performed to quantify the protective effect of human
serum against oxLDL toxicity. The HMDM cells were incubated with 2 mg/mL
oxLDL in the presence of increasing serum concentrations expressed as serum protein
(fig. 6.11). Normal extracellular protein concentration of the whole medium at 10%
human serum was ∼7 mg of protein per mL. (The average serum protein content was
70 ± 3 mg/mL (SD, n=12) which is in the published range (Barrett et al., 2010)
(p. 2)). Extracellular protein concentration above 2 mg/mL (2.86% serum, v/v)
significantly prevented oxLDL–mediated HMDM cell viability loss when compared to
oxLDL–treated HMDM in the absence of serum (fig. 6.11). The curve of extracellular
serum effect plateaued after 3 mg of protein per mL (4.29% serum). In the current
experimental design, the protection mediated by serum was almost complete (viability
rise from 50 to 95%) (fig. 6.11b). The steep slope in the 0–2 mg/mL protein range
indicated that incremental change in serum concentration within this range had a
large effect on oxLDL–mediated toxicity. Large error bars at 0.75 and 1 mg/mL on
the combined data (fig. 6.11b), but not on individual experimental data (fig. 6.11a)
indicated the large variability between the experiments (indicative of variability in
HMDM response between HMDM preparations) in this region of rapid change. It is
worth noting that for all other points the SEM bars were a moderate ± 10% (fig.
6.11b), suggesting that experimental methodology was not the source of this large
variation.
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Figure 6.11: Extracellular serum inhibits oxLDL-mediated HMDM toxicity
in a concentration–dependent manner.
HMDM cells (1x106 cells mL-1) were treated with 2 mg/mL oxLDL for 24 hours in
RPMI-1640 supplemented with increasing concentration of human serum (expressed
as mg/mL serum protein). Cell viability was assessed via MTT reduction. Results
are displayed as percentage of remaining cell viability relative to the respective control
(no oxLDL, matched serum concentration), shown as mean ± SEM of (A) triplicate
measurements from a single experiment, and (B) combined means from three separate
experiments. Significance is indicated from control, **, p<0.01, ***, p<0.001 (one-way
repeated measures ANOVA on A) single experiment B) combined data, Dunnetts post
test).
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Since albumin comprises the majority of serum protein and is the primary “sacri-
ficial” antioxidant in serum, the ability of albumin to protect HMDM from oxLDL
toxicity was investigated. A concentration of simple albumin solution (BSA dissolved
in PBS) was matched to the concentration of serum protein and used to supplement
oxLDL–treated HMDM cells. The effect of albumin in the extracellular medium al-
most exactly replicated the effect of serum (fig. 6.12), which suggested that the
majority of the serum effect was attributable to serum albumin. However, at protein
concentrations higher than 1 mg/mL a small but noticeable difference between the
serum and BSA supplementation was observed (fig. 6.12). The difference was not
statistically significant, but it was consistently replicated in the three experiments
(fig. 6.12b), suggesting that the effect may have been real.
Asmis & Wintergerst (1998) showed that extracellular serum inhibited the uptake
of Texas red–labelled oxLDL by HMDM cells. This experiment was repeated here,
but amended to include extracellular protein. 7-Ketocholesterol (7KC), an advanced
oxidation product of cholesterol in oxLDL, was used as a proxy of total intracellular
oxLDL uptake. As discussed in chapter 5, 7KC is a good indicator of oxLDL uptake as
it utilises an inherent component of oxLDL instead of being an exogenous compound
like Texas red or DiI. Intracellular free and esterified 7KC was measured in HMDM
cells exposed to a sub-toxic level of oxLDL for 24 hours (fig. 6.13). Extracellular
serum and BSA inhibited 7KC and, therefore, oxLDL uptake, by 12 nmol/mg protein
(or 25%) and by 18 nmol/mg protein (or 38%), respectively.
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Figure 6.12: Extracellular protein inhibits oxLDL-mediated HMDM toxicity
in a concentration–dependent manner.
HMDM cells (1x106 cells mL-1) were treated with 2 mg/mL oxLDL for 24 hours in
RPMI-1640 supplemented with the indicated concentration of protein added as native
bovine serum albumin (BSA, squares) or human serum (human serum, HS, circles).
Cell viability was assessed via MTT reduction. Results are displayed as percentage of
remaining cell viability relative to the respective control (no oxLDL, matched serum
concentration), shown as mean ± SEM of (A) triplicate measurements from a single
experiment (B) combined means from three separate experiments. Treatments were
not statistically different (one-way ANOVA, Bonferroni comparison of treatments at
each concentration of (A) and (B)).
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Figure 6.13: Effect of extracellular protein (added as BSA or as human
serum) on oxLDL uptake by HMDM cells.
HMDM cells (1x106 cells mL-1) were treated with 1 mg/mL oxLDL for 24 hours in
RPMI-1640, RPMI-1640 supplemented with 10% human serum or 2mg/mL of native
BSA. OxLDL uptake was assessed via total 7-ketocholesterol uptake. Results were
normalised to the no oxLDL control and are displayed as mean ± SEM of triplicate
measurements from a single experiment. No statistically significant difference was de-
tected (one-way ANOVA with Dunnet’s post test)
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6.4.2 Cell density is a factor in oxLDL toxicity
Another variable of HMDM cell culture was the effective concentration of cells per
well. Cellular density was suspected to influence the protection from oxLDL–mediated
cell death when U937 cells failed to die in an experiment where cell number was tripled
against the usual 5x105 cells/mL. The effect of cell density on toxicity was identified
as a potential source of variability between HMDM cell preparations, because the
proportion of seeded monocytes which differentiated into HMDM cells was subject to
inter-experimental variability.
U937 cells were used to test the effect of cell density on oxLDL–induced cell death,
due to ease of controlling cell number compared to HMDM cells. Cell density was
observed to have a large effect on oxLDL–induced cell toxicity in these cells. At the
lowest density range (0.1x 106 cells mL-1), virtually all cells were dead in the presence
of 0.5 mg/mL oxLDL after 24 hours (examined through the microscope and via MTT
assay) (fig. 6.14). Conversely, at the highest density range (1.25–1.5 x 106 cells mL-1),
cellular viability remained above 60–80% at the end of 24 hour incubation. For U937
cell density above 0.5 x 106 cells/mL the decrease in oxLDL toxicity (increase in re-
maining cell viability) was 21% per 4x105 cells (or 5.3% per 1x105 cells). All tested
cell densities fell within the linear detection range as indicated in figure 6.14a.
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Figure 6.14: Effect of cell number on oxLDL–mediated U937 cell viability
loss.
U937 cells incubated at increasing cell densities in 12 well plates were treated with (filled
squares) or without (empty circles) 0.5 mg/mL of oxLDL in RPMI-1640 without phenol
red for 24 hours. Cell viability was assessed by MTT reduction. Results are expressed as
raw absorbance units displayed as mean ± SEM of (A) duplicate measurements from a
single experiment, representative of three separate experiments and (B) as percentage
remaining cell viability relative to the respective control, combined data from three
experiments. OxLDL-mediated cell viability loss is influenced by cell density (two-
factor ANOVA, interaction highly significant), ***, p<0.001.
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The experiment was repeated with HMDM cells. HMDM cells were cultured as usual,
detached from the well with AccutaseTM, counted and re-plated at the indicated
densities in the presence of 2% human serum (fig. 6.15). After a 20 hour adjustment
period, the cells were incubated with 2.5 mg/mL oxLDL for 24 hours and assessed for
cellular viability with PrestoBlueTM. To yield linear response in the cell only control,
the experimental design included a broad range of densities and oxLDL treatment
was followed by 3 hour incubation with PrestoBlueTM (fig. 6.15). As with U937
cells, increasing cell density had a large protective effect against oxLDL toxicity (fig.
6.15). The result varied slightly with HMDM cell preparation, going from 10% to
almost 90% cell viability gain in fig. 6.15b and from 35% to 75% in fig. 6.15d, or
approximately 18 to 21% viability gain per 4x104 cell density for both experiments
(based on the regression slope).
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Figure 6.15: Effect of cell number on oxLDL–mediated HMDM cell viability
loss, continued.
HMDM cells were lifted with AccutaseTM treatment, counted and seeded at the indi-
cated density into 48 well plates. After a 20 hour adjustment period, the cells were in-
cubated with (filled squares) or without (empty circles) 2.5 mg/mL oxLDL for 24 hours
in the presence of 2% human serum. Cell viability was assessed by PrestoBlueTM assay
after 3 hour incubation. Results are mean ± SEM of triplicate measurements from
two separate experiments (A,B and C,D); expressed as raw fluorescence values (A,C)
and percentage of remaining cell viability relative to the respective no oxLDL control
(B,D). OxLDL–mediated cell viability loss was influenced by cell density (two-factor
ANOVA, interaction highly significant, p<0.001) and the presence of oxLDL (p<0.001).
Regression slopes were significantly non-zero, p<0.001.203
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6.5 HMDM cell resistance to oxLDL toxicity
6.5.1 Defining HMDM cell resistance to oxLDL
The research presented in this section is a case study of HMDM cell resistance to
oxLDL. It investigates the underlying mechanisms by characterising oxidative flux
and damage in resistant cells. HMDM cells cultured in the presence of GM-CSF are
robust to condition perturbations and toxic agents (personal communications with
Dr. H. Kruth of National Heart Lund and Blood Institute, USA). As seen earlier,
concentrations above 1–2 mg/mL oxLDL were required for any toxicity to occur.
Among the overall robust culture, a proportion of HMDM preparations displayed little
or no cell viability loss when exposed to otherwise toxic (2.5-3 mg/mL) concentrations
of oxLDL (8 out of 20 since the start of observation). Although such cells were
not used for the core experiments in this thesis, this persistent phenomenon was
investigated further in an attempt to establish governing factors. This was necessary
for the experiments that required toxicity. The “resistant” HMDM preparations were
identified as showing no cell death when exposed to 2.5 mg/mL oxLDL for 24 hours in
the culture medium supplemented with 0%, 2%, 5% or 10% human serum (fig. 6.16).
A range of serum concentrations was tested because extracellular serum emerged as
a protective factor against cellular death (fig. 6.4). More narrowly, the definition of
resistant HMDM cells was chosen to be “HMDM cells that show less than 15% cell
viability loss (when compared to cell only control, p>0.05) upon 24 hour incubation
with 2.5 mg/mL oxLDL in the medium supplemented with 2% human serum” (as
the complete absence of serum could be disputed as non-physiological). To unravel
the mechanisms of this phenomenon, the investigation focused on two experimental
components: oxLDL and HMDM cells.
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Figure 6.16: Resistance of HMDM to toxic concentration of oxLDL at a
range of serum concentrations in the incubation medium.
HMDM cells (1x106 cells mL-1) cultured in the whole medium, were treated with (filled
signs and bars) or without (empty signs and bars) 2.5 mg/mL oxLDL for 24 hours in the
medium containing the indicated concentration of serum. Cell viability was assessed
by MTT reduction assay. Results are displayed as (A) mean ± SEM of triplicate
measurements from a single experiment, (B) four separate experiments (only two of
which had 0% serum measurement). None of the oxLDL treatments were statistically
different from the respective no oxLDL control (one-factor ANOVA with Dunnett’s post
test).
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6.5.2 LDL oxidation is not a factor in the HMDM cell resis-
tance
The extent of LDL oxidation was measured to address the possibility that the oxLDL
particle itself was the root of the resistance issue. LDL appeared to be fully oxidised
after 24 hour oxidation with 500 µM Cu2+ ions at 37 ◦C. It lost its characteristic yel-
low colour and displayed increased relative electrophoretic mobility (REM) compared
to native LDL on the native agarose gel (fig. 6.17). OxLDL in this study had a smaller
REM of 3.65 compared to 4.20 ± 0.42 reported by Gerry et al. (2008). This REM was
still high enough to indicate full oxidation. Amit (2008), who used a different method-
ology for Cu–mediated LDL oxidation, reported a REM of 2.67 and Katouah (2012),
whose protocol was identical to the one used here, reported a REM of 3.33. Thus, the
REM of oxLDL to which HMDM showed resistance was comparable to the published
literature and the results obtained by the previous researchers in the same laboratory.
HMDM resistance was not due to a particular oxLDL preparation’s inability to in-
duce toxicity in cells. This was tested in U937 cells, a monocyte-like cell line shown
to elicit similar response to HMDM cells when treated with oxLDL (U937 cellular
death: Baird et al. (2004); HMDM cell death: Gieseg et al. (2010a), comparison:
Katouah (2012)). OxLDL preparations that failed to kill HMDM cells were success-
ful at killing U937 cells, thus eliminating oxLDL as the source of the problem. The
remaining cell viability after 24 hour incubation of 5x105 cells/mL with 0.5 mg/mL
oxLDL was 44.7% ± 12.9 (SEM) (n=3). In view of these results, it was concluded
that the source of HMDM resistance to oxLDL was not the properties of the oxLDL
molecule, but the HMDM cells themselves and their response to oxLDL.
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Oxidation method REM
Published, Gerry et al. (2008) 4.20 ± 0.42
Present study 3.65
Figure 6.17: Lipoprotein gel electrophoresis.
Relative electrophoretic mobility (REM) of oxidised (lane 4, 5) and native (lane 6) LDL
was established (A) and quantified (B) by native gel electrophoresis using Sebia©
materials stained with sudan black. The arrows indicate the distance (mm) travelled
by the lipoprotein, which was used to calculate the REM.
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6.5.3 Delayed oxidative damage
Oxidative stress in oxLDL–resistant HMDM cells. A case study
To investigate the effect of oxLDL–mediated oxidative stress and damage, DHE flu-
orescence and GSH loss were assessed in “resistant” cell preparations. The following
case study compares the development of oxidative flux over time in HMDM cell prepa-
rations that had varying susceptibility to oxLDL toxicity.
Two HMDM cell preparations cultured alongside each other were treated with 2.5
mg/mL oxLDL for 24 hours in the presence of varying concentrations of serum (fig.
6.18). The toxicity of oxLDL to batch A was only evident in the absence of serum.
This batch was, therefore, called “resistant”. OxLDL toxicity to batch B at 2%
serum was statistically significant, and, thus, this batch was called “susceptible”.
Oxidative flux in “resistant” vs. “susceptible” HMDM cells was investigated, since
oxidative stress had already been shown to be a prominent event in oxLDL toxicity to
macrophages (fig. 3.3). Time-dependant intracellular ROS release was studied using
a flow cytometry–based DHE fluorescence assay. After oxLDL treatment, the cells
were detached with AccutaseTM, stained with DHE and analysed by flow cytome-
tery. DHE product fluorescence was monitored in the FL3 channel and a shift to the
right (higher fluorescence) was indicative of ROS increase. The gates were set as an
overall FL3 gate, low fluorescence gate (determined based on control cell frequency
distribution) and high fluorescence gate (high FL3 values) (fig. 6.19c-f). Control cells
had minimal fluorescence in the right section of the FL3 flowgram. As the ROS flux
increased, population frequency shifted to the right into the high fluorescence gate.
The shift in median cellular fluorescence intensity (MFI) in the overall FL3 gate
started at 24 hours and increased towards 48 hours in susceptible batch B (fig. 6.20).
This shift was not apparent in control or cells from resistant batch A, which showed
a significant shift only after 48 hours. Thus, overall oxidative burden was prominent
at 24 hours in the susceptible batch, but was delayed in the resistant HMDM cells.
At 48 hours, susceptible batch B cells reached 175,000 units, which was 25% higher
than batch B increase at the same time (fig. 6.20).
The shift to higher DHE fluorescence was also evaluated as the proportion of to-
tal cells located in the high fluorescence region (fig. 6.21). The proportion of cells in
this region at 24 hours was considerably lower for the resistant batch A, 25% vs. 50%
for batch B. However, by the end of the 48th hour, the proportion of cells staining
highly for DHE in both batches converged and reached about 50%. This was also
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reflected by the cellular viability (fig. 6.22). At 24 hours, the toxicity of resistant
HMDM batch A was considerably lower than that of susceptible batch B, but this
difference between batches was reduced by the 48th hour (fig. 6.21). These results
suggest that the oxidative stress manifesting as ROS release in the resistant HMDM
cells was delayed (onset in the second rather than the first 24 hour period).
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Figure 6.18: Differential oxLDL–mediated toxicity to HMDM preparations.
HMDM cells (1x106 cells mL-1), cultured in the whole medium, were treated with
(filled bars) or without (empty bars) 2.5 mg/mL oxLDL for 24 hours in the medium
containing the indicated concentration of serum. Cell viability was assessed by MTT
reduction assay and displayed as mean ± SEM of triplicate measurements. (A) and (B)
represent two HMDM cell batches grown alongside one another. Statistical significance
as indicated (one-factor ANOVA with Bonferroni post test between the respective no
oxLDL control and treatment): *, p<0.05, **, p<0.01, ***, p<0.001).
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[Fig 1.17]
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Figure 6.19: DHE measurement of resistant and susceptible oxLDL–treated
HMDM cells.
HMDM (1x106 cells well-1) were treated with 2.5 mg/mL oxLDL in the presence of 2%
human serum for the indicated period of time. Cells were harvested into AccutaseTM
and assessed for ROS production using DHE probe. Presented are the histograms of
cell count (out of 10,000 total events) in the FL3 channel. Shown is the “high DHE
fluorescence” gate.
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Figure 6.20: Differential oxLDL-mediated intracellular ROS flux in HMDM
preparations.
HMDM cells (1x106 cells mL-1) of batch A (circles) and batch B (squares), cultured in
the whole medium, were treated with 2.5 mg/mL oxLDL for 24 hours in the medium
containing 2% serum. Intracellular ROS was assessed by DHE flow cytometry-based
assay. Results are displayed as mean ± SEM of fluorescence per “all-including” section
based on 10,000 events. This experiment was performed once. Statistical significance
is indicated between the batches at the respective time point (one-factor ANOVA with
Bonferroni pairwise comparison, *, p<0.05, **, p<0.01.
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Figure 6.21: Differential oxLDL-mediated intracellular ROS flux in HMDM
preparations, percentage shift into high DHE-fluorescence gate.
HMDM cells (1x106 cells mL-1) of batch A (circles) and batch B (squares), cultured in
the whole medium, were treated with 2.5 mg/mL oxLDL for 24 hours in the medium
containing 2% serum. Intracellular ROS was assessed by DHE flow cytometry-based
assay and expressed as percentage shift into “high DHE fluorescence” of total events
in HMDM gate. Results are displayed as mean ± SEM of triplicate measurements
from a single experiment. Statistical significance is indicated between the batches at
the respective time point (one-factor ANOVA with Bonferroni pairwise comparison, **,
p<0.01, ***, p<0.001.
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Figure 6.22: Cell viability after 24 vs. 48 hour incubation of HMDM cells
with oxLDL.
HMDM cells (1x106 cells mL-1) were incubated with 2.5 mg/mL oxLDL in the medium
(2% serum) for 24 and 48 hours. Cell viability was assessed via MTT reduction assay.
The data are expressed as a percentage of the untreated control. Results are displayed
as mean ± SEM of triplicates from a single experiment. Statistical significance was
determined by one-factor ANOVA with Bonferroni post test between the respective
0 hour control and treatment *, p<0.05, **, p<0.01; and between the 24–48 hour
treatments ##, p<0.01, $, p<0.05.
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GSH loss in “resistant” HMDM cells with oxLDL
Intracellular GSH loss was not observed in the “resistant” HMDM cells to the extent
it was described in chapter 3. No GSH loss was observed over the course of incubation
(fig. 6.23). A minor decrease at around 6 hours was observed, followed by a significant
increase by the 24th hour. This result mirrored the one obtained by Cho et al. (1999)
in kinetics, though not in magnitude.
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Figure 6.23: Time-course of intracellular GSH in “resistant” HMDM cells
in response to oxLDL treatment.
HMDM cells (1x106 cells mL-1) were incubated with (black squares) or without (white
circles) 2.5 mg/mL oxLDL in RPMI-1640 supplemented with 5% human serum for
the indicated period of time. Intracellular GSH was assessed via HPLC. The data
are expressed as a percentage of the untreated control and displayed as mean ± SEM
of triplicates from a single experiment. For reference, [GSH] in control cells was 5.2
nmol/well. Significance (t-test on raw data) is as indicated, *, p<0.05. [GSH] in control
cells was 5.18 nmol/well.
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The developing effect of oxLDL on GSH in a 24–48 hour time-frame was investigated
further in two more HMDM preparations. Both experiments 1 and 2 showed no cell
viability loss at 24 hours in the presence of 2.5 mg/mL oxLDL and 2% human serum
and thus were considered “resistant” (figures 6.24a and 6.25a). In alignment with
cell viability loss, both HMDM batches lost intracellular GSH in 0% serum within
24 hours (figures 6.24b and 6.25b). Also in agreement with the metabolic activity,
GSH level in the rest of the treatments was did not change (figures 6.24b and 6.25b).
At 48 hours (black bars), however, cell viability loss became evident in the 2% and
5% serum treatments (figures 6.24a and 6.25a). A similar pattern was observed for
intracellular GSH confirming the colose association between oxidative damage and
loss of cellular metabolism. Thence, oxidative damage in these “resistant” HMDM
cells was delayed until after 24 hours. Metabolic activity loss followed the same trend.
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Figure 6.24: Viability and GSH loss in “resistant” HMDM cells at 24 and
48 hours after oxLDL treatment. Experiment 1.
HMDM cells (1x106 cells mL-1) were incubated with 2.5 mg/mL oxLDL in RPMI-1640
supplemented with increasing concentrations of human serum for 24 (white bars) and
48 (black bars) hours. Cell viability and GSH were assessed via PrestoBlueTM reduc-
tion and MBB-HPLC assays, respectively. The data are expressed as a percentage of
untreated control and displayed as mean ± SEM of triplicates from a single experiment.
Statistical significance was determined by one-factor ANOVA with Bonferroni post test
between the respective 0 hour control and treatment ***, p<0.001; and between the
24–48 hour treatments #, p<0.01, ###, p<0.001).
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Figure 6.25: Viability and GSH loss in “resistant” HMDM cells at 24 and
48 hours after oxLDL treatment. Experiment 2.
HMDM cells (1x106 cells mL-1) were incubated with 2.5 mg/mL oxLDL in RPMI-1640
supplemented with increasing concentrations of human serum for 24 (white bars) and
48 (black bars) hours. Cell viability and GSH were assessed via PrestoBlueTM reduc-
tion and MBB-HPLC assays, respectively. The data are expressed as a percentage of
untreated control and displayed as mean ± SEM of triplicates from a single experiment.
Statistical significance was determined by one-factor ANOVA with Bonferroni post test
between the respective 0 hour control and treatment ***, p<0.001; and between the
24–48 hour treatments ###, p<0.001).
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6.6 Discussion
6.6.1 HMDM cell culture
Reproducible culture and experimentation on primary cells is associated with chal-
lenges. This study attempted to standardise the methodology and explore the impact
of the external experimental factors on oxLDL toxicity to cultured macrophages.
An overall success of HMDM cell culture in the presence of GM-CSF was quanti-
fied and is reported here for future reference, since no prior data on this subject is
readily available. The growth and development of monocytes into macrophages was
enhanced by 50% with the inclusion of the growth factor (fig. 6.1). Seventy percent
of HMDM preparations grown with GM-CSF were of quality suitable for experiments
(fig. 6.2). GM-CSF predominantly drives the differentiation of monocyte into the so
called “M1” macrophage (Waldo et al., 2008). This type was relevant to the present
study, as IFN-γ, which is the in vivo stimulus for M1 macrophage differentiation, also
enhances the production of 7,8-NP (Weiss et al., 1999).
The effect of plate type and supplier on HMDM cell culture was tested with the goal
of improving the uniformity of culture and increasing the experimental unit number.
Cellstar were considered a superior plate type to Nunc based on the cost comparison,
given a similar culture success rate (fig. 6.3). A move away from the 12 to 48 well
plates was made after establishing the plating concentration of 1x106 (fig. 6.4). This
tripled the number of experimental units (i.e. wells) per batch of HMDM cells.
Serum supplementation was found to have a significant effect on HMDM cell dif-
ferentiation and growth (figures 6.5 and 6.6). Three out of 7 serum batches tested
conveyed a higher differentiation and growth–promoting capacity than the rest. At
present, it is difficult to suggest a mechanism for the observed phenomenon. Cloudy
or “lipid-rich” sera, which was most likely due to high triglyceride content, often re-
sulted in higher macrophage differentiation and growth, although this trend was not
restricted to cloudy serum. Due to time and funding restrictions, the underlying cause
of serum–driven differentiation and growth disparity was not pursued further. The
information gained through these experiments led to the combining (or “pooling”) of
multiple batches of sera in order to standardise the HMDM cell culture methodology.
This allowed a reduction of some of the inter-donor variation and increased the vol-
ume of a “pooled” batch of serum. The latter enabled a higher number of experiments
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to be performed in similar serum conditions. Serum pooling did not alter HMDM
growth (figures 6.5 and 6.6). Heat–inactivation of human serum was discontinued af-
ter the review of the literature (Biochrom AG, 2010; Hyclone®, 1996; Leshem et al.,
1999). Heat–inactivation of serum neither induced nor inhibited HMDM cell growth
(fig. 6.6).
6.6.2 Utility of U937 cells as a model of 7,8-NP–mediated
oxLDL uptake regulation
The U937 cell line was tested as a potential replacement of the heterogeneous primary
HMDM cell culture. As in HMDM cells, two protein products of molecular weights of
80 and 100 kDa were observed. Compared to HMDM cells, U937 monocytic cell line
displayed an up-regulation of the lower molecular weight band (intracellular CD36,
according to Alessio et al. (1996)) with increasing 7,8-NP concentrations (fig. 6.8).
The higher molecular weight band ( plasma membrane CD36) was down-regulated
by 30% at 250 µM of 7,8-NP. This was almost 1.5–2 times lower compared to the
HMDM cells’ 50% down-regulation (fig. 6.8). This result suggested that despite hav-
ing a less prominent 100 kDa protein product, U937 and HMDM cells share similar
underlying processes in this area. Nakagawa et al. (1998) observed that CD36 levels
increase with macrophage maturation. PMA–differentiation of U937 cells increased
the amount of highly glycosylated CD36 (Alessio et al., 1996). Thus PMA stimulus
could be used to drive CD36 expression in U937 cells, if required for future study.
However, the induction of protein kinase C and the activation of inflammatory status
in such cells should be taken into account. Napolitano & Bravo (2003) reported that
PMA–activated PKC pathways interfered with the optimal ligand-induced phospho-
rylation of the receptors, compromising the processes of degradation of modified LDL.
U937 cells showed no 7,8-NP–mediated decrease in oxLDL uptake (fig. 6.9). This
might be due to the absence of serum in the experimental medium. The experimental
conditions for U937 cells (RPMI-1640 in the absence of serum) could not be altered
easily, as experiments with oxLDL toxicity to U937 cells were typically done in the
absence of serum (Katouah, 2012). This made U937 cells an unsuitable substitute for
HMDM cells for this work.
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6.6.3 Extracellular factors
Serum supplementation is protective against oxLDL toxicity
The concentration–dependant oxLDL toxicity to HMDM cell varied substantially, as
indicated by the mean ± range plots in figure 6.10. This presented a hindrance to the
research because the cells for which LC50 was outside the common 2–3 mg/mL range
were considered outliers and were not used for key experiments. Thus, conditions
that favoured HMDM resistance to oxLDL toxicity were investigated.
The troubleshooting process started with investigating the effect of serum. As dis-
cussed above, different sera had different capacities to promote cellular differentiation
and growth. However, minor difference in oxLDL toxicity was observed when the same
batch of HMDM cells, that was cultured and incubated in sera from different donors,
was treated with oxLDL (data not shown). Research indicates, however, that extra-
cellular serum per se inhibits oxLDL toxicity to HMDM, ECs and SMC cells (Asmis
& Wintergerst, 1998; Henriksen et al., 1979; Hessler et al., 1979; Wintergerst et al.,
2000). The effect of serum supplementation was, therefore, pursued as a potential
factor of HMDM resistance.
The effect of serum supplementation was investigated further, revealing that it was
highly protective against oxLDL–induced toxicity (fig. 6.11). Extracellular serum
above ∼3% (v/v) almost completely protected against the toxicity of 2 mg/mL
oxLDL. The curve of extracellular serum effect plateaued after 3 mg of protein per
mL (or 4.86% serum), indicating a saturation effect. (Normal extracellular protein
concentration of the whole medium at 10% human serum was a consistent ∼7 mg of
protein per mL). The steep slope in the 0–2 mg/mL serum protein range indicated
that incremental change in serum concentration within this range had a large effect
on oxLDL–mediated toxicity. There was large variability between the experiments in
this region of rapid change. This was not associated with experimental error, since a)
higher concentration points showed lower variability and b) individual experimental
replicates showed consistent variance at concentrations of 0.75 and 1 mg cell protein
(fig. 6.12a). The sensitivity of this region of protein concentration could potentially
be utilised in future experiments. If one was to pursue the inherent HMDM differ-
ences that cause differential response to toxicity, the experimental conditions within
this region are more likely to yield a range of results.
Macrophage morphology during cell death was not affected by the reduction in serum
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concentration, only the overall magnitude of toxicity. The presence of extracellular
protein had no effect on apoptosis/necrosis ratio in U937 cells, only the timing of
toxicity (data not shown). Thus, it appears that the cell death processes were de-
layed but not altered in the presence of serum. A similar theme emerged for the
phenomenon of HMDM resistance, as will be discussed below.
Protein conveys the protective effect against oxLDL toxicity
Protection by serum factor(s) may occur either at the cellular level, rendering HMDM
cells resistant to oxLDL, or at the level of oxLDL molecule, inactivating the cytotoxic
moieties of oxLDL and hindering oxLDL binding sites (Asmis & Wintergerst, 1998).
The majority of the protective effect was attributable to protein and not other compo-
nents of serum (fig. 6.12). Simple protein solution and serum were equally protective
against oxLDL up to a concentration of 0.75 mg protein/mL in the extracellular
medium (fig. 6.12). From 1 mg/mL onwards, the protective effect of serum was, on
average, 10% higher than that of BSA solution matched to serum by the concentra-
tion of protein (fig. 6.12). Thus, the majority of the serum protective effect was likely
to be due to serum albumin.
The presence of serum and BSA reduced the levels of intracellular oxLDL by 25
and 40% as indicated by 7KC uptake (fig. 6.13). The flexibility of albumin tertiary
structure enables it to bind a wide range of ligands, from metal ions to fatty acids
(Roche et al., 2008). Suginohara et al. (1996) also indicated that heparin-bound
fraction of human lipoprotein–deficient serum inhibits endocytic uptake of oxLDL by
macrophages. Thus, sequestration of oxLDL and its components by serum albumin
was a possible protective mechanism. Also, some evidence exists that albumin acts
as a cholesterol efflux acceptor, similar to HDL (Ha et al., 2003; Han et al., 1997).
(The unphysiological state of HMDM cell culture in the absence of serum may have
an unknown effect on the cells.)
Activated monocyte-macrophages are known to release extracellular ROS (Naka-
gawara et al., 1981). Other cell types, like endothelial cells, also generated extra-
cellular superoxide in response to oxLDL which was capable of promoting the induc-
tion of apoptosis (Harada-Shiba et al., 1998). Albumin is a multifunctional protein
that has been shown to act as an oxidant “sink” (Roche et al., 2008). Albumin has
been shown to effectively scavenge O2
•–, H2O2, HOCl reactive oxygen species in cell
culture and in cell free conditions (Kouoh et al., 1999; Roche et al., 2008). Direct
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antioxidant activity of albumin is associated with its abundance which enables it to
act as a sacrificial target for ROS (Bourdon & Blache, 2001). A reduced cysteine
residue, Cys34, and six methionine residues on human serum albumin are likely to be
involved in ROS scavenging (Oettl & Stauber, 2007).
The remaining difference between serum and BSA–mediated protection (10%) could
be attributed to the antioxidant effect of other components of human serum, although
consensus on this topic is lacking. While some researchers observed a protective ca-
pacity of serum antioxidants such as ascorbate or dehydroascorbate against oxLDL
(Asmis & Wintergerst, 1998; Siow et al., 1998), others found no effect of ascorbate
(Harris et al., 2006) or α-TocH Asmis & Jelk (2000b). In a review, Bourdon & Blache
(2001) also suggested that α-TocH or ascorbate provided a limited contribution to
serum antioxidant activity. Lipid and lipoprotein deficient serum conveyed virtually
the same protection as whole serum, indicating that lipid–associated antioxidants
were not involved in protection (Asmis & Wintergerst, 1998; Hessler et al., 1979).
Extracellular GSH, on the other hand, has been unanimously protective (Baoutina &
Dean, 2001; Hardwick et al., 1999; Hulte´n et al., 2005; Siow et al., 1998; Wang et al.,
2006) and may have played a role in this study, as well. Another potential source of
protection is cholesterol and oxidised cholestrol products’ efflux onto HDL in serum
(reviewed in Jessup et al. (2002) and Yvan-Charvet et al. (2010)).
Since protein emerged as the major protective component of serum, protein sup-
plementation in cell culture could be used instead of serum supplementation. In
experiments when serum components like lipoproteins, antioxidants and growth fac-
tors may interfere with the outcome being measured, serum could be substituted for
BSA while retaining the beneficial effect on cells. Protein concentration in the sera
batches used in this study was reasonably consistent (70 ± 3 mg/mL (SD)). This sug-
gested that although serum protein may have been the source of HMDM resistance
to toxicity it was unlikely to be the source of variation.
Increased cell density is protective against oxLDL cytotoxicity
Cell density also had a major effect on oxLDL toxicity to both U937 and HMDM
cells. The magnitudes of the effects were approximately 20% protection per 4x105
U937 and 4x104 HMDM cells. To the author’s knowledge this is the first attempt
to quantitatively measure the effect of cell density on the oxLDL toxicity outcome.
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Previously, Hessler et al. (1979) reported that for EC and SMC “cellular suscepti-
bility to LDL toxicity appeared to be a function of culture density and possibly cell
cycle phase”. Doubling of the SMC culture density resulted in a 24% to 64% viability
increase after 66 hour incubation with LDL (oxidised by cells) (Hessler et al., 1979).
It is difficult to propose a mechanism of cell-density–mediated protection with any
certainty. Potentially, spatial hindrance in high density cultures may lead to reduced
binding and uptake of oxLDL as cell clumping leads to lower number of receptors
available for oxLDL binding/uptake. This phenomenon has been described for LDL.
Stein & Stein (1975) and Vlodavsky et al. (1977) (cited in Hessler et al. (1979)) have
shown that SMC and EC cells internalise LDL depending on cell culture density (con-
fluent vs. sub-confluent).
Another possible mechanism could be that cells release protective substances, such as
growth factors, cytokines and thiol–containing proteins. Macrophages are known to
release a suite of chemo– and cytokines in response to oxLDL (Hansson & Hermans-
son, 2011; McLaren et al., 2011), some of which could be priming the neighbouring
cells for resistance. In addition, HMDM cells have been shown to release extracel-
lular thiols that could react with oxLDL components neutralising cholesteryl ester
hydroperoxides in oxLDL, an antioxidant action that is proportional to cell number
(Baoutina, 2000; Baoutina & Dean, 2001). HMDM cell density–associated thiol re-
lease had also been observed in this study (data not shown).
The implications of cell density–dependant toxicity for in vitro experiments are large.
If oxLDL toxicity is dependant on density to the extent described here (20% per
40,000 fully grown HMDM cells), this would contribute to inter-batch variation be-
tween HMDM cells. As they differentiate from the seeded monocytes, the final number
of cells per well would vary. Thus cell density is certainly a factor in the inter-batch
variability between the HMDM cell cytotoxicity in response to oxLDL. Moreover, the
effect of cell density would influence the magnitude of toxicity between the published
studies that used different monocyte seeding densities. Indeed, cell density condi-
tions varied between the laboratory groups presented in table 6.1. The Asmis group
preferred seeding at 0.15 x 106 cells/well in 12 well plates or on 22 mm diameter
Aclar film (Asmis & Begley, 2003; Asmis & Wintergerst, 1998; Asmis et al., 2005;
Wang et al., 2006; Wintergerst et al., 2000). Our group used 5 x 106 cells/well in
12 well plates (Gieseg et al., 2009, 2010a), whereas Mitchinson’s group favoured 3 x
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103 cells/well in 24 well plates (Carpenter et al., 2001; Hardwick et al., 1996, 1999;
Marchant et al., 1995).
A collection of 15 studies featuring Cu-oxLDL toxicity to HMDM cells is presented
in table 6.1. The following experimental parameters were included: time of exposure,
concentration of oxLDL (in µg LDL protein/mL, which is 5 times smaller than the µg
LDL cholesterol/mL used in this study), percentage cell death, either obtained from
text or calculated from the figures of the manuscript, percentage cell death in the
respective control (if applicable, depending on the assay), concentration of serum in
the medium and cell seeding density. Since cellular death was measured by different
means, the type of assay is also shown. For studies 2, 4, 6, 8, 12 and 15 more than
one concentration of oxLDL or more than one time of exposure were included.
A number of observations could be made from the comparative analysis of the stud-
ies in the table 6.1. A third of the studies performed experiments in the absence
of supplementary serum. Asmis & Wintergerst (1998) and Wintergerst et al. (2000)
explicitly stated that the presence of serum inhibited oxLDL–mediated cell death at
100 mg/mL (equivalent to 0.5 mg/mL as used in the present study). Another third of
the authors did not report serum concentration during experimental conditions (al-
though most reported it during cell culture). Serum concentrations were a constant
10% in the remaining (but one) of the studies included in the table. Cell density also
varied between the laboratory groups as outlined above.
Differences between the absolute oxLDL toxicity were also observed. The same
oxLDL concentration often yielded a range of toxicity values. For the three stud-
ies that utilised 100 µg/mL oxLDL over 24 hours, the reported viability loss (using a
variety of assays) ranged from 20% (Wintergerst et al., 2000) to 50% (Asmis & Beg-
ley, 2003) to 27–65% (Hardwick et al., 1996). Likewise, for the six studies that used
200 µg/mL oxLDL over 24 hours, the viability loss ranged from 0% (Gieseg et al.,
2009), to 40–50% (Carpenter et al., 2001; Gieseg et al., 2010a), to 75–86% (Hardwick
et al., 1996, 1999; Marchant et al., 1995).
The hypothesis of the association between highest toxicity with lowest serum and
lowest cell density values did not hold for this data set. Although some of the highest
toxicity results coincided with serum-devoid experimental design (Hardwick et al.,
1999), others did not (Hardwick et al., 1996; Marchant et al., 1995). Similarly, the
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studies with lowest HMDM seeding density (1-5, table 6.1) did not demonstrate the
highest overall toxicity. Not all studies with at least one common author reported
similar range of toxicity. For example, 50% in Asmis & Begley (2003) contrasts with
20% in Wintergerst et al. (2000); and 0% in Gieseg et al. (2009) contrasts with 50% in
Gieseg et al. (2010a). Overall, these differences indicate that much more information
is required to explain the inter-experimental variation within and between laborato-
ries, than just level of serum and cell density. In the light of the current findings,
the interpretation and comparison of relative oxLDL toxicity in the studies included
in the table 6.1 should proceed with caution, as the interaction between the serum
inclusion and cell seeding density could have unpredicted effect.
The extracellular composition within the atherosclerotic plaque is unknown. Plaques
contain oxidised LDL constituents (Li et al., 2006; Waddington et al., 2003; Yla¨-
Herttuala et al., 1989) in regions characterised by extensive cellular death (Hegyi
et al., 1996; Isner et al., 1995; Kockx et al., 1998; Martinet et al., 2011). This sug-
gests that LDL oxidation and cell death do take place. Since both of these are
inhibited in the presence of serum (Henriksen et al., 1979; Hessler et al., 1979), the
effective concentration of serum in plaque is probably low (unless its distribution is
compartmentalised either spatially or temporally). If, indeed, a spectrum of serum
conditions exists within the lesion (evidenced by the presence of serum-derived an-
tioxidants (Carpenter et al., 1995; Suarna et al., 1995)), the in vitro experiments that
model a range of serum conditions will all provide information on cellular behaviour
in plaques.
227
6. HMDM CELL CULTURE METHOD DEVELOPMENT AND
TROUBLESHOOTING
T
a
b
le
6
.1
:
O
x
L
D
L
to
x
ic
it
y
to
H
M
D
M
c
e
ll
s
a
n
d
e
x
p
e
ri
m
e
n
ta
l
c
o
n
d
it
io
n
s
in
th
e
p
u
b
li
sh
e
d
li
te
ra
tu
re
.
N
o
S
tu
d
y
C
e
ll
ty
p
e
T
im
e
C
o
n
c
.
C
e
ll
d
e
a
th
D
e
a
th
in
c
o
n
tr
o
l
S
e
ru
m
C
e
ll
d
e
n
si
ty
h
r
µ
g
/
m
L
%
%
%
v
/
v
x
1
0
6
c
/
w
1
A
sm
is
&
W
in
te
rg
er
st
(1
9
9
8
)
H
M
D
M
1
5
1
0
0
1
5
.1
A
V
,
2
2
.2
a
p
o
2
.7
,
1
1
H
,
<
1
P
I
<
2
A
V
,
a
p
o
2
.7
,
P
I
,
1
2
H
–
#
0
.1
5
2
A
sm
is
&
B
eg
le
y
(2
0
0
3
)
H
M
D
M
2
4
1
0
0
∼5
0
H
<
1
0
H
N
S
0
.1
5
2
A
sm
is
&
B
eg
le
y
(2
0
0
3
)
H
M
D
M
2
4
1
5
0
∼9
0
H
<
1
0
H
N
S
0
.1
5
3
A
sm
is
et
a
l.
(2
0
0
5
)
H
M
D
M
4
8
1
0
0
1
0
0
H
6
.4
H
N
S
0
.1
5
4
W
in
te
rg
er
st
et
a
l.
(2
0
0
0
)
H
M
D
M
2
4
1
0
0
2
0
a
p
o
2
.7
4
a
p
o
2
.7
–
0
.1
5
4
W
in
te
rg
er
st
et
a
l.
(2
0
0
0
)
H
M
D
M
4
8
1
0
0
3
7
a
p
o
2
.7
2
0
a
p
o
2
.7
–
0
.1
5
4
W
in
te
rg
er
st
et
a
l.
(2
0
0
0
)
H
M
D
M
4
8
1
0
0
<
2
a
p
o
2
.7
<
2
a
p
o
2
.7
5
,
H
S
0
.1
5
5
W
a
n
g
et
a
l.
(2
0
0
6
)
H
M
D
M
2
4
7
5
4
8
H
6
H
N
S
0
.1
5
6
C
a
rp
en
te
r
et
a
l.
(2
0
0
1
)
H
M
D
M
2
4
2
0
0
3
8
L
D
H
,
∼4
0
H
1
5
L
D
H
,
∼2
3
H
–
li
k
el
y
3
x
6
C
a
rp
en
te
r
et
a
l.
(2
0
0
1
)
H
M
D
M
4
8
2
0
0
7
3
L
D
H
,
5
5
H
1
5
L
D
H
,
3
2
H
–
li
k
el
y
3
x
7
C
a
rp
en
te
r
et
a
l.
(2
0
0
3
)
H
M
D
M
4
8
2
0
0
*
6
7
L
D
H
4
7
L
D
H
–
li
k
el
y
3
y
8
H
a
rd
w
ic
k
et
a
l.
(1
9
9
6
)
H
M
D
M
2
4
1
0
0
∼4
0
H
,
∼2
7
L
D
H
,
∼6
5
M
T
T
<
2
0
H
,
<
1
5
L
D
H
,
<
2
7
M
T
T
1
0
,
L
P
D
F
C
S
3
-4
8
H
a
rd
w
ic
k
et
a
l.
(1
9
9
6
)
H
M
D
M
2
4
2
0
0
∼8
0
H
,
∼3
7
L
D
H
,
∼7
5
M
T
T
<
2
0
H
,
<
1
5
L
D
H
,
<
2
7
M
T
T
1
0
,
L
P
D
F
C
S
3
-4
9
H
a
rd
w
ic
k
et
a
l.
(1
9
9
9
)
H
M
D
M
2
4
2
0
0
8
6
H
3
2
H
–
3
1
0
Is
a
et
a
l.
(2
0
1
1
)
H
M
D
M
2
4
4
0
3
0
M
T
S
N
A
M
T
S
N
S
N
S
1
1
G
er
ry
&
L
ea
k
e
(2
0
0
8
)
H
M
D
M
4
8
2
0
0
*
*
*
∼3
7
A
V
∼5
A
V
2
0
,
F
B
S
1
1
2
G
ie
se
g
et
a
l.
(2
0
0
9
)
H
M
D
M
2
4
6
0
0
a
∼5
5
M
T
T
N
A
M
T
T
1
0
,
H
IH
S
5
1
2
G
ie
se
g
et
a
l.
(2
0
0
9
)
H
M
D
M
2
4
2
0
0
b
∼0
M
T
T
N
A
M
T
T
1
0
,
H
IH
S
5
1
3
G
ie
se
g
et
a
l.
(2
0
1
0
a
)
H
M
D
M
2
4
2
0
0
b
∼5
0
M
T
T
N
A
M
T
T
1
0
,
H
IH
S
5
1
4
M
a
rc
h
a
n
t
et
a
l.
(1
9
9
5
)
H
M
D
M
2
4
2
0
0
*
*
∼8
0
H
2
3
H
1
0
,
L
P
D
F
B
S
3
1
5
M
u
ll
er
et
a
l.
(2
0
0
1
)
H
M
D
M
2
4
5
0
*
*
∼5
A
V
,
∼4
.5
A
V
+
P
I
,
∼2
4
L
D
H
∼1
A
V
,
∼2
A
V
+
P
I
,
∼2
4
L
D
H
1
0
,
L
P
D
F
C
S
0
.1
–
2
1
5
M
u
ll
er
et
a
l.
(2
0
0
1
)
H
M
D
M
4
8
5
0
*
*
∼6
A
V
,
∼1
1
A
V
+
P
I
,
∼3
6
L
D
H
∼1
A
V
,
∼2
A
V
+
P
I
,
∼2
4
L
D
H
1
0
,
L
P
D
F
C
S
0
.1
–
2
H
:
H
3
ra
d
io
a
ct
iv
e
a
d
en
in
e
re
le
a
se
,
L
D
H
:
L
a
ct
a
te
d
eh
y
d
ro
g
en
a
se
re
le
a
se
,
A
V
:
A
n
n
ex
in
V
,
a
p
o
2
.7
:
a
p
o
p
to
si
s
m
a
rk
er
,
P
I
:
P
ro
p
id
iu
m
io
d
id
e,
M
T
T
:
M
T
T
a
ss
ay
,
M
T
S
:
a
ss
ay
N
S
:
n
o
t
st
a
te
d
,
N
A
:
n
o
t
a
p
p
li
ca
b
le
;
*
m
o
d
er
a
te
ly
ox
L
D
L
;
*
*
st
ro
n
g
ly
ox
L
D
L
;
*
*
*
ox
y
st
er
o
l
ri
ch
ox
L
D
L
#
a
p
o
p
to
si
s
w
a
s
p
re
v
en
te
d
in
th
e
p
re
se
n
ce
o
f
se
ru
m
a
:
3
m
g
/
m
L
ch
o
le
st
er
o
l;
b
:
1
m
g
/
m
L
ch
o
le
st
er
o
l;
x
:
re
fe
re
n
ce
to
H
a
rd
w
ic
k
et
a
l.
(1
9
9
6
);
y
:
re
fe
re
n
ce
to
C
a
rp
en
te
r
et
a
l.
(2
0
0
1
)
228
6.6 Discussion
6.6.4 HMDM cell resilience not resistance to oxLDL
At least 8 HMDM preparations were identified to be resistant to oxLDL during the
last stage of the project. The phenomenon was defined as displaying no significant
metabolic loss after 24 hours of oxLDL exposure in the presence of 2% serum (fig.
6.16). The presence of serum ensured that HMDM were not pro-apoptotic. Absence
of cell death was not due to incomplete LDL oxidation, as colour, REM and choles-
terol oxidation confirmed that LDL molecule was fully oxidised to the standard set
by the literature (figures 6.17). In addition, such oxLDL caused U937 cells to loose
viability, showing its potency (sec. 6.5.2).
Thus, the investigation focused on HMDM cell response to oxLDL. Oxidative stress
and damage were assessed in two case studies. Firstly, oxidative stress detection with
DHE revealed that the “resistant” cells had a delayed onset of ROS flux compared to
more “susceptible” cells. By the 48th hour of incubation with oxLDL, oxidative stress
was prominent in both resistant and susceptible cells. Similarly, oxidative damage
(as GSH loss) in resistant cells also developed between 24 and 48 hours of incubation.
This tightly correlated with the loss of metabolic capacity (figures 6.23, 6.24, 6.25).
These results suggested that oxLDL toxicity to the “resistant cells” was delayed rather
than completely abolished. Those cells were, therefore, resilient rather than resistant
to oxLDL toxicity.
A few authors had used 48 hour exposure time to observe oxLDL toxicity (Asmis
et al., 2005; Baird et al., 2005; Carpenter et al., 2001, 2003; Wintergerst et al., 2000).
The reason for using the 48 hour time-frame over any other was not specified. Yuan
et al. (1997), Wintergerst et al. (2000), Carpenter et al. (2001), Harris et al. (2006)
and Isa et al. (2011) observed an increase in cell death with prolonged exposure (24 vs.
48 hours). Similarly, in this study, the extended incubation time allowed moderately
“susceptible” HMDM cells (made so in the presence of low serum concentration) to
increase viability loss from 24 to 48 hours (figures 6.24 and 6.25).
Serum supplementation played an important role in HMDM resilience to oxLDL.
The full application of this knowledge requires understanding of the serum protec-
tive mechanisms. As discussed earlier, (sec. 6.4) uptake prevention and antioxidant
capacity of serum albumin may be involved in this phenomenon of cellular resilience.
Cellular density could also be a factor (sec. 6.4), however, cell density was not mea-
sured routinely on the performed experiments so no data is available to test the
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hypothesis. It is likely, however, that cell–specific mechanisms are also important. As
shown in figure 6.18, the two HMDM preparations grown and treated in the presence
of the same serum batch and the same serum concentration, responded to oxLDL
differently. Intracellular GSH levels have been shown to influence HOCl–mediated
macrophage loss, where higher starting GSH levels conveyed protection against the
oxidant (Yang et al., 2012). Due to the oxidative nature of oxLDL–inflicted dam-
age, similar mechanism may be involved in the HMDM cell resilience to oxLDL. This
could be pursued in further study, especially if the starting intracellular GSH levels
are pre-determined by external stimuli or genetic background. Two enzymes in the
GSH synthesis have been reported to influence the cellular GSH status. The first and
rate limiting step in GSH synthesis is catalysed by γ-glutamate cysteine ligase (GCL)
composed of catalytic (GCLC) and modifier (GCLM) subunits (Nichenametla et al.,
2008). There is known genetic variation in the promoter region of both GCLC and
GCLM that appears to influence the inducibility of these genes and, hence, the ex-
pression of the encoded proteins (Nichenametla et al., 2008). The variation in protein
function may, in turn, determine the variability of GSH content between donors. The
second step in GSH synthesis is catalysed by glutathione synthetase. A correlation
between the glutathione synthetase activity and the level of glutathione in cultured
fibroblasts was reported (Konrad et al. (1972) cited in Nja¨lsson & Norgren (2005)).
Another source of resilience may be the antioxidant enzymes within macrophage
cells. Manganese SOD (MnSOD), heme oxygenase-1 have been shown to respond to
oxygen tension, and inflammatory cytokine regulation (Lakari et al., 2001; Miao &
Clair, 2009). Moreover, MnSOD genetic polymorphism have been shown to affect
susceptibility to apoptosis and correlate with the occurrence of myocardial infarction
(Fujimoto et al., 2010). The presence of alanine instead of valine in the targeting pep-
tide for human MnSOD cause an increase in enzyme activity due to more effective
targeting of protein to mitochondria, which led to higher protection against oxLDL–
induced apoptosis. The alanine allele was also found to reduce the risk of coronary
artery disease and acute myocardial infarction (Fujimoto et al., 2010). Moreover,
macrophages within the plaques have been show to display differential MPO activity
with both MPO-positive and MPO-negative macrophages being detected (Sugiyama
et al., 2001). Thus, a range of oxidant and antioxidant enzymatic expression could
contribute to macrophage resilience to oxLDL. The understanding of these processes
may provide prognostic value, if the mechanisms of HMDM resilience to oxLDL tox-
icity are, in part, genetic.
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Another distinguishing factor may be macrophage cell heterogeneity. M2 macrophage
subtypes show higher sensitivity to oxLDL in vitro, whereas M1 macrophages are more
resistant (Isa et al., 2011). M2 macrophage are thought to be responsible for anti-
inflammatory and wound healing processes, while M1–polarised state predominantly
displays pro-inflammatory characteristics. Thus if the cultures of HMDM cells were
heterogeneous due to unknown serum components, some cells would have been more
resilient than others. In the future, it would be beneficial to characterise cultured
HMDM cell cultures with subtype-specific markers.
6.7 Summary
Experimental conditions have been found to heavily affect the overall level of oxLDL
toxicity to HMDM cells. Extracellular serum inhibited oxLDL toxicity, conveying
resilience to HMDM cells. This effect followed saturation kinetics and was largely
dependant on the protein component of serum. Cell death was also inhibited by in-
creased HMDM and U937 cell density, although the present study did not investigate
the actual mechanism(s) of this phenomenon. It is likely that cell density was one
of the factors behind the variability in oxLDL–driven HMDM cell death. The re-
sults obtained in this section provide insight into the mechanisms governing cellular
interaction in vitro, but they could not be used to predict the relative toxicity be-
tween published studies. Nonetheless, these results indicate the direction in which cell
culture conditions could be optimised in order to improve the consistency of oxLDL–
mediated cell death response in HMDM culture.
HMDM cell resistance was a recurrent phenomenon. Such cells had a delayed on-
set of oxidative flux yet they too underwent oxidative damage and lost metabolic
activity when exposed to oxLDL for a longer period of time. Hence, these HMDM
cells were resilient rather than resistant to oxLDL. Inter-batch variation among the
resilient/susceptible cells could not be explained by serum or cellular density alone.
Thus, future work could focus on the intracellular mechanisms of protection, such as
GSH, to provide an answer to the issue of variable cytotoxicity.
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7General discussion, conclusions
and future work
Primate macrophages produce 7,8-dihydroneopterin (7,8-NP) upon inflammatory stim-
ulation. This thesis argues that in an atherosclerotic plaque, where macrophages are
exposed to high levels of toxic oxidised lipoproteins, 7,8-NP could provide antioxidant
protection against high intracellular oxidative stress associated with acute cell death.
7,8-NP could also modulate accumulation and processing of the modified lipids in
lipid–loaded foam cells, thus potentially alleviating atherosclerotic burden.
7.1 Mechanisms of 7,8-NP–mediated protection:
ROS scavenging vs. oxLDL processing
The research set out to investigate how 7,8-dihydroneopterin protects macrophage
cells from acute oxLDL toxicity. We recently reported that 7,8-NP was able to protect
HMDM cells from oxLDL toxicity and oxidative damage to glutathione (GSH). We
demonstrated that 7,8-NP both inhibited the ROS generation and partially prevented
DiI–labelled oxLDL uptake (Gieseg et al., 2010a). However, the relative contribution
of these processes was unclear. Therefore, two lines of evidence were pursued: the
antioxidant capacity of intracellular 7,8-NP and its effect on oxLDL internalisation.
The initial hypothesis stated that both mechanisms equally contributed to the 7,8-
NP–mediated protection.
Acute oxLDL toxicity was defined as HMDM cell viability loss after 24 hour ex-
posure to the LC50 levels of Cu-oxidised LDL. LC50 was established to be in the
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range of 2–3 mg/mL oxLDL. Initially, the nature of the cellular response was in-
vestigated. As expected, oxLDL caused a concentration and time–dependant loss of
cell viability in HMDM cells (figures 3.1 and 3.2). The majority of the damage took
place during the first 12 hours of exposure (fig. 4.2). Furthermore, the exposure
to toxic concentration of oxLDL for 6 hours with subsequent incubation in the ab-
sence of extracellular oxLDL was sufficient to irreversibly affect cellular metabolism
(fig. 3.6). Neither concentrations nor time of exposure of macrophages to oxidised
lipoproteins in atherosclerotic plaques are known. The evidence of cellular death in
plaques favours the school of thought that the concentration of toxic agents is suffi-
cient to cause cell death in such conditions (Ball et al., 1995; Lusis, 2000; Moore &
Tabas, 2011). The data presented here suggests that even a short-term exposure to
the toxic concentration of oxLDL is sufficient to cause irreversible damage to cellular
metabolism. Such quick inactivation of cell metabolism may explain the observed
lack of mobility in macrophages that had been exposed to oxLDL. Previously oxLDL
had been show to inhibit macrophage migration (Quinn et al., 1987), induce actin de-
polymerisation and cell spreading (Park et al., 2009) thus preventing the cells from
exiting the atherosclerotic lesion. Rapid metabolic damage could also play a role
in this process, perpetuating the disease, as monocytes/macrophages infiltrate the
lesion attracted by cytokines and endothelial cell factors (Hansson & Hermansson,
2011; Ross, 1993).
The toxicity of oxLDL to HMDM cells was characterised by a rapid generation of
ROS (as measured by DHE fluorescent probe) (fig. 3.3). Intracellular ROS levels
were highly elevated at 3 hours, peaked at 12 hours and started declining in the next
12–24 hours. The rate of ROS production was highest in the first 6 hours. This
coincided with the loss of intracellular GSH that occurred during the first 6 hours
and reached maximum 9 hours after oxLDL exposure (fig. 3.5). The timing of events
is significant as it permits the examination of the inter-relationship of the cellular
processes that underpin pathology. ROS flux coincided with GSH loss indicating ox-
idative stress and damage within the first 6 hours of exposure and more generally
in the first half of the 24 hour incubation. Meanwhile, 7,8-NP provided an almost
complete protection during this time, which declined over the following 12 hours (fig.
4.2). The same trend was observed by Gieseg et al. (2010a) with 7,8-NP–mediated
protection of intracellular GSH. This suggested that the protective mechanism of 7,8-
NP was particularly suited to counter-balance the type of processes that caused early
toxicity to HMDM cells.
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The ability of 7,8-NP to prevent cell death and oxidation of cellular molecules has
been documented (Duggan et al., 2002; Gieseg et al., 2001b). The authors reported
a 10 to 20% protection against Fe++, H2O2, HOCl and peroxyl radical–induced cell
death in U937 cells, as well as inhibition of thiol loss and hydroperoxide, TBARS and
dityrosine formation (Duggan et al., 2002; Gieseg et al., 2001b). Based on the chem-
istry, 7,8-NP was likely to react with cellular ROS, reducing the oxidative burden
and its damaging effects. This hypothesis was supported by the data. 7,8–NP more
than halved intracellular ROS produced by the HMDM cells in response to oxLDL
(fig. 4.9). 7,8-NP was most effective at 3 and 6 hours of oxLDL exposure, which fur-
ther supported the idea of an early oxidative stress. Moreover, 7,8-NP was oxidised
into neopterin within HMDM cells treated with oxLDL (fig. 4.10) providing further
evidence that it was reacting with intracellular oxidants. Indirect evidence suggested
that 7,8-NP was also oxidised into 7,8-dihydroxanthopterin. The final levels of 7,8-NP
in the media between control and oxLDL treatment for 24 hours showed a net loss of
approximately 20 µM indicating potential oxidation into non-neopterin product (fig.
4.13). Thus, 7,8-NP was scavenging ROS generated by HMDM cells.
Other antioxidant compounds such as probucol, probucol analogs and vitamin E
have also been shown to inhibit cellular death in vitro and inhibited the progres-
sion of atherosclerosis in the animal models, suggesting that ROS is important to
the disease pathology (Steinberg, 2009). Interestingly, both vitamin E and probucol
demonstrated additional effects: down-regulation of CD36 receptor (vitamin E: Ozer
et al. (2006); Ricciarelli et al. (2000)) and acceleration of cholesterol efflux (probucol:
(Zhong et al., 2010)), which were also characteristic of 7,8-NP.
7,8-NP caused a 40% decrease in total 7-ketocholesterol accumulation, which was
used as an oxLDL uptake marker (figures 5.4 and 5.5). This was primarily achieved
through lowering the intracellular 7KC esters, which suggests a link to the foam cell
formation (Brown et al., 1979). In addition, 7,8-NP down-regulated CD36 scavenger
receptor protein and mRNA levels by 40% (figures 5.6, 5.7 and 5.9). CD36 has been
implicated in oxLDL signalling (Silverstein et al., 2010), foam cell formation (Ra-
haman et al., 2006) and cell death (Higashi et al., 2005; Wintergerst et al., 2000). In
order to evaluate the role these processes play in 7,8-NP–mediated protection in the
present study, their time-frame was considered. Contrary to the antioxidant activity
of 7,8-NP, the down-regulation of oxLDL uptake, or what was later hypothesised as
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effect on oxLDL processing, was a late effect. The onset of the regulation of total 7KC
levels did not commence until the start of the esterification process which took place
between 9 and 12 hours (figures 5.1 and 5.4). The down-regulation of CD36 protein
also occurred no earlier than 12 hours into the incubation and was highly significant
at 24 hours (fig. 5.7). mRNA down-regulation was measured at 24 hours (fig. 5.9).
The timing of these processes suggested their importance in longer term foam cell
formation and homoeostasis rather than acute cell death. Moreover, an experiment
that investigated the effect of 7,8-NP pre-incubation on oxLDL toxicity during and
after the 6 hour oxLDL exposure in the absence of 7,8-NP did not show any protec-
tion against cell death (fig. 5.14). Neither was oxLDL uptake inhibited by the lower
CD36 availability due to pre-incubation (fig. 5.16). A minor protective effect of in-
tracellular GSH levels was observed (fig. 5.15), suggesting oxidative flux was slightly
reduced in the presence of down-regulated CD36, yet the effect did not transfer onto
cell survival. Although the role of CD36 in oxLDL–mediated cell death is established
(Higashi et al., 2005; Rusin˜ol et al., 2000; Wintergerst et al., 2000), other SR receptors
such as SR-A were also shown to facilitate cell death (DeVries-Seimon et al., 2005).
SR-A also mediated oxLDL uptake (Wintergerst et al., 2000), which may explain the
lack of effect in the presence of partially down-regulated CD36. Differences in cell
type and methodology could limit the ability to make direct comparison between the
studies.
Therefore, the main conclusion of this work is that 7,8-NP primarily acts as an antiox-
idant and ROS scavenger when protecting HMDM cells from acute oxLDL toxicity.
Its effect on oxLDL processing may have a secondary effect in this cell death model.
The latter process might be implicated in chronic cell death and foam cell formation
(discussed below). Thus, in an atherosclerosis plaque, 7,8-NP might act as an indige-
nous antioxidant providing the initial protection against oxidative stress mounted by
the cells in response to oxidised lipid. This action is dependant on sufficient intracel-
lular 7,8-NP concentrations, which is still a matter of debate. However, an empirical
calculation of provisional plasma 7,8-NP concentration in chapter 4 showed that our
current knowledge of its production levels and mechanisms is unable to account for
the elevated levels observed in disease pathology. Therefore, it may be possible that
7,8-NP concentrations in the vicinity of cells are sufficient to scavenge the generated
oxidants.
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7.2 Source and types of ROS during oxLDL toxi-
city to HMDM cells
While addressing the primary aim of the research project, the present study identified
three areas that are highlighted for future investigation. These are the contribution
of NADPH oxidase to oxLDL toxicity, the role of MPO–produced HOCl in oxLDL–
mediated damage and the effect of 7,8-NP on the reverse cholesterol transport in
macrophage foam cells.
NADPH oxidase as a source of ROS
NADPH oxidase was suspected to be the source of superoxide due to the exponen-
tial rise in DHE–reactive ROS in the first 6 hours of oxLDL treatment (fig. 3.3).
NOX activation by oxLDL has been reported in Sukhanov et al. (2006) and Park
et al. (2009). The NOX activity was investigated with the use of apocynin, a NOX
inhibitor, and the chemical properties of 7,8-NP oxidation reaction. Approximately
50% of 7,8-NP oxidation to neopterin was blocked by the addition of apocynin (fig.
4.14), suggesting that a similar proportion of oxLDL–triggered ROS is produced by
the cellular NOX. Despite this, cellular viability was not protected in the presence of
apocynin (figures 4.16, 4.18 and 4.19). Lack of protection suggests potential involve-
ment of other sources of ROS and oxidative damage upon oxLDL exposure, such as
mitochondrial enzymes. This might have implications for pharmacological interven-
tion (Paterniti et al., 2010; Wingler et al., 2011). If pro-atherogenic cellular ROS was
targeted for therapy, a combined inhibition/scavenging of these ROS generating sys-
tems should be considered. The action of 7,8-NP was superior than that of apocynin
at protecting cells, potentially due to its ability to scavenge oxidants from a variety of
sources. This research proposed that NOX–mediated ROS production upon oxLDL
treatment on the basis of apocynin inhibition studies. Reports have been made about
the unspecific action of apocynin in NOX inhibition (Altenho¨fer et al., 2012; Wind
et al., 2010). Recently, a VAS family of more specific NOX inhibitors has emerged
(Altenho¨fer et al., 2012). Therefore, it may be valuable to confirm the NOX involve-
ment in ROS production and subsequent cellular death in oxLDL–exposed HMDM
cells with these small molecule inhibitors.
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HOCl as a mediator of oxidative damage
This study used chemical properties of 7,8-NP oxidation reaction to gain insight
into the mechanisms of ROS production in cells exposed to oxLDL. HOCl is the
only physiological oxidant known to produce neopterin from 7,8-NP as the primary
reaction product (Widner et al., 2000). Therefore, oxidation of 7,8-NP into neopterin
in oxLDL–treated HMDM cells suggests an HOCl–mediated oxidative stress within
these cells. HMDM cells cultured in the presence of GM-CSF are known to express
active MPO which converts H2O2 and Cl
- into HOCl (Sugiyama et al., 2001). A
proposed route for ROS flux based on the use of neopterin as an ROS probe in this
study is: NOX activation → O2•– → H2O2 → HOCl (MPO–catalysed). This system
could be explored further to obtain a direct evidence of HOCl, active MPO and
quantify its activity in oxLDL–treated macrophages.
7.3 The effect of 7,8-NP on oxLDL processing: po-
tential for cholesterol ester efflux regulation
As discussed above, 7,8-NP was found to have an effect on the accumulation of intra-
cellular oxLDL as measured by total 7-ketocholesterol. Based on the data obtained
through this study it was hypothesised that 7,8-NP may have affected the reverse
cholesterol transport of oxLDL. This was based on three lines of evidence. Firstly,
the down–regulation of total 7KC and, therefore, oxLDL in cells was found to coincide
with the esterified portion of intracellular 7KC and commence after the esterification
process started in control cells (figures 5.1 and 5.4). Cholesterol ester accumulation
is a hallmark of foam cell formation and oxLDL is known to inhibit cholesterol efflux
(Gelissen et al., 1996; Jessup & Kritharides, 2000). Secondly, down-regulation of the
CD36 receptor for 24 hours with subsequent oxLDL treatment for 6 hours did not
lead to the reduction of intracellular 7KC and, thus, oxLDL uptake (figures 5.13 and
5.16). This could be explained by the observation that during the initial 6 hours of ex-
posure, all incoming 7KC was hydrolysed and remained as free 7KC. Free cholesterol
accumulation was the first part of oxLDL oxysterol trafficking (Brown et al., 1979;
Zanotti et al., 2012) and was not affected by 7,8-NP. Thirdly, the down-regulation
depended on the presence of extracellular serum, hinting at reverse cholesterol traf-
ficking and efflux (fig. 5.17). A minor possibility of serum-less environment ad-
versely affecting cellular processes is acknowledged. Ten percent serum supplemented
medium contained HDL and ApoA-1 as well as serum albumin as cholesterol/7KC
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acceptors (Amit, 2008; Han et al., 1997; Johnson et al., 1991). Further research is
required to validate this hypothesis. Focusing on the enzymes and proteins that are
involved in cholesterol esterification (ACAT) and hydrolysis (neutral hydrolase) and
efflux (ABCA1 and ABCG1 transporters) (Zanotti et al., 2012) is suggested. The
research demonstrates that in vivo 7,8-NP may be involved in macrophage choles-
terol ester homeostasis and foam cell development. Foam cell formation and death in
the atherosclerotic plaque is associated with the development of plaque necrotic core
(Hegyi et al., 1996), and can promote its instability (Nishi et al., 2002), which often
leads to thromobosis (Rittersma, 2005). The relevance of 7,8-NP–mediated action on
atherosclerotic plaque progression and morphology is unclear at present, as the con-
centration of 7,8-NP, time-frame and magnitude of the effect need to be considered.
Since this contribution may be both positive and negative it is valuable to understand
the underlying mechanisms.
7.4 Conclusion
This thesis set out to explore the mechanism of 7,8-dihydroneopterin–mediated pro-
tection of HMDM from acute oxLDL–mediated cell death. The results obtained
suggest that antioxidant capacity of 7,8-NP in these cells is the most probable mech-
anism for the observed protection and may be so in vivo. Rapid rise of intracellular
ROS levels, its effective scavenging by 7,8-NP and the resulting oxidation of 7,8-NP to
neopterin all support this claim. This work showed that ROS production is the initial
response of HMDM to toxic concentration of oxLDL and the majority of damage to
cellular viability takes place during the first 6-12 hours of incubation.
7,8-NP was also found to decrease intracellular 7-ketocholesterol ester accumulation
(as a proxy of oxLDL uptake) and down–regulate CD36 protein and mRNA expression
in HMDM cells. These effects were delayed until after the 12th hour of incubation,
thus emerging as less probable protective mechanisms during acute oxLDL toxicity.
However, 7,8-NP–mediated regulation of CD36 receptor and oxLDL uptake might be
relevant during foam cell formation and chronic oxLDL–mediated cellular death. This
work also opened up new exciting areas of 7,8-NP research, including its application
in oxidative stress monitoring and effect on reverse cholesterol transport in foam cells.
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Appendix A
Method development and
validation
Experimental techniques that were new to this laboratory were developed and vali-
dated during the course of this research project. These included: PrestoBlueTM cell
viability test, AccutaseTM–facilitated detachment for flow cytometry and RT-qPCR
protocol.
Cell viability assay comparison
Cell metabolism and viability were routinely measured via MTT assay, which utilises
the reducing power of cellular metabolic products like NADH and NADPH (Mos-
mann, 1983; Shen & Sevanian, 2001). The reduced formazan product is quantified
spectrophotometrically and provides a reliable measure of both the number of cells
and their metabolic activity. Terminal nature of the measurement (both formazan
crystal toxicity to cells and the requirement to solubilise them with a detergent) is
a disadvantage of the MTT assay. PrestoBlueTM (Invitrogen) also measures the re-
ducing power of cells per well based on their ability to reduce resazurin. It has the
advantage of being non-toxic and can be measured without cell lysis. PrestoBlueTM
was compared to MTT to establish the level of similarity between the two assays.
MTT and PrestoBlueTM produced identical results of HMDM cell density measure-
ment (fig. A.1). The measurement of cell viability upon exposure to toxic oxLDL
treatment (2 mg/mL at different concentrations of extracellular serum) was also very
similar for both assays (fig. A.2). These results indicated that the two assays could
be interchanged without the need for correction.
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Figure A.1: Comparison of MTT and resazurin (PrestoBlueTM) reduction
assays in determining HMDM cell density.
HMDM cells were seeded at various cell densities in 48 well plates (with an initial pulse
of 25 ng/well GM-CSF) and assayed for cell number/viability by MTT (clear bars)
and resazurin (checked bars) reduction 11 days after seeding. Results are displayed as
mean ± SEM of triplicate measurements from a single experiment. The results of the
two assays were not significantly different (one-factor ANOVA with Bonferroni pairwise
comparison).
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Figure A.2: Comparison of MTT and resazurin (PrestoBlueTM) reduction
assays in determining HMDM cell viability after oxLDL treatment.
HMDM (1x106 cells/well) treated with 2 mg/mL oxLDL in the presence of different
concentrations of serum. MTT (filled circles) and resazurin (empty squares) reduction
was performed concurrently on identical samples. Results are displayed as mean ± SEM
of triplicate measurements from a single experiment. The results of the two assays were
not significantly different (one-factor ANOVA with Bonferroni pairwise comparison)
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AccutaseTM–facilitated harvesting of HMDM cells
Several analyses in this project required HMDM cell detachment from the plate.
These included flow cytometry and experiments with specific HMDM cell density. A
method for HMDM detachment with AccutaseTM was, therefore, adopted from the one
kindly suggested by Dr. H. Medbury (Sydney Medical School, Australia). Briefly, the
adherent HMDM cells were rinsed with PBS and incubated with AccutaseTM (130µL
per well for 48 well plate) for 20 min at 37 ◦C. The cells were observed through the
inverted microscope before and after being pipetted to dislodge the adherent cells (7-
10 times with a 1mL pipette). HMDM cell detachment was facilitated by AccutaseTM
as seen from the figures A.3, A.4 and A.5. After incubation with AccutaseTM the cells
appeared more round and less spread (fig. A.3b). Pipetting, accompanied by light
scraping of the well, was effective at dislodging the majority of cells (figures A.3c and
A.4b). AccutaseTM treatment was significantly more effective than control PBS at
dislodging HMDM cells (fig. A.5). Moreover, AccutaseTM was not toxic to HMDM
cells up to 2h 50 minutes of treatment (fig. A.6). HMDM cells re-attached effectively
when seeded into new plates after being dislodged with AccutaseTM (fig. A.7)
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Figure A.3: HMDM cell morphology before and after AccutaseTM treatment.
HMDM were rinsed with warm PBS and treated with AccutaseTM for 20 min, after
which the cells were pipetted x10 to dislodge the adherent macrophages and aliquoted
for further processing. A: before AccutaseTM B: after incubation with AccutaseTM C:
after pipetting. Scale bar = 50 µm.
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(a) before (b) after
Figure A.4: AccutaseTM treatment of HMDM removes the majority of cells.
HMDM were treated with AccutaseTM (a) and removed by vigorous pipetting (b). Scale
bar = 100 µm.
Accutase PBS
0
5000
10000
15000
20000
25000
D
et
ac
he
d 
ce
lls
 p
er
 w
el
l
Viable
Dead
Figure A.5: Efficiency of AccutaseTM–facilitated detachment of HMDM cells.
HMDM, cultured in 48 well plate in the whole medium were rinsed with PBS and
incubated with either AccutaseTM or PBS for 20 minutes. Cell number was counted
with trypan blue assay after gentle re-pipetting of the cell suspension.
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Figure A.6: AccutaseTM is not toxic to HMDM cells up to 3 hours after
treatment.
HMDM, cultured in 48 well plate (Cellstar®) in the whole medium were rinsed with
PBS and incubated with either AccutaseTM or whole medium followed by PBS for
the indicated time. Cellular viability was assessed with PrestoBlueTM reagent added
directly to the wells. No significant difference between the treatments was detected.
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Figure A.7: HMDM cells re-attach effectively after AccutaseTM–facilitated
removal.
HMDM were lifted up with AccutaseTM, re-plated at 2 x 105 cells/well (48 well), allowed
to adhere and adjust for 19 hours and photographed. Scale bar = 50 µm.
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PCR method development
Primer validation
Primer pairs for CD36 and a range of potential housekeeping genes were obtained
from the published literature. CD36 and β-actin primer sequences were kindly pro-
vided by Wong et al. (2011); HPRT and RPL13A were from Jedidi et al. (2006);
β-microglobulin and GAPDH were from Kielar et al. (2001) and e-GAPDH primers
were from Lai et al. (2003). All primer pair sequences and expected amplicon sizes
are presented in table A.1, together with actual amplicon sizes and melting temper-
atures, which were determined experimentally.
All primer pairs were checked for amplification success and amplicon specificity.
Table A.1: List of PCR primers tested.
Gene Abbr. Expected
size, bp
Amplified
size, bp
Melting
temp., ◦C
Forward primer, Reverse primer
CD36 receptor CD36 190 200 82 CTGGGGCTGTCATTGGTG
TGTGGATTTTGCACATCA
β-Microglobulin B2M 236 140 82.7 CTCGCGCTACTCTCTCTTTCT
TGTCGGATTGATGAAACCCAG
Glyceraldehyde-3-phosphate GAPDH 270 270 90.1 TTGGTATCGTGGAAGGACTCA
dehydrogenase TGTCATCATATTTGGCAGGTTT
Ribosomal protein L13A RPL13A 126 125 82 CCTGGAGGAGAAGAGGAAAGAGA
TTGAGGACCTCTGTGTATTTGTCAA
Hypoxanthine phosphoribosyl HPRT 94 95 82 TGACACTGGCAAAACAATGCA
transferase 1 GGTCCTTTTCACCAGCAAGCT
Glyceraldehyde-3-phosphate GAPDH-e 127 120 88 GGTGGTCTCCTCTGACTTCAACA
dehydrogenase GTTGCTGTAGCCAAATTCGTTGT
β-Actin actin 352 330 90.5 CTGGCACCACACCTTCTA
GGTGGTGAAGCTGTAGCC
Undiluted cDNA from untreated HMDM cells was amplified in the presence of CD36
and potential reference gene primers to verify the amplification of the desired prod-
uct. The PCR products were electrophoresed on an agarose gel and visualised under
the UV illumination. Figure A.8 presents the gel, and the calculated amplification
product sizes are incorporated into table A.1. All primer pairs specifically amplified
the desired products (see expected vs. amplified in the table). Amplicon melting
temperatures were also determined, as these were used to confirm product identity
post-RT qPCR (table A.1).
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Figure A.8: Primer product size verification.
cDNA of untreated HMDM cells was amplified in the presence of the CD36 primers and
potential reference gene primers to verify the amplification of the desired product(s).
The PCR products were run on an agarose gel and visualised under the UV illumination.
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“Housekeeping” gene selection
Since all of the chosen reference gene primers amplified products, reference genes for
CD36 RT-qPCR assay were chosen on the basis of a combination of NormafinderTM
output (Andersen et al., 2004) and personal judgement. GAPDH was ruled out be-
cause its Cq values varied between the control and the highest treatment concentration
(300 µM 7,8-NP). β-Actin was chosen due to its ubiquity and because it was also used
as a reference gene in CD36 Western blots. HPRT and RPL13A had a similar like-
lihood of being suitable (Normfinder, Andersen et al. (2004)) and HPRT was chosen
arbitrarily. The trio: CD36, β-actin and HPRT was then assessed for suitability us-
ing a PCR standard curve (fig. A.9). A standard curve of five cDNA dilutions was
run on the qPCR machine to establish amplification efficiency and compare the slopes
between gene of interest (CD36) and reference genes (HPRT and β-actin). Amplifica-
tion efficiency was 100 ± 4% and the slopes were identical (fig. A.9). Together these
results indicated that the combination primers for the gene of interest and reference
genes was suitable for the assay. A typical RT-qPCR output of CD36, HPRT, and
β-actin is presented in figure A.10.
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Figure A.9: RT-qPCR standard curve of CD36, HPRT and β-actin primer
amplification.
A standard curve of five cDNA dilutions was run on the qPCR machine to establish
amplification efficiency and compare the slopes between gene of interest (CD36, green)
and reference genes (HPRT, blue, and β-actin, brown). Amplification efficiency was
100 ± 4% and the slopes were identical.
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Figure A.10: Typical RT-qPCR amplification curve of CD36, HPRT and
β-actin primers.
A typical RT-qPCR output of CD36 (blue) and two reference gene primers: HPRT
(brown) and β-actin (green) is presented. Briefly, 7,8-NP–treated HMDM cells were
collected into TRIzol. Sample RNA was isolated and converted to cDNA with subse-
quent amplification on a RT-qPCR.
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Appendix B
Publication
The following paper, “Oxidant production, oxLDL uptake, and CD36 levels in human
monocyte-derived macrophages are downregulated by the macrophage–generated an-
tioxidant 7,8-dihydroneopterin”, includes one figure (fig. 7b,c) that was generated
during this PhD thesis.
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Oxidant Production, oxLDL Uptake, and CD36 Levels
in Human Monocyte–Derived Macrophages
Are Downregulated by the Macrophage-Generated
Antioxidant 7,8-Dihydroneopterin
Steven P. Gieseg, Zunika Amit, Ya-Ting Yang, Anastasia Shchepetkina, and Hanadi Katouah
Abstract
The severity of atheroma burden in patients strongly correlates to increasing levels of plasma neopterin, the
oxidation product of 7,8-dihydroneopterin. Interferon-g stimulation of macrophages causes the synthesis of 7,8-
dihydroneopterin, a potent antioxidant that inhibits oxidative damage to cells, and the cytotoxicity of oxidized
low-density lipoprotein (oxLDL) to monocyte-like U937 cells but not THP-1 cells. With human monocyte–
derived macrophages (HMDMs), oxLDL triggered a large oxidative stress, causing the rapid loss of cellular
glutathione, glyceradehyde-3-phosphate dehydrogenase (GAPDH) inhibition, and eventual loss of viability
without caspase-3 activation. Inhibition of oxLDL cytotoxicity to HMDMs occurred at 7,8-dihydroneopterin
concentrations >100 mM. The oxLDL-mediated glutathione loss and GAPDH inactivation was inhibited by 7,8-
dihydroneopterin. 7,8-Dihydroneopterin rapidly entered the HMDMs, suggesting that much of the protective
effect was scavenging of intracellular oxidants generated in response to oxLDL. OxLDL uptake by HMDMs was
reduced by 30% by 7,8-dihydroneopterin. Immunoblot analysis suggests that this decrease in oxLDL uptake was
due to a significant downregulation in the levels of CD36. These results imply that 7,8-dihydroneopterin protects
human macrophages both by scavenging oxidants generated in response to oxLDL and by decreasing CD36-
mediated uptake of oxLDL. Antioxid. Redox Signal. 13, 1525–1534.
Introduction
Increased clinical use of plasma neopterin is seen as amarker of a patient’s level of inflammation in conditions as
diverse as cancer and tuberculosis infection. Neopterin is the
oxidation product of 7,8-dihydroneopterin, a pterin synthe-
sized by macrophages when stimulated by g-interferon re-
leased by Th-1 cells (17, 52). The increase of plasma neopterin
levels has been strongly correlated with increased athero-
sclerotic burden (1, 43, 47). Significant amounts of neopterin
and 7,8-dihydroneopterin have been reported in the interior
of an atherosclerotic plaque (13, 17), which represents local-
ized sites of chronic inflammation (36). Although neopterin is
a sensitive marker of inflammation, it is becoming increas-
ingly apparent that 7,8-dihydroneopterin and neopterin have
distinct biologic properties. They may have significant influ-
ence on the inflammatory process, especially in chronic in-
flammation, such as atherosclerosis.
In vitro studies have shown that 7,8-dihydroneopterin is a
potent antioxidant that can protect a range of biomolecules
and cells from various oxidants, including hydroxyl and
peroxyl radicals (21, 24, 25, 31). Oxidized low-density lipo-
protein (OxLDL) formation with copper, peroxyl, or cellular
oxidants is effectively inhibited by scavenging of the chain
carrying lipid-peroxyl radical within the LDL particle by 7,8-
dihydroneopterin (13, 15, 23, 24). 7,8-Dihydroneopterin ac-
celerates copper-mediated oxidation if added after the lag
phase because of increased metal reduction (26).
7,8-Dihydroneopterin is effective in protecting the mono-
cyte-like U937 cells from the cytotoxic effects of oxidized low-
density lipoprotein (oxLDL) (5). Cell death due to oxLDL
cytotoxicity is considered to be a major factor in the develop-
ment of a necrotic core in advanced atherosclerotic plaques (28,
30). Our previous studies have shown 7,8-dihydroneopterin
protects U937 cells from oxLDL by preventing the loss of
intracellular glutathione and the initiation of necrosis (5).
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Although oxLDL itself is not capable of directly generating
oxidants, exposure to U937 cells causes a large intracellular
oxidant flux, which can be scavenged or inhibited by 7,8-
dihydroneopterin.
Surprisingly, 7,8-dihydroneopterin cannot protect the re-
lated monocyte-like THP-1 cells from oxLDL-induced cyto-
toxicity (5). In THP-1 cells, oxLDL triggers caspase activation
and apoptosis without the loss of glutathione (4). This non-
oxidative stress mechanism in THP-1 cells does not appear to
be inhibited by 7,8-dihydroneopterin. OxLDL-induced cell
death occurs through a number of mechanisms, depending on
the type of cell under study and the level to which the LDL has
oxidized (22). The proposed mechanisms include calpain
activation through oxysterol-induced alterations in lipid rafts–
associated calcium channels (6), dephosphorylation and inhi-
bition of protein kinase B, leading to mitochondrial dysfunction
through Bcl-2 and MAPK (9, 45), lysozyme destabilization (7,
34), and CD36-linked NADPH oxidase activation (33, 37).
Human macrophages derived from peripheral blood
monocytes, usually described as human monocyte–derived
macrophages (HMDMs) have been described undergoing
both caspase and caspase-independent cell death (3, 22, 53).
We have observed oxLDL causing HMDMs to undergo a
caspase-independent cell death characterized by a rapid loss
of glutathione, caspase inactivation, and the appearance of
necrotic cell morphology (22). In this study, we examined
whether 7,8-dihydroneopterin can inhibit oxLDL-induced
death in HMDMs and whether the mechanism involves the
reduction of intracellular oxidative stress, as observed with
U937 cells.
Materials and Methods
All reagents and chemicals were AR grade or better and
obtained from either the Sigma Chemical Company (St. Louis,
MO) or BDH Chemicals New Zealand Limited. Solutions
were prepared by using high-purity water generated from an
NANOpure ultrapure water system from Barnstead=
Thermolyne (Dubuque, IA). Cells were grown in Nunc plates
supplied by In Vitro New Zealand Ltd., and the remaining
plastic ware was supplied by Greiner Bio-one through Raylab
New Zealand Ltd. Neopterin and 7,8-dihydroneopterin were
obtained from Schirck’s Laboratories, Jona, Switzerland.
Phosphate-buffered saline (PBS) solution consisted of 150 mM
sodium chloride and 10 mM sodium phosphate, pH 7.4.
LDL was purified by buoyant density-gradient ultracen-
trifugation by using a Beckman SW41 rotor from EDTA-
treated plasma collected by venipuncture from healthy male
and female donors after an overnight fast, as previously de-
scribed (5, 10, 23). LDL concentration (total mass) was deter-
mined by enzymatic cholesterol assay with the Chol MPR 2 kit
supplied by Roche Chemicals (Bern, Switzerland) (20).
Heavily oxidized oxLDL with the properties previously de-
scribed (5) was prepared by incubating LDL at a concentra-
tion of 3 mg=ml (600mg=ml protein) with 400 mM CuCl2
solution for 24 h at 378C before stirring with chelex-100 resin
for 2 h to remove copper ions. The oxLDL was concentrated
by using a Vivapore membrane concentrator (Millipore,
Billerica, MA) before filter sterilization through a 0.22-mm
membrane filter and then stored at 48C.
Human monocyte–derived macrophages (HMDMs) were
prepared from whole blood donated by clinically healthy
hemochromatosis patients at the NZ Blood Services
(Christchurch) under ethics approval CTY=98=07=069 gran-
ted by the New Zealand Upper South B Ethics Committee.
The monocytes were purified by centrifugation over Lym-
phoprep and differentiated into adherent macrophages in
adherent 12-well plates (14). The cells were maintained in
RPMI 1640 supplemented with 10% heat-inactivated human
serum plus 100 U=ml penicillin and 100 mg=ml streptomycin.
Cell viability was determined by MTT reduction (38). Cell
protein concentration was determined by using the BCA
Protein Determination kit supplied by Pierce, (Rockford, IL)
with bovine serum albumin as the standard.
Cellular glutathione levels were measured by deriva-
tion with monobromobimane and reverse-phase C18 high-
performance liquid chromatography (HPLC) analysis of
the fluorescent derivative by using monobromobimane-
derivatized GSH as a standard (11). Neopterin and 7,8-
dihydroneopterin were measured with reverse-phase HPLC
analysis of cell lysates after removal of proteins by precipi-
tation with trichloroacetic acid (13, 21). GAPDH activity was
measured in cell lysates by monitoring the rate of conversion
of NADPþ to NADPH in the presence of glyceraldehyde-
3-phosphate over a 4-min period (49). OxLDL uptake by
HMDMs was measured by using DiI-labelled oxLDL (12, 50).
The DiI uptake was measured by lysing cells into isopropanol
and measuring the native DiI fluorescence intensity. The cel-
lular protein concentration was determined by analysis of cell
pellets collected after centrifugation of the isopropanol. In-
tracellular superoxide release was detected with dihy-
droethidium (DHE) staining (8) of cells grown on sterile glass
coverslips. The cells were incubated for 20 min with DHE
before examination with fluorescence microscopy.
Caspase-3, CD36, and scavenger receptor-A (SCR-A) were
detected by immunoblotting after SDS-PAGE electrophoresis
cells were harvested by scraping in lysis buffer (40 mM
HEPES, 50 mMNaCl, 1 mM EDTA, and 1 mM EGTA, plus one
tablet of Roche Complete mini protease inhibitor per 10 ml).
Immunoblots were probed with either anti-CD36 rabbit
polyclonal (NB400-145, Novus Biologicals, Cambridge, UK),
diluted 1:1,000, followed by peroxidase-conjugated goat
polyclonal anti-rabbit IgG (NB730-H, Novus Biologicals) at
1:2,000 dilution; or anti-caspase-3 (E-8) (SC-7272, Santa Cruz
Biotechnology, Santa Cruz, CA) followed by conjugated goat
anti-mouse IgG (Fc) (31434; Pierce Biotechnology); or anti-SR-
A (I-20) (SC-20441, Santa Cruz Biotechnology) followed by
peroxidase-conjugated donkey anti-goat IgG (SC-2020, Santa
Cruz Biotechnology). Lane loading was accessed by reblotting
with anti-b-actin (A5316, Sigma-Aldrich Chemical, St. Louis,
MO) followed by peroxidase-conjugated sheep anti-mouse
IgG (RPN4401, Amersham Biosciences, Amersham, England).
Immunoblots were visualised by using Supersignal West
Dura chemiluminescence from Pierce. The image was re-
corded on a Syngene Chemigenius-2 bioimaging system by
using Genesnap software (Global, Aotearoa, NZ).
Phosphatidylserine (PS) translocation to the cell surface as a
marker of apoptosis was measured by staining cells grown on
coverslips with annexin-V-FITC by using the Annexin V
Apoptosis Kit form Santa Cruz Biotechnology and viewing by
fluorescence microscope by using Zeiss AxioImager.M1 epi-
fluorescent microscope.
The data were analyzed by using the Prism software
package supplied by Graphpad Software Inc. (San Diego,
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CA). Comparisons among treatments were performed by
using one-way analysis of variance (ANOVA). All results are
expressed as the mean SD of triplicate treatments. Results
shown are from single experiments, representative of a min-
imum of three. Where appropriate, significance is indicated as
(***)p 0.001; (**)p 0.01, or (*)p 0.05.
Results
OxLDL induced cell death in the HMDMs only after 12 h of
incubation (Fig. 1A). Up to the 12-h time point, the cell mor-
phology appeared normal, but after this, increasing numbers
of lysed cells were observed. The appearance of lysed cells
corresponded with the loss of cell viability, as measured by
the ability to reduce MTT to the purple formazan product. The
oxLDL-induced loss of viability was significantly inhibited
by 50 mM 7,8-dihydroneopterin added 10 min before the
oxLDL treatment (Fig. 1B). One hundred micromolar 7,8-
dihydroneopterin reduced the loss of viability to a mean value
of 20%, with the majority of the cells displaying normal
morphology.
To understand the nature of the 7,8-dihydroneopterin
protection, the mechanism of the oxLDL-induced death in the
HMDMs was further examined, as conflicting reports in the
literature exist on the oxLDL-induced death mechanism (22).
Western blot analysis constantly failed to show any sign of
proteolytic activation of caspase-3 in the oxLDL-treated
HMDMs. The 32-kDa band of procaspase-3 was clearly seen
(Fig. 2A), but no active 17- or 20-kDa band was evident. This
confirms our earlier investigations, in which no caspase en-
zyme activity was observed with oxLDL exposure (22).
Phosphatidylserine externalization in the plasma membrane
appeared to increase, as indicated by staining with annexin-V
after 3 and 6 h after the treatment with oxLDL (Fig. 2B–E). This
process was significantly slowed and reduced in the presence
of 7,8-dihydroneopterin (Fig. 2F–H). Although the effector
caspase-3 appears not to be activated by oxLDL exposure,
phosphatidylserine translocation, another classic marker of
apoptosis, occurs.
We previously observed the loss of caspase activity during
oxLDL-induced death of U937 cells (4). This was also accom-
panied by a large loss of glutathione, suggesting inhibition of
caspase-3 activity through oxidative loss of key thiols within
the enzyme. With the HMDMs, we observed a similar and very
rapid loss of glutathione (Fig. 3A). Within 6 h of adding the
oxLDL, nearly 50% of the glutathione was lost, with the level
dropping to 36% of the control by 24 h. Generally, no signifi-
cant loss was observed in the absence of oxLDL, although a
small loss was observed at 24 h in this experiment. As with
previous studies using 7,8-dihydroneopterin on macrophage-
like cells (5, 25), addition of 7,8-dihydroneopterin alone had no
significant effect on the levels of glutathione, but in the pres-
ence of oxLDL, a dose-dependent protection of the glutathione
levels was noted at the end of a 24-h incubation (Fig. 3B). The
200mM 7,8-dihydroneopterin maintained the glutathione level
at 68% of the control value.
Based on studies with monocyte-like U937 cells (4, 29) and
endothelial cells (51), we suspect that oxLDL induced the
HMDM cells to generate reactive oxidants that depleted
the intracellular glutathione levels. Treatment of cells with the
fluorescent dye DHE confirmed that oxLDL was inducing an
oxidative stress over the first 6 h (Fig. 4A–C), which was re-
duced by the addition of 7,8-dihydroneopterin (Fig. 4D and
E). This suggested that the 7,8-dihydroneopterin was either
inhibiting the oxidant production or scavenging the oxidant
directly.
Like the caspases, the glycolytic enzyme glyceraldehyde
3-phosphate dehydrogenase (GAPDH) has a critical thiol
within its active site that, when oxidized, results in the loss of
FIG. 1. OxLDL loss of HMDM cell viability is inhibited
by 7,8-dihydroneopterin. (A) HMDMs were incubated with
1 mg=ml oxLDL in RPMI-1640 supplemented with 10%
human serum. At indicated time points, the medium was
removed, and the cell viability was determined by measur-
ing MTT reduction. (B) Increasing concentrations of 7,8-
dihydroneopterin inhibited oxLDL-induced loss of HMDM
cell viability during a 24-h incubation with 1 mg=ml oxLDL.
The 7,8-dihydroneopterin was added 10 min before the oxLDL.
*p 0.05; **p 0.01; ***p 0.001.
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enzymatic activity. In HMDMs, oxLDL was observed to cause
a rapid reduction of GAPDH activity, which paralleled the
loss of glutathione (Fig. 5A). Within 6 h of oxLDL addition, the
GAPDH activity had been reduced to 50% of the control. No
loss in GAPDH activity was observed in the absence of
oxLDL or in the presence of only 7,8-dihydroneopterin. At
50 mM 7,8-dihydroneopterin, a small but statistically signifi-
cant protection of the GAPDH activity steadily increased with
7,8-dihydroneopterin concentration. 7,8-Dihydroneopterin at
200 mM completely prevented the oxLDL-induced loss of
GAPDH activity (Fig. 5B).
The data strongly suggest that 7,8-dihydroneopterin may
be scavenging oxidants generated by the cell in response
to the oxLDL binding or internalization. Such a mode of
activity would require 7,8-dihydroneopterin to enter the
cells. This was examined by incubating HMDMs with 7,8-
dihydroneopterin and analyzing cell lysates at various time
points. A gradual loss of 7,8-dihydroneopterin was observed
in the media, with the concentration decreasing by 50% over a
24-h period (Fig. 6). This loss is due to oxidation of the 7,8-
dihydroneopterin to 7,8-dihydroxanthopterin and neopterin
(13, 18). Intracellularly, the 7,8-dihydroneopterin level in-
creased rapidly, with half the maximum concentration
reached within 4 h and maximum at 12 h (Fig. 6). No signifi-
cant loss of intracellular 7,8-dihydroneopterin was noted over
the following 12-h period, even though the media concen-
tration dropped by 25%. As the cells were not stimulated with
g-interferon, the intracellular generation was negligible.
Although intracellular oxidant scavenging by 7,8-
dihydroneopterin appeared to explain the cellular protection
from oxLDL, reduced uptake of oxLDL into the cells was also
explored. By using DiI-labeled oxLDL, we measured oxLDL
uptake by HMDMs and found that 7,8-dihydroneopterin re-
duced the uptake, but only by a third when compared with
cells without 7,8-dihydroneopterin (Fig. 7A). The concentra-
tion of oxLDL used was below the cytotoxic concentration,
thus removing the compounding factor of cell death and lysis
from the analysis. A simple explanation for this decrease in
oxLDL uptake is downregulation in the levels of the main
scavenger receptors of oxLDL, scavenger receptor-A (SR-A)
FIG. 2. OxLDL does not activate HMDM cell caspase-3 but causes phosphatidylserine translocation to the plasma
membrane, which is inhibited by 7,8-dihydroneopterin. (A) HMDMs were incubated under various conditions before
washing, and cell lysates were collected for immunoblot staining for caspase-3 activation and b-actin as a loading control.
Lane 1: control cells at zero time; lane 2: with 1 mg=ml oxLDL for 12 h; lane 3: with 2 mg=ml oxLDL for 12 h; lane 4: with
1 mg=ml oxLDL for 24 h; lane 5: with 2 mg=ml oxLDL for 24 h. Cells were grown on coverslips before exposure to 1 mg=ml
oxLDL for 0 h. (B) 3 h (C, F), 6 h (D, G), and 12 h (E–H) with (F–H) or without 200mM 7,8-dihydroneopterin (C–E). Phos-
phatidylserine exposure on the cells surface was visualized by staining with annexin-V under fluorescence microscopy.
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and CD36. Immunoblot analysis of HMDMs treated with 7,8-
dihydroneopterin showed no significant change in SR-A
levels (data not shown), but a significant concentration-
dependent loss of the CD36 was observed with both the 83-
and 100-kDa bands (Fig. 7B). The greatest loss appears with
the 100-kDa plasma membrane form, in which 200 mM 7,8-
dihydroneopterin almost completely inhibited the appear-
ance of this isoform.
Discussion
OxLDL induces a large oxidative stress in the HMDMs,
causing cellular death, similar to that with U937 cells (4). This
study shows that the oxidant release, detected as DHE fluo-
rescence, is associated with rapid loss of glutathione, inacti-
vation of GAPDH, and possible loss of caspase activity. The
oxidative stress develops rapidly with>25% of the glutathi-
one and GAPDH activity lost within 3 h of oxLDL addition
(Figs. 3 and 5). It is not until 12 h later that this intracellular
damage appears as a significant loss of cell viability (Fig. 1).
Also similar to the U937 cells (5) is that the presence of
7,8-dihydroneopterin effectively inhibits oxLDL-induced
oxidant production and cell death in HMDMs, as shown
by decrease in DHE staining, and maintenance of glutathi-
one levels and GAPDH enzyme activity. The presence of
7,8-dihydroneopterin within the cells and the known radical-
scavenging properties of 7,8-dihydroneopterin (19, 24, 41)
strongly support an intracellular scavenging mechanism for
the observed protection.
The heavily oxidized oxLDL used in this study is relatively
inert chemically, because most of the LDL components have
been oxidized and can no longer sustain any significant oxi-
dant production (16, 51). Treatment of oxLDL with antioxi-
dant before addition to cells does not reduce the oxLDL
cytotoxicity (5, 51). It is, therefore, reasonable to assume that
the oxLDL-induced intracellular oxidant production is a cel-
lular response to oxLDL. In the case of HMDMs, we have
shown that this response is large enough to be cytotoxic.
A number of mechanisms responsible for oxLDL-induced
intracellular oxidant production have been reported. Mi-
tochondrial dysfunction (3), NADPH-oxidase activation (33),
and lipoxygenase activity (51) have all been demonstrated to
occur in response to oxLDL. Our DHE data suggest that su-
peroxide may be the primary reactive oxygen species gener-
ated within the cells, possibly due to NADPH-oxidase
activation, as has been reported in U937 cells (40, 48). How-
ever, DHE is not sufficiently discriminative between super-
oxide and other ROS, so it is likely that a range of reactive
oxygen species is generated.
A strong experimental link exists between CD36 binding of
oxLDL and superoxide=oxidant generation. Cell experiments
in which CD36 binding of oxLDL is inhibited by anti-CD36
antibodies, or in which the receptor is absent, still take up
oxLDL, (likely through SR-A), yet have significantly re-
duced levels of reactive oxygen species (ROS) production,
caspase activation, and cell death (51, 53). OxLDL binding to
CD36 of HMDMs has been reported to generate large
amounts of hydrogen peroxide (37), which would have
originated as superoxide. 7,8-Dihydroneopterin is an effec-
tive scavenger of superoxide and also appears to be able to
inhibit NADPH-oxidase (32). Both mechanisms may operate
within the HMDMs. In addition to radical scavenging, 7,8-
dihydroneopterin induced downregulation of the 100-kDa
plasma membrane glycoform of CD36 on the HMDMs may
also reduce the level of superoxide production. The superoxide
generated is then scavenged by the 7,8-dihydroneopterin that
has collected within the HMDM cells.
FIG. 3. OxLDL causes a rapid loss of intracellular gluta-
thione, which is inhibited by 7,8-dihydroneopterin. (A)
Cells in RPMI1640 supplemented with 10% human serum
were incubated with (&) and without (&) oxLDL before cell
GSH levels were measured with HPLC analysis at indicated
time points. (B) HMDMs were incubated for 24 h in the in-
dicated 7,8-dihydroneopterin concentrations, without (con-
trol) or with 1 mg=ml oxLDL, before the intracellular GSH
concentration was determined by HPLC analysis. *p 0.05;
**p 0.01; ***p 0.001.
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7,8-Dihydroneopterin only decreased DiI-oxLDL uptake
by 30% over a 24-h period, suggesting that oxLDL was still
entering the cell through another receptor(s), possibly SR-A.
This is similar to the effect reported when CD36 was blocked
by using an antibody, causing a decrease but not inhibition of
oxLDL uptake (53). Increased SR-A activity has been reported
to decrease oxLDL cytotoxicity to THP-1 cells, suggesting that
SR-A is responsible for uptake and foam cell formation (35)
but not for the toxic effects after oxLDL binding and inter-
nalization. This suggests that the CD36 downregulation in the
HMDMs has an important contribution to the observed pro-
tection against oxLDL.
The combination of these arguments led us to advocate that
with HMDMs and U937 cells, oxLDL triggers an excessive
respiratory-burst response, which is effectively inhibited or
quenched by 7,8-dihydroneopterin. This response is not seen
with THP-1 cells (4) or cells treated with 7-ketocholesterol, in
which changes in the key intracellular kinases and lipid raft–
associated calcium channels results in cytochrome c release,
caspase activation, and apoptosis (6). In the apoptotic mech-
anism, the oxidative stress is much reduced, and the gluta-
thione levels are reasonably well maintained during the first
12 h of the response (4, 46). Monocyte-like THP-1 cells have
significantly lower levels of CD36 expression on the plasma
membrane compared with U937 cells (2). This may explain the
much lower oxidative-stress levels observed in THP-1 cells
exposed to oxLDL. The reason the mechanism triggered in
THP-1 cells is not activated in our HMDMs treated with 7,8-
dihydroneopterin is uncertain. The oxLDL preparations used
in these experiments were rich in oxysterols and therefore
should have triggered the caspase-mediated mechanism seen
in THP-1 and other cell types. The mechanism we have pro-
posed for 7,8-dihydroneopterin action should only have
changed the HMDM death mechanism from necrosis to ap-
optosis by protecting the caspase activity. Ascorbate has
been reported to do just that with HMDMs and, as a result,
increased the strength of the apoptotic response to oxLDL (27).
The exact mechanism by which oxLDL causes deactivation
FIG. 4. OxLDL causes the intracellular
generation of reactive oxygen species, which
is reduced by 7,8-dihydroneopterin. HMDMs
grown on coverslips in six-well plates were
incubated for various times with the indicated
oxLDL and 7,8-dihydroneopterin concentra-
tion described below for each panel. The in-
tracellular distribution of reactive oxidant
species was detected by staining the cells with
DHE. (A) Untreated cells at 0 h; (B) 1 mg=ml
oxLDL after 3 h; (C) 1 mg=ml oxLDL after 6 h;
(D) 1 mg=ml oxLDL with 200 mM 7,8-dihy-
droneopterin after 3 h; and (E) 1 mg=ml oxLDL
with 200mM 7,8-dihydroneopterin after 6 h.
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of AKT kinase with subsequent cJNK activation and apoptosis
is uncertain (9, 45), and from our data, does not appear to
occur in U937 or our HMDMs.
How 7,8-dihydroneopterin is downregulating the level of
the CD36 protein in HMDMs also is uncertain. Studies on
CD36 in THP-1 and U937 cells clearly show that the 100-kDa
band is the active plasma membrane form, whereas the 83-
kDa form is the less-glycosylated intracellular precursor form,
possibly held within the Golgi (2). The 7,8-dihydroneopterin
caused the complete disappearance of the 100-kDa form,
whereas only a partial decrease in the intracellular 83-kDa
form was observed (Fig. 7). The downregulation with 7,8-
dihydroneopterin is very different from the inhibition of
CD36 transcription induced by another antioxidant, a-
tocopherol (44). a-Tocopherol has an antagonistic effect on
oxLDL-induced CD36 expression by preventing oxLDL-
induced protein kinase B phosphorylation action on the per-
oxisome proliferator–activated receptor-g (PPAR-g) (39). As
7,8-dihydroneopterin downregulation of CD36 still occurs in
the absence of oxLDL, we suspect a different mechanism from
that reported with a-tocopherol.
The loss of GAPDH activity within the first hours of oxLDL
exposure would potentially exacerbate cellular stress.
GAPDH inhibition would cause the glycolytic carbohydrate
intermediates to be shunted into the pentose phosphate
pathway, generating more NADPH (42). Although increased
NADPH generation would normally increase the cells’ ability
to regenerate GSH (42), with HMDMs and U937 cells, it also
provides more NADPH for the NADPH-oxidase. The loss of
GSH in the HMDMs (Fig. 3) and U937 cells (4) shows that the
increase in GSH regenerative capacity was not enough to
protect the cells. As MTT reduction is dependent on NADPH
reductases (38), this would also explain the high MTT-
reducing potential of the HMDMs for the first 12 h, even
though GAPDH and general cell metabolism was failing.
Within actual atherosclerotic plaques, total neopterin levels
(neopterin plus 7,8-dihydroneopterin) have been measured in
the low micromolar range (13), and this concentration varies
along the length of the plaque (17), suggesting that a range
of pathologies is occurring. These are advanced plaques in which
the possible protective mechanisms of 7,8-dihydroneopterin on
FIG. 5. OxLDL loss of macrophage GAPDH enzyme ac-
tivity is inhibited by 7,8-dihydroneopterin. (A) Monocyte-
derived macrophages in RPMI1640 supplemented with heat-
inactivated human serum were incubated with 2 mg=ml
oxLDL for24 h (), or 200mM 7,8-dihydroneopterin was
added to the medium before the oxLDL (*). At indicated
time points, the cells were collected, and the GAPDH activity
was measured. (B) Level of GAPDH protection from oxLDL
is related to 7,8-dihydroneopterin concentration. Cells were
incubated for 24 h with increasing concentrations of 7,8-
dihydroneopterin with 2 mg=ml oxLDL () or without (*).
FIG. 6. 7,8-Dihydroneopterin is taken up by HMDMs.
HMDMs were incubated with 200mM 7,8-dihydroneopterin
in RPMI-1640 with 10% human serum. At indicated time
points, the cells were washed and lysed, and the intracellular
7,8-dihydroneopterin concentration (&) was determined
with HPLC analysis. The incubation medium (&) was also
analyzed by HPLC to measure the oxidative loss of 7,8-
dihydroneopterin over time.
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macrophage cell death explored in this research, and the in-
hibition of oxLDL formation (14, 24), have been over-
whelmed. In middle-aged and older subjects with low levels
of vascular disease, the action of 7,8-dihydroneopterin may be
an important process in slowing or preventing the effects of
oxLDL formation.
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